
<html lang="en"     class="pb-page"  data-request-id="58204fe0-4c14-400d-8665-9758ece3efda"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm401427c;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2014.57.issue-11"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress" /></meta><meta name="dc.Creator" content="J. Jean  Cui" /></meta><meta name="dc.Description" content="The HGF/MET signaling pathway is critical in mediating a wide range of normal physiological functions including embryological development, wound healing, and tissue regeneration. Aberrant activatio..." /></meta><meta name="Description" content="The HGF/MET signaling pathway is critical in mediating a wide range of normal physiological functions including embryological development, wound healing, and tissue regeneration. Aberrant activatio..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 18, 2013" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401427c" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401427c" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401427c" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401427c" /></link>
        
    
    

<title>Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401427c" /></meta><meta property="og:title" content="Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0018.jpeg" /></meta><meta property="og:description" content="The HGF/MET signaling pathway is critical in mediating a wide range of normal physiological functions including embryological development, wound healing, and tissue regeneration. Aberrant activation of the pathway has frequently been found in human cancers via protein overexpression, mutation, gene amplification, and also paracrine or autocrine up-regulation. In addition, the activation of HGF/MET signaling confers resistance to the effects of cancer treatments. Therefore, inhibition of the HGF/MET signaling pathway has great potential for therapeutic intervention in cancer. Currently, there are three approaches toward modulating HGF/MET signaling in human clinical studies of cancer: anti-HGF monoclonal antibodies, MET monoclonal antibodies, and small molecule MET inhibitors. Preliminary clinical benefit from inhibition of HGF or MET has been reported. This Perspective will provide an overview of the HGF/MET signaling pathway in cancer and then will review the development of small molecule MET inhibitors and their progress in clinical applications." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401427c"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401427c">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401427c&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401427c&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401427c&amp;href=/doi/10.1021/jm401427c" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4427-4453</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400533t" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm401431x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Jean++Cui">J. Jean Cui</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">TP Therapeutics, Inc., 6150 Lusk Boulevard, Suite B100, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 858-692-6798. E-mail: <a href="/cdn-cgi/l/email-protection#066c6367682865736f467276726e637467766373726f65752865696b"><span class="__cf_email__" data-cfemail="e68c838788c885938fa69296928e839487968393928f8595c885898b">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401427c&amp;href=/doi/10.1021%2Fjm401427c" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4427â4453</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 9, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 September 2013</li><li><span class="item_label"><b>Published</b> online</span>18 December 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 June 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401427c" title="DOI URL">https://doi.org/10.1021/jm401427c</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4427%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJ.%2BJean%2BCui%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D11%26contentID%3Djm401427c%26title%3DTargeting%2BReceptor%2BTyrosine%2BKinase%2BMET%2Bin%2BCancer%253A%2BSmall%2BMolecule%2BInhibitors%2Band%2BClinical%2BProgress%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4453%26publicationDate%3DJune%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401427c"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5884</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">132</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401427c" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Jean Cui&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;4427-4453&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401427c&quot;},&quot;abstract&quot;:&quot;The HGF/MET signaling pathway is critical in mediating a wide range of normal physiological functions including embryological development, wound healing, and tissue regeneration. Aberrant activation of the pathway has frequently been found in human cancers via protein overexpression, mutation, gene amplification, and also paracrine or autocrine up-regulation. In addition, the activation of HGF/MET signaling confers resistance to the effects of cancer treatments. Therefore, inhibition of the HGF/MET signaling pathway has great potential for therapeutic intervention in cancer. Currently, there are three approaches toward modulating HGF/MET signaling in human clinical studies of cancer: anti-HGF monoclonal antibodies, MET monoclonal antibodies, and small molecule MET inhibitors. Preliminary clinical benefit from inhibition of HGF or MET has been reported. This Perspective will provide an overview of the HGF/MET signaling pathway in cancer and then will review the development of small molecule MET inhibitors and &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401427c&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401427c" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401427c&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401427c" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401427c&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401427c" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401427c&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401427c&amp;href=/doi/10.1021/jm401427c" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401427c" /></input><a href="/doi/pdf/10.1021/jm401427c" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401427c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401427c%26sid%3Dliteratum%253Aachs%26pmid%3D24320965%26genre%3Darticle%26aulast%3DCui%26date%3D2014%26atitle%3DTargeting%2BReceptor%2BTyrosine%2BKinase%2BMET%2Bin%2BCancer%253A%2BSmall%2BMolecule%2BInhibitors%2Band%2BClinical%2BProgress%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D11%26spage%3D4427%26epage%3D4453%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jmcmar.2014.57.issue-11/production/jmcmar.2014.57.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0018.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The HGF/MET signaling pathway is critical in mediating a wide range of normal physiological functions including embryological development, wound healing, and tissue regeneration. Aberrant activation of the pathway has frequently been found in human cancers via protein overexpression, mutation, gene amplification, and also paracrine or autocrine up-regulation. In addition, the activation of HGF/MET signaling confers resistance to the effects of cancer treatments. Therefore, inhibition of the HGF/MET signaling pathway has great potential for therapeutic intervention in cancer. Currently, there are three approaches toward modulating HGF/MET signaling in human clinical studies of cancer: anti-HGF monoclonal antibodies, MET monoclonal antibodies, and small molecule MET inhibitors. Preliminary clinical benefit from inhibition of HGF or MET has been reported. This Perspective will provide an overview of the HGF/MET signaling pathway in cancer and then will review the development of small molecule MET inhibitors and their progress in clinical applications.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer is the uncontrolled growth of abnormal cells in the body. Protein kinases are key regulators for cell growth, proliferation, and survival. The activity, localization, and function of many proteins are tightly controlled by protein kinases via the modulation of protein phosphorylation. Genetic and epigenetic alterations accumulate in cancer cells leading to abnormal activation of signal transduction pathways that drive malignant processes. Pharmacological inhibition of these signaling pathways presents promising intervention opportunities for targeted cancer therapies. There are more than 518 protein kinases encoded by the human genome, and many of them are associated with human cancers.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The successes of the HER2/<i>neu</i> antibody trastuzumab for the treatment of patients with HER2-positive metastatic breast cancer and of the ABL inhibitor imatinib for the treatment of chronic myelogenous leukemia patients bearing <i>BCR-ABL</i> translocation validated the critical roles of protein kinases in cancers and the âdruggabilityâ of the protein kinase family. Identification of abnormal protein kinases that are key drivers of cancer progression and development of pharmacological inhibitors of those kinases are the forefront of research for molecularly targeted therapy. Receptor tyrosine kinases (RTKs) play fundamental roles in cellular processes, including cell proliferation, migration, metabolism, differentiation, and survival. Humans have 58 known RTKs that can be further classified into 20 subfamilies.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> All RTKs share a similar molecular architecture, including a ligand binding extracellular region, a single transmembrane helix, an intracellular regulatory domain (juxtamembrane), and a cytoplasmic tyrosine kinase domain. Enhanced RTK activities caused by point mutation, amplification or rearrangement of the corresponding genes, and autocrine or paracrine ligand-dependent activation have been implicated in the development and progression of many types of cancer.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> A number of RTK inhibitors have been successfully discovered and developed to inhibit aberrant RTK signaling in various cancers, including sunitinib and axitinib (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) which target the VHL-dependent VEGF pathway in renal cell carcinoma, erlotinib and gefitinib (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) which target mutant EGFR in non-small-cell lung cancer (NSCLC), and crizotinib (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>) which targets MET, ALK, and ROS1 in NSCLC.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Examples of Receptor Tyrosine Kinase Drugs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Receptor tyrosine kinase MET, also called hepatocyte growth factor receptor (HGFR), belongs to a unique subfamily of receptor tyrosine kinases that also contains the protein kinase RON. Hepatocyte growth factor (HGF), also known as scatter factor (SF), is the high-affinity natural ligand of MET. The HGF/MET signaling pathway is critical for invasive growth during embryo development and postnatal organ regeneration. In adults, it is normally only fully active during wound healing and tissue regeneration processes. However, the HGF/MET axis is frequently reactivated by cancer cells for tumorigenesis, invasive growth, and metastasis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> HGF and/or MET are expressed at abnormally high levels in a wide variety of solid tumors such as liver, breast, pancreas, lung, kidney, bladder, ovary, brain, prostate, and many other cancers.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Overexpression of MET and/or HGF is often associated with a metastatic phenotype and poor prognosis.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In addition, the activation of HGF/MET signaling confers resistance to cancer therapies. HGF up-regulation in the tumor microenvironment may cause resistance to the effects of anticancer kinase inhibitors, highlighting another important role for HGF/MET inhibitors in cancer therapy.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Activation of HGF/MET signaling confers resistance to EGFR and BRAF kinase inhibitors.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> Because of the role of aberrant HGF/MET signaling in human oncogenesis, invasion/metastasis, and resistance to cancer therapies, the inhibition of HGF/MET signaling presents great potential in cancer treatment. There are three approaches toward modulating HGF/MET signaling currently in human clinical studies of cancer: the anti-HGF monoclonal antibodies, MET monoclonal antibodies, and small molecule MET inhibitors.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> This Perspective will focus on the development of MET small molecule inhibitors and their clinical applications.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2 MET Signaling</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1 MET Structure</h3><div class="NLM_p">MET was first discovered in 1984 as a transforming fusion protein, TPR-MET, in a human osteogenic sarcoma (HOS) cell line after prolonged exposure to the chemical carcinogen <i>N</i>-methyl-<i>N</i>â²-nitro-<i>N</i>-nitrosoguanidine.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The new transforming gene was named as <i>MET</i> after the chemical carcinogenâs name. In <i>TPR-MET</i>, the 3â² region of <i>MET</i> is rearranged with the 5â² region of <i>TPR</i> (translocation promoter region) to produce a hybrid transcript.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Cloning of the full-length <i>MET</i> cDNA revealed that the encoded protein is a receptor tyrosine kinase.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> MET is produced mainly in cells of epithelial origin, first as a single chain precursor of 170 kDa, which undergoes co-translational glycosylation and is then cleaved to yield a mature 190 kDa transmembrane receptor, MET. The mature MET exists as an Î±âÎ² heterodimer with an extracellular Î±-chain (50 kDa) disulfide linked to the membrane-spanning Î²-chain (145 kDa) containing the intracellular tyrosine kinase domain.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The extracellular region of MET has three functional domains: the N-terminal sema domain (residues 25â514) that covers the whole Î±-subunit and part of the Î²-subunit; the cystine-rich (CR) domain (residues 515â561) with four conserved disulfide bonds followed by four immunoglobin-like (Ig) domains (residues 562â922) that connect with transmembrane helix (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> After the transmembrane helix (residues 923â956), the intracellular segment (residues 957â1390) is composed of three regulation sites: a juxtamembrane domain with a phosphorylation site Tyr-1003 that down-regulates kinase activity via internalization; a catalytic region that positively modulates kinase activity via transphosphorylation of Tyr-1234 and Tyr-1235; and a carboxy-terminal multifunctional docking site with two docking tyrosines (Tyr-1349 and Tyr-1356) for the recruitment of transducers and adaptors to relay MET signaling.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of MET and HGF/SF.<a onclick="showRef(event, 'cit4b'); return false;" href="javascript:void(0);" class="ref cit4b">(4b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2 HGF Structure</h3><div class="NLM_p last">Hepatocyte growth factor, also known as scatter factor, is the only known high-affinity natural ligand of MET.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> HGF/SF belongs to the plasminogen-related growth factor family (PRGF-1), and is synthesized in cells of mesenchymal origin as a single-chain, inactive precursor (pro-HGF), which is subsequently converted proteolytically into a disulfide linked active Î±âÎ² heterodimer HGF. Three serine proteases contribute to the activation of pro-HGF: the soluble HGF activator and the membrane-bound matriptase and hepsin found on MET-expressing cells. Activation of HGF is further balanced by the expression of HGF activator inhibitor 1 (HAI1)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and HGF activator inhibitor 2 (HAI2).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The structure of HGF consists of six domains (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b): the N-terminal domain (N), the four kringle domains (K1âK4) in the Î±-chain, and the serine protease homology domain (SPH) in the Î²-chain. The N and K1 domains in the Î±-chain recognize the Ig3 and Ig4 domains of MET with high affinity that is independent of HGF processing and maturation. Following HGF activation and maturation, the SPH domain in the Î²-chain interacts with the sema domain of MET with low affinity.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.3 HGF/MET Signaling</h3><div class="NLM_p">HGF/MET signaling is important in mediating a wide range of normal physiological activities, e.g., embryological development, wound healing, and tissue regeneration. HGF is secreted from cells of mesenchymal origin, is fully activated on the surface of epithelial cells expressing MET, and acts in a paracrine manner with MET kinase. Upon HGF binding, MET is dimerized and transphosphorylated at two catalytic tyrosine residues (Tyr-1234 and Tyr-1235) in the activation loop (A-loop). This leads to autophosphorylation of Tyr-1349 and Tyr-1356 in the multifunctional docking site at the C-terminus and recruitment of multiple cytoplasmic effectors such as GAB1, GRB2, PLC, and SRC.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> GAB1 is a universal docking protein of MET. The phosphorylated GAB1 bound to MET at the plasma membrane further attracts docking molecules such as SHP2, PI3K, CRKL, and others.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The resulting multiprotein signaling complex activates a series of intracellular downstream signal transduction pathways including the RAS-MAPK cascade, PI3K-AKT axis, and signal transducer and activator of transcription proteins (STATs) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. HGF/MET signaling.<a onclick="showRef(event, 'cit22b'); return false;" href="javascript:void(0);" class="ref cit22b">(22b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">HGF/MET signaling is regulated tightly under normal physiological conditions. MET expression at the cell surface is finely controlled by extracellular shedding, intracellular cleavage, and ubiquitin-mediated degradation. Similar to other RTKs, HGF-activated MET is internalized through endocytosis.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The internalized MET, still capable of signaling, is delivered to endosomal and lysosomal compartments and then either degraded or recycled to the plasma membrane.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The phosphorylated Tyr-1003 residue within the juxtamembrane domain of MET is recognized by the ubiquitin E3 ligase CBL, causing monoubiquitylation at multiple sites of MET. This leads to the delivery of activated MET to the endosomal network and to accumulation on the limiting and internal membranes of multivesicular bodies. The fusion of multivesicular bodies with the lysosomes causes the activated MET to undergo proteolytic degradation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Another mechanism of down-regulation of MET expression is ligand- and ubiquitin-independent proteolytic cleavages. The shedding of the MET extracellular domain via ADAM metalloproteases releases a soluble decoy MET fragment, leaving behind a membrane-anchored cytoplasmic tail that then undergoes intracellular proteolysis by Î³-secretase to release a labile intracellular fragment, followed by further rapid proteasome-mediated degradation.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The decoy MET fragment interacts with both HGF and full-length MET, leading to further inhibition of MET signaling.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.4 Biology and Physiology of MET</h3><div class="NLM_p">High levels of MET have been found in human liver, gastrointestinal tract, and kidney.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Although a high level of MET mRNA has been detected in the thyroid, the protein was barely detectable. MET protein was also detected in the brain.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The tissue distribution of MET in adult rats was studied using <sup>125</sup>I-labeled rat hepatocyte growth factor as a ligand. High affinity binding (<i>K</i><sub>d</sub> of 20â30 pM) of the labeled HGF was found in the plasma membranes of the liver, spleen, kidney, lung, adrenal gland, pituitary glands, and the thyroid.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The maximum number of binding sites was 400â3000 sites per nanogram of plasma membrane protein of rat, and the liver had the highest number.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The broad distribution of MET in several rat organs, and not only in the liver, implies an important role for HGF/MET signaling in growth control of epithelial cells in tissues other than hepatocytes.</div><div class="NLM_p">The physiological functions of HGF/MET signaling have been elucidated with genetic studies in mice. HGF/MET signaling is essential for the growth and survival of hepatocytes and placental trophoblast cells during development. In <i>HGF</i>- and <i>MET</i>-null mutant embryos, the liver size is reduced significantly,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and the labyrinthine trophoblast cells are also markedly reduced, leading to severely impaired placentas and prenatal death.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Ablation of the <i>HGF</i> or <i>MET</i> gene results in a complete absence of muscle groups in the mouse embryo, indicating the decisive role of HGF/MET signaling in the control of migration and growth of muscle precursor cells and the generation of skeletal muscle.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In the embryo, myogenic progenitor cells are released from the epithelial dermomyotome in a MET- and GAB1-dependent manner. HGF/MET signaling controls the epithelial-to-mesenchymal transition (EMT) of these epithelial dermomyotome cells and drives their migration over long distances in embryo.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In addition, HGF/MET signaling is required for sensory nerve development, axonal growth, and survival of sensory neurons.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The signal transduction adaptor GAB1 plays an essential role in MET-based signal transduction pathway. The <i>GAB1</i>-null mice have similar phenotypes to <i>HGF</i> and <i>MET</i> knockout embryos, and the mechanism of recruitment of GAB1 to MET is tissue-specific for different biological outcomes in vivo.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p last">HGF/MET signaling plays an important role in branching morphogenesis, also known as invasive growth, of epithelial cells. The complex morphogenetic program includes cell spreading, cellâcell dissociation, acquisition of a motile phenotype, migration, settling in a new environment, proliferation, and generation of a new pseudopodium structure.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The role of HGF/MET signaling in organ regeneration has been studied both in vitro with morphogenetic assays under three-dimensional culture conditions and in vivo with conditional deletion of MET in selected tissues. Although hepatocyte-specific loss of MET appeared not to be detrimental to hepatocyte function under physiological conditions, the adaptive responses of the liver to injury were dramatically affected.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> HGF/MET is activated in hepatocytes for DNA synthesis and cytokine production shortly after partial hepatectomy, indicating the important role of HGF/MET in liver regeneration.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> HGF/MET displays a similar protective activity in the kidney by inducing intense proliferative and antiapoptotic responses in renal epithelial cells to prevent acute renal failure because of tubular necrosis and accelerating kidney regeneration.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In skin, it is shown both in vitro and in vivo that MET is essential for wound repair.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Overall, HGF/MET signaling mediates invasive growth and plays important roles in embryonic development and organ formation. In adults, MET-mediated invasive growth becomes quiescent; however, it can be reactivated during wound healing and organ damage to expand and migrate residual cells to the injured tissues.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">3 MET and Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sustaining proliferative signaling, evading growth suppression, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis are the well-established hallmarks of cancer.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Reprogramming of energy metabolism, evading immune destruction, and recruitment of the tumor microenvironment are emerging as additional hallmarks of cancer.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Receptor tyrosine kinases are the main mediators of the signaling network that transmit extracellular signals into the cell and control many fundamental cell functions. Dysregulation of RTK activities is pivotal to tumorigenesis and cancer progression, which is underscored by the success of anti-RTK drugs, such as trastuzumab, gefitinib, and crizotinib.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.1 Up-Regulation of HGF/MET Signaling in Cancers</h3><div class="NLM_p">Cancer cells often hijack the signaling pathways and the genetic programs that orchestrate embryonic development and tissue morphogenesis for the neoplastic dissemination of tumors.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The HGF/MET signaling pathway is important in mediating a wide range of biological activities via a complex biological program called âinvasive growthâ.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Under normal physiological conditions, HGF/MET signaling is tightly controlled by ligand activation at the cell surface, ligand-activated receptor internalization/degradation, and paracrine ligand delivery. Aberrant MET activation is reported in almost all of human malignancies and is often caused by receptor overexpression, gene amplification, gene translocation, gain-of-function mutations, and autocrine or paracrine activation.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> MET activation can cause tumor cells to grow, dissociate from their neighbors, leave their original environment by degrading the basement membrane, reach the circulation, survive in the bloodstream, extravasate, and eventually colonize new sites.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">HGF and/or MET are expressed at abnormally high level in neoplastic tissue compared with normal surrounding tissue, especially in the invasive front.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> Overexpression of MET frequently results from transcriptional up-regulation in the absence of gene aberrations. Hypoxia is a characteristic of cancer, especially late stage cancer. It has been demonstrated that hypoxia promotes tumor invasion by sensitizing cells to HGF stimulation and activating transcription of the <i>MET</i> protooncogene to produce higher levels of MET.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Inhibition of MET expression prevents hypoxia-induced invasive growth. Receptor tyrosine kinases have a crucial role in establishing highly choreographed patterns of cellular organization, proliferation, and movement during development and tissue homeostasis.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Spatial dysregulation of RTKs is likely to contribute broadly to cancer development and may affect the sensitivity and resistance of cancer to pharmacological RTK inhibitors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Therefore, MET overexpression can be oncogenic and essential for the maintenance of the cancer phenotype. Overexpression of MET <i>can convert</i> primary human osteoblasts into osteosarcoma cells with the transformed phenotype in vitro and with the distinguishing features of human osteosarcomas in vivo.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p"><i>MET</i> amplification has been reported in different human cancers including gastresophageal carcinomas,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> colorectal cancers,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> NSCLC,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> medulloblastomas,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and glioblastomas.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> An increased <i>MET</i> gene copy number is an independent negative prognostic factor and is associated with aggressiveness and metastasis of cancers.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57, 58)</a> Although MET activation has primarily been linked with tumor cell migration and invasiveness, <i>MET</i> gene amplification causes protein overexpression and constitutive activation of the kinase domain that is required for cell survival.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div class="NLM_p">A diverse set of both germline and somatic <i>MET</i> mutations in the tyrosine kinase domain (21 mutations), juxtamembrane domain (5 mutations), and extracellular domain (16 mutations) have been described in many solid tumors, including hereditary and sporadic human papillary renal carcinomas, lung cancer, ovarian cancer, childhood hepatocellular carcinomas, squamous cell carcinoma of the head and neck, and gastric cancer.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60, 61)</a> Even though next generation sequencing technology is accelerating the discovery of sequence variants, understanding the impact of specific <i>MET</i> mutations on tumorigenesis and tumor development at the molecular, cellular, and organismal levels remains a major challenge. Activating mutations of MET in the tyrosine kinase domain have been identified in both hereditary and sporadic forms of papillary renal carcinoma (PRC)<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and exhibit distinct biological effects. For example, D1228H/N and M1250T mutants showed enhanced kinase activity followed by RAS pathway activation and focus formation, while L1195V and Y1230C mutants activated PI3K more effectively to promote cell survival, soft agar colony formation, and matrix invasion.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Mutations of RTKs often result in increased kinase activity and transforming potential. However, the requirement of the mutated RTKs for the transformation process may vary. The transforming ability of <i>MET</i> mutations in papillary renal carcinoma has been investigated in genetically engineered mice.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Mice harboring D1226N, Y1228C, and M1248T/L1193V mutations developed sarcomas with high frequency and some lymphomas, whereas the M1248T mice developed carcinomas and lymphomas. The MET-activating point mutation Y1253D in patients with advanced squamous cell carcinoma of the head and neck (HNSCC) was associated with distant metastasis-free survival.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> These studies illustrate the importance of activating MET mutations in tumorigenesis, and the mutations within the kinase domain distinctly affect downstream signaling. Some cell lines with point mutations resulting in MET kinase activation are also sensitive and dependent on the presence of HGF for ligand-induced receptor dimerization.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> It remains challenging to distinguish âaddictiveâ oncogenic mutations from âpassengerâ mutations. In lung cancer, the mutations of MET were predominantly present in the extracellular sema domain and intracellular juxtamembrane domain. It is MET and/or HGF overexpression, but not MET mutations, which correlate with progression of non-small-cell lung cancer.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> The JM domain regulates ligand-dependent MET internalization via phosphorylation of Y1003 to recruit c-CBL, leading to MET ubiquitination and degradation. Mutations of the <i>MET</i> JM domain, e.g., deletion of exon 14, may prevent MET degradation and result in persistent HGF-stimulated signaling that leads to increased transforming activity and tumorigenic potential.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Overall, MET mutations occur at a lower frequency than other mechanisms of pathway activation, like overexpression, and the mutationâs oncogenic potential for proliferation, survival, invasive growth, and metastasis requires further investigation to guide clinical interventions.</div><div class="NLM_p last">Autocrine or paracrine stimulation is one of mechanisms for aberrant MET activation. MET autocrine activation has been shown to play a causal role in the development of malignant melanoma and acquisition of the metastatic phenotype.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> For glioblastoma (GBM), HGF autocrine expression correlated with MET phosphorylation levels in HGF autocrine cell lines and showed high sensitivity to MET inhibition in vivo, while an HGF paracrine environment could enhance glioblastoma growth in vivo but did not demonstrate sensitivity to MET inhibition.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> HGF autocrine GBM tumors with constitutively activated MET could serve as a biomarker for GBM patients who would benefit from MET inhibitor therapy.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The aberrant expression of HGF is a crucial element in acute myeloid leukemia (AML) pathogenesis that leads to autocrine activation of MET in nearly half of the AML cell lines and clinical samples.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Although MET is normally expressed on cells of epithelial origin, the MET protein was immunohistochemically detected in myofibroblasts in the invasive area for 53% of the lung adenocarcinomas investigated.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> A significant relationship between myofibroblast MET expression and shortened patient survival was observed, suggesting that the autocrine activation loop of HGF/MET in cancer-stromal myofibroblasts may play a role in invasion and metastasis of lung adenocarcinoma.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.2 MET and Anticancer Therapy Resistance</h3><div class="NLM_p">Emerging evidence indicates the important roles of HGF/MET signaling in mediating primary and secondary resistance to cancer therapies. Cancer therapies that deprive tumors of oxygen (e.g., antiangiogenic therapies) can be very effective at reducing tumor burden initially, but this can also cause further tumor hypoxia, leading to diminished therapeutic response and malignant progression, such as regional spread and distant metastases that escape the oxygen-deficient environment and establish new (and more aggressive) clones.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> As described previously, HGF/MET signaling plays important roles in embryonic development. During early pregnancy, the invasion of trophoblast cells in a relatively low-oxygen environment into the deciduas of the uterus is stimulated by the up-regulation of MET that is directly induced by hypoxia-inducible factor 1 (HIF-1) Î±.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The transcription factor HIF-1Î± is a major regulator of tumor cell adaptation to hypoxic stress. MET is up-regulated by HIF-1Î± in a hypoxic environment and is associated with advanced cancer and metastasis. MET up-regulation has been associated with resistance to various cancer treatments including radiation, chemotherapies, and kinase targeted therapies.</div><div class="NLM_p">Because its location can be carefully controlled, radiotherapy is one of the most effective and least toxic treatments for many solid tumors. However, some of tumor cells become resistant to radiation and cause relapse and systemic dissemination of disease through induction of the epithelialâmesenchymal transition.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Elevation of MET expression after radiotherapy has been noted in various tumors and is known to contribute to treatment resistance.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> MET expression has been shown to increase up to 5-fold after radiation treatment, and tumor cells that survived irradiation subsequently became more invasive. MET inhibition counteracted this increased invasiveness and promoted apoptotic death of tumor cells.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> MET expression was reported to be correlated to the resistance of oropharyngeal cancer to ionizing radiation and inversely correlated with failure-free survival.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> As a prognostic marker, high levels of MET expression predicted poor 5-year overall survival rates for patients with nasopharyngeal carcinoma treated with radiotherapy.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p">Cytotoxic chemotherapy was the dominant cancer treatment paradigm in the 1970s and 1980s and is used as first-line treatment against many different forms of cancer even today. The relative sensitivity of neoplastic cells to DNA damaging agents varies and changes over the course of cancer therapy. Several distinct molecular mechanisms have been reported to be involved with chemoresistance, including drug efflux by ATP binding cassette (ABC) transporters, increased DNA repair, dysregulation of the apoptotic machinery, enhanced cytoplasmic inactivation of drug metabolites, and overexpression of oncogenes or down-regulation of tumor suppressor genes. A growing body of evidence has linked HGF/MET signaling with resistance to DNA-damaging agents. For example, HGF protects Burkittâs lymphoma cell lines which express MET from death induced by DNA damaging agents commonly used in tumor therapy.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The mechanism is associated with the inhibition of doxorubicin- and etoposide-induced suppression of the antiapoptotic proteins Bcl-X(L). Pretreating U373 human glioblastoma cells with recombinant HGF partially abrogated their cytotoxic responses to Î³ irradiation, cisplatin, camptothecin, adriamycin, and paclitaxel in vitro because MET receptor activation led to activation of the PI3K- and AKT-dependent antiapoptotic pathways.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Ovarian cancer is one of the most aggressive female reproductive tract tumors, and paclitaxel is widely used for its treatment. It was found that lower levels of miR31 and higher expression of MET in human ovarian cancer specimens were significantly correlated with paclitaxel chemoresistance and poor prognosis.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> MiR31 was found to bind to the 3â²-UTR of mRNA of MET to regulate MET expression. This miR31-dependent regulation of MET for chemoresistance of ovarian cancer raises the possibility that combination therapy of paclitaxel with a MET inhibitor will increase paclitaxel efficacy.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Ovarian cancer cells were shown to acquire a remarkable resistance to anoikis and apoptosis after exposure to clinically relevant doses of two front-line chemotherapeutic drugs, cisplatin and paclitaxel, when grown in three-dimensional cultures.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Inhibition of MET blocked the acquired anoikis resistance and restored the chemosensitivity.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> MET is also characterized as a marker of pancreatic cancer stem cells (CSC), playing a key role in metastasis and chemoresistance in the most lethal pancreatic ductal adenocarcinoma (PDAC).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> The MET inhibitor crizotinib synergistically enhanced the antiproliferative and proapoptotic activity of gemcitabine against PDAC cells, including gemcitabine-resistant capan-1 cells.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">Molecularly targeted therapies with genomically defined targets in human tumors have produced remarkable clinical responses in genomically stratified patient populations, even in those with advanced diseases. However, acquired resistance to such treatments in virtually all cases overshadows the success of targeted therapy. The clinical implementation of cancer genome sequencing is leading to a deeper understanding of the genetic basis of acquired drug resistance. The mechanism of drug resistance can be either intrinsic (altering the original target) or extrinsic (compensatory signaling through other pathways).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Common intrinsic resistance mechanisms to abrogate the effectiveness of kinase inhibitor drugs include target gene amplification and the development of secondary mutations.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> In extrinsic resistance, cancer cells respond to chronic drug treatment by adapting their signaling circuitry, taking advantage of pathway redundancy and routes of feedback and cross-talk to maintain their function and eventually develop drug resistance.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Up-regulation of HGF/MET signaling has been frequently reported as a compensatory signaling pathway that confers resistance to kinase targeted therapies. MET amplification has been detected in 4â20% of NSCLC patients with the EGFR mutations who acquired resistance to gefitinib or erlotinib treatment.<a onclick="showRef(event, 'ref8 ref87'); return false;" href="javascript:void(0);" class="ref ref8 ref87">(8, 87)</a> The resistance mechanism is associated with the activation of ERBB3/PI3K/AKT signaling. Analysis of lung cancer patients and cell lines using the high-throughput FISH method indicated that before exposure to EGFR inhibitor drugs, the subpopulation of cells with MET gene amplification was less than 1% of the entire population and that clonal selection of cells with pre-existing MET gene amplification occurs during treatment with the drugs, conferring resistance.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Up-regulation of ligand HGF represents another mechanism of EGFR-TKI resistance. High HGF expression was discovered among clinical specimens with acquired resistance that did not have a T790M mutation or MET amplification, as well as among cases that exhibited primary resistance despite having EGFR-TKI sensitive activating EGFR gene mutations.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> HGF mediates EGFR TKI resistance in a distinct mechanism by rescuing both PI3K/AKT and ERK signaling through the signaling adaptor GAB1.<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88, 89)</a> In addition, HGF accelerates MET amplification in HCC827 cells both in vitro and in vivo in the presence of EGFR inhibition.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> EGFR-targeted monoclonal antibodies cetuximab and panitumumab are an effective treatment for KRAS wild type colon cancer, which develop drug resistance through emergence of KRAS mutations in approximately 50% of the cases.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Amplification of <i>MET</i> is associated with acquired resistance to cetuximab or panitumumab in metastatic colorectal cancer patients who do not develop KRAS mutations during anti-EGFR therapy.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> In addition, patient-derived xenografts demonstrated that <i>MET</i> amplification plays an important role in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer. Growth-factor-driven resistance from the tumor microenvironment represents a potential common mechanism for reducing the efficacy of anticancer kinase inhibitors.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> HGF is present in stromal cells of melanoma patients and correlates with a poor response to treatment with the BRAF inhibitor vemurafenib. The up-regulation of stromal HGF also confers resistance to the BRAF inhibitor ramurafenib in BRAF mutant melanoma cells.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">Coactivation of HGF and/or MET with other protein kinases has been reported in many cancers and may represent innate or intrinsic resistance to cancer therapies. Kentsis et al. used a loss-of-function RNA interference genomic screen on AML cell lines and on clinical samples to identify aberrant expression of HGF as a crucial element in AML pathogenesis, and the autocrine activation of MET occurred in nearly half of the studies.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Treatment of the leukemic cells having aberrant HGF expression and MET activation with crizotinib led to acquired resistance in a short period of time because compensatory up-regulation of HGF expression allowed restoration of MET signaling. It was discovered that FGFR1 activity was required for compensatory up-regulation of HGF in response to MET inhibition in KG-1 cells bearing <i>FOP2-FGFR1</i> chromosomal translocation. The combination of crizotinib with the FGFR1 inhibitor <i>N</i>-[2-[[4-(diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-<i>d</i>]pyrimidin-7-yl]-<i>N</i>â²-(1,1-dimethylethyl)urea (PD-173074)<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> led to sustained inhibition of MET phosphorylation in KG-1 cells and to near-complete regression of AML in vivo, whereas crizotinib or the FGFR1 inhibitor as single agents only produced very moderate inhibitory effects. The simultaneous blockade of MET activation with crizotinib and of compensatory HGF up-regulation with the FGFR1 inhibitor generates highly synergistic efficacy both in vitro and in xenograft models in vivo.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Clearly, blocking adaptive cellular responses that drive compensatory ligand expression is necessary to achieve optimal and sustained antitumor effects. Trastuzumab is an effective treatment for ERBB2 positive breast cancer patients. However, near half of the breast cancer patients that overexpress ERBB2 are either nonresponsive to trastuzumab or develop resistance. Paulson et al. reported that MET and ERBB2 are coexpressed in ERBB2<sup>+</sup> breast cancers and contribute to innate resistance to trastuzumab treatment.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> A significant percentage (45%) of tumors coexpress MET and ERBB2 in ERBB2<sup>+</sup> breast cancers. MET depletion resulted in increased ERBB2 activation, and conversely ERBB2 depletion resulted in increased MET activation. Activation of EGFR and ERBB3 was not observed after MET or ERBB2 depletion.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> These studies have significant clinical implications on potential combination strategies for ERBB2<sup>+</sup> breast cancer patients with high MET expression.</div><div class="NLM_p last">Harbinski et al. reported a high-throughput platform for systematically screening a cDNA library encoding 3432 secreted proteins in cellular assays for the potential RTKs to compensate in driving cancer growth.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Ligand-mediated activation of alternative receptor tyrosine kinases was observed in cancer cells originally dependent on MET, FGFR2, or FGFR3. The studies indicated a broad and versatile potential for RTKs from the HER and FGFR families as well as MET to compensate for loss of each other and indicate that combined inhibition of simultaneously active RTKs can lead to an added anticancer effect.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">4 Protein Structure of the Unphosphorylated MET Kinase Domain</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">MET is a receptor tyrosine kinase with activity that is highly dependent on the phosphorylation state of its catalytic domain. Autophosphorylation of the catalytic domain proceeds through sequential phosphorylation events on the activation loop at Tyr-1235 and then Tyr-1234, leading to a large enhancement in catalytic power (<i>k</i><sub>cat</sub>/<i>K</i><sub>m</sub> = 425â000 s<sup>â1</sup> M<sup>â1</sup>).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> The <i>K</i><sub>m</sub> of ATP for the activated MET was 36 Î¼M for the immunoprecipitated MET from cells and 70.4 Î¼M for the recombinantly expressed cytoplasmic domain of MET.<a onclick="showRef(event, 'cit94a'); return false;" href="javascript:void(0);" class="ref cit94a">(94a)</a> MET variants with activating mutations have been shown to autophosphorylate faster than the wild type and to achieve the same maximum activity because the second autophosphorylation at Tyr-1234 is no longer required for the full activation of mutant MET, suggesting a lower threshold for kinase activation than wild-type MET.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> The increased autophosphorylation rate is based on the enhancement in <i>k</i><sub>cat</sub>, but not <i>K</i><sub>m</sub> for any substrate, which indicates that the effects are not substrate-specific.<a onclick="showRef(event, 'cit94a'); return false;" href="javascript:void(0);" class="ref cit94a">(94a)</a> Therefore, the mutant MET provides an oncogenic predisposition, and sustained ligand stimulation or receptor overexpression is required to achieve a fully transformed phenotype.<a onclick="showRef(event, 'cit94b'); return false;" href="javascript:void(0);" class="ref cit94b">(94b)</a></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. apo-MET crystal structures: (A) PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W">1R1W</a> and (B) PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G15">2G15</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The crystal structure of the unphosphoryalted MET kinase domain was solved by two groups using different protein constructs (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95, 96)</a> In general, the MET kinase domain follows the canonical bilobal protein kinase architecture with an N-terminal, mainly Î²-sheet-containing domain linked through a hinge segment to the mainly Î±-helical C lobe. Schiering et al. reported a unique autoinhibitory conformation of the MET kinase domain using the unphosphorylated but enzymatically active Y1194F, Y1234F, and Y1235D mutant construct (1049â1360) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W">1R1W</a>).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The mutant construct was designed to mimic the negative charge of the Y1235 phosphotyrosine. Indeed, the specific activity of the mutated protein was found to be comparable to that of the wild-type MET using gastrin as substrate, indicating that the mutant construct is able to adopt an active A-loop conformation. However, an inactive kinase conformation was observed in the apo-MET crystal structure that shares certain similarity with the inactive conformation of unphosphorylated insulin receptor kinase (IRK).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The salt bridge between residues Lys-1110 and Glu-1127 typically observed in the active kinase conformation is not present. Similar to IRK, an inactive A-loop conformation (magenta color in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A) is observed with the segment blocking peptide substrate binding. The segment 1223â1226 at the N terminus of the A-loop forms a unique type IIâ² Î²-turn to bulge up to the N lobe that constrains the Î±-C helix in an inactive orientation that does not allow proper catalytic positioning of Glu-1127, and residues 1228â1230 are in a position that would interfere with nucleotide binding. The unique bulged conformation of the A-loop of the unphosphorylated apo-MET kinase domain is consistent with the reported structure of the wild-type, unphosphorylated MET in complex with an oxindole inhibitor bound in the ATP cleft in a patent application,<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> indicating that this conformation is a unique structural feature of MET and could be used for the design of selective MET inhibitors.</div><div class="NLM_p last">Wang et al. reported a crystal structure of the apo-MET tyrosine kinase domain at 2.15 Ã resolution using the wild-type, unphosphorylated protein produced in bacteria by PTP coexpression (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B),<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> which is dramatically different from the mutant MET structure A reported by Schiering et al. The unique type IIâ² Î²-turn bulge at the N-terminus of the A-loop is consistent in both structures. However, the subsequent structures of the activation loop and the whole P-loop differ significantly. In the apo-MET structure B, the A-loop forms a series of autoinhibitory interactions with the P-loop, with the Î±-C helix, and with itself. Met-1229, a point of divergence between the A-loops in the two crystal structures, here projects into the ATP-binding pocket and is sandwiched between the P-loop residue, Phe-1089, and the side chain of Lys-1110, which pushes away the P-loop compared to the apo-MET structure A. The P-loop conformation is further stabilized through interactions with Tyr-1230 and Lys-1232, as the activation loop turns in the direction of the Î±-C helix and then traverses to the lower lobe. Tyr-1234 and Tyr-1235, the two phosphorylation sites at the A-loop required for MET activation, project in opposite directions, with Tyr-1234 pointing inward and forming a hydrogen bond with catalytic residue, Glu-1127, and with Tyr-1235 pointing to solvent.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">5 MET Small Molecule Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41156" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41156" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pharmaceutical strategies to regulate the HGF/MET pathway include HGF antagonists (NK2 and NK4), anti-HGF antibodies, anti-MET monoclonal antibodies, and MET small molecule inhibitors. Several classes of small molecule MET inhibitors with different binding modes and selectivity profiles have been discovered and progressed to clinical development. In this section, MET small molecule inhibitors are grouped into four classes (classes Ia, Ib, II, and other) according to their binding mode with MET.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">5.1 Class Ia of Selective MET Inhibitors</h3><div class="NLM_p">Small molecule MET inhibitors are categorized as class Ia (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>) if they are type I kinase inhibitors with a U-shaped binding mode at the ATP binding site. In general, class Ia MET inhibitors exhibit relatively good cellular selectivity profiles with a limited number of off-target kinase hits. Crizotinib (<b>3</b>), a prototype compound of class Ia, is a multitargeted kinase inhibitor of MET, ALK, ROS1, and RON.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The U.S. Food and Drug Administration granted fast-track approval of crizotinib in August 26, 2011, and full approval in November 20, 2013, based on the marked efficacy by patients with ALK-positive advanced NSCLC and its good safety profile.</div><figure id="cht2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Class Ia of Selective MET Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">3-Substituted indolin-2-ones were discovered as a class of potent kinase inhibitors with a representative drug sunitinib approved for GIST and RCC treatment.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> The selectivity of indolin-2-ones against particular kinases is mediated by substituents on the indolin-2-one core. 4-Substituted indolin-2-ones<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> and 5-substituted indolin-2-ones<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> were explored for MET inhibition leading to the discovery of <b>1</b> (SU11274) with an enzymatic IC<sub>50</sub> of 10 nM against MET and a complete inhibition of HGF-induced MET autophosphorylation at 1 Î¼M.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Compound <b>1</b> was an important tool in late 1990s to validate MET biology and establish assays to measure inhibition of a variety of HGF/MET-dependent cellular processes, including cell proliferation, motility, invasion, and morphogenesis.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Structural modifications of <b>1</b> led to the discovery of <b>2</b> (PHA-665752), a selective MET inhibitor with significantly improved cellular potency (IC<sub>50</sub> = 9 nM in GTL16 cell line) and selectivity (>50-fold for MET compared to a panel of diverse tyrosine and serine/threonine kinases).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Studies of <b>2</b> in vitro showed it potently inhibited MET phosphorylation, in either HGF-stimulated or constitutively activated MET cell lines. It also inhibited downstream signal transduction of MET and development of HGF/MET driven phenotypes (e.g., cell growth, cell motility, invasion, and morphology) in a variety of tumor cells.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p">The MET kinase domain has unique structural features that can be used for the design of selective MET kinase inhibitors. The cocrystal structure of <b>2</b> bound to the unphosphorylated MET KD revealed unique binding interactions (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WKM">2WKM</a>).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> In the complex with <b>2</b>, the MET KD adopts the same autoinhibitory conformation observed previously in the crystal structures of the apo-enzyme and in a complex with the staurosporine analogue K252a.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> In these MET crystal structures, the beginning of the kinase activation loop (residues 1222â1227) forms a turn that wedges between the Î²-sheet and the Î±-C-helix. Consequently, the activation loop significantly displaces the Î±-C-helix from a catalytically competent position and the downstream activation loop residues (1228â1245) occupy a position that interferes with ATP and substrate binding. This unusual kinase activation loop conformation creates a unique inhibitor binding pocket that presents an opportunity for the design of selective inhibitors. Furthermore, the binding conformation of <b>2</b> in the MET KD is surprising. Instead of passing through the gatekeeper to the hydrophobic back pocket, the benzylsulfonyl group folded over to interact with Tyr-1230. This rationalizes the dramatic improvement in cellular potency when the <i>N</i>-methylsulfonamide linker in <b>1</b> was replaced with a more flexible methylenesulfonyl linker in <b>2</b>. To make space for the benzyl group, the plane of the oxindolepyrrole system in <b>2</b> is tilted away from the MET P-loop significantly (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). This lower inhibitor position in MET is permitted by the flexible (and compressed) Met-1211 and is stabilized by the critical ÏâÏ stacking interaction between the inhibitor benzyl group and the Tyr-1230 of the A-loop. A hydrogen bond between the oxygen of the sulfonyl group and the backbone NâH of Asp-1222 is also stabilizing this orientation. Although <b>2</b> demonstrated potent and selective inhibition of MET autophosphorylation and related biological functions in both in vitro and in vivo studies, its poor pharmaceutical properties (low solubility, high metabolic clearance, and poor permeability) limited its further development for human clinical studies.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of <b>2</b> bound to the kinase domain of unphosphorylated MET. The backbone trace of the activation loop is highlighted in cyan and hydrogen bonds are indicated as dashed lines (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WKM">2WKM</a>).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the unique crystal structures of apo-MET and the MET complex with <b>2</b>, a 2-amino-5-aryl-3-benzyloxypyridine series was designed for more efficient interaction with unphosphorylated MET KD. The monoaromatic 2-aminopyridine was designed to replace the indolin-2-one of <b>2</b> as a hinge binder and to allow the flexible 3-benzyloxy group to reach the same hydrophobic pocket occupied by the 2,6-dichlorophenyl group in <b>2</b> but from a more direct angle that required less molecular weight and conformational constraint. Lead optimization of the 2-amino-5-aryl-3-benzyloxypyridine series generated clinical candidate <b>3</b> (PF-02341066), which is a selective inhibitor of MET, ALK, ROS1, and RON at the cellular level.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Compound <b>3</b> potently inhibited MET phosphorylation and MET-dependent proliferation, migration, and invasion of human tumor cells in vitro (IC<sub>50</sub> values of 5â20 nM) and demonstrated dose-dependent antitumor efficacy, including cytoreductive antitumor activity at well tolerated dose levels in several tumor models that express activating MET. The cocrystal structure of the unphosphorylated MET KD with <b>3</b> demonstrated a similar binding environment as <b>2</b>, and the 2,6-dichloro-3-fluorophenyl group of <b>3</b> reached the same position as the 2,6-dichlorophenyl group of <b>2</b> to form the key ÏâÏ stacking interaction with Tyr-1230 in A-loop (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of <b>2</b> and <b>3</b> bound to MET (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WKM">2WKM</a>, cyan colore, and PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WGJ">2WGJ</a>, gray colore).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, compound <b>3</b> inhibited tumor cell growth in cell lines harboring fusion variants or activating mutations of ALK, including Karpas 299 (NPM-ALK), SU-DHL-1 (NPM-ALK), Kelly neuroblastoma (activating mutation), and NCI-H3122 (EML4-ALK variant 1) with IC<sub>50</sub> values ranging from 74 to 566 nM.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Compound <b>3</b>, later named crizotinib, was given fast track approval by the U.S. Food and Drug Administration on August 26, 2011, to treat certain patients with late-stage (locally advanced or metastatic), non-small-cell lung cancers who express the abnormal anaplastic lymphoma kinase gene.</div><div class="NLM_p">Several newer class Ia MET inhibitors use the critical <i>R</i>-(2,6-dichloro-3-fluorophenyl)methyl group to capture key interactions with the MET KD (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>). Compound <b>4</b>, the thioether analogue of <b>3</b>, showed reduced potency against MET (enzymatic IC<sub>50</sub> of 7.7 nM and cell proliferation IC<sub>50</sub> of 190 nM in SNU-5 cell line).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Compound <b>5</b>, which has a 1â²-methylspiro[indoline-3,4â²-piperidine]-2-one at the 5-position of the 2-aminopyridine, is a potent, highly selective, well tolerated, and orally efficacious MET (cell IC<sub>50</sub> of 22 nM) and ALK (cell IC<sub>50</sub> of 39 nM) dual inhibitor. Compound <b>5</b> showed pharmacodynamic effects on inhibiting MET phosphorylation in vivo and significant tumor growth inhibition (>50%) in the GTL-16 human gastric carcinoma xenograft models.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Compound <b>6</b> (OSI-296), which has a furo[3,2-<i>c</i>]pyridin-6-ylamine as the kinase hinge binder, is a potent and selective inhibitor of MET (cell IC<sub>50</sub> of 40 nM) and RON (cell IC<sub>50</sub> of 200 nM).<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Compound <b>6</b> shows in vivo efficacy in tumor xenograft models upon oral dosing and is well tolerated.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The cocrystal structure of MET in complex with <b>6</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KNB">4KNB</a>) revealed a similar binding interaction as <b>4</b>. With a quinoline as its kinase hinge binder, <b>7</b> retained the binding characteristics of <b>4</b> with MET KD and had a MET enzymatic potency of 9.3 nM and MKN-45 cell potency of 93 nM.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Compound <b>8</b> (X-376), having the pyridazin-3-ylamine group as a hinge binder and the 6-amide extending to the solvent area, is a more potent ALK inhibitor (cell IC<sub>50</sub> of 77 nM in H3122 cell line) than MET inhibitor (cell IC<sub>50</sub> of 150 nM in MKN-45 cell line).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Compound <b>9</b>, a close analogue of <b>8</b> but having a less lipophilic pyridone hinge binder, inhibited MET with an IC<sub>50</sub> of 12 nM in enzymatic assay and 2200 nM in EBC-1 cell assay.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">The reported enzymatic and primary cell potencies along with the calculated physical properties of class Ia MET inhibitors are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. The ligand efficiency (LE), lipophilic ligand efficiency (LLE), and ligand-efficiency-dependent lipophilicity (LELP) based on the primary cell potency are calculated as comprehensive indices for druglike properties.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Studies on the predictive performance of LLE and LELP with multiple data sets including fragment and HTS hits and leads, development candidates, phase II compounds, and launched drugs indicate that both LLE and LELP correlate significantly with ADME and safety profiles while LELP outperforms LLE in risk assessment.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Wager et al. analyzed 95 CNS drugs, and the median LE, LLE, and LELP values for the drug set were 0.52, 6.3, and 5.9, respectively.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Although it is expected that higher molecular weight and lipophilicity of the kinase drugs on average would generate lower LE and LLE and higher LELP than the average values of CNS drugs, the rank order of LLE and LELP of the inhibitors for a specific kinase target can be used as indices for overall druglike properties. Crizotinib has the highest LLE and the second best LELP among class Ia MET inhibitors, and <b>6</b> with a LELP of 10.5 has higher potential to be successful in clinic trials.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of MET Inhibitors of Class Ia</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">MW</th><th class="colsep0 rowsep0" align="center">cLogPâ<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cLogDâ<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">enzyme <i>K</i><sub>i</sub> or IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">cell IC<sub>50</sub> (nM) (cell line)</th><th class="colsep0 rowsep0" align="center">cell LE<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cell LLE<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">cell LELP<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">status</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></td><td class="colsep0 rowsep0" align="left">568</td><td class="colsep0 rowsep0" align="left">4.43</td><td class="colsep0 rowsep0" align="left">0.859</td><td class="colsep0 rowsep0" align="left">44.5Â (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">132 (A549)</td><td class="colsep0 rowsep0" align="left">0.247</td><td class="colsep0 rowsep0" align="left">6.02</td><td class="colsep0 rowsep0" align="left">17.9</td><td class="colsep0 rowsep0" align="left">discovery</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></td><td class="colsep0 rowsep0" align="left">642</td><td class="colsep0 rowsep0" align="left">5.21</td><td class="colsep0 rowsep0" align="left">2.56</td><td class="colsep0 rowsep0" align="left">2.2 (<i>K</i><sub>i</sub>)</td><td class="colsep0 rowsep0" align="left">7.5 (A549)</td><td class="colsep0 rowsep0" align="left">0.265</td><td class="colsep0 rowsep0" align="left">5.56</td><td class="colsep0 rowsep0" align="left">19.7</td><td class="colsep0 rowsep0" align="left">discovery</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></td><td class="colsep0 rowsep0" align="left">450</td><td class="colsep0 rowsep0" align="left">4.29</td><td class="colsep0 rowsep0" align="left">1.06</td><td class="colsep0 rowsep0" align="left">2.0 (<i>K</i><sub>i</sub>)</td><td class="colsep0 rowsep0" align="left">8.0 (A549)</td><td class="colsep0 rowsep0" align="left">0.378</td><td class="colsep0 rowsep0" align="left">7.03</td><td class="colsep0 rowsep0" align="left">11.4</td><td class="colsep0 rowsep0" align="left">approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b><a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></td><td class="colsep0 rowsep0" align="left">466</td><td class="colsep0 rowsep0" align="left">4.10</td><td class="colsep0 rowsep0" align="left">0.87</td><td class="colsep0 rowsep0" align="left">7.7 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">190 (SNU-5)</td><td class="colsep0 rowsep0" align="left">0.313</td><td class="colsep0 rowsep0" align="left">5.85</td><td class="colsep0 rowsep0" align="left">13.1</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b><a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></td><td class="colsep0 rowsep0" align="left">515</td><td class="colsep0 rowsep0" align="left">5.06</td><td class="colsep0 rowsep0" align="left">1.04</td><td class="colsep0 rowsep0" align="left">1.87 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">22 (MKN45)</td><td class="colsep0 rowsep0" align="left">0.306</td><td class="colsep0 rowsep0" align="left">6.61</td><td class="colsep0 rowsep0" align="left">16.5</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b><a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></td><td class="colsep0 rowsep0" align="left">465</td><td class="colsep0 rowsep0" align="left">3.52</td><td class="colsep0 rowsep0" align="left">4.01</td><td class="colsep0 rowsep0" align="left">26 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">40 (MKN45)</td><td class="colsep0 rowsep0" align="left">0.334</td><td class="colsep0 rowsep0" align="left">3.39</td><td class="colsep0 rowsep0" align="left">10.5</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b><a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></td><td class="colsep0 rowsep0" align="left">419</td><td class="colsep0 rowsep0" align="left">4.86</td><td class="colsep0 rowsep0" align="left">3.98</td><td class="colsep0 rowsep0" align="left">9.2 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">93 (MKN45)</td><td class="colsep0 rowsep0" align="left">0.251</td><td class="colsep0 rowsep0" align="left">3.05</td><td class="colsep0 rowsep0" align="left">19.4</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b><a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></td><td class="colsep0 rowsep0" align="left">519</td><td class="colsep0 rowsep0" align="left">5.41</td><td class="colsep0 rowsep0" align="left">3.47</td><td class="colsep0 rowsep0" align="left">0.69 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">150 (MKN45)</td><td class="colsep0 rowsep0" align="left">0.195</td><td class="colsep0 rowsep0" align="left">3.35</td><td class="colsep0 rowsep0" align="left">27.7</td><td class="colsep0 rowsep0" align="left">discovery</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b><a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></td><td class="colsep0 rowsep0" align="left">519</td><td class="colsep0 rowsep0" align="left">4.31</td><td class="colsep0 rowsep0" align="left">3.50</td><td class="colsep0 rowsep0" align="left">12 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">2200Â (EBC-1)</td><td class="colsep0 rowsep0" align="left">0.162</td><td class="colsep0 rowsep0" align="left">2.15</td><td class="colsep0 rowsep0" align="left">26.7</td><td class="colsep0 rowsep0" align="left">NA</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">cLogP is the calculated logarithm of the partition coefficient in octanol/water using the BioByte program ClogP, version 4.3.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">cLogD is the calculated logarithm of the octanol/water distribution coefficient using ACD pchbat, version 12.1.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Cell LE = â1.4 logÂ IC<sub>50</sub>Â [M]/number of heavy atoms.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Cell LLE = âlogÂ IC<sub>50</sub>Â [M] â cLogD.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Cell LELP = cLogP/LE.</p></div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">5.2 Class Ib of Exquisitely Selective MET Inhibitors</h3><div class="NLM_p">The MET tyrosine kinase possesses a unique autoinhibitory conformation in the kinase domain with a Î²â²-turn at the beginning of the A-loop, and the A-loop could interact with inhibitors directly. Therefore, MET has a more closed and smaller adenine binding site that can be used for the design of specific MET kinase inhibitors with desired druglike properties. Class Ib MET kinase inhibitors capture these unique binding characteristics of the unphosphorylated MET conformation and have exquisitely selective profiles even though they are type I kinase inhibitors with a U-shaped binding mode.</div><figure id="cht3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 3. Discovery of Highly Selective MET Inhibitors<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A unique and highly specific MET inhibitor <b>10</b> (Chart <a class="ref internalNav" href="#cht3" aria-label="3">3</a>) was identified from an HTS campaign of the MET program at Pharmacia.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Optimization of <b>10</b> by Koenig et al. afforded <b>11</b> which has an enzymatic <i>K</i><sub>i</sub> of 1.3 nM and an IC<sub>50</sub> of 7 nM for the inhibition of MET autophosphorylation in A549 cell line, as well as an exquisite kinase selectivity profile.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The cocrystal structure of the unphosphorylated MET kinase domain complexed to <b>11</b> revealed a unique binding mode (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Surprisingly, the oxindole ring is not interacting with the hinge as originally suspected, and instead the phenolic moiety of <b>11</b> functions as the hinge binder with the phenol oxygen forming a hydrogen bond with the NâH of the hinge Met-1160.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Also, a water network links the phenol hydroxyl and Met-1160 carbonyl group. As the molecule makes a turn at the methylene linker, the large coplanar structure of the hydrazideâoxindole allows for strong ÏâÏ interactions with Tyr-1230 at the A-loop. The protein crystal structure of the unphosphorylated MET with <b>11</b> reveals a similar conformation as the unphosphorylated apo-MET (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W">1R1W</a>) and the protein complex with <b>2</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WKM">2WKM</a>). A unique Î²-turn at the beginning of the A-loop is formed, and MET protein adopts an autoinhibitory conformation with the A-loop occupying the binding site for the triphosphate of ATP. The exquisite selectivity profile of <b>11</b> is largely a result of the unique and extensive interactions with the A-loop and fewer interactions with the common and conserved areas in the kinase domain.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal structure of unphosphorylated MET kinase domain with <b>11</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZZE">3ZZE</a>).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the cocrystal structure of MET in the complex with <b>11</b>, Vojkovsky et al. designed the tetracyclic aromatic scaffold, exemplified by <b>12</b>, which proved to be an effective mimic of original oxindole hydrazide series.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Zhang et al. further simplified the nondruglike tetracyclic scaffold down to the bicyclic triazolotriazine scaffold, exemplified by <b>13</b>, which gave better ligand efficiency against MET than the tetracyclic scaffold despite the loss of the hydrogen bond with the carbonyl group of Arg-1208.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> The electron deficiency of the bicyclic aromatic ring governs the strength of the interaction with Tyr-1230 at the A-loop and is a determining factor for the potency and selectivity. Therefore, the triazolopyrazine scaffold, exemplified by <b>14</b>,<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> and the triazolopyridazine scaffold, exemplified by <b>15</b>, are less potent in general.</div><figure id="cht4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 4. Class Ib of the Exquisitely Selective MET Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Discovery of unique and exquisitely selective MET inhibitors at SUGEN enabled identification of a class of highly selective and potent MET inhibitors that have been developed into clinical candidates for cancer therapy. The original phenol hinge binder was successfully replaced with conventional kinase hinge binders, e.g., quinoline. Although it provided the best potency, the triazolotriazine scaffold of <b>13</b> was proved to be metabolically unstable in human hepatocyte assay.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> The less potent but metabolically stable triazolopyrazine and triazolopyridazine scaffolds were optimized to produce <b>16</b> (PF-04217903)<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> and <b>17</b> (PF-04254644).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Both <b>16</b> and <b>17</b> demonstrated potent inhibition of MET in cell assays in vitro and target modulation in vivo, marked tumor growth inhibition in MET-driven tumor models, and good oral pharmacokinetic (PK) properties.<a onclick="showRef(event, 'ref115 ref120'); return false;" href="javascript:void(0);" class="ref ref115 ref120">(115, 120)</a> When screened against a panel of 208 different protein kinases, both <b>16</b> and <b>17</b> exhibited exquisitely selective profiles.<a onclick="showRef(event, 'ref115 ref120'); return false;" href="javascript:void(0);" class="ref ref115 ref120">(115, 120)</a> However, compound <b>17</b> was also found to be a potent phosphodiesterase family inhibitor, which led to a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration in rats.<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121, 122)</a> Thus, compound <b>17</b> was terminated as a preclinical candidate because of its cardiac safety issues and <b>16</b> was forwarded into clinical studies.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> The crystal structure of the unphosphorylated MET kinase domain complexed to <b>16</b> revealed a binding environment very similar to that seen with <b>11</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cocrystal structure of unphosphorylated MET kinase domain with <b>16</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZXZ">3ZXZ</a>).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Hybrid design leading to the discovery of <b>22</b>.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several highly potent and selective MET inhibitors have been reported (Chart <a class="ref internalNav" href="#cht4" aria-label="4">4</a>), including <b>18</b> (JNJ-38877605),<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a><b>19</b> (SGX-523),<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a><b>20</b> (NVP-BUV972),<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a><b>21</b> (INCB-28060 or INC-280),<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a><b>22</b> (AMG-208),<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a><b>23</b>,<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> and <b>24</b>.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The published cocrystal structures of MET in the complexes with <b>19</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DKF">3DKF</a>) and <b>20</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QTI">3QTI</a>) revealed the same binding mode as <b>11</b>, where the ÏâÏ stacking interaction with the A-loop Tyr-1230 is a key driver for the potency and the exquisite kinase selectivity. Albrecht et al. reported an elegant hybrid design of a novel chemical series based on an analogue of a SUGEN patent compound and an Amgen quinoline MET inhibitor, which eventually led to <b>22</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>).<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Although the bicyclic triazolopyridazine heteroaryl group had been preserved for its interaction with Tyr-1230, the connection with quinoline at 4-position and an additional oxygen atom in the linker distinguished <b>22</b> from most of the exquisitely selective MET inhibitors in Chart <a class="ref internalNav" href="#cht4" aria-label="4">4</a>. Boezio et al. further modified this series by replacing the oxygen linkage with NH and replacing the quinoline with [1,5]naphthyridine, thus introducing an intramolecular hydrogen bond to lock the favored conformation, resulting in <b>23</b>. The new naphthyridine series also solved the issue of time dependent inhibition of CYP3A4.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> In <b>24</b>, Bode et al. used a triazolopyridinone interacting with the A-loop Tyr-1230, as opposed to the bicyclic heteroaryl group found in the rest of the class Ib MET inhibitors.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The cocrystal structure of MET complexed to <b>24</b> revealed the conserved MET selective binding mode and demonstrated that the carbonyl group of the triazolopyridinone formed an intramolecular hydrogen bond with the hydrogen of C-5 in quinoline to lock the U-shaped conformation. Meanwhile, the (<i>S</i>)-methyl group extended into a small, lipophilic pocket in MET (defined by the side chains of Val-1092, Leu-1157, Ala-1226, and Lys-1110), boosting potency 10-fold.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The binding mode of <b>25</b> (EMD-1204831) has not been reported, so it was grouped with the class Ib MET inhibitors based on its reported MET-specific selectivity profile.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Overall, the class Ib MET inhibitors demonstrated potent and exquisitely selective inhibition against MET in vitro and in vivo and exhibited excellent pharmaceutical properties associated with marked tumor growth inhibition in animal models. The physical properties and reported potencies of the class Ib MET inhibitors are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> with the calculated LE, LLE, and LELP. The clinical status is based on the public Web site information.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Summary of the Exquisitely Selective MET Inhibitors<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">MW</th><th class="colsep0 rowsep0" align="center">cLogPâ<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cLogDâ<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">enzyme <i>K</i><sub>i</sub> or IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">cell IC<sub>50</sub> (nM) (cell line)</th><th class="colsep0 rowsep0" align="center">cell LE<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cell LLE<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">cell LELP<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">status<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b><a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></td><td class="colsep0 rowsep0" align="left">372</td><td class="colsep0 rowsep0" align="left">0.525</td><td class="colsep0 rowsep0" align="left">1.67</td><td class="colsep0 rowsep0" align="left">5 (<i>K</i><sub>i</sub>)</td><td class="colsep0 rowsep0" align="left">4.0 (A549)</td><td class="colsep0 rowsep0" align="left">0.420</td><td class="colsep0 rowsep0" align="left">6.73</td><td class="colsep0 rowsep0" align="left">1.25</td><td class="colsep0 rowsep0" align="left">phaseÂ IÂ terminated</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b><a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></td><td class="colsep0 rowsep0" align="left">355</td><td class="colsep0 rowsep0" align="left">1.99</td><td class="colsep0 rowsep0" align="left">2.71</td><td class="colsep0 rowsep0" align="left">10.3 (<i>K</i><sub>i</sub>)</td><td class="colsep0 rowsep0" align="left">6.0Â (A549)</td><td class="colsep0 rowsep0" align="left">0.426</td><td class="colsep0 rowsep0" align="left">5.51</td><td class="colsep0 rowsep0" align="left">4.67</td><td class="colsep0 rowsep0" align="left">terminated</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></td><td class="colsep0 rowsep0" align="left">377</td><td class="colsep0 rowsep0" align="left">1.28</td><td class="colsep0 rowsep0" align="left">1.96</td><td class="colsep0 rowsep0" align="left">4.0 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">phase I terminated</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b><a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></td><td class="colsep0 rowsep0" align="left">359</td><td class="colsep0 rowsep0" align="left">2.14</td><td class="colsep0 rowsep0" align="left">3.45</td><td class="colsep0 rowsep0" align="left">2.7 (<i>K</i><sub>i</sub>)</td><td class="colsep0 rowsep0" align="left">12 (A549)</td><td class="colsep0 rowsep0" align="left">0.427</td><td class="colsep0 rowsep0" align="left">4.47</td><td class="colsep0 rowsep0" align="left">5.02</td><td class="colsep0 rowsep0" align="left">phase I terminated</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b><a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></td><td class="colsep0 rowsep0" align="left">340</td><td class="colsep0 rowsep0" align="left">2.42</td><td class="colsep0 rowsep0" align="left">2.74</td><td class="colsep0 rowsep0" align="left">14 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">22 (A549)</td><td class="colsep0 rowsep0" align="left">0.412</td><td class="colsep0 rowsep0" align="left">4.91</td><td class="colsep0 rowsep0" align="left">5.87</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b><a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></td><td class="colsep0 rowsep0" align="left">411</td><td class="colsep0 rowsep0" align="left">2.96</td><td class="colsep0 rowsep0" align="left">2.74</td><td class="colsep0 rowsep0" align="left">0.13Â (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">0.7 (A549)</td><td class="colsep0 rowsep0" align="left">0.413</td><td class="colsep0 rowsep0" align="left">6.41</td><td class="colsep0 rowsep0" align="left">7.16</td><td class="colsep0 rowsep0" align="left">phase I completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b><a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></td><td class="colsep0 rowsep0" align="left">387</td><td class="colsep0 rowsep0" align="left">1.98</td><td class="colsep0 rowsep0" align="left">3.03</td><td class="colsep0 rowsep0" align="left">9 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">46 (PC3)</td><td class="colsep0 rowsep0" align="left">0.354</td><td class="colsep0 rowsep0" align="left">4.31</td><td class="colsep0 rowsep0" align="left">5.59</td><td class="colsep0 rowsep0" align="left">phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b><a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></td><td class="colsep0 rowsep0" align="left">404</td><td class="colsep0 rowsep0" align="left">2.64</td><td class="colsep0 rowsep0" align="left">2.94</td><td class="colsep0 rowsep0" align="left">5 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">3 (PC3)</td><td class="colsep0 rowsep0" align="left">0.411</td><td class="colsep0 rowsep0" align="left">5.58</td><td class="colsep0 rowsep0" align="left">6.42</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b><a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></td><td class="colsep0 rowsep0" align="left">465</td><td class="colsep0 rowsep0" align="left">1.92</td><td class="colsep0 rowsep0" align="left">3.37</td><td class="colsep0 rowsep0" align="left">1 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">2 (PC3)</td><td class="colsep0 rowsep0" align="left">0.369</td><td class="colsep0 rowsep0" align="left">5.33</td><td class="colsep0 rowsep0" align="left">5.20</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b><a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></td><td class="colsep0 rowsep0" align="left">493</td><td class="colsep0 rowsep0" align="left">3.40</td><td class="colsep0 rowsep0" align="left">1.40</td><td class="colsep0 rowsep0" align="left">4 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">6 (A549)</td><td class="colsep0 rowsep0" align="left">0.311</td><td class="colsep0 rowsep0" align="left">6.82</td><td class="colsep0 rowsep0" align="left">10.93</td><td class="colsep0 rowsep0" align="left">phase I</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">cLogP is the calculated logarithm of the partition coefficient in octanol/water using the BioByte program ClogP, version 4.3.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">cLogD is the calculated logarithm of the octanol/water distribution coefficient using ACD pchbat, version 12.1.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Cell LE = â1.4 logÂ IC<sub>50</sub>Â [M]/number of heavy atoms.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Cell LLE = âlogÂ IC<sub>50</sub>Â [M] â cLogD.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">Cell LELP = cLogP/LE.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">NA, not available.</p></div></div></div><div class="NLM_p last">In summary, the exquisitely selective class Ib MET inhibitors demonstrated excellent druglike properties with the average of LLE and LELP aligned with marketed drugs, and <b>16</b> has the lowest LELP. Solubility may be a common issue for the majority of the class Ib MET inhibitors that have two bicyclic aromatic rings plus another heteroaromatic ring in the molecule. Open access to the C-2 position of quinoline may be a risk factor for aldehyde oxidase (AO) catalyzed oxidation of the quinoline ring which can lead to poor human PK and PK variations among patients because of high and variable AO activity in humans.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Compound <b>19</b> was withdrawn from phase I studies because of acute renal failure secondary to crystal nephropathy from insoluble metabolites at levels not seen in preclinical rat or dog toxicology studies.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The formation of crystals both within the renal tubules and within giant cell macrophages was later observed in primate toxicology evaluation. Diamond et al. identified a 2-quinolinone metabolite of <b>19</b>, which was formed by AO oxidation of the quinoline core at C-2 position in human and monkey liver S-9 and to a lesser extent in rat S-9 incubation but absent in the dog.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> This metabolite was found at â¼70-fold greater concentration than the parent <b>19</b> in urine and was markedly less soluble. Although the AO oxidation profiles of the other quinoline MET inhibitors in Chart <a class="ref internalNav" href="#cht4" aria-label="4">4</a> have not been reported, <b>18</b> was terminated early in phase I studies because of increase in serum creatinine levels and minimal PD activity.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Additional human clinical observation will clarify if the renal toxicity observed with <b>18</b> and <b>19</b> is common to this scaffold.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">5.3 Class II of Nonselective MET Inhibitors</h3><div class="NLM_p">The class II MET inhibitors are multitargeted MET inhibitors that pass the gatekeeper and occupy the deep hydrophobic back pocket (Chart <a class="ref internalNav" href="#cht5" aria-label="5">5</a>). A significant movement of the A-loop is required for entering the MET back pocket which is compensated by additional interactions with the hydrophobic back pocket, often leading to compounds with high molecular weights and high lipophilicities.</div><figure id="cht5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 5. Class II of Nonselective MET Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">4-Phenoxyquinolines with additional substituents on the 4-phenyl ring are widely used as kinase inhibitor scaffolds for VEGFRs, PDGFRs, and many other kinases. The first patent application of MET inhibitors based on a 4-phenoxyquinoline/quinazoline template was published in 2003 by Kirin.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a><i>N</i>-[4-[(6,7-Dimethoxy-4-quinolyl)oxy]-3-fluorophenyl]-<i>N</i>â²-(phenylacetyl)thiourea (<b>26</b>) showed potent inhibition of MET phosphorylation (IC<sub>50</sub> of 0.0087 Î¼M) in epidermoid carcinoma cells (A431) stimulated by human recombinant HGF. Compound <b>26</b> inhibited tumor growth by 70% at a dose of 100 mg/kg in nude mice which had been transplanted with U87MG, a human brain tumor cell line.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> In contrast to type II PDGFR and VEGFR2 inhibitors, the acyl thiourea linkage is the key structural motif that allows an additional phenyl group to enter the deep hydrophobic pocket for potent MET inhibition. Many teams from different companies have focused on replacing the chemically unstable acyl thiourea linkage and/or on finding alternative heteroaryl templates to replace the quinoline/quinazoline cores that bind to the kinase hinge region. A number of compounds (Chart <a class="ref internalNav" href="#cht5" aria-label="5">5</a>) have been discovered and taken into human clinical trials. Cabozatinib (<b>27</b>) was granted marketing approval by the U.S. FDA on November 29, 2012, under the name Cometriq for treatment of medullary thyroid cancer.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div><div class="NLM_p">The inactive form of the MET protein has a unique autoinhibitory conformation with a turn at the beginning of the A-loop which will block the inhibitor from entering into the hydrophobic back pocket. Class Ia and class Ib U-shaped MET inhibitors retain or further strengthen this autoinhibitory conformation and thus demonstrate high binding efficiency and a highly selective profile. It is expected that a high energy barrier exists to move the Î²â²-turn at the N-terminus of the A-loop to open the âgateâ to the back pocket. In general, the MET inhibitors in class II (Chart <a class="ref internalNav" href="#cht5" aria-label="5">5</a>) have higher molecular weights than the type II VEGFR inhibitors, low ligand efficiency, and a broad spectrum of kinase acivity. <b>27</b> (XL-184, cabozantinib), which has a novel cyclopropyl-1,1-dicarboxamide linkage instead of the acyl thiourea found in <b>26</b>, is a multitargeted kinase inhibitor with enzymatic activities against VEGFR2 (IC<sub>50</sub> of 0.035 nM), MET (IC<sub>50</sub> of 1.3 nM), RET (IC<sub>50</sub> 4 nM), KIT (IC<sub>50</sub> of 4.6 nM), FLT1/2/3 (IC<sub>50</sub> of 12/11.3/6 nM), TIE-2 (IC<sub>50</sub> of 14.3 nM), and AXL (IC<sub>50</sub> of 7 nM).<a onclick="showRef(event, 'ref136 ref137'); return false;" href="javascript:void(0);" class="ref ref136 ref137">(136, 137)</a> Cabozantinib has relatively weak inhibition against RON (IC<sub>50</sub> of 124 nM) and PDGFR (IC<sub>50</sub> of 234 nM). In cellular assays, cabozantinib inhibits phosphorylation of VEGFR2 and MET, as well as KIT, FLT3, and AXL with IC<sub>50</sub> values of 1.9, 7.8, 5.0, 7.5, and 42 nM, respectively. Cabozantinib inhibits MET and VEGFR2 phosphorylation in tumor models in vivo and demonstrates potent antimetastatic, antitumor, and antiangiogenic activity in preclinical models.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> In an experimental model of metastasis, treatment with cabozantinib did not increase lung tumor burden, which had been observed after treatment with inhibitors of VEGF signaling that do not target MET.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Overall, cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling. Inhibitor <b>28</b> (XL-880, foretinib) has a very similar structure to <b>27</b> except that it has a long morpholinylpropyl group in the solvent-exposed area. Similar to <b>27</b>, <b>28</b> is also a multitargeted kinase inhibitor with enzymatic activities against MET (IC<sub>50</sub> of 0.4 nM), VEGFR2 (IC<sub>50</sub> of 0.86), RON (IC<sub>50</sub> of 3 nM), FLT1/3/4 (IC<sub>50</sub> of 6.8/3.6/2.8 nM), KIT (IC<sub>50</sub> of 6.7 nM), PDGFRÎ±/Î² (IC<sub>50</sub> of 3.6/9.6 nM), and TIE-2 (IC<sub>50</sub> of 1.1 nM).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The cocrystal structure of MET with <b>28</b> shows that the inhibitor is deeply bound in the MET kinase back pocket with the 4-fluorophenylamine motif pushing Phe-1223 out of the active position (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). Compound <b>28</b> inhibits HGF-induced MET phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation in vitro and prevents both HGF-induced responses of tumor cells and HGF/VEGF induced responses of endothelial cells. In addition, <b>28</b> prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions. In vivo, <b>28</b> generates significant dose-dependent inhibition of tumor burden in an experimental model of lung metastasis.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><figure id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Interaction surface of <b>28</b> with MET having DFG out conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8">3LQ8</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similarly, <b>29</b> (E7050, golvatinib) with a 2-aminopyridine hinge binder also inhibits both MET (cell IC<sub>50</sub> of 14 nM) and VEGFR2 (16 nM),<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> whereas <b>30</b> (MGCD-265) has the same acyl thiourea linker as <b>26</b> but a thienopyridine motif as a hinge binder, and it is a multitargeted kinase inhibitor with potent inhibition against MET (enzymatic IC<sub>50</sub> of 1 nM), VEGFR1/2/3 (3/3/4 nM), RON (2 nM), and TIE-2 (7 nM).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Amgen scientists successfully used a pyrazolone amide to replace the acylthiourea linker in <b>26</b> to generate a series of MET inhibitors.<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141, 142)</a> In contrast to typical kinase inhibitors that have a motif in the hydrophobic back pocket to make the protein adopt a DFG-out conformation (such as imatinib bound with ABL and <b>28</b> with MET in Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), the five-member pyrazolone amide delivers the phenyl group into the Ile-1145 pocket while leaving Phe-1223 of the DFG motif in its cognate hydrophobic pocket for MET (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Interestingly, the VEGFR2 protein adopts a DFG-out conformation when complexed to the same molecule, showing the structural diversity in the kinase hydrophobic back pocket.<a onclick="showRef(event, 'cit142a'); return false;" href="javascript:void(0);" class="ref cit142a">(142a)</a> An elegant medicinal chemistry effort aimed at achieving selectivity over the VEGFR family of kinases and removing the reactive aniline metabolite that is present in many class II MET inhibitors led to the discovery of <b>31</b> (AMG-485).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a><b>31</b>, with a <i>tert</i>-butylhydroxyl motif to achieve selectivity over VEGFRs and a 2-aminopyridine group to replace the aniline, demonstrated potent inhibition against MET (<i>K</i><sub>i</sub> of 1.2 nM and cell IC<sub>50</sub> of 60 nM), â¼350-fold selectivity over VEGFR2 in cells, and good pharmacokinetic properties.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> When dosed orally, <b>31</b> significantly inhibited tumor growth in the NIH3T3/TPR-MET and U-87MG xenograft models with no adverse effect on body weight.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> A team at Bristol-Myers Squibb used a six-member pyridonylamide to replace the acylurea linker in <b>26</b> and 3-chloro-2-aminopyridine to replace the quinoline hinge binder and generated the clinical compound <b>32</b> (BMS-777607), a potent and selective kinase inhibitor with biochemical activity against MET (enzyme IC<sub>50</sub> of 3.9 nM), RON (1.8 nM), AXL (1.1 nM), and TYRO3 (4.3 nM).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Moderate selectivity over VEGFR2 (180 nM) is achieved with <b>32</b>. Complete tumor stasis in a MET-dependent GTL-16 human gastric carcinoma xenograft model was observed following oral administration of <b>32</b>. MET adopts a DFG-out conformation in the complex with <b>32</b>, which is similar to the complex of <b>28</b> but distinct from the analogue of <b>31</b>. Inhibitor <b>33</b> (MP470, amuvatinib) is structurally different from most of the MET inhibitors in Chart <a class="ref internalNav" href="#cht5" aria-label="5">5</a>, as it has a piperazinyl ring to deliver the aryl group into the back pocket instead of a phenoxy group.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Compound <b>33</b> is reported to be a multitarget tyrosine kinase inhibitor that has demonstrated in vitro and in vivo activity against multiple validated cancer targets including mutant KIT, mutant PDGFR, mutant FLT3, MET, and RET.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><figure id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Interaction surface of an analogue of <b>31</b> with MET having DFG-in conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3U6I">3U6I</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Summary of Class II Multitargeted MET Inhibitors<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">MW</th><th class="colsep0 rowsep0" align="center">cLogPâ<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cLogDâ<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">enzyme <i>K</i><sub>i</sub> or IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">cell IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">cell LE<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cell LLE<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">cell LELP<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">status<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b><a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></td><td class="colsep0 rowsep0" align="left">492</td><td class="colsep0 rowsep0" align="left">5.19</td><td class="colsep0 rowsep0" align="left">3.89</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">8.7 (A431)</td><td class="colsep0 rowsep0" align="left">0.322</td><td class="colsep0 rowsep0" align="left">4.17</td><td class="colsep0 rowsep0" align="left">16.10</td><td class="colsep0 rowsep0" align="left">patent</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b><a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></td><td class="colsep0 rowsep0" align="left">502</td><td class="colsep0 rowsep0" align="left">4.94</td><td class="colsep0 rowsep0" align="left">3.05</td><td class="colsep0 rowsep0" align="left">1.3 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">7.8 (PC3)</td><td class="colsep0 rowsep0" align="left">0.307</td><td class="colsep0 rowsep0" align="left">5.05</td><td class="colsep0 rowsep0" align="left">16.10</td><td class="colsep0 rowsep0" align="left">approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b><a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></td><td class="colsep0 rowsep0" align="left">615</td><td class="colsep0 rowsep0" align="left">5.37</td><td class="colsep0 rowsep0" align="left">1.90</td><td class="colsep0 rowsep0" align="left">0.4 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">23 (PC3)</td><td class="colsep0 rowsep0" align="left">0.238</td><td class="colsep0 rowsep0" align="left">5.74</td><td class="colsep0 rowsep0" align="left">22.6</td><td class="colsep0 rowsep0" align="left">phaseÂ I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b><a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></td><td class="colsep0 rowsep0" align="left">634</td><td class="colsep0 rowsep0" align="left">1.63</td><td class="colsep0 rowsep0" align="left">0.412</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">14 (MKN45)</td><td class="colsep0 rowsep0" align="left">0.239</td><td class="colsep0 rowsep0" align="left">7.44</td><td class="colsep0 rowsep0" align="left">6.82</td><td class="colsep0 rowsep0" align="left">phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b><a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></td><td class="colsep0 rowsep0" align="left">518</td><td class="colsep0 rowsep0" align="left">5.12</td><td class="colsep0 rowsep0" align="left">2.82</td><td class="colsep0 rowsep0" align="left">1.0 (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">20 (MKN45)</td><td class="colsep0 rowsep0" align="left">0.299</td><td class="colsep0 rowsep0" align="left">6.07</td><td class="colsep0 rowsep0" align="left">17.1</td><td class="colsep0 rowsep0" align="left">phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b><a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></td><td class="colsep0 rowsep0" align="left">540</td><td class="colsep0 rowsep0" align="left">3.04</td><td class="colsep0 rowsep0" align="left">2.88</td><td class="colsep0 rowsep0" align="left">1.2 (<i>K</i><sub>i</sub>)</td><td class="colsep0 rowsep0" align="left">60 (PC3)</td><td class="colsep0 rowsep0" align="left">0.253</td><td class="colsep0 rowsep0" align="left">4.34</td><td class="colsep0 rowsep0" align="left">12.0</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b><a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></td><td class="colsep0 rowsep0" align="left">513</td><td class="colsep0 rowsep0" align="left">4.41</td><td class="colsep0 rowsep0" align="left">2.49</td><td class="colsep0 rowsep0" align="left">3.9Â (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">20Â (GTL-16)</td><td class="colsep0 rowsep0" align="left">0.299</td><td class="colsep0 rowsep0" align="left">5.21</td><td class="colsep0 rowsep0" align="left">14.73</td><td class="colsep0 rowsep0" align="left">phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b><a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></td><td class="colsep0 rowsep0" align="left">448</td><td class="colsep0 rowsep0" align="left">4.43</td><td class="colsep0 rowsep0" align="left">3.84</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">phase I</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">cLogP is the calculated logarithm of the partition coefficient in octanol/water using the BioByte program ClogP, version 4.3.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">cLogD is the calculated logarithm of the octanol/water distributin coefficient using ACD pchbat, version 12.1.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Cell LE = â1.4 logÂ IC<sub>50</sub>Â [M]/number of heavy atoms.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Cell LLE = âlogÂ IC<sub>50</sub>Â [M] â cLogD.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Cell LELP = cLogP/LE.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">NA, not available.</p></div></div></div><div class="NLM_p last">Overall, class II MET inhibitors (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) have the lowest LLE and the highest LELP among the three classes of MET inhibitors, which correlates with more off-target hits, at least in the protein kinase family. The more potent VEGFR activity in some analogues may lead to suboptimal dosing for MET inhibition in clinical applications because of VEGFR-related side effects.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">5.4 Other MET Inhibitors</h3><div class="NLM_p">A novel orally available multitargeted kinase inhibitor, <b>34</b> (MK-2461, Chart <a class="ref internalNav" href="#cht6" aria-label="6">6</a>), inhibits MET (enzyme IC<sub>50</sub> of 2 nM, GTL-16 cell IC<sub>50</sub> of 56 nM) and several other oncology kinase targets, including RON (enzyme IC<sub>50</sub> of 7 nM), FLT1/3/4 (enzyme IC<sub>50</sub> of 10/22/78 nM), MER (enzyme IC<sub>50</sub> of 24 nM), FGFR1/2/3 (enzyme IC<sub>50</sub> of 65/39/50 nM), VEGFR2 (enzyme IC<sub>50</sub> of 44 nM), and TRKA/B (enzyme IC<sub>50</sub> of 46/61 nM).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The cocrystal structure of activated MET in the complex with an analogue of <b>34</b> (which has a 4-piperidine ring on the pyrazole instead of the methyl group of <b>34</b>) shows that the small molecule fully occupies the adenine pocket from the gatekeeper Leu-1157 to the solvent exposed area (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>). The molecule makes a U-turn at the sulfonamide to orient the NâH for a hydrogen bond with the carbonyl of Asp-1222.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The unique A-loop autoinhibitory conformation of the unphosphorylated MET seen in the apo-crystal structure (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) should not prefer the large, conjugated, coplanar structure of <b>34</b>, so it is not surprising that <b>34</b> preferentially binds to active MET (<i>K</i><sub>D</sub> of 4.4 nM) over unphosphorylated MET (<i>K</i><sub>D</sub> of 27.2 nM). Compound <b>34</b> demonstrates different inhibition activities depending upon the autophosphorylation sites of MET. Compound <b>34</b> is substantially more potent against the autophosphorylation of Y1349 (IC<sub>50</sub> of â¼100 nM) and Y1365 (IC<sub>50</sub> of â¼26 nmol/L) in the C-terminal docking site than against the autophosphorylation of the activation loop residues (IC<sub>50</sub> of â¼900 nmol/L and >2 Î¼mol/L as measured by an anti-pMET [Y1234/Y1235] antibody and an anti-pMET [Y1230/1234/1235] antibody, respectively).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Further testing showed <b>34</b> has significant in vitro and in vivo antitumor activity against MET and FGFR2-driven tumors and good pharmaceutical and safety profiles.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><figure id="cht6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 6. Other MET Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Cocrystal structure of activated MET with an analogue of <b>34</b> having 4-piperidine ring on pyrazole (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7O">3R7O</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inhibitor <b>35</b> (ARQ-197, tivantinib, Chart <a class="ref internalNav" href="#cht6" aria-label="6">6</a>) was discovered with a phenotype cell viability assay in metastatic cancer cell lines.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Subsequent experiments identified MET as the molecular target of <b>35</b>. Further characterization showed <b>35</b> was a highly selective and non-ATP competitive inhibitor with a <i>K</i><sub>i</sub> of 355 nM. It inhibited MET phosphorylation in HT29 and MKN-45 cells with constitutively active MET activity, and HGF-induced MET phosphorylation in MDA-MB-231 and NCI-H441 cells with an IC<sub>50</sub> of 100â300 nM. Exposure to <b>35</b> resulted in the inhibition of proliferation of MET-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive MET activity. Moderate growth inhibition of human tumors following oral administration of <b>35</b> (200 mg/kg) in multiple mouse xenograft efficacy studies was observed.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">Although <b>35</b> was identified as a moderate non-ATP competitive MET inhibitor, two independent research groups reported that <b>35</b> exerted its pharmacologic action in cells not dependent on MET for growth and survival.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148, 149)</a> Katayama et al. showed that <b>35</b> inhibited cell viability with similar potency in both MET-addicted and nonaddicted cells, which suggests that the antitumor activity of <b>35</b> is independent of MET status.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Furthermore, it was shown that <b>35</b> inhibited microtubule polymerization in addition to inhibiting MET.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Basilico et al. reported that <b>35</b> did not inhibit HGF-dependent or -independent MET tyrosine autophosphorylation in all cell models they analyzed.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Instead, <b>35</b> perturbed microtubule dynamics, induced G2/M arrest, and promoted apoptosis. Therefore, <b>35</b> displayed cytotoxic activity that was independent of its ability to bind to MET.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The physical properties and calculated LE, LLE, and LELP of <b>34</b> and <b>35</b> are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Summary of MET Inhibitors <b>34</b> and <b>35</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">MW</th><th class="colsep0 rowsep0" align="center">cLogPâ<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cLogDâ<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">enzyme IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">cell IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">cell LE<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cell LLE<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">cell LELP<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">status<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></td><td class="colsep0 rowsep0" align="left">496</td><td class="colsep0 rowsep0" align="left">1.31</td><td class="colsep0 rowsep0" align="left">2.04</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">56 (GTL-16)</td><td class="colsep0 rowsep0" align="left">0.290</td><td class="colsep0 rowsep0" align="left">5.21</td><td class="colsep0 rowsep0" align="left">4.52</td><td class="colsep0 rowsep0" align="left">phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b><a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></td><td class="colsep0 rowsep0" align="left">369</td><td class="colsep0 rowsep0" align="left">2.90</td><td class="colsep0 rowsep0" align="left">3.37</td><td class="colsep0 rowsep0" align="left">355</td><td class="colsep0 rowsep0" align="left">100â300Â (HT-29)</td><td class="colsep0 rowsep0" align="left">0.35â0.326</td><td class="colsep0 rowsep0" align="left">3.63â3.15</td><td class="colsep0 rowsep0" align="left">8.28â8.89</td><td class="colsep0 rowsep0" align="left">phaseÂ III</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">cLogP is the calculated logarithm of the partition coefficient in octanol/water using the BioByte program ClogP, version 4.3.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">cLogD is the calculated logarithm of the octanol/water distributin coefficient using ACD pchbat, version 12.1.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Cell LE = â1.4 logÂ IC<sub>50</sub>Â [M]/number of heavy atoms.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Cell LLE = âlogÂ IC<sub>50</sub>Â [M] â cLogD.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Cell LELP = cLogP/LE.</p></div></div></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">6 Targeting the HGF/MET Pathway in the Clinic</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63734" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63734" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A broad spectrum of inhibitors targeting the HGF/MET pathway have reached clinical development and have been extensively reviewed recently.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Anti-HGF humanized antibodies, MET extracellular domain monoclonal antibodies, and MET small molecule inhibitors currently being studied in the clinic are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Most of the MET inhibitors in clinical development, including highly specific HGF and MET antibodies, as well as specific and multitargeted small molecule MET inhibitors, demonstrated pharmacokinetic properties suitable to cover the preclinically predicted efficacy concentrations and exhibited acceptable safety profiles in phase I studies. The relatively few serious adverse events observed with the selective HGF and MET antibodies imply noncritical roles for the HGF/MET pathway in normal tissues. Peripheral edema seems to be a common mechanism-based side effect. Although a broad spectrum of antitumor efficacies have been reported in many preclinical animal models, only moderate clinical benefits have been observed for MET inhibitors currently in clinical development as single agents for cancers associated with HGF/MET signaling abnormalities. This section will review the clinical efficacy reports pertaining to major cancers with aberrant HGF/MET signaling.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Summary of Specific HGF/MET Inhibitors in Clinical Development<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">agent</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">selected clinical studies based on HGF/MET signaling</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rilotumumab (AMG-102), Amgen</td><td class="colsep0 rowsep0" align="left">HGF</td><td class="colsep0 rowsep0" align="left">Phase III: +ECX first line for MET + untreated advanced gastric or GEJ adenocarcinoma.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: FOLFOX alone or in combination with AMG102 or panitumumab as first-line treatment in patients with advanced gastresophageal cancer.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: +avastin for recurrent malignant glioma.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I/II: +erlotinib for previously treated patients with advanced NSCLC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ficlatuzumab (AV-299), Aveo</td><td class="colsep0 rowsep0" align="left">HGF</td><td class="colsep0 rowsep0" align="left">Phase Ib/II in Asian subjects with NSCLC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TAK701, Millennium</td><td class="colsep0 rowsep0" align="left">HGF</td><td class="colsep0 rowsep0" align="left">Phase I study in adult patients with advanced solid tumors.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">onartuzumab (MetMab), Genentech</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="left">Phase III: +mFOLFOX6 for Her-2 negative and MET-positive stomach or gastresophageal cancer.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase III: +erlotinib in patients with unresectable stage IIIb or IV, MET positive NSCLC carrying an activating EGFR mutation.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase III: +erlotinib in patients with advanced MET positive NSCLC who have received standard chemotherapy for advanced/metastatic disease.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: +bevacizumab in comparison with bevacizumab alone or MetMab monotherapy for recurrent glioblastoma.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: +paclitaxel + cisplatin or carboplatin first-line for stage IIIb or IV squamous NSCLC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: combination with either bevacizumab + platinum + paclitaxel or pemetrexed + platinum in patients with untreated stage IIIb or IV nonsquamous NSCLC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase Ib: single or +sorafenib for advanced HCC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b> (PF-04217903), Pfizer</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="left">Phase I: prematurely discontinued due to a strategic development decision by Pfizer, not based on any safety concerns.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b> (JNJ38877605), J&J</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="left">Phase I: early termination due to increase in serum creatinine levels and minimal PD activity.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b> (SGX-523), SGX</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="left">Phase I: terminated due to acute renal toxicity.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b> (INC280) (INCB28060), Novartis/Incyte</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="left">Phase II: advanced HCC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase Ib/II: +gefitinib in patients with EGFR mutated, MET-amplified NSCLC who have progressed after EGFRi treatment.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I: MET dependent advanced solid tumors.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b> (AMG-208), Amgen</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="left">Phase I: advanced solid tumors.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b> (EMD1204831), EMD</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="left">Phase I: terminated for reasons other than safety</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Summary of Multitargeted MET Inhibitors in Clinical Development<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">agent</th><th class="colsep0 rowsep0" align="center">target<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">selected clinical studies based on MET target</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b> (PF-2341066) (crizotinib), Pfizer</td><td class="colsep0 rowsep0" align="left">MET/ALKROS1/RON</td><td class="colsep0 rowsep0" align="left">Phase I: +pazopanib or pemetrexed followed by the triplet in patients with advanced malignancies.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I: +dasatinib in patients with advanced malignancies.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I: +pan-Her inhibitor PF-0299804 for NSCLC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b> (XL184) (cabozantinib), Exelixis</td><td class="colsep0 rowsep0" align="left">VEGFR2/MET/RET/KIT/FLTs/TIE2/AXL</td><td class="colsep0 rowsep0" align="left">Phase III: vs everolimus in metastatic RCC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase III: vs prednisone in metastatic castration-resistant prostate cancer patients who have received prior docetaxel and prior abiraterone or MDV3100.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: castration-resistant prostate cancer with visceral metastases.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: castration-resistant prostate cancer with bone metastases.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: HCC patients who have received prior sorafenib.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I/II: relapsed or refractory myeloma.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I: relapsed/refractory multiple myeloma with bone disease.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I: +gemcitabine in advanced pancreatic cancer.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b> (XL-880) (GSK-1363089) (foretinib), GSK/Exelixis</td><td class="colsep0 rowsep0" align="left">MET/VEGFR2/RON/FLTs/KIT/PDGFRs/TIE2</td><td class="colsep0 rowsep0" align="left">Multiple phase IIs (completed): patients with SCC of the head and neck; metastatic gastric cancer; papillary renal-cell carcinoma.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase 1/2: patients with previously treated NSCLC receiving standard erlotinib.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase 1/2: +lapatinib for HER-2 positive metastatic breast cancer.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase 1/2: adults with HCC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b> (E7050) (golvatinib), Eisai</td><td class="colsep0 rowsep0" align="left">MET/VEGFR2</td><td class="colsep0 rowsep0" align="left">Phase I/II: +sorafinib vs sorafinib alone as a first-line for HCC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I/II: +cetuximab vs cetuximab alone for platinum-resistant HNSCC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I/II: +E7080 for patients with recurrent glioblastoma or unresectable stage III or IV melanoma after prior systemic therapy.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b> (MGCD-265), MethylGene</td><td class="colsep0 rowsep0" align="left">MET/VEGFRs/RON/TIE2</td><td class="colsep0 rowsep0" align="left">Phase I/II: +erlotinib or docetaxel for patients with advanced NSCLC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b> (BMS-777607), BMS</td><td class="colsep0 rowsep0" align="left">MET/AXL/RON/TYRO3</td><td class="colsep0 rowsep0" align="left">Phase I: multiple ascending dose study in subjects with advanced or metastatic solid tumors (ASLAN002).</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b> (MP-470) (amuvatinib), Astex</td><td class="colsep0 rowsep0" align="left">MET/KIT/PDGFRÎ± /FLT3</td><td class="colsep0 rowsep0" align="left">Phase II: +platinum-etoposide chemotherapy for small cell lung cancer who have not responded to or relapsed after standard treatment.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b> (MK-2461), Merck</td><td class="colsep0 rowsep0" align="left">MET/RON/FLT1/FGFRs</td><td class="colsep0 rowsep0" align="left">Phase I/II (completed): advanced solid tumors.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b> (ARQ-197) (tivantinib), ArQule</td><td class="colsep0 rowsep0" align="left">MET and microtubing target(s)</td><td class="colsep0 rowsep0" align="left">Phase II: +erlotinib vs single agent chemotherapy in previously treated KRAS mutation positive subjects with locally advanced or metastatic NSCLC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: +cetuximab in EGFRi-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase II: metastatic triple negative breast cancer.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase Ib: +pazopani in patients with refractory advanced solid tumors.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Phase I: advanced HCC.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AMG-337 (structure undisclosed), Amgen</td><td class="colsep0 rowsep0" align="left">MET (unknown selectivity profile)</td><td class="colsep0 rowsep0" align="left">Phase I: advanced solid tumors.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">The selectivity profile was obtained based on the literature that may not represent the complete selectivity profile.</p></div></div></div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">6.1 Lung Cancer</h3><div class="NLM_p">Lung cancer is the leading cause of cancer-related mortality worldwide with many patients presenting advanced disease at initial diagnosis. Overexpression of HGF and/or MET has been observed in lung cancer and associated with a poorer prognosis.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Activated MET is detected in the invasive fronts of NSCLC tumor tissues.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a><i>MET</i> gene amplification (a mean increase of five or more gene copies) has been reported in approximately 4% of NSCLC and is an independent negative prognostic factor in surgically resected NSCLC.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a><i>MET</i> amplification is also responsible for acquired resistance to EGFR tyrosine kinase inhibitors in 5â20% of EGFR-mutant patients.<a onclick="showRef(event, 'ref8 ref87'); return false;" href="javascript:void(0);" class="ref ref8 ref87">(8, 87)</a> The resistance mechanism is associated with ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to the EGFR/ERBB family of receptors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> MET mutations in lung cancer occur mainly in the non-tyrosine kinase domains, namely, in the juxtamembrane and sema domains, and are found preferentially in metastatic lesions instead of primary lesions.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Preclinical studies with the MET small molecule inhibitor crizotinib or with RNA interference-mediated MET depletion in lung cancer cells which are positive or negative for either MET amplification or MET mutation revealed that MET signaling is essential for the survival of cells with <i>MET</i> amplification but not for those with a MET mutation.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Up-regulation of BIM, a proapoptotic member of the Bcl-2 family, and down-regulation of survivin, a member of the inhibitor of apoptosis protein family, contribute to the proapoptotic effect induced by crizotinib via inhibition of AKT and extracellular signal-regulated kinase phosphorylation in lung cancer cells with <i>MET</i> amplification but not in cells with a MET mutation or in those without amplification or mutation of MET.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><div class="NLM_p">Several MET inhibitors have been studied in clinical trials for lung cancer. The first rapid and durable response from inhibition of MET signaling in lung cancer was reported in a patient treated with crizotinib as a single agent for NSCLC with de novo <i>MET</i> amplification but without ALK rearrangement.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Because of the low frequency of <i>MET</i> amplification (<5%), the ongoing phase I/II or phase II clinical trials of MET inhibitors largely involve combination therapy with EGFR inhibitors or cytotoxic chemotherapy agents: the combination of rilotumumab with erlotinib is being studied in patients with advanced NSCLC who had previously been treated with at least one and a maximum of two prior chemotherapy regimens; a combination of ficlatuzumab with gefitinib is being studied in clinically selected Asian patients with previously untreated lung adenocarcinoma; foretinib combined with erlotinib is being investigated in patients with locally advanced or metastatic NSCLC who had not responded to previous chemotherapy; cabozantinib in combination with erlotinib is being tested in patients who had acquired resistance to erlotinib alone; <b>30</b> is being studied with erlotinib and docetaxel; amuvatinib in combination with standard chemotherapy is being investigated in SCLC patients who have not responded to or who have relapsed after standard treatment.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p">A phase II double blind randomized trial of onartuzumab (15 mg/kg iv every 3 weeks) in combination with erlotinib (150 mg oral daily) versus placebo plus erlotinib was conducted as a second or third line treatment for 128 NSCLC patients who had no previous exposure to an EGFR-TKI.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Patients were divided into subgroups based on IHC MET expression, irrespective of EGFR and KRAS status. In the MET + IHC group, onartuzumab/erlotinib improved time to progression 2-fold (3 months versus 1.5 months) and overall survival 3-fold (12.6 months versus 4.6 months).<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><div class="NLM_p last">The combination of crizotinib (150 or 200 mg b.i.d.) with erlotinib (100 mg daily) in 25 patients with previously treated NSCLC and no prior MET targeted therapy demonstrated initial efficacy with one patient showing partial response (duration of 61 weeks) at 200 mg b.i.d. dose of crizotinib and nine patients with stable disease (duration of 7â54 weeks).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> The most common treatment related adverse effects included grade 1â2 diarrhea (72%), rash (56%), and fatigue (44%), and the MTD observed for erlotinib was 100 mg daily and for crizotinib, 150 mg b.i.d.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">6.2 Hepatocellular Carcinoma</h3><div class="NLM_p">Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third most common cause of global cancer related mortality with a median overall survival (OS) of 5â8 months for metastatic or locally advanced disease.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Overexpression of MET is observed in 25â100% of human HCC samples and correlated independently with worse survival in multivariate analysis.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Somatic mutations (T1191I, K1262R, and M1268I) in the MET kinase domain were reported in childhood HCC.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Antiagiogenesis has been emerging as an important anticancer therapy with several agents approved in the market including bevacizumab and sunitinib. However, inhibition of VEGF signaling may increase tumor hypoxia leading to increased expression and activity of MET, which supports tumor invasion and metastasis, and may limit response.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> MET is an independent angiogenic factor, and it interacts with angiogenic survival signals promoted through VEGF. Therefore, dual VEGF and MET inhibition may represent a novel therapy for HCC.</div><div class="NLM_p last">Clinical studies of MET inhibitors for HCC have been actively pursued. A phase II trial using tivantinib in 107 patients with unresectable HCC with ECOG PS 0-1 and Child-Pugh A in a 2:1 randomization to either second-line tivantinib or placebo with crossover allowed was conducted.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Although no difference in median OS was observed overall, patients with high MET expression versus those with low MET expression who received tivantinib demonstrated significant improvement in both OS and TTP (7.2 versus 3.8 months, HR = 0.38, <i>P</i> = 0.01; 11.7 versus 6.8 weeks, HR 0.43, <i>P</i> = 0.03; respectively).<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> The positive phase II data for tivantinib need to be considered carefully because it has cytotoxic activity independent of its ability to bind with MET.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148, 149)</a> The potent and multitargeted MET/VEGFR inhibitor cabozantinib demonstrated activity in HCC patients regardless of prior sorafenib treatment in a phase II randomized discontinuation trial.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> First, all patients (41) were treated with cabozantinib at 100 mg q.d. for 12 weeks first, and then only patients with partial response (PR) continued in the study. Patients with PR remained on the open-label arm, but patients with stable disease (SD) were randomized to cabozantinib or placebo. A total of 29 patients (71%) completed the lead-in stage with a median PFS of 4.2 months. Confirmed PR (cPR) was achieved by 2/36 patients at 12 weeks and by 1 patient at 18 weeks. Tumor regression was observed in 28/36 patients (78%) regardless of prior sorafenib therapy. The overall disease control rate (DCR = PR + SD) at week 12 was 68% (Asian subgroup, 73%). The safety profile was comparable to those of other VEGFR TKIs. In this study, it is unclear how much clinical efficacy is attributable to MET inhibition alone, considering the broad activity of cabozantinib and the unknown MET expression level in the selected HCC patients.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">6.3 Papillary Renal Cell Carcinoma</h3><div class="NLM_p last">Papillary renal cell carcinoma (RCC) is the most prevalent nonclear cell histological subtype of renal carcinoma and constitutes approximately 10% of renal cancers. Activating MET mutations are present in the majority of hereditary papillary RCCs and up to 13% of sporadic papillary RCCs.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> A phase II study evaluating the efficacy and safety of the fully humanized monoclonal anti-HGF antibody rilotumumab in patients with metastatic renal cell carcinoma was reported.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> In 61 patients with metastatic renal cell carcinoma (40 at 10 mg/kg; 21 at 20 mg/kg), one patient in the 10 mg/kg group had confirmed partial response and maintained for over 2.5 years, and 43% of all patients had stable disease.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> A report of a prolonged response to the treatment of the exquisitely MET-selective small molecule inhibitor <b>16</b> in a patient with MET-mutated papillary RCC suggests an oncogenically addictive role of the MET pathway in this disease.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> A 58-year-old white man having papillary RCC with M1268T mutation had a 35% reduction of target lesions after receiving <b>16</b> for 53 weeks and continued to be treated for 26 months. The role of MET in papillary RCC is further demonstrated with foretinib, an oral multikinase inhibitor targeting MET, VEGFRs, RON, AXL, and TIE-2 receptors.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> A study of 74 patients enrolled in two dosing cohorts found an objective response rate of 13.5% and mean median PFS of 9.3 months. The presence of a germline MET mutation was highly predictive of a positive response (5 of 10 vs 5 of 57 patients with vs without germline MET mutations, respectively).<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">6.4 Gastric and Esophagogastric Cancers</h3><div class="NLM_p"><i>MET</i> amplification has been reported in gastric and esophagogastric cancers and is associated with poor prognosis.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> A durable and complete response was reported with the MET monoclonal antibody onartuzumab in a 48 year-old female patient with chemorefractory metastatic gastric cancer.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> The primary tumor revealed high <i>MET</i> gene polysomy and evidence for autocrine production of HGF. A complete response following four doses from March 2008 to June 2008 was observed, which lasted 2 years even though the treatment was discontinued in September 2008. It is confounding that the patient had been treated previously with a MET small molecule inhibitor (having a broad spectrum of kinase activities including VEGFRs) for 4 months, resulting in a transient partial response after 2 months, and then disease progression occurred after the next 2 months.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> The unexpected rarity of <i>MET</i> amplification in GEC patients (â¼2%) and the aggressive nature of GEC make it challenging to select patients who meet entry criteria for clinical trials.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> In one study, four patients with <i>MET</i>-amplified GEC were treated with crizotinib (250 mg b.i.d.), and two patients with stage IV junctional GEC with <i>MET</i>/CEP7 of greater than 5 demonstrated clinical benefit. One patient experienced a rapid symptomatic response with improvement in appetite, reduction of pain, and improvement in performance status after 1 week on crizotinib, and a partial response with a 41% reduction in tumor measurements was confirmed at 12 weeks. However, the disease progressed after approximately 112 days on crizotinib. Another patient also showed rapid clinical improvement, with decreased pain and improved performance status after 1 week on crizotinib and 16% reduction in multiple target lesions after two cycles of treatment. The time to progression on crizotinib was 105 days for this patient.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p last">Although a limited number of patients with clinical benefit from inhibition of the MET signaling pathway in gastric and esophagogastric cancers have been reported, the preliminary findings indicate that <i>MET</i> amplification has the potential to act as an oncogenic driver in gastric cancer, and a large clinical trial of patients with <i>MET</i>-amplified gastric cancer is necessary to understand the observed response patterns and identify the predictive biomarkers and the right combination strategies.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">6.4 Glioblastoma</h3><div class="NLM_p last">MET is overexpressed in â¼29% and amplified in â¼5% of gliolastomas and is rarely mutated.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> A multicenter, open-label, single-agent, two-stage phase II study of rilotumumab (10 or 20 mg/kg infusion every 2 weeks) was conducted in patients with histologically confirmed, measurable recurrent GBM or gliosarcoma and â¤3 relapses or prior systemic therapies.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> There were no objective responses (per central assessment). However, a 51-year-old white male patient (10 mg/kg cohort) diagnosed with stage IV GBM was receiving rilotumumab for 167.7 weeks, as of May 2010. There was no report on the genomic characteristics of this patient. A case report of a patient with <i>MET</i>-amplified GBM who experienced rapid and durable clinical improvement when treated with the MET inhibitor crizotinib implies the importance of identifying the right biomarkers to predict responsiveness to specific therapies.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> A 62-year-old woman with a grade 4 recurrent GBM developed resistance to the standard treatment. She had <i>MET</i> gene amplication in her tumor sample and entered a phase I trial of crizotinib (A8081001). Within 2 weeks on crizotinib (250 mg/b.i.d.), her headaches and short-term memory had significantly improved, and a 40% reduction of her brain tumor was achieved after two 28-day cycles of crizotinib. The patient was neurologically stable and was treated with crizotinib for 6 months until disease progression. Although there is only one case report, it suggests a subset of GBMs may be dependent on <i>MET</i> amplification and therefore sensitive to MET inhibition.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">6.5 Squamous Cell Carcinoma of the Head and Neck</h3><div class="NLM_p">Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common cancer worldwide, affecting 600â000 new patients each year.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The MET/HGF signaling axis is frequently up-regulated in HNSCC. In one study, MET was overexpressed in 84% of HNSCC patient samples, and <i>MET</i> amplification (>10 copies per cell) was present in 3 of 23 (13%) tumor tissues.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> In addition, HGF overexpression is detected in 45% of HNSCC, suggesting a paracrine activation mechanism.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Mutations have been detected in multiple domains, including the extracellular MET ligand-binding domain (T230M/E168D), the JM domain (R988C, T1010I), and the tyrosine kinase domain (T1275I, Y1230C, Y1235D, and V14333I) in HNSCC tumor samples.<a onclick="showRef(event, 'ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref173 ref174">(173, 174)</a> It is interesting to note that the tyrosine kinase domain mutations were often detected in metastatic sites; e.g., the activation loop Y1235D mutation is present in 50% of metastatic tumor sites versus 2â6% in primary tumor sites, indicating the potential role of kinase domain mutations in acquiring a metastatic phenotype and having a selective advantage for growth and/or survival in metastatic sites.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Although activating EGFR mutations are infrequent in HNSCC, EGFR gene amplification remains a strong indicator for poor patient survival, radioresistance, and locoregional failure.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> In March 2006, the U.S. Food and Drug Administration granted approval for the addition of cetuximab to radiation therapy in locally or regionally advanced HNSCC or for use as monotherapy for patients with platinum-refractory, recurrent, or metastatic HNSCC. However, the success of cetuximab has not been replicated with the small molecule EGFR inhibitors gefitinib and erlotinib. RTK crosstalk or compensatory pathway activity may contribute to resistance to the combination treatment with small molecule EGFR inhibitors.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Preclinically, the combination of the MET inhibitor crizotinib with the EGFR inhibitor gefitinib abrogated HNSCC cell proliferation, invasion, and wound healing significantly more than inhibition of each pathway alone in HNSCC cell lines, indicating compensatory RTK signaling between MET and EGFR.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> The preclinical studies support the potential combinational strategy of dual inhibition of MET and EGFR for treating HNSCC.</div><div class="NLM_p last">The clinical results of MET inhibitors for HNSCC are emerging. An open-label, single-arm, multicenter trial of foretinib, a multitargeted MET/VEGFR inhibitor, was conducted with a total of 14 patients enrolled.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Foretinib was administered at 240 mg orally for 5 consecutive days of a 14-day treatment cycle (5/9 schedule) to patients with recurrent and/or metastatic HNSCC. Under this regimen, 40% of patients (7/14) showed stable disease (SD) and 43% of patients (6/14) experienced tumor shrinkage. Among them, two patients had prolonged disease stabilization for â¥13 months. Foretinib at 240 mg on a 5-day-on and 9-day-off schedule was generally well tolerated, and the most common adverse events were fatigue, constipation, and hypertension.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">7 Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11715" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11715" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the first discovery of the MET kinase in 1984, the number of studies and publications related to the biology of HGF/MET and the pathological relationship of the pathway to diseases has been increasing exponentially, especially in the past decade. The prevalence of HGF/MET pathway activation in human malignancies has driven a rapid growth in drug discovery programs targeting HGF/MET signaling. More than 20 different therapeutic agents, including HGF monoclonal antibodies, MET monoclonal antibodies, and small molecule MET kinase inhibitors, have entered human clinical trials which will ultimately validate the pathogenic role of HGF/MET in cancers and provide new medicines for oncology application.</div><div class="NLM_p">Dysregulation of MET and/or HGF via activating mutations, gene amplifications, or overexpression and autocrine or paracrine loop regulation evoke cell growth, proliferation, angiogenesis, invasion, survival, and metastasis and lead to tumorigenisis and tumor metastasis. Although the pathology of HGF/MET signaling together with the preclinical data suggests that the inhibition of HGF/MET signaling may have a profound effect on many cancers, the limited efficacy results from clinical trials to date highlight the clinical challenges in the right application of MET inhibitors. Marked antitumor activity of MET inhibitors as single agents has been observed in carefully characterized patients with abnormal HGF/MET signaling as in the examples of (a) the durable response of a NSCLC patient with de novo <i>MET</i> amplification to crizotinib, (b) the prolonged response of a papillary RCC patient with M1268T mutation to exquisitely MET-selective inhibitor <b>16</b> for up to 26 months, and (c) the patient with <i>MET</i>-amplified GBM who experienced rapid and durable clinical improvement when treated with MET inhibitor crizotinib. These successful individual examples highlight the importance of identifying the appropriate biomarkers to predict responsiveness to specific therapies, and the necessity of prospective molecular profiling to ensure successful clinical trials.</div><div class="NLM_p">Intratumoral heterogeneity presents major challenges to personalized medicine and biomarker development and has a substantial impact on both innate and acquired resistance to tyrosine kinase inhibitors. Overall, the frequency of <i>MET</i> mutations and amplification is relatively low and MET inhibitors as single agents may be important only in a subset of patients. MET and/or HGF is frequently overexpressed even without mutations or gene amplifications in a number of cancers. Increasing evidence links activation of MET to adaptive response mechanisms for resistance to certain anticancer therapies, e.g., resistance to the treatments of kinase inhibitors, chemotherapy, and radiotherapy. The combination of a MET inhibitor with kinase inhibitor or with general chemotherapy or radiotherapy in clinical trials has drawn a lot of attention with many combination clinical trials ongoing.</div><div class="NLM_p">More than three classes of small molecule MET inhibitors with distinct binding modes, selectivity, and safety profiles have been discovered and developed into clinical trials. Crizotinib, a prototype MET inhibitor of class Ia, and cabozantinib, a multitargeted MET inhibitor of class II, have been approved based on the indications of ALK and RET targets, respectively. The approved drugs provide tools to further validate the important role of HGF/MET signaling in the development of human cancer, especially in cancer metastasis. Several exquitely selective class Ib MET inhibitors are actively under development in clinical trials. The clinical results from class Ib MET inhibitors will provide unambiguous answers to MET cancer biology. The highly selective class Ib MET inhibitors provide invaluable opportunities for the combination with other therapies safely to achieve the optimal efficacy.</div><div class="NLM_p last">In summary, MET remains as a promising target in cancers because of its causative roles in cell survival, growth, angiogenesis, and metastasis. There are still many challenges for the development of MET inhibitors into useful drugs. These challenges include identifying the genetically defined responsive patient subset that could benefit from MET inhibition, developing analytically accurate biomarkers for diagnostic and pharmacodynamic application, and determining the right combinations of therapies. With a rich collection of HGF/MET inhibitors targeting HGF or MET, clinical studies with carefully characterized patients will provide the deep understanding of the roles of HGF/MET signaling in cancer needed to translate the preclinical research into effective therapeutic strategies and to accelerate the development of MET inhibitors into drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm401427c" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37651" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37651" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Jean Cui</span> - <span class="hlFld-Affiliation affiliation">TP Therapeutics, Inc., 6150 Lusk Boulevard, Suite B100, San Diego, California 92121, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d1bbb4b0bfffb2a4b891a5a1a5b9b4a3b0a1b4a4a5b8b2a2ffb2bebc"><span class="__cf_email__" data-cfemail="721817131c5c11071b320602061a170013021707061b11015c111d1f">[emailÂ protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81573" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81573" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">J. Jean Cui</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=BIO-d2158e3615-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>J. Jean Cui</b> earned her Ph.D. in Organic Chemistry from The Ohio State University under the direction of Professor Derek Horton and received her B.S. and M.S. in Chemistry from University of Science and Technology of China. Jean worked at Pfizer for more than 14 years including 4 years at SUGEN/Pharmacia conducting oncology drug discovery. She recently started up TP Therapeutics focusing on turning point medicines for cancer patients. Jean is the lead inventor of crizotinib (Xalkori). Jean and the crizotinib chemistry team were selected for the 38th National Inventor of the Year Award in 2011 and for the 2013 American Chemical Societyâs Heroes of Chemistry Program for the discovery of crizotinib. Jean received Pfizer Achievement Awards in 2006 and 2012 and Innovation Award in 2011.</p></figure></div><div class="ack" id="ACK-d2158e3620-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80707" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80707" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The author is grateful to Pfizer colleagues Ben Burke, Susan Kephart, Wei Tan, and Baohua Xin for their critical reading, editing, and suggestions; to Asako Nagata for help on the preparation of figures; and to reviewers for their critical suggestions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i39" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i39"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i40" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i40"> Abbreviations Used</h2><tr><td class="NLM_term">3â²-UTR</td><td class="NLM_def"><p class="first last">3â² untranslated region</p></td></tr><tr><td class="NLM_term">ABL</td><td class="NLM_def"><p class="first last">Abelson murine leukemia viral oncogene homologue 1</p></td></tr><tr><td class="NLM_term">AO</td><td class="NLM_def"><p class="first last">aldehyde oxidase</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">breakpoint cluster region protein</p></td></tr><tr><td class="NLM_term">A-loop</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">CBL</td><td class="NLM_def"><p class="first last">casitas B-lineage lymphoma protein</p></td></tr><tr><td class="NLM_term">CR</td><td class="NLM_def"><p class="first last">cystine-rich</p></td></tr><tr><td class="NLM_term">CRKL</td><td class="NLM_def"><p class="first last">crk-like protein</p></td></tr><tr><td class="NLM_term">CSC</td><td class="NLM_def"><p class="first last">cancer stem cell</p></td></tr><tr><td class="NLM_term">DCR</td><td class="NLM_def"><p class="first last">disease control rate</p></td></tr><tr><td class="NLM_term">ERBB2</td><td class="NLM_def"><p class="first last">v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2</p></td></tr><tr><td class="NLM_term">ECX</td><td class="NLM_def"><p class="first last">epirubicin, cisplatin, and capecitabine</p></td></tr><tr><td class="NLM_term">FISH</td><td class="NLM_def"><p class="first last">fluorescence in situ hybridization</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">FOLFOX</td><td class="NLM_def"><p class="first last">folinic acid, fluorouracil, and oxaliplatin</p></td></tr><tr><td class="NLM_term">GAB1</td><td class="NLM_def"><p class="first last">GRB2-associated-binding protein 1</p></td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glioblastoma</p></td></tr><tr><td class="NLM_term">GEC</td><td class="NLM_def"><p class="first last">gastric and esophagogastric cancers</p></td></tr><tr><td class="NLM_term">GEJ</td><td class="NLM_def"><p class="first last">gastroesophageal junction</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">GRB2</td><td class="NLM_def"><p class="first last">growth factor receptor-bound protein 2</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">HGFR</td><td class="NLM_def"><p class="first last">hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">HIF-1</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor 1</p></td></tr><tr><td class="NLM_term">HNSCC</td><td class="NLM_def"><p class="first last">squamous cell carcinoma of the head and neck</p></td></tr><tr><td class="NLM_term">HOS</td><td class="NLM_def"><p class="first last">human osteogenic sarcoma</p></td></tr><tr><td class="NLM_term">HPRC</td><td class="NLM_def"><p class="first last">hereditary papillary renal carcinoma</p></td></tr><tr><td class="NLM_term">Ig</td><td class="NLM_def"><p class="first last">immunoglobin-like</p></td></tr><tr><td class="NLM_term">IRK</td><td class="NLM_def"><p class="first last">insulin receptor kinase</p></td></tr><tr><td class="NLM_term">JM</td><td class="NLM_def"><p class="first last">juxtamembrane</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">ORR</td><td class="NLM_def"><p class="first last">objective response rate</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">PDAC</td><td class="NLM_def"><p class="first last">pancreatic ductal adenocarcinoma</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression free survival</p></td></tr><tr><td class="NLM_term">PLC</td><td class="NLM_def"><p class="first last">phospholipase C</p></td></tr><tr><td class="NLM_term">PRC</td><td class="NLM_def"><p class="first last">papillary renal carcinoma</p></td></tr><tr><td class="NLM_term">PRGF</td><td class="NLM_def"><p class="first last">plasminogen-related growth factor family</p></td></tr><tr><td class="NLM_term">PTP</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">ROS1</td><td class="NLM_def"><p class="first last">c-ros oncogene 1</p></td></tr><tr><td class="NLM_term">SCC</td><td class="NLM_def"><p class="first last">squamous cell carcinoma</p></td></tr><tr><td class="NLM_term">SF</td><td class="NLM_def"><p class="first last">scatter factor</p></td></tr><tr><td class="NLM_term">SPH</td><td class="NLM_def"><p class="first last">serine protease homology</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription proteins</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">TRK</td><td class="NLM_def"><p class="first last">neurotrophic tyrosine kinase</p></td></tr><tr><td class="NLM_term">TPR</td><td class="NLM_def"><p class="first last">translocated promotor region</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">von HippelâLindau tumor suppressor</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 177 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">â</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0lj-8oidLf7o5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">â</span> <span class="NLM_lpage">1134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0ljDDuMGJsG0iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">â</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0ljDDuMGJsG0iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Trusolino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">MET signalling: principles and functions in development, organ regeneration and cancer</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrm3012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21102609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGrurfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=834-848&author=L.+Trusolinoauthor=A.+Bertottiauthor=P.+M.+Comoglio&title=MET+signalling%3A+principles+and+functions+in+development%2C+organ+regeneration+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">MET signalling: principles and functions in development, organ regeneration and cancer</span></div><div class="casAuthors">Trusolino, Livio; Bertotti, Andrea; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">834-848</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The MET tyrosine kinase receptor (also known as the HGF receptor) promotes tissue remodelling, which underlies developmental morphogenesis, wound repair, organ homeostasis and cancer metastasis, by integrating growth, survival and migration cues in response to environmental stimuli or cell-autonomous perturbations.  The versatility of MET-mediated biol. responses is sustained by qual. and quant. signal modulation.  Qual. mechanisms include the engagement of dedicated signal transducers and the subcellular compartmentalization of MET signalling pathways, whereas quant. regulation involves MET partnering with adaptor amplifiers or being degraded through the shedding of its extracellular domain or through intracellular ubiquitylation.  Controlled activation of MET signalling can be exploited in regenerative medicine, whereas MET inhibition might slow down tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzaWXvEKEpVrVg90H21EOLACvtfcHk0ljDDuMGJsG0iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGrurfI&md5=c97f7b6ff2522bc0d20d0371d07c5ea2</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrm3012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3012%26sid%3Dliteratum%253Aachs%26aulast%3DTrusolino%26aufirst%3DL.%26aulast%3DBertotti%26aufirst%3DA.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DMET%2520signalling%253A%2520principles%2520and%2520functions%2520in%2520development%252C%2520organ%2520regeneration%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D834%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span> </span><span class="NLM_article-title">Targeting MET in cancer: rationale and progress</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">â</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc3205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22270953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSmu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=89-103&author=E.+Gherardiauthor=W.+Birchmeierauthor=C.+Birchmeierauthor=G.+Vande+Woude&title=Targeting+MET+in+cancer%3A+rationale+and+progress"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MET in cancer: rationale and progress</span></div><div class="casAuthors">Gherardi, Ermanno; Birchmeier, Walter; Birchmeier, Carmen; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-103</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of cancer.  Genetic and biochem. data have demonstrated that the growth and motility factor hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, the tyrosine kinase MET, have a causal role in all of these processes, thus providing a strong rationale for targeting these mols. in cancer.  Parallel progress in understanding the structure and function of HGF/SF, MET and assocd. signalling components has led to the successful development of blocking antibodies and a large no. of small-mol. MET kinase inhibitors.  In this Review, we discuss these advances, as well as results from recent clin. studies that demonstrate that inhibiting MET signalling in several types of solid human tumors has major therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6JxJEFNd5E7Vg90H21EOLACvtfcHk0ljDDuMGJsG0iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSmu7s%253D&md5=ea16195614f1dd385ed48fd29bad9a8d</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrc3205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3205%26sid%3Dliteratum%253Aachs%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DTargeting%2520MET%2520in%2520cancer%253A%2520rationale%2520and%2520progress%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D89%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKinnon, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramnath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Expression and mutational analysis of <i>MET</i> in human solid cancers</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1025</span><span class="NLM_x">â</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fgcc.20604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18709663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1025-1037&author=P.+C.+Maauthor=M.+S.+Tretiakovaauthor=A.+C.+MacKinnonauthor=N.+Ramnathauthor=C.+Johnsonauthor=S.+Dietrichauthor=T.+Seiwertauthor=J.+G.+Christensenauthor=R.+Jagadeeswaranauthor=T.+Krauszauthor=E.+E.+Vokesauthor=A.+N.+Husainauthor=R.+Salgia&title=Expression+and+mutational+analysis+of+MET+in+human+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and mutational analysis of MET in human solid cancers</span></div><div class="casAuthors">Ma, Patrick C.; Tretiakova, Maria S.; MacKinnon, Alexander C.; Ramnath, Nithya; Johnson, Candace; Dietrich, Sascha; Seiwert, Tanguy; Christensen, James G.; Jagadeeswaran, Ramasamy; Krausz, Thomas; Vokes, Everett E.; Husain, Aliya N.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1025-1037</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) regulate a variety of cellular functions, many of which can be dysregulated in human cancers.  Activated MET signaling can lead to cell motility and scattering, angiogenesis, proliferation, branching morphogenesis, invasion, and eventual metastasis.  We performed systematic anal. of the expression of the MET receptor and its ligand HGF in tumor tissue microarrays (TMA) from human solid cancers.  Std. immunohistochem. (IHC) and a computerized automated scoring system were used.  DNA sequencing for MET mutations in both nonkinase and kinase domains was also performed.  MET was differentially overexpressed in human solid cancers.  The ligand HGF was widely expressed in both tumors, primarily intratumoral, and nonmalignant tissues.  The MET/HGF likely is functional and may be activated in autocrine fashion in vivo.  MET and stem cell factor (SCF) were found to be pos. stained in the bronchioalevolar junctions of lung tumors.  A no. of novel mutations of MET were identified, particularly in the extracellular semaphorin domain and the juxtamembrane domain.  MET-HGF pathway can be assayed in TMAs and is often overexpressed in a wide variety of human solid cancers.  MET can be activated through overexpression, mutation, or autocrine signaling in malignant cells.  Mutations in the nonkinase regions of MET might play an important role in tumorigenesis and tumor progression.  MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnenTNgIcAbVg90H21EOLACvtfcHk0li9FJCXguoOvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE&md5=cf53884177f20939300673fb034ac91f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fgcc.20604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.20604%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DMacKinnon%26aufirst%3DA.%2BC.%26aulast%3DRamnath%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DDietrich%26aufirst%3DS.%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DExpression%2520and%2520mutational%2520analysis%2520of%2520MET%2520in%2520human%2520solid%2520cancers%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2008%26volume%3D47%26spage%3D1025%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikhande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kijima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of the hepatocyte growth factor receptor, MET, in oncogenesis and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">â</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2FS1359-6101%2801%2900029-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=11750879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=41-59&author=G.+Maulikauthor=A.+Shrikhandeauthor=T.+Kijimaauthor=P.+C.+Maauthor=P.+T.+Morrisonauthor=R.+Salgia&title=Role+of+the+hepatocyte+growth+factor+receptor%2C+MET%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition</span></div><div class="casAuthors">Maulik, Gautam; Shrikhande, Amol; Kijima, Takashi; Ma, Patrick C.; Morrison, Paul T.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-59</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review is given.  Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic molecularly targeted therapies.  C-Met is a receptor tyrosine kinase shown to be over-expressed and mutated in a variety of malignancies.  Stimulation of c-Met via its ligand hepatocyte growth factor also known as scatter factor (HGF/SF), leads to a plethora of biol. and biochem. effects in the cell.  There has been considerable knowledge gained on the role of c-Met-HGF/SF axis in normal and malignant cells.  This review summarizes the structure of c-Met and HGF/SF and their family members.  Since there are known mutations of c-Met in solid tumors, particularly in papillary renal cell carcinoma, we have summarized the various mutations and over-expression of c-Met known thus far.  Stimulation of c-Met can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  The biol. functions altered by c-Met are quite unique and described in detail.  Along with biol. functions, various signal transduction pathways, including the cytoskeleton are altered with the activation of c-Met-HGF/SF loop.  We have recently shown the phosphorylation of focal adhesion proteins, such as paxillin and p125FAK in response to c-Met stimulation in lung cancer cells, and this is detailed here.  Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2mu2QMKr_7Vg90H21EOLACvtfcHk0li9FJCXguoOvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D&md5=aead14efa103c522ef374b0a16e51b35</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2801%2900029-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252801%252900029-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DKijima%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMorrison%26aufirst%3DP.%2BT.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%252C%2520MET%252C%2520in%2520oncogenesis%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2002%26volume%3D13%26spage%3D41%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wilson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridlyand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penuel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">â</span> <span class="NLM_lpage">509</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=505-509&author=T.+R.+Wilsonauthor=J.+Fridlyandauthor=Y.+Yanauthor=E.+Penuelauthor=L.+Burtonauthor=E.+Chanauthor=J.+Pengauthor=E.+Linauthor=Y.+Wangauthor=J.+Sosmanauthor=A.+Ribasauthor=J.+Liauthor=J.+Moffatauthor=D.+P.+Sutherlinauthor=H.+Koeppenauthor=M.+Merchantauthor=R.+Neveauthor=J.+Settleman&title=Widespread+potential+for+growth-factor-driven+resistance+to+anticancer+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DFridlyand%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DNeve%26aufirst%3DR.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DWidespread%2520potential%2520for%2520growth-factor-driven%2520resistance%2520to%2520anticancer%2520kinase%2520inhibitors%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D505%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">MET amplication leads to gefitinib resistance in lung cancer by activating ERBB signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">â</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+amplication+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplication%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toschi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=77-88&author=A.+B.+Turkeauthor=K.+Zejnullahuauthor=Y.+L.+Wuauthor=Y.+Songauthor=D.+Dias-Santagataauthor=E.+Lifshitsauthor=L.+Toschiauthor=A.+Rogersauthor=T.+Mokauthor=L.+Sequistauthor=N.+I.+Lindemanauthor=C.+Murphyauthor=S.+Akhavanfardauthor=B.+Y.+Yeapauthor=Y.+Xiaoauthor=M.+Capellettiauthor=A.+J.+Iafrateauthor=C.+Leeauthor=J.+G.+Christensenauthor=J.+A.+Engelmanauthor=P.+A.+J%C3%A4nne&title=Preexistence+and+clonal+selection+of+MET+amplification+in+EGFR+mutant+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DRogers%26aufirst%3DA.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DSequist%26aufirst%3DL.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DMurphy%26aufirst%3DC.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPreexistence%2520and%2520clonal%2520selection%2520of%2520MET%2520amplification%2520in%2520EGFR%2520mutant%2520NSCLC%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26spage%3D77%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Straussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barzily-Rokni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mongare, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span> </span><span class="NLM_article-title">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnature11183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22763439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=500-504&author=R.+Straussmanauthor=T.+Morikawaauthor=K.+Sheeauthor=M.+Barzily-Rokniauthor=Z.+R.+Qianauthor=J.+Duauthor=A.+Davisauthor=M.+M.+Mongareauthor=J.+Gouldauthor=D.+T.+Frederickauthor=Z.+A.+Cooperauthor=P.+B.+Chapmanauthor=D.+B.+Solitauthor=A.+Ribasauthor=R.+S.+Loauthor=K.+T.+Flahertyauthor=S.+Oginoauthor=J.+A.+Wargoauthor=T.+R.+Golub&title=Tumour+micro-environment+elicits+innate+resistance+to+RAF+inhibitors+through+HGF+secretion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span></div><div class="casAuthors">Straussman, Ravid; Morikawa, Teppei; Shee, Kevin; Barzily-Rokni, Michal; Qian, Zhi Rong; Du, Jinyan; Davis, Ashli; Mongare, Margaret M.; Gould, Joshua; Frederick, Dennie T.; Cooper, Zachary A.; Chapman, Paul B.; Solit, David B.; Ribas, Antoni; Lo, Roger S.; Flaherty, Keith T.; Ogino, Shuji; Wargo, Jennifer A.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">500-504</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drug resistance presents a challenge to the treatment of cancer patients.  Many studies have focused on cell-autonomous mechanisms of drug resistance.  By contrast, the authors proposed that the tumor micro-environment confers innate resistance to therapy.  Here the authors developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs.  The authors found that stroma-mediated resistance is common, particularly to targeted agents.  The authors characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance.  Proteomic anal. showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signaling pathways, and immediate resistance to RAF inhibition.  Immunohistochem. expts. confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment.  Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma.  A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines.  More generally, this study indicates that the systematic dissection of interactions between tumors and their micro-environment can uncover important mechanisms underlying drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwanlhJUTP4LVg90H21EOLACvtfcHk0ljbGLczjMGCUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J&md5=0616b5feed3c5dc2a53ee2ee382a6c33</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature11183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11183%26sid%3Dliteratum%253Aachs%26aulast%3DStraussman%26aufirst%3DR.%26aulast%3DMorikawa%26aufirst%3DT.%26aulast%3DShee%26aufirst%3DK.%26aulast%3DBarzily-Rokni%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DZ.%2BR.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DMongare%26aufirst%3DM.%2BM.%26aulast%3DGould%26aufirst%3DJ.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DTumour%2520micro-environment%2520elicits%2520innate%2520resistance%2520to%2520RAF%2520inhibitors%2520through%2520HGF%2520secretion%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D500%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Cooper, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, D. G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tainsky, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croce, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Molecular cloning of a new transforming gene from a chemically transformed human cell line</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=1984&pages=29-33&author=C.+S.+Cooperauthor=M.+Parkauthor=D.+G+Blairauthor=M.+A.+Tainskyauthor=K.+Huebnerauthor=C.+M.+Croceauthor=G.+F.+Vande+Woude&title=Molecular+cloning+of+a+new+transforming+gene+from+a+chemically+transformed+human+cell+line"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DC.%2BS.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DD.%2BG%26aulast%3DTainsky%26aufirst%3DM.%2BA.%26aulast%3DHuebner%26aufirst%3DK.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DMolecular%2520cloning%2520of%2520a%2520new%2520transforming%2520gene%2520from%2520a%2520chemically%2520transformed%2520human%2520cell%2520line%26jtitle%3DNature%26date%3D1984%26volume%3D311%26spage%3D29%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Dean, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Beau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robins, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">The human MET oncogene is related to the tyrosine kinase oncogenes</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">â</span> <span class="NLM_lpage">388</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=1985&pages=385-388&author=M.+Deanauthor=M.+Parkauthor=M.+M.+Le+Beauauthor=T.+S.+Robinsauthor=M.+O.+Diazauthor=J.+D.+Rowleyauthor=D.+G.+Blairauthor=G.+F.+Vande+Woude&title=The+human+MET+oncogene+is+related+to+the+tyrosine+kinase+oncogenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DRobins%26aufirst%3DT.%2BS.%26aulast%3DDiaz%26aufirst%3DM.%2BO.%26aulast%3DRowley%26aufirst%3DJ.%2BD.%26aulast%3DBlair%26aufirst%3DD.%2BG.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DThe%2520human%2520MET%2520oncogene%2520is%2520related%2520to%2520the%2520tyrosine%2520kinase%2520oncogenes%26jtitle%3DNature%26date%3D1985%26volume%3D318%26spage%3D385%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaul, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonda, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">6379</span><span class="NLM_x">â</span> <span class="NLM_lpage">6383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1987&pages=6379-6383&author=M.+Parkauthor=M.+Deanauthor=K.+Kaulauthor=M.+J.+Braunauthor=M.+A.+Gondaauthor=G.+F.+Vande+Woude&title=Sequence+of+MET+protooncogene+cDNA+has+features+characteristic+of+the+tyrosine+kinase+family+of+growth-factor+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DM.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DKaul%26aufirst%3DK.%26aulast%3DBraun%26aufirst%3DM.%2BJ.%26aulast%3DGonda%26aufirst%3DM.%2BA.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DSequence%2520of%2520MET%2520protooncogene%2520cDNA%2520has%2520features%2520characteristic%2520of%2520the%2520tyrosine%2520kinase%2520family%2520of%2520growth-factor%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1987%26volume%3D84%26spage%3D6379%26epage%3D6383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponzetto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Tyrosine kinase receptor indistinguishable from the MET protein</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">â</span> <span class="NLM_lpage">156</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1989&pages=155-156&author=S.+Giordanoauthor=C.+Ponzettoauthor=M.+F.+Di+Renzoauthor=C.+S.+Cooperauthor=P.+M.+Comoglio&title=Tyrosine+kinase+receptor+indistinguishable+from+the+MET+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DPonzetto%26aufirst%3DC.%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26aulast%3DCooper%26aufirst%3DC.%2BS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DTyrosine%2520kinase%2520receptor%2520indistinguishable%2520from%2520the%2520MET%2520protein%26jtitle%3DNature%26date%3D1989%26volume%3D339%26spage%3D155%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youles, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miguel, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blundell, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iamele, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gough, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandyopadhyay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, P. J. G.</span><span> </span><span class="NLM_article-title">Functional map and domain structure of MET, the product of the MET protooncogene and receptor for hepatocyte growth factor/scatter factor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12039</span><span class="NLM_x">â</span> <span class="NLM_lpage">12044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12039-12044&author=E.+Gherardiauthor=M.+E.+Youlesauthor=R.+N.+Miguelauthor=T.+L.+Blundellauthor=L.+Iameleauthor=J.+Goughauthor=A.+Bandyopadhyayauthor=G.+Hartmannauthor=P.+J.+G.+Butler&title=Functional+map+and+domain+structure+of+MET%2C+the+product+of+the+MET+protooncogene+and+receptor+for+hepatocyte+growth+factor%2Fscatter+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DYoules%26aufirst%3DM.%2BE.%26aulast%3DMiguel%26aufirst%3DR.%2BN.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DIamele%26aufirst%3DL.%26aulast%3DGough%26aufirst%3DJ.%26aulast%3DBandyopadhyay%26aufirst%3DA.%26aulast%3DHartmann%26aufirst%3DG.%26aulast%3DButler%26aufirst%3DP.%2BJ.%2BG.%26atitle%3DFunctional%2520map%2520and%2520domain%2520structure%2520of%2520MET%252C%2520the%2520product%2520of%2520the%2520MET%2520protooncogene%2520and%2520receptor%2520for%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D12039%26epage%3D12044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ponzetto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maina, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dalla Zonca, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panayotou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">â</span> <span class="NLM_lpage">271</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1994&pages=261-271&author=C.+Ponzettoauthor=A.+Bardelliauthor=Z.+Zhenauthor=F.+Mainaauthor=P.+dalla+Zoncaauthor=S.+Giordanoauthor=A.+Grazianiauthor=G.+Panayotouauthor=P.+M.+Comoglio&title=A+multifunctional+docking+site+mediates+signaling+and+transformation+by+the+hepatocyte+growth+factor%2Fscatter+factor+receptor+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPonzetto%26aufirst%3DC.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DZ.%26aulast%3DMaina%26aufirst%3DF.%26aulast%3Ddalla%2BZonca%26aufirst%3DP.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DGraziani%26aufirst%3DA.%26aulast%3DPanayotou%26aufirst%3DG.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DA%2520multifunctional%2520docking%2520site%2520mediates%2520signaling%2520and%2520transformation%2520by%2520the%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520receptor%2520family%26jtitle%3DCell%26date%3D1994%26volume%3D77%26spage%3D261%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Bottaro, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faletto, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kmiecik, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aaronson, S. A.</span><span> </span><span class="NLM_article-title">Identification of the hepatocyte growth factor receptor as the MET proto-oncogene product</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">251</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">â</span> <span class="NLM_lpage">804</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1991&pages=802-804&author=D.+P.+Bottaroauthor=J.+S.+Rubinauthor=D.+L.+Falettoauthor=A.+M.+Chanauthor=T.+E.+Kmiecikauthor=G.+F.+Vande+Woudeauthor=S.+A.+Aaronson&title=Identification+of+the+hepatocyte+growth+factor+receptor+as+the+MET+proto-oncogene+product"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBottaro%26aufirst%3DD.%2BP.%26aulast%3DRubin%26aufirst%3DJ.%2BS.%26aulast%3DFaletto%26aufirst%3DD.%2BL.%26aulast%3DChan%26aufirst%3DA.%2BM.%26aulast%3DKmiecik%26aufirst%3DT.%2BE.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DAaronson%26aufirst%3DS.%2BA.%26atitle%3DIdentification%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520as%2520the%2520MET%2520proto-oncogene%2520product%26jtitle%3DScience%26date%3D1991%26volume%3D251%26spage%3D802%26epage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Shimomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagaya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, N.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">6370</span><span class="NLM_x">â</span> <span class="NLM_lpage">6376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=6370-6376&author=T.+Shimomuraauthor=K.+Dendaauthor=A.+Kitamuraauthor=T.+Kawaguchiauthor=M.+Kitoauthor=J.+Kondoauthor=S.+Kagayaauthor=L.+Qinauthor=H.+Takataauthor=K.+Miyazawaauthor=N.+Kitamura&title=Hepatocyte+growth+factor+activator+inhibitor%2C+a+novel+Kunitz-type+serine+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimomura%26aufirst%3DT.%26aulast%3DDenda%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DA.%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DKito%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DJ.%26aulast%3DKagaya%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DTakata%26aufirst%3DH.%26aulast%3DMiyazawa%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DN.%26atitle%3DHepatocyte%2520growth%2520factor%2520activator%2520inhibitor%252C%2520a%2520novel%2520Kunitz-type%2520serine%2520protease%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D6370%26epage%3D6376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kawaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, N.</span><span> </span><span class="NLM_article-title">Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">27558</span><span class="NLM_x">â</span> <span class="NLM_lpage">27564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=27558-27564&author=T.+Kawaguchiauthor=L.+Qinauthor=T.+Shimomuraauthor=J.+Kondoauthor=K.+Matsumotoauthor=K.+Dendaauthor=N.+Kitamura&title=Purification+and+cloning+of+hepatocyte+growth+factor+activator+inhibitor+type+2%2C+a+Kunitz-type+serine+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DShimomura%26aufirst%3DT.%26aulast%3DKondo%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DDenda%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DN.%26atitle%3DPurification%2520and%2520cloning%2520of%2520hepatocyte%2520growth%2520factor%2520activator%2520inhibitor%2520type%25202%252C%2520a%2520Kunitz-type%2520serine%2520protease%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D27558%26epage%3D27564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Holmes, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillozzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deakin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carafoli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherardi, E.</span><span> </span><span class="NLM_article-title">Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">â</span> <span class="NLM_lpage">408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2007&pages=395-408&author=O.+Holmesauthor=S.+Pillozziauthor=J.+A.+Deakinauthor=F.+Carafoliauthor=L.+Kempauthor=P.+J.+Butlerauthor=M.+Lyonauthor=E.+Gherardi&title=Insights+into+the+structure%2Ffunction+of+hepatocyte+growth+factor%2Fscatter+factor+from+studies+with+individual+domains"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DO.%26aulast%3DPillozzi%26aufirst%3DS.%26aulast%3DDeakin%26aufirst%3DJ.%2BA.%26aulast%3DCarafoli%26aufirst%3DF.%26aulast%3DKemp%26aufirst%3DL.%26aulast%3DButler%26aufirst%3DP.%2BJ.%26aulast%3DLyon%26aufirst%3DM.%26aulast%3DGherardi%26aufirst%3DE.%26atitle%3DInsights%2520into%2520the%2520structure%252Ffunction%2520of%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520from%2520studies%2520with%2520individual%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D367%26spage%3D395%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnesano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span> </span><span class="NLM_article-title">A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of MET</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">21267</span><span class="NLM_x">â</span> <span class="NLM_lpage">21277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=21267-21277&author=C.+Basilicoauthor=A.+Arnesanoauthor=M.+Galluzzoauthor=P.+M.+Comoglioauthor=P.+Michieli&title=A+high+affinity+hepatocyte+growth+factor-binding+site+in+the+immunoglobulin-like+region+of+MET"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DArnesano%26aufirst%3DA.%26aulast%3DGalluzzo%26aufirst%3DM.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DMichieli%26aufirst%3DP.%26atitle%3DA%2520high%2520affinity%2520hepatocyte%2520growth%2520factor-binding%2520site%2520in%2520the%2520immunoglobulin-like%2520region%2520of%2520MET%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D21267%26epage%3D21277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Birchmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">MET, metastasis, motility and more</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">â</span> <span class="NLM_lpage">925</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrm1261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=14685170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFeju7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=915-925&author=C.+Birchmeierauthor=W.+Birchmeierauthor=E.+Gherardiauthor=G.+F.+Vande+Woude&title=MET%2C+metastasis%2C+motility+and+more"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Met, metastasis, motility and more</span></div><div class="casAuthors">Birchmeier, Carmen; Birhcmeier, Walter; Gherardi, Ermanno; Vande Woude, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-925</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatocyte growth factor. scatter factor and its receptor, the tyrosine kinase Met, arose late in evolution and are unique to vertebrates.  In spite of this, Met uses mols. such as Gab1 - homologues of which are present in Caenorhabditis elegans and Drosophila melanogaster - for downstream signalling. Pivotal roles for Met in development and cancer have been established: Met controls cell migration and growth in embryogenesis; it also controls growth, invasion and metastasis in cancer cells; and activating Met mutations predispose to human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_-6XRpZ-sLVg90H21EOLACvtfcHk0ljdJekdWD4PEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFeju7s%253D&md5=ff5a02c73415784480c628fe65299a81</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1038%2Fnrm1261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1261%26sid%3Dliteratum%253Aachs%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DMET%252C%2520metastasis%252C%2520motility%2520and%2520more%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D915%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">Novel therapeutic inhibitors of the c-Met signaling pathway in cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2207</span><span class="NLM_x">â</span> <span class="NLM_lpage">2214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-08-1306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19318488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVWltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=2207-2214&author=J.+P.+Ederauthor=G.+F.+Vande+Woudeauthor=S.+A.+Boernerauthor=P.+M.+LoRusso&title=Novel+therapeutic+inhibitors+of+the+c-Met+signaling+pathway+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer</span></div><div class="casAuthors">Eder, Joseph Paul; Vande Woude, George F.; Boerner, Scott A.; Lo Russo, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2207-2214</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  A wide variety of human malignancies exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the breast, liver, lung, ovary, kidney, and thyroid.  Notably, activating mutations in c-Met have been pos. identified in patients with a particular hereditary form of papillary renal cancer, directly implicating c-Met in human tumorigenesis.  Aberrant signaling of the c-Met signaling pathway due to dysregulation of the c-Met receptor or overexpression of its ligand, hepatocyte growth factor (HGF), has been assocd. with an aggressive phenotype.  Extensive evidence that c-Met signaling is involved in the progression and spread of several cancers and an enhanced understanding of its role in disease have generated considerable interest in c-Met and HGF as major targets in cancer drug development.  This has led to the development of a variety of c-Met pathway antagonists with potential clin. applications.  The three main approaches of pathway-selective anticancer drug development have included antagonism of ligand/receptor interaction, inhibition of the tyrosine kinase catalytic activity, and blockade of the receptor/effector interaction.  Several c-Met antagonists are now under clin. investigation.  Preliminary clin. results of several of these agents, including both monoclonal antibodies and small-mol. tyrosine kinase inhibitors, have been encouraging.  Several multitargeted therapies have also been under investigation in the clinic and have demonstrated promise, particularly with regard to tyrosine kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QBC0vQz8BrVg90H21EOLACvtfcHk0ljdJekdWD4PEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVWltrY%253D&md5=48b4fc788b2b2cab1ce523047e33721d</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1306%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DNovel%2520therapeutic%2520inhibitors%2520of%2520the%2520c-Met%2520signaling%2520pathway%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D2207%26epage%3D2214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Weidner, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cesare, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span> </span><span class="NLM_article-title">Interaction between Gab1 and the MET receptor tyrosine kinase is responsible for epithelial morphogenesis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=1996&pages=173-176&author=K.+M.+Weidnerauthor=S.+Di+Cesareauthor=M.+Sachsauthor=V.+Brinkmannauthor=J.+Behrensauthor=W.+Birchmeier&title=Interaction+between+Gab1+and+the+MET+receptor+tyrosine+kinase+is+responsible+for+epithelial+morphogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeidner%26aufirst%3DK.%2BM.%26aulast%3DDi%2BCesare%26aufirst%3DS.%26aulast%3DSachs%26aufirst%3DM.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DBehrens%26aufirst%3DJ.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DInteraction%2520between%2520Gab1%2520and%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520is%2520responsible%2520for%2520epithelial%2520morphogenesis%26jtitle%3DNature%26date%3D1996%26volume%3D384%26spage%3D173%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Mosesson, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarden, Y.</span><span> </span><span class="NLM_article-title">Derailed endocytosis: an emerging feature of cancer. <i>Nat. Rev</i></span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">â</span> <span class="NLM_lpage">850</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=835-850&author=Y.+Mosessonauthor=G.+B.+Millsauthor=Y.+Yarden&title=Derailed+endocytosis%3A+an+emerging+feature+of+cancer.+Nat.+Rev"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMosesson%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DDerailed%2520endocytosis%253A%2520an%2520emerging%2520feature%2520of%2520cancer.%2520Nat.%2520Rev%26jtitle%3DCancer%26date%3D2008%26volume%3D8%26spage%3D835%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Joffre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ©nard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calleja, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kermorgant, S.</span><span> </span><span class="NLM_article-title">A direct role for MET endocytosis in tumorigenesis</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">â</span> <span class="NLM_lpage">837</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fncb2257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21642981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlCnsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=827-837&author=C.+Joffreauthor=R.+Barrowauthor=L.+M%C3%A9nardauthor=V.+Callejaauthor=I.+R.+Hartauthor=S.+Kermorgant&title=A+direct+role+for+MET+endocytosis+in+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A direct role for Met endocytosis in tumorigenesis</span></div><div class="casAuthors">Joffre, Carine; Barrow, Rachel; Menard, Ludovic; Calleja, Veronique; Hart, Ian R.; Kermorgant, Stephanie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">827-837</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Compartmentalization of signals generated by receptor tyrosine kinase (RTK) endocytosis has emerged as a major determinant of various cell functions.  Here, using tumor-assocd. Met-activating mutations, we demonstrate a direct link between endocytosis and tumorigenicity.  Met mutants exhibit increased endocytosis/recycling activity and decreased levels of degrdn., leading to accumulation on endosomes, activation of the GTPase Rac1, loss of actin stress fibers and increased levels of cell migration.  Blocking endocytosis inhibited mutants' anchorage-independent growth, in vivo tumorigenesis and metastasis while maintaining their activation.  One mutant resistant to inhibition by a Met-specific tyrosine kinase inhibitor was sensitive to endocytosis inhibition.  Thus, oncogenicity of Met mutants results not only from activation but also from their altered endocytic trafficking, indicating that endosomal signalling may be a crucial mechanism regulating RTK-dependent tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmd_oor_T__LVg90H21EOLACvtfcHk0lhFzN2-b0q-8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlCnsLY%253D&md5=db50f30287d6c1024265275baf80e695</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fncb2257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb2257%26sid%3Dliteratum%253Aachs%26aulast%3DJoffre%26aufirst%3DC.%26aulast%3DBarrow%26aufirst%3DR.%26aulast%3DM%25C3%25A9nard%26aufirst%3DL.%26aulast%3DCalleja%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DI.%2BR.%26aulast%3DKermorgant%26aufirst%3DS.%26atitle%3DA%2520direct%2520role%2520for%2520MET%2520endocytosis%2520in%2520tumorigenesis%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2011%26volume%3D13%26spage%3D827%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Hammond, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UrbÃ©, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clague, M. J.</span><span> </span><span class="NLM_article-title">Down-regulation of MET, the receptor for hepatocyte growth factor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2761</span><span class="NLM_x">â</span> <span class="NLM_lpage">2770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=2761-2770&author=D.+E.+Hammondauthor=S.+Urb%C3%A9author=G.+F.+Vande+Woudeauthor=M.+J.+Clague&title=Down-regulation+of+MET%2C+the+receptor+for+hepatocyte+growth+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHammond%26aufirst%3DD.%2BE.%26aulast%3DUrb%25C3%25A9%26aufirst%3DS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DClague%26aufirst%3DM.%2BJ.%26atitle%3DDown-regulation%2520of%2520MET%252C%2520the%2520receptor%2520for%2520hepatocyte%2520growth%2520factor%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D2761%26epage%3D2770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Foveau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vingtdeux, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fafeur, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulasne, D.</span><span> </span><span class="NLM_article-title">Down-regulation of the MET receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2495</span><span class="NLM_x">â</span> <span class="NLM_lpage">2507</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1091%2Fmbc.E08-09-0969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19297528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotVyqur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=2495-2507&author=B.+Foveauauthor=F.+Ancotauthor=C.+Leroyauthor=A.+Petrelliauthor=K.+Reissauthor=V.+Vingtdeuxauthor=S.+Giordanoauthor=V.+Fafeurauthor=D.+Tulasne&title=Down-regulation+of+the+MET+receptor+tyrosine+kinase+by+presenilin-dependent+regulated+intramembrane+proteolysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis</span></div><div class="casAuthors">Foveau, Benedicte; Ancot, Frederic; Leroy, Catherine; Petrelli, Annalisa; Reiss, Karina; Vingtdeux, Valerie; Giordano, Silvia; Fafeur, Veronique; Tulasne, David</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2495-2507</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Hepatocyte growth factor/scatter factor (HGF/SF) acts through the membrane-anchored Met receptor tyrosine kinase to induce invasive growth.  Deregulation of this signaling is assocd. with tumorigenesis and involves, in most cases, overexpression of the receptor.  We demonstrate that Met is processed in epithelial cells by presenilin-dependent regulated intramembrane proteolysis (PS-RIP) independently of ligand stimulation.  The proteolytic process involves sequential cleavage by metalloproteases and the Î³-secretase complex, leading to generation of labile fragments.  In normal epithelial cells, although expression of cleavable Met by PS-RIP is down-regulated, uncleavable Met displayed membrane accumulation and induced ligand-independent motility and morphogenesis.  Inversely, in transformed cells, the Met inhibitory antibody DN30 is able to promote Met PS-RIP, resulting in down-regulation of the receptor and inhibition of the Met-dependent invasive growth.  This demonstrates the original involvement of a proteolytic process in degrdn. of the Met receptor implicated in neg. regulation of invasive growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryEBvF43sQbLVg90H21EOLACvtfcHk0lhFzN2-b0q-8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotVyqur0%253D&md5=68e1b3d30567e1a746b3947cb8670905</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1091%2Fmbc.E08-09-0969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.E08-09-0969%26sid%3Dliteratum%253Aachs%26aulast%3DFoveau%26aufirst%3DB.%26aulast%3DAncot%26aufirst%3DF.%26aulast%3DLeroy%26aufirst%3DC.%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DReiss%26aufirst%3DK.%26aulast%3DVingtdeux%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DFafeur%26aufirst%3DV.%26aulast%3DTulasne%26aufirst%3DD.%26atitle%3DDown-regulation%2520of%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520by%2520presenilin-dependent%2520regulated%2520intramembrane%2520proteolysis%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2009%26volume%3D20%26spage%3D2495%26epage%3D2507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavassa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sottile, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naldini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Targeting the tumor and its microenvironment by a dual-function decoy MET receptor</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">â</span> <span class="NLM_lpage">73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=61-73&author=P.+Michieliauthor=M.+Mazzoneauthor=C.+Basilicoauthor=S.+Cavassaauthor=A.+Sottileauthor=L.+Naldiniauthor=P.+M.+Comoglio&title=Targeting+the+tumor+and+its+microenvironment+by+a+dual-function+decoy+MET+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DMazzone%26aufirst%3DM.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DCavassa%26aufirst%3DS.%26aulast%3DSottile%26aufirst%3DA.%26aulast%3DNaldini%26aufirst%3DL.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DTargeting%2520the%2520tumor%2520and%2520its%2520microenvironment%2520by%2520a%2520dual-function%2520decoy%2520MET%2520receptor%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D61%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narsimhan, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medico, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaglia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Expression of the MET/HGF receptor in normal and neoplastic human tissues</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1997</span><span class="NLM_x">â</span> <span class="NLM_lpage">2003</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=1719465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK38XhvFSluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1991&pages=1997-2003&author=M.+F.+Di+Renzoauthor=R.+P.+Narsimhanauthor=M.+Oliveroauthor=S.+Brettiauthor=S.+Giordanoauthor=E.+Medicoauthor=P.+Gagliaauthor=P.+Zaraauthor=P.+M.+Comoglio&title=Expression+of+the+MET%2FHGF+receptor+in+normal+and+neoplastic+human+tissues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the Met/HGF receptor in normal and neoplastic human tissues</span></div><div class="casAuthors">Di Renzo, M. F.; Narsimhan, R. P.; Olivero, M.; Bretti, S.; Giordano, S.; Medico, E.; Gaglia, P.; Zara, P.; Comoglio, P. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1997-2003</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The MET oncogene encodes a transmembrane tyrosine kinase receptor.  Recently, hepatocyte growth factor (HGF), a potent growth factor for hepatocytes involved in liver regeneration, has been proposed as a ligand.  In this paper, the physiol. role of the human Met/HGF receptor is investigated by studying its specific distribution in normal and neoplastic tissues.  Northern blot anal. has shown that the MET gene is selectively expressed in several epithelial tissues.  High levels of MET mRNA have been found in liver, gastrointestinal tract, thyroid and kidney.  Western blot anal. has shown that the levels of the Met protein generally correspond to those of the mRNA.  However, in the thyroid, where there is a high level of MET mRNA, the protein was barely detectable, suggesting translational or posttranslational regulation.  The protein was also detected in the brain.  Normal or increased levels of MET mRNA and Met protein were consistently found in fresh samples of carcinomas as well as in epithelial tumor cell lines.  In thyroid carcinomas of a specific histiotype the amt. of Met protein, almost undetectable in the normal counterpart, was found to be increased more than 100-fold.  The tissue distribution of the Met/HGF receptor indicates that this mol. is involved in growth control of epithelial cells other than hepatocytes and suggests that its increased expression may confer a growth advantage to neoplastic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobwF4weEnvMLVg90H21EOLACvtfcHk0lhwb_VJ4vJADQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvFSluw%253D%253D&md5=d58184b28f486759cc74906ecd9bf3b9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26aulast%3DNarsimhan%26aufirst%3DR.%2BP.%26aulast%3DOlivero%26aufirst%3DM.%26aulast%3DBretti%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DMedico%26aufirst%3DE.%26aulast%3DGaglia%26aufirst%3DP.%26aulast%3DZara%26aufirst%3DP.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DExpression%2520of%2520the%2520MET%252FHGF%2520receptor%2520in%2520normal%2520and%2520neoplastic%2520human%2520tissues%26jtitle%3DOncogene%26date%3D1991%26volume%3D6%26spage%3D1997%26epage%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Tajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higuchi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span> </span><span class="NLM_article-title">Tissue distribution of hepatocyte growth factor receptor and its exclusive down-regulation in a regenerating organ after injury</span> <span class="citation_source-journal">J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">â</span> <span class="NLM_lpage">406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=1316892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK38XhvFWqtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1992&pages=401-406&author=H.+Tajimaauthor=O.+Higuchiauthor=K.+Mizunoauthor=T.+Nakamura&title=Tissue+distribution+of+hepatocyte+growth+factor+receptor+and+its+exclusive+down-regulation+in+a+regenerating+organ+after+injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue distribution of hepatocyte growth factor receptor and its exclusive down-regulation in a regenerating organ after injury</span></div><div class="casAuthors">Tajima, Hisao; Higuchi, Osamu; Mizuno, Kensaku; Nakamura, Toshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry </span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">401-6</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    </div><div class="casAbstract">Using 125I-labeled hepatocyte growth factor (HGF) as a ligand, the authors examd. the tissue distribution of the HGF receptor in adult rats.  Specific binding of 125I-HGF was detected in the plasma membranes of liver, spleen, kidney, lung, adrenal gland, pituitary, and thyroid.  Scatchard anal. of HGF binding in liver, spleen, kidney, lung, and adrenal gland revealed the presence of a single class of high affinity receptor with a dissocn. const. (Kd) of 20-30 pM.  The max. no. of binding sites (Bmax) was 400-3,000 sites per ng of plasma membrane protein, the highest no. being in the liver.  Such a wide distribution of a high affinity HGF receptor indicates that HGF may be a multifunctional growth factor, targeting to a variety of organs, and not restricted to liver.  After 70% partial hepatectomy, specific binding of 125I-HGF to membranes of the residual liver rapidly decreased, but there was no change in the kidney, lung, and spleen.  After unilateral nephrectomy rapid down-regulation of the HGF receptor was evident in the remaining kidney, but not in other organs including the liver.  These findings suggest the presence of control mechanisms governing HGF receptor function only in a regenerating organ after injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8WmbEALbtQLVg90H21EOLACvtfcHk0lhwb_VJ4vJADQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvFWqtbc%253D&md5=3e1fcf9c606aa4a589bb1a6209df70b9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTajima%26aufirst%3DH.%26aulast%3DHiguchi%26aufirst%3DO.%26aulast%3DMizuno%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DTissue%2520distribution%2520of%2520hepatocyte%2520growth%2520factor%2520receptor%2520and%2520its%2520exclusive%2520down-regulation%2520in%2520a%2520regenerating%2520organ%2520after%2520injury%26jtitle%3DJ.%2520Biochem.%26date%3D1992%26volume%3D111%26spage%3D401%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span> </span><span class="NLM_article-title">Invasive growth: from development to metastasis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">â</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=857-862&author=P.+M.+Comoglioauthor=L.+Trusolino&title=Invasive+growth%3A+from+development+to+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DTrusolino%26aufirst%3DL.%26atitle%3DInvasive%2520growth%253A%2520from%2520development%2520to%2520metastasis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D857%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Schmidt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bladt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goedecke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zschiesche, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, C.</span><span> </span><span class="NLM_article-title">Scatter factor/hepatocyte growth factor is essential for liver development</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">â</span> <span class="NLM_lpage">702</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=699-702&author=C.+Schmidtauthor=F.+Bladtauthor=S.+Goedeckeauthor=V.+Brinkmannauthor=W.+Zschiescheauthor=M.+Sharpeauthor=E.+Gherardiauthor=C.+Birchmeier&title=Scatter+factor%2Fhepatocyte+growth+factor+is+essential+for+liver+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DBladt%26aufirst%3DF.%26aulast%3DGoedecke%26aufirst%3DS.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DZschiesche%26aufirst%3DW.%26aulast%3DSharpe%26aufirst%3DM.%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DBirchmeier%26aufirst%3DC.%26atitle%3DScatter%2520factor%252Fhepatocyte%2520growth%2520factor%2520is%2520essential%2520for%2520liver%2520development%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D699%26epage%3D702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Uehara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minowa, O..</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuno, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, N.</span><span> </span><span class="NLM_article-title">Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">702</span><span class="NLM_x">â</span> <span class="NLM_lpage">705</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=702-705&author=Y.+Ueharaauthor=O..+Minowaauthor=C.+Moriauthor=K.+Shiotaauthor=J.+Kunoauthor=T.+Nodaauthor=N.+Kitamura&title=Placental+defect+and+embryonic+lethality+in+mice+lacking+hepatocyte+growth+factor%2Fscatter+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUehara%26aufirst%3DY.%26aulast%3DMinowa%26aufirst%3DO..%26aulast%3DMori%26aufirst%3DC.%26aulast%3DShiota%26aufirst%3DK.%26aulast%3DKuno%26aufirst%3DJ.%26aulast%3DNoda%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DN.%26atitle%3DPlacental%2520defect%2520and%2520embryonic%2520lethality%2520in%2520mice%2520lacking%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D702%26epage%3D705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Bladt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riethmacher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isenmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguzzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, C.</span><span> </span><span class="NLM_article-title">Essential role for the MET receptor in the migration of myogenic precursor cells into the limb bud</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">768</span><span class="NLM_x">â</span> <span class="NLM_lpage">771</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=768-771&author=F.+Bladtauthor=D.+Riethmacherauthor=S.+Isenmannauthor=A.+Aguzziauthor=C.+Birchmeier&title=Essential+role+for+the+MET+receptor+in+the+migration+of+myogenic+precursor+cells+into+the+limb+bud"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBladt%26aufirst%3DF.%26aulast%3DRiethmacher%26aufirst%3DD.%26aulast%3DIsenmann%26aufirst%3DS.%26aulast%3DAguzzi%26aufirst%3DA.%26aulast%3DBirchmeier%26aufirst%3DC.%26atitle%3DEssential%2520role%2520for%2520the%2520MET%2520receptor%2520in%2520the%2520migration%2520of%2520myogenic%2520precursor%2520cells%2520into%2520the%2520limb%2520bud%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D768%26epage%3D771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Maina, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponzetto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, R.</span><span> </span><span class="NLM_article-title">MET receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3341</span><span class="NLM_x">â</span> <span class="NLM_lpage">3350</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=3341-3350&author=F.+Mainaauthor=M.+C.+Hiltonauthor=C.+Ponzettoauthor=A.+M.+Daviesauthor=R.+Klein&title=MET+receptor+signaling+is+required+for+sensory+nerve+development+and+HGF+promotes+axonal+growth+and+survival+of+sensory+neurons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaina%26aufirst%3DF.%26aulast%3DHilton%26aufirst%3DM.%2BC.%26aulast%3DPonzetto%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DKlein%26aufirst%3DR.%26atitle%3DMET%2520receptor%2520signaling%2520is%2520required%2520for%2520sensory%2520nerve%2520development%2520and%2520HGF%2520promotes%2520axonal%2520growth%2520and%2520survival%2520of%2520sensory%2520neurons%26jtitle%3DGenes%2520Dev.%26date%3D1997%26volume%3D11%26spage%3D3341%26epage%3D3350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Sachs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brohmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zechner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">HÃ¼lsken, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeper, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span> </span><span class="NLM_article-title">Essential role of Gab1 for signaling by the MET receptor in vivo</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">1375</span><span class="NLM_x">â</span> <span class="NLM_lpage">1384</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2000&pages=1375-1384&author=M.+Sachsauthor=H.+Brohmannauthor=D.+Zechnerauthor=T.+M%C3%BCllerauthor=J.+H%C3%BClskenauthor=I.+Waltherauthor=U.+Schaeperauthor=C.+Birchmeierauthor=W.+Birchmeier&title=Essential+role+of+Gab1+for+signaling+by+the+MET+receptor+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSachs%26aufirst%3DM.%26aulast%3DBrohmann%26aufirst%3DH.%26aulast%3DZechner%26aufirst%3DD.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%26aulast%3DH%25C3%25BClsken%26aufirst%3DJ.%26aulast%3DWalther%26aufirst%3DI.%26aulast%3DSchaeper%26aufirst%3DU.%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DEssential%2520role%2520of%2520Gab1%2520for%2520signaling%2520by%2520the%2520MET%2520receptor%2520in%2520vivo%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2000%26volume%3D150%26spage%3D1375%26epage%3D1384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Huh, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Factor, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SÃ¡nchez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conner, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorgeirsson, S. S.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor/MET signaling pathway is required for efficient liver regeneration and repair</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">4477</span><span class="NLM_x">â</span> <span class="NLM_lpage">4482</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=4477-4482&author=C.+G.+Huhauthor=V.+M.+Factorauthor=A.+S%C3%A1nchezauthor=K.+Uchidaauthor=E.+A.+Connerauthor=S.+S.+Thorgeirsson&title=Hepatocyte+growth+factor%2FMET+signaling+pathway+is+required+for+efficient+liver+regeneration+and+repair"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuh%26aufirst%3DC.%2BG.%26aulast%3DFactor%26aufirst%3DV.%2BM.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DA.%26aulast%3DUchida%26aufirst%3DK.%26aulast%3DConner%26aufirst%3DE.%2BA.%26aulast%3DThorgeirsson%26aufirst%3DS.%2BS.%26atitle%3DHepatocyte%2520growth%2520factor%252FMET%2520signaling%2520pathway%2520is%2520required%2520for%2520efficient%2520liver%2520regeneration%2520and%2520repair%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D4477%26epage%3D4482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Michalopoulos, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeFrances, M. C.</span><span> </span><span class="NLM_article-title">Liver regeneration</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">â</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1126%2Fscience.276.5309.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=9082986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK2sXitlyqt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=60-66&author=G.+K.+Michalopoulosauthor=M.+C.+DeFrances&title=Liver+regeneration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Liver regeneration</span></div><div class="casAuthors">Michalopoulos, George K.; DeFrances, Marie C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5309</span>),
    <span class="NLM_cas:pages">60-66</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 98 refs.  Liver regeneration after the loss of hepatic tissue is a fundamental parameter of liver response to injury.  Recognized as a phenomenon from mythol. times, it is now defined as an orchestrated response induced by specific external stimuli and involving sequential changes in gene expression, growth factor prodn., and morphol. structure.  Many growth factors and cytokines, most notably hepatocyte growth factor, epidermal growth factor, transforming growth factor-Î±, interleukin-6, tumor necrosis factor-Î±, insulin, and norepinephrine, appear to play important roles in this process.  This review attempts to integrate the findings of the last three decades and looks toward clues as to the nature of the causes that trigger this fascinating organ and cellular response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryWZQ48IfGpbVg90H21EOLACvtfcHk0lgN5hcC5cIzrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitlyqt78%253D&md5=3961787026f78ecfbd3032e6c6f8fc90</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.276.5309.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.276.5309.60%26sid%3Dliteratum%253Aachs%26aulast%3DMichalopoulos%26aufirst%3DG.%2BK.%26aulast%3DDeFrances%26aufirst%3DM.%2BC.%26atitle%3DLiver%2520regeneration%26jtitle%3DScience%26date%3D1997%26volume%3D276%26spage%3D60%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Liu, Y.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action</span> <span class="citation_source-journal">Am. J. Physiol.: Renal Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">F7</span><span class="NLM_x">â</span> <span class="NLM_lpage">F16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2004&pages=F7-F16&author=Y.+Liu&title=Hepatocyte+growth+factor+in+kidney+fibrosis%3A+therapeutic+potential+and+mechanisms+of+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DHepatocyte%2520growth%2520factor%2520in%2520kidney%2520fibrosis%253A%2520therapeutic%2520potential%2520and%2520mechanisms%2520of%2520action%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Renal%2520Physiol.%26date%3D2004%26volume%3D287%26spage%3DF7%26epage%3DF16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Chmielowiec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, W. G.</span><span> </span><span class="NLM_article-title">MET is essential for wound healing in the skin</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">162</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2007&pages=151-162&author=J.+Chmielowiecauthor=F.+Rugeauthor=P.+Priceauthor=K.+G.+Hardingauthor=W.+G.+Jiang&title=MET+is+essential+for+wound+healing+in+the+skin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChmielowiec%26aufirst%3DJ.%26aulast%3DRuge%26aufirst%3DF.%26aulast%3DPrice%26aufirst%3DP.%26aulast%3DHarding%26aufirst%3DK.%2BG.%26aulast%3DJiang%26aufirst%3DW.%2BG.%26atitle%3DMET%2520is%2520essential%2520for%2520wound%2520healing%2520in%2520the%2520skin%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2007%26volume%3D177%26spage%3D151%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">â</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lgN5hcC5cIzrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Cepero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sierra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1396</span><span class="NLM_x">â</span> <span class="NLM_lpage">1409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.2174%2F138161210791033905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20166985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFynsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1396-1409&author=V.+Ceperoauthor=J.+R.+Sierraauthor=S.+Giordano&title=Tyrosine+kinases+as+molecular+targets+to+inhibit+cancer+progression+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis</span></div><div class="casAuthors">Cepero, V.; Sierra, J. R.; Giordano, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1396-1409</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  During the last decades, the improvement of our knowledge of the mechanisms responsible for cancer development has led to the introduction of new promising strategies of treatment, based on "mol. targeted" drugs.  These drugs are designed to act on specific mols., identified as major players in the maintenance of the malignant status.  The development of inhibitors, mainly monoclonal antibodies and small-mols., directed against activated oncogenes has been the most widely used approach for this kind of treatment.  Among the oncogenes implicated in human cancers, tyrosine kinases play a crit. role.  This observation, together with the discovery that cancer cells can be dependent for their survival from the continuous expression of activated oncogenes (a concept defined as "oncogene addiction"), has made protein kinases ideal targets for targeted therapy in cancer.  As the field of targeted therapies is now rapidly growing and a comprehensive survey would be too wide, this review will thus mainly focus on strategies aimed at inhibiting tyrosine kinases and their signal transduction pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovwa2l5kFkH7Vg90H21EOLACvtfcHk0lhF1n0FNvGrhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFynsrg%253D&md5=1e5b7e673a31ae4d85bdc91b6ac63117</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F138161210791033905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210791033905%26sid%3Dliteratum%253Aachs%26aulast%3DCepero%26aufirst%3DV.%26aulast%3DSierra%26aufirst%3DJ.%2BR.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DTyrosine%2520kinases%2520as%2520molecular%2520targets%2520to%2520inhibit%2520cancer%2520progression%2520and%2520metastasis%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D1396%26epage%3D1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span> </span><span class="NLM_article-title">Drug development of MET inhibitors: targeting oncogene addiction and expedience</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">504</span><span class="NLM_x">â</span> <span class="NLM_lpage">516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=504-516&author=P.+M.+Comoglioauthor=S.+Giordanoauthor=L.+Trusolino&title=Drug+development+of+MET+inhibitors%3A+targeting+oncogene+addiction+and+expedience"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DTrusolino%26aufirst%3DL.%26atitle%3DDrug%2520development%2520of%2520MET%2520inhibitors%253A%2520targeting%2520oncogene%2520addiction%2520and%2520expedience%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D504%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Boccaccio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Invasive growth: a MET-driven genetic programme for cancer and stem cells</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">â</span> <span class="NLM_lpage">645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc1912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=16862193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFGlu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=637-645&author=C.+Boccaccioauthor=P.+M.+Comoglio&title=Invasive+growth%3A+a+MET-driven+genetic+programme+for+cancer+and+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Invasive growth: a MET-driven genetic programme for cancer and stem cells</span></div><div class="casAuthors">Boccaccio, Carla; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metastasis follows the inappropriate activation of a genetic program termed invasive growth, which is a physiol. process that occurs during embryonic development and post-natal organ regeneration.  Burgeoning evidence indicates that invasive growth is also executed by stem and progenitor cells, and is usurped by cancer stem cells.  The MET proto-oncogene, which is expressed in both stem and cancer cells, is a key regulator of invasive growth.  Recent findings indicate that the MET tyrosine-kinase receptor is a sensor of adverse microenvironmental conditions (such as hypoxia) and drives cell invasion and metastasis through the transcriptional activation of a set of genes that control blood coagulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNb2dfp5v27Vg90H21EOLACvtfcHk0lhF1n0FNvGrhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFGlu70%253D&md5=79319c46d57d395726d389e6cd03068f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrc1912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1912%26sid%3Dliteratum%253Aachs%26aulast%3DBoccaccio%26aufirst%3DC.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DInvasive%2520growth%253A%2520a%2520MET-driven%2520genetic%2520programme%2520for%2520cancer%2520and%2520stem%2520cells%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D637%26epage%3D645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span>Hepatocyte Growth Factor/Scatter Factor (HGF/SF), MET and Cancer References. <a href="http://www.vai.org/MET/Index.aspx" class="extLink">http://www.vai.org/MET/Index.aspx</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hepatocyte+Growth+Factor%2FScatter+Factor+%28HGF%2FSF%29%2C+MET+and+Cancer+References.+http%3A%2F%2Fwww.vai.org%2FMET%2FIndex.aspx."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Migliore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">Molecular cancer therapy: Can our expectation be MET?</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=641-651&author=C.+Miglioreauthor=S.+Giordano&title=Molecular+cancer+therapy%3A+Can+our+expectation+be+MET%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMigliore%26aufirst%3DC.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DMolecular%2520cancer%2520therapy%253A%2520Can%2520our%2520expectation%2520be%2520MET%253F%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeesh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nallasura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lader, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarbaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Functional expression and mutations of MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">â</span> <span class="NLM_lpage">1488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1479-1488&author=P.+C.+Maauthor=R.+Jagadeeswaranauthor=S.+Jagadeeshauthor=M.+S.+Tretiakovaauthor=V.+Nallasuraauthor=E.+A.+Foxauthor=M.+Hansenauthor=E.+Schaeferauthor=K.+Naokiauthor=A.+Laderauthor=W.+Richardsauthor=D.+Sugarbakerauthor=A.+N.+Husainauthor=J.+G.+Christensenauthor=R.+Salgia&title=Functional+expression+and+mutations+of+MET+and+its+therapeutic+inhibition+with+SU11274+and+small+interfering+RNA+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DJagadeesh%26aufirst%3DS.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DNallasura%26aufirst%3DV.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DSchaefer%26aufirst%3DE.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DLader%26aufirst%3DA.%26aulast%3DRichards%26aufirst%3DW.%26aulast%3DSugarbaker%26aufirst%3DD.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DFunctional%2520expression%2520and%2520mutations%2520of%2520MET%2520and%2520its%2520therapeutic%2520inhibition%2520with%2520SU11274%2520and%2520small%2520interfering%2520RNA%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D1479%26epage%3D1488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">van Leenders, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sookhlall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teubel, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ridder, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reneman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacchetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vissers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Weerden, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenster, G.</span><span> </span><span class="NLM_article-title">Activation of MET induces a stem-like phenotype in human prostate cancer</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e26753</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e26753&author=G.+J.+van+Leendersauthor=R.+Sookhlallauthor=W.+J.+Teubelauthor=C.+M.+de+Ridderauthor=S.+Renemanauthor=A.+Sacchettiauthor=K.+J.+Vissersauthor=W.+van+Weerdenauthor=G.+Jenster&title=Activation+of+MET+induces+a+stem-like+phenotype+in+human+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BLeenders%26aufirst%3DG.%2BJ.%26aulast%3DSookhlall%26aufirst%3DR.%26aulast%3DTeubel%26aufirst%3DW.%2BJ.%26aulast%3Dde%2BRidder%26aufirst%3DC.%2BM.%26aulast%3DReneman%26aufirst%3DS.%26aulast%3DSacchetti%26aufirst%3DA.%26aulast%3DVissers%26aufirst%3DK.%2BJ.%26aulast%3Dvan%2BWeerden%26aufirst%3DW.%26aulast%3DJenster%26aufirst%3DG.%26atitle%3DActivation%2520of%2520MET%2520induces%2520a%2520stem-like%2520phenotype%2520in%2520human%2520prostate%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De26753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Pennacchietti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">â</span> <span class="NLM_lpage">361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=347-361&author=S.+Pennacchiettiauthor=P.+Michieliauthor=M.+Galluzzoauthor=M.+Mazzoneauthor=S.+Giordanoauthor=P.+M.+Comoglio&title=Hypoxia+promotes+invasive+growth+by+transcriptional+activation+of+the+MET+protooncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPennacchietti%26aufirst%3DS.%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DGalluzzo%26aufirst%3DM.%26aulast%3DMazzone%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DHypoxia%2520promotes%2520invasive%2520growth%2520by%2520transcriptional%2520activation%2520of%2520the%2520MET%2520protooncogene%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D3%26spage%3D347%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Casaletto, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClatchey, A. I.</span><span> </span><span class="NLM_article-title">Spatial regulation of receptor tyrosine kinases in development and cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">â</span> <span class="NLM_lpage">400</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc3277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22622641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xntlyks7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=387-400&author=J.+B.+Casalettoauthor=A.+I.+McClatchey&title=Spatial+regulation+of+receptor+tyrosine+kinases+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Spatial regulation of receptor tyrosine kinases in development and cancer</span></div><div class="casAuthors">Casaletto, Jessica B.; McClatchey, Andrea I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-400</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  During development and tissue homeostasis, patterns of cellular organization, proliferation and movement are highly choreographed.  Receptor tyrosine kinases (RTKs) have a crucial role in establishing these patterns.  Individual cells and tissues exhibit tight spatial control of the RTKs that they express, enabling tissue morphogenesis and function, while preventing unwarranted cell division and migration that can contribute to tumorigenesis.  Indeed, RTKs are deregulated in most human cancers and are a major focus of targeted therapeutics.  A growing appreciation of the essential role of spatial RTK regulation during development prompts the realization that spatial deregulation of RTKs is likely to contribute broadly to cancer development and may affect the sensitivity and resistance of cancer to pharmacol. RTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0roP5DmwDDrVg90H21EOLACvtfcHk0lhnTyHgU7ByhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xntlyks7Y%253D&md5=87d62276b4319a41ec37befe62dde0a1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrc3277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3277%26sid%3Dliteratum%253Aachs%26aulast%3DCasaletto%26aufirst%3DJ.%2BB.%26aulast%3DMcClatchey%26aufirst%3DA.%2BI.%26atitle%3DSpatial%2520regulation%2520of%2520receptor%2520tyrosine%2520kinases%2520in%2520development%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D387%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">PatanÃ¨, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coltella, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sponza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliverom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigna, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naldini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferracini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span> </span><span class="NLM_article-title">MET overexpression turns human primary osteoblasts into osteosarcomas</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">4750</span><span class="NLM_x">â</span> <span class="NLM_lpage">4757</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4750-4757&author=S.+Patan%C3%A8author=S.+Avnetauthor=N.+Coltellaauthor=B.+Costaauthor=S.+Sponzaauthor=M.+Oliveromauthor=E.+Vignaauthor=L.+Naldiniauthor=N.+Baldiniauthor=R.+Ferraciniauthor=S.+Corsoauthor=S.+Giordanoauthor=P.+M.+Comoglioauthor=M.+F.+Di+Renzo&title=MET+overexpression+turns+human+primary+osteoblasts+into+osteosarcomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatan%25C3%25A8%26aufirst%3DS.%26aulast%3DAvnet%26aufirst%3DS.%26aulast%3DColtella%26aufirst%3DN.%26aulast%3DCosta%26aufirst%3DB.%26aulast%3DSponza%26aufirst%3DS.%26aulast%3DOliverom%26aufirst%3DM.%26aulast%3DVigna%26aufirst%3DE.%26aulast%3DNaldini%26aufirst%3DL.%26aulast%3DBaldini%26aufirst%3DN.%26aulast%3DFerracini%26aufirst%3DR.%26aulast%3DCorso%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26atitle%3DMET%2520overexpression%2520turns%2520human%2520primary%2520osteoblasts%2520into%2520osteosarcomas%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4750%26epage%3D4757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Houldsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordon-Cardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelsen, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaganti, R. S.</span><span> </span><span class="NLM_article-title">Gene amplification in gastric and esophageal adenocarcinomas</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">6417</span><span class="NLM_x">â</span> <span class="NLM_lpage">6422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1990&pages=6417-6422&author=J.+Houldsworthauthor=C.+Cordon-Cardoauthor=M.+Ladanyiauthor=D.+P.+Kelsenauthor=R.+S.+Chaganti&title=Gene+amplification+in+gastric+and+esophageal+adenocarcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHouldsworth%26aufirst%3DJ.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DKelsen%26aufirst%3DD.%2BP.%26aulast%3DChaganti%26aufirst%3DR.%2BS.%26atitle%3DGene%2520amplification%2520in%2520gastric%2520and%2520esophageal%2520adenocarcinomas%26jtitle%3DCancer%2520Res.%26date%3D1990%26volume%3D50%26spage%3D6417%26epage%3D6422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Umeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiota, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, H.</span><span> </span><span class="NLM_article-title">Clinical significance of MET oncogene alterations in human colorectal cancer</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=314-321&author=K.+Umekiauthor=G.+Shiotaauthor=H.+Kawasaki&title=Clinical+significance+of+MET+oncogene+alterations+in+human+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUmeki%26aufirst%3DK.%26aulast%3DShiota%26aufirst%3DG.%26aulast%3DKawasaki%26aufirst%3DH.%26atitle%3DClinical%2520significance%2520of%2520MET%2520oncogene%2520alterations%2520in%2520human%2520colorectal%2520cancer%26jtitle%3DOncology%26date%3D1999%26volume%3D56%26spage%3D314%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Beau-Faller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegeli, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuville, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legrain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mennecier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wihlm, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quoix, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaub, M. P.</span><span> </span><span class="NLM_article-title">MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naÃ¯ve cohort</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">â</span> <span class="NLM_lpage">339</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1097%2FJTO.0b013e318168d9d4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18379349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BD1c3it1Gjsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=331-339&author=M.+Beau-Fallerauthor=A.+M.+Ruppertauthor=A.+C.+Voegeliauthor=A.+Neuvilleauthor=N.+Meyerauthor=E.+Guerinauthor=M.+Legrainauthor=B.+Mennecierauthor=J.+M.+Wihlmauthor=G.+Massardauthor=E.+Quoixauthor=P.+Oudetauthor=M.+P.+Gaub&title=MET+gene+copy+number+in+non-small+cell+lung+cancer%3A+molecular+analysis+in+a+targeted+tyrosine+kinase+inhibitor+na%C3%AFve+cohort"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort</span></div><div class="casAuthors">Beau-Faller Michele; Ruppert Anne-Marie; Voegeli Anne-Claire; Neuville Agnes; Meyer Nicolas; Guerin Eric; Legrain Michele; Mennecier Bertrand; Wihlm Jean-Marie; Massard Gilbert; Quoix Elisabeth; Oudet Pierre; Gaub Marie P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Recent clinical success of epidermal growth factor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) have raised hopes that targeting other deregulated growth factor signaling, such as the hepatocyte growth factor/MET pathway, will lead to new therapeutic options for NSCLC.  Furthermore, NSCLC present secondary EGFR-TKIs resistance related to exons 20 and 19 EGFR mutations or more recently to MET amplification.  The aim of this study was to determine MET copy number related to EGFR copy number and K-Ras mutations in a targeted TKI naive NSCLC cohort.  METHODS:  We investigated 106 frozen tumors from surgically resected NSCLC patients.  Genes copy number of MET and EGFR were assessed by quantitative relative real-time polymerase chain reaction and K-Ras mutations by sequencing.  RESULTS:  MET is amplified in 22 cases (21%) and deleted in nine cases (8.5%).  EGFR is amplified in 31 cases (29%).  K-Ras is mutated in 11 cases (10.5%).  As observed for EGFR amplification, MET amplification is never associated with K-Ras mutation.  MET amplification could be associated with EGFR amplification.  MET amplification is not related to clinical and pathologic features.  MET amplification and EGFR amplification showed a trend toward poor prognosis in adenocarcinomas.  CONCLUSION:  In EGFR-TKIs naive NSCLC patients, MET amplification is a frequent event, which could be associated with EGFR amplification, but not with K-Ras mutation.  MET amplification may identify a subset of NSCLC for new targeted therapy.  It will also be important to evaluate MET copy number to properly interpret future clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQu7DmD4BD9JQxyojvcjibhfW6udTcc2eZKguMCUL7-27ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3it1Gjsw%253D%253D&md5=1457e4a0a360a8344356cee8a538ad55</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e318168d9d4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e318168d9d4%26sid%3Dliteratum%253Aachs%26aulast%3DBeau-Faller%26aufirst%3DM.%26aulast%3DRuppert%26aufirst%3DA.%2BM.%26aulast%3DVoegeli%26aufirst%3DA.%2BC.%26aulast%3DNeuville%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DGuerin%26aufirst%3DE.%26aulast%3DLegrain%26aufirst%3DM.%26aulast%3DMennecier%26aufirst%3DB.%26aulast%3DWihlm%26aufirst%3DJ.%2BM.%26aulast%3DMassard%26aufirst%3DG.%26aulast%3DQuoix%26aufirst%3DE.%26aulast%3DOudet%26aufirst%3DP.%26aulast%3DGaub%26aufirst%3DM.%2BP.%26atitle%3DMET%2520gene%2520copy%2520number%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520molecular%2520analysis%2520in%2520a%2520targeted%2520tyrosine%2520kinase%2520inhibitor%2520na%25C3%25AFve%2520cohort%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2008%26volume%3D3%26spage%3D331%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Tong, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, H. K.</span><span> </span><span class="NLM_article-title">Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization</span> <span class="citation_source-journal">J. Neurosurg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">â</span> <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=14758948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Glt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2004&pages=187-193&author=C.+Y.+Tongauthor=A.+B.+Huiauthor=X.+L.+Yinauthor=J.+C.+Pangauthor=X.+L.+Zhuauthor=W.+S.+Poonauthor=H.+K.+Ng&title=Detection+of+oncogene+amplifications+in+medulloblastomas+by+comparative+genomic+hybridization+and+array-based+comparative+genomic+hybridization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization</span></div><div class="casAuthors">Tong, Carol Y. K.; Hui, Angela B. Y.; Yin, Xiao-Lu; Pang, Jesse C. S.; Zhu, Xian-Lun; Poon, Wai-Sang; Ng, Ho-Keung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurosurgery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">2, Suppl.</span>),
    <span class="NLM_cas:pages">187-193</span>CODEN:
                <span class="NLM_cas:coden">JONSAC</span>;
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    
            (<span class="NLM_cas:orgname">American Association of Neurological Surgeons</span>)
        </div><div class="casAbstract">Object: Few studies have been conducted to investigate the genomic survey of oncogene amplification in medulloblastoma.  Low frequency of N-myc, C-myc, and epidermal grow factor receptor (EGFR) gene amplification (< 10%) has been reported in medulloblastoma.  Previous comparative genomic hybridization (CGH) study of primary medulloblastomas has revealed chromosomal amplification on 2p21, 3p, 5p15.3, 7q, 8q24, 11q22.3, and 17q.  The aim of this study was to detect common oncogenes involved in medulloblastoma tumorigenesis.  Methods: The authors studied a series of 14 samples by performing CGH and array-based CGH.  The CGH anal. detected nonrandom losses on 8p, 17p, 16q, 8q, and 1p, whereas gains were found on 17q, 12q, 7q, and 1p.  Array-based CGH was conducted to investigate amplification of 58 oncogenes throughout the genome of these samples.  Gene amplifications identified for the first time included PGY1 at 7q21.1, MDM2 at 12q14.3-q15, and ERBB2 at 17q21.2.  The highest frequencies of oncogene gain were detected in D17S1670 (61.5%), PIK3CA (46.2%), PGY1 (38.5%), MET (38.5%), ERBB2 (38.5%), and CSE1L (38.5%).  The gain in gene copy nos. was confirmed in 34 addnl. archival medulloblastoma cases by using fluorescence in situ hybridization anal.  Conclusions: This is the first genome-wide survey of multiple oncogene amplifications involved in the development of medulloblastoma.  Gains of several candidate oncogenes such as D17S1670, ERBB2, PIK3CA, PGY1, MET, and CSE1L were frequently detected.  These genes may be used as mol. markers and therapeutic targets of medulloblastomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMsX-htjJnZbVg90H21EOLACvtfcHk0lixvJs1CmMFNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Glt78%253D&md5=2fcd8ee56c687a8f4ae5771a3ade51c1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DC.%2BY.%26aulast%3DHui%26aufirst%3DA.%2BB.%26aulast%3DYin%26aufirst%3DX.%2BL.%26aulast%3DPang%26aufirst%3DJ.%2BC.%26aulast%3DZhu%26aufirst%3DX.%2BL.%26aulast%3DPoon%26aufirst%3DW.%2BS.%26aulast%3DNg%26aufirst%3DH.%2BK.%26atitle%3DDetection%2520of%2520oncogene%2520amplifications%2520in%2520medulloblastomas%2520by%2520comparative%2520genomic%2520hybridization%2520and%2520array-based%2520comparative%2520genomic%2520hybridization%26jtitle%3DJ.%2520Neurosurg.%26date%3D2004%26volume%3D100%26spage%3D187%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Beroukhim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nghiemphu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsueh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linhart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kau, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prensner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiasi, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demichelis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lander, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellinghoff, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span> </span><span class="NLM_article-title">Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">20007</span><span class="NLM_x">â</span> <span class="NLM_lpage">20012</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=20007-20012&author=R.+Beroukhimauthor=G.+Getzauthor=L.+Nghiemphuauthor=J.+Barretinaauthor=T.+Hsuehauthor=D.+Linhartauthor=I.+Vivancoauthor=J.+C.+Leeauthor=J.+H.+Huangauthor=S.+Alexanderauthor=J.+Duauthor=T.+Kauauthor=R.+K.+Thomasauthor=K.+Shahauthor=H.+Sotoauthor=S.+Pernerauthor=J.+Prensnerauthor=R.+M.+Debiasiauthor=F.+Demichelisauthor=C.+Hattonauthor=M.+A.+Rubinauthor=L.+A.+Garrawayauthor=S.+F.+Nelsonauthor=L.+Liauauthor=P.+S.+Mischelauthor=T.+F.+Cloughesyauthor=M.+Meyersonauthor=T.+A.+Golubauthor=E.+S.+Landerauthor=I.+K.+Mellinghoffauthor=W.+R.+Sellers&title=Assessing+the+significance+of+chromosomal+aberrations+in+cancer%3A+methodology+and+application+to+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DNghiemphu%26aufirst%3DL.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DHsueh%26aufirst%3DT.%26aulast%3DLinhart%26aufirst%3DD.%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DJ.%2BH.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DKau%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DSoto%26aufirst%3DH.%26aulast%3DPerner%26aufirst%3DS.%26aulast%3DPrensner%26aufirst%3DJ.%26aulast%3DDebiasi%26aufirst%3DR.%2BM.%26aulast%3DDemichelis%26aufirst%3DF.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DLiau%26aufirst%3DL.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BA.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DAssessing%2520the%2520significance%2520of%2520chromosomal%2520aberrations%2520in%2520cancer%253A%2520methodology%2520and%2520application%2520to%2520glioma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D20007%26epage%3D20012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Lennerz, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackerman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauwers, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4803</span><span class="NLM_x">â</span> <span class="NLM_lpage">4810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2011.35.4928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22042947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslygs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4803-4810&author=J.+K.+Lennerzauthor=E.+L.+Kwakauthor=A.+Ackermanauthor=M.+Michaelauthor=S.+B.+Foxauthor=K.+Bergethonauthor=G.+Y.+Lauwersauthor=J.+G.+Christensenauthor=K.+D.+Wilnerauthor=D.+A.+Haberauthor=R.+Salgiaauthor=Y.+J.+Bangauthor=J.+W.+Clarkauthor=B.+J.+Solomonauthor=A.+J.+Iafrate&title=MET+amplification+identifies+a+small+and+aggressive+subgroup+of+esophagogastric+adenocarcinoma+with+evidence+of+responsiveness+to+crizotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib</span></div><div class="casAuthors">Lennerz, Jochen K.; Kwak, Eunice L.; Ackerman, Allison; Michael, Michael; Fox, Stephen B.; Bergethon, Kristin; Lauwers, Gregory Y.; Christensen, James G.; Wilner, Keith D.; Haber, Daniel A.; Salgia, Ravi; Bang, Yung-Jue; Clark, Jeffrey W.; Solomon, Benjamin J.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4803-4810</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a mol. marker for targeted therapy.  We examd. a GEC cohort with follow-up and reported the clin. response of four addnl. patients with MET-amplified tumors to the small mol. inhibitor crizotinib as part of an expanded phase 1 cohort study.  Patients and Methods: From 2007 to 2009, patients with GEC were genetically screened as a consecutive series of 489 tumors (stages 0, I, and II, 39%; III, 25%; IV, 36%; n = 222 esophageal, including n = 21 squamous carcinomas).  MET, EGFR, and HER2 amplification status was assessed by using fluorescence in situ hybridization.  Results: Ten (2%) of 489 patients screened harbored MET amplification; 23 (4.7%) harbored EGFR amplification; 45 (8.9%) harbored HER2 amplification; and 411 (84%) were wild type for all three genes (ie, neg.).  MET-amplified tumors were typically high-grade adenocarcinomas that presented at advanced stages (5%; n = 4 of 80).  EGFR-amplified tumors showed the highest fraction of squamous cell carcinoma (17%; n = 4 of 23).  HER2, MET, and EGFR amplification were, with one exception (MET and EGFR pos.), mutually exclusive events.  Survival anal. in patients with stages III and IV disease showed substantially shorter median survival in MET/EGFR-amplified groups, with a rank order for all groups by median survival (from most to least aggressive): MET (7.1 mo; P < .001) less than EGFR (11.2 mo; P = .16) less than HER2 (16.9 mo; P = .89) when compared with the neg. group (16.2 mo).  Two of four patients with MET-amplified tumors treated with crizotinib experienced tumor shrinkage (-30% and -16%) and experienced progression after 3.7 and 3.5 mo.  Conclusion MET amplification defines a small and aggressive subset of GEC with indications of transient sensitivity to the targeted MET inhibitor crizotinib (PF-02341066).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvuLInpDQR7Vg90H21EOLACvtfcHk0ljuf8sdGD3usw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslygs7w%253D&md5=c98cb00019310228b39247e23c18d5c4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.4928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.4928%26sid%3Dliteratum%253Aachs%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DAckerman%26aufirst%3DA.%26aulast%3DMichael%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DS.%2BB.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DLauwers%26aufirst%3DG.%2BY.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DMET%2520amplification%2520identifies%2520a%2520small%2520and%2520aggressive%2520subgroup%2520of%2520esophagogastric%2520adenocarcinoma%2520with%2520evidence%2520of%2520responsiveness%2520to%2520crizotinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D4803%26epage%3D4810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Zeng, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiser, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forslund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimbel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culliford, A. T.,  4th</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAlessio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barany, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paty, P. B.</span><span> </span><span class="NLM_article-title">MET gene amplification is associated with advanced stage colorectal cancer and liver metastases</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">258</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2Fj.canlet.2008.02.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18395971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtlWhsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=2008&pages=258-269&author=Z.+S.+Zengauthor=M.+R.+Weiserauthor=E.+Kuntzauthor=C.+T.+Chenauthor=S.+A.+Khanauthor=A.+Forslundauthor=G.+M.+Nashauthor=M.+Gimbelauthor=Y.+Yamaguchiauthor=A.+T.+Cullifordauthor=M.+D%E2%80%99Alessioauthor=F.+Baranyauthor=P.+B.+Paty&title=MET+gene+amplification+is+associated+with+advanced+stage+colorectal+cancer+and+liver+metastases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases</span></div><div class="casAuthors">Zeng, Zhao-Shi; Weiser, Martin R.; Kuntz, Eleanor; Chen, Chin-Tung; Khan, Sajid A.; Forslund, Ann; Nash, Garrett M.; Gimbel, Mark; Yamaguchi, Yuka; Culliford, Alfred T.; D'Alessio, Matthew; Barany, Francis; Paty, Philip B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">258-269</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The c-Met proto-oncogene encodes a receptor tyrosine kinase (TK) that promotes invasive tumor growth and metastasis.  Recent studies show that the presence of c-Met gene amplification is predictive for selective c-Met TK inhibitors in gastric cancer and lung cancer.  In this study, the authors utilized a highly quant. PCR/ligase detection reaction technique to quantify c-Met gene copy no. in primary colorectal cancer (CRC) (N = 247), liver metastases (N = 147), and paired normal tissues.  The authors identified no differences in c-Met gene copy no. between normal colonic mucosa and liver tissue.  However, mean c-Met gene copy no. was significantly elevated in CRC compared with normal mucosa (P < 0.001), and in liver metastases compared with normal liver (P < 0.001).  Furthermore, a significant increase in c-Met was seen in liver metastases compared with primary CRC (P < 0.0001).  C-Met gene amplification was obsd. in 2% (3/177) of localized cancers, 9% (6/70) of cancers with distant metastases (P < 0.02), and 18% (25/147) of liver metastases (P < 0.01).  Among patients treated by liver resection, there was a trend toward poorer 3-yr survival in assocn. with c-Met gene amplification (P = 0.07).  Slight increases in c-Met copy no. can be detected in localized CRCs, but gene amplification is largely restricted to Stage IV primary cancers and liver metastases.  C-Met gene amplification is linked to metastatic progression, and is a viable target for a significant subset of advanced CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw_J0gO8jQzbVg90H21EOLACvtfcHk0ljuf8sdGD3usw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtlWhsbw%253D&md5=82b091ddcc6225d0068b3b3f59e906fc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.02.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.02.049%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DZ.%2BS.%26aulast%3DWeiser%26aufirst%3DM.%2BR.%26aulast%3DKuntz%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DKhan%26aufirst%3DS.%2BA.%26aulast%3DForslund%26aufirst%3DA.%26aulast%3DNash%26aufirst%3DG.%2BM.%26aulast%3DGimbel%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DCulliford%26aufirst%3DA.%2BT.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DM.%26aulast%3DBarany%26aufirst%3DF.%26aulast%3DPaty%26aufirst%3DP.%2BB.%26atitle%3DMET%2520gene%2520amplification%2520is%2520associated%2520with%2520advanced%2520stage%2520colorectal%2520cancer%2520and%2520liver%2520metastases%26jtitle%3DCancer%2520Lett.%26date%3D2008%26volume%3D265%26spage%3D258%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Smolen, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohapatra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barmettler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sgroi, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">2316</span><span class="NLM_x">â</span> <span class="NLM_lpage">2321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=2316-2321&author=G.+A.+Smolenauthor=R.+Sordellaauthor=B.+Muirauthor=G.+Mohapatraauthor=A.+Barmettlerauthor=H.+Archibaldauthor=W.+J.+Kimauthor=R.+A.+Okimotoauthor=D.+W.+Bellauthor=D.+C.+Sgroiauthor=J.+G.+Christensenauthor=J.+Settlemanauthor=D.+A.+Haber&title=Amplification+of+MET+may+identify+a+subset+of+cancers+with+extreme+sensitivity+to+the+selective+tyrosine+kinase+inhibitor+PHA-665752"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DG.%2BA.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DMuir%26aufirst%3DB.%26aulast%3DMohapatra%26aufirst%3DG.%26aulast%3DBarmettler%26aufirst%3DA.%26aulast%3DArchibald%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DW.%2BJ.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSgroi%26aufirst%3DD.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DAmplification%2520of%2520MET%2520may%2520identify%2520a%2520subset%2520of%2520cancers%2520with%2520extreme%2520sensitivity%2520to%2520the%2520selective%2520tyrosine%2520kinase%2520inhibitor%2520PHA-665752%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D2316%26epage%3D2321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKinnon, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramnath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Expression and mutational analysis of MET in human solid cancers</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1025</span><span class="NLM_x">â</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fgcc.20604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18709663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1025-1037&author=P.+C.+Maauthor=M.+S.+Tretiakovaauthor=A.+C.+MacKinnonauthor=N.+Ramnathauthor=C.+Johnsonauthor=S.+Dietrichauthor=T.+Seiwertauthor=J.+G.+Christensenauthor=R.+Jagadeeswaranauthor=T.+Krauszauthor=E.+E.+Vokesauthor=A.+N.+Husainauthor=R.+Salgia&title=Expression+and+mutational+analysis+of+MET+in+human+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and mutational analysis of MET in human solid cancers</span></div><div class="casAuthors">Ma, Patrick C.; Tretiakova, Maria S.; MacKinnon, Alexander C.; Ramnath, Nithya; Johnson, Candace; Dietrich, Sascha; Seiwert, Tanguy; Christensen, James G.; Jagadeeswaran, Ramasamy; Krausz, Thomas; Vokes, Everett E.; Husain, Aliya N.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1025-1037</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) regulate a variety of cellular functions, many of which can be dysregulated in human cancers.  Activated MET signaling can lead to cell motility and scattering, angiogenesis, proliferation, branching morphogenesis, invasion, and eventual metastasis.  We performed systematic anal. of the expression of the MET receptor and its ligand HGF in tumor tissue microarrays (TMA) from human solid cancers.  Std. immunohistochem. (IHC) and a computerized automated scoring system were used.  DNA sequencing for MET mutations in both nonkinase and kinase domains was also performed.  MET was differentially overexpressed in human solid cancers.  The ligand HGF was widely expressed in both tumors, primarily intratumoral, and nonmalignant tissues.  The MET/HGF likely is functional and may be activated in autocrine fashion in vivo.  MET and stem cell factor (SCF) were found to be pos. stained in the bronchioalevolar junctions of lung tumors.  A no. of novel mutations of MET were identified, particularly in the extracellular semaphorin domain and the juxtamembrane domain.  MET-HGF pathway can be assayed in TMAs and is often overexpressed in a wide variety of human solid cancers.  MET can be activated through overexpression, mutation, or autocrine signaling in malignant cells.  Mutations in the nonkinase regions of MET might play an important role in tumorigenesis and tumor progression.  MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnenTNgIcAbVg90H21EOLACvtfcHk0ljuf8sdGD3usw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE&md5=cf53884177f20939300673fb034ac91f</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2Fgcc.20604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.20604%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DMacKinnon%26aufirst%3DA.%2BC.%26aulast%3DRamnath%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DDietrich%26aufirst%3DS.%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DExpression%2520and%2520mutational%2520analysis%2520of%2520MET%2520in%2520human%2520solid%2520cancers%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2008%26volume%3D47%26spage%3D1025%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Ghiso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">Targeting MET: why, where and how?</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">â</span> <span class="NLM_lpage">518</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2Fj.coph.2013.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23797036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSmurnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=511-518&author=E.+Ghisoauthor=S.+Giordano&title=Targeting+MET%3A+why%2C+where+and+how%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MET: why, where and how?</span></div><div class="casAuthors">Ghiso, Elena; Giordano, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-518</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite the initial skepticism, targeted therapies represent a new perspective in the treatment of cancer.  Tyrosine kinases, and in particular receptor tyrosine kinases (RTKs), are considered ideal targets for this type of therapy.  MET, the tyrosine kinase receptor for the Hepatocyte Growth Factor (HGF), has recently become a very interesting and studied target in oncol.  In this review we discuss firstly 'why' the MET/HGF pathway can be considered a target in human tumors; secondly 'where' MET/HGF inhibition can be useful in cancer treatment and finally 'how' MET and HGF can be inhibited using either monoclonal antibodies or tyrosine kinase inhibitors.  We also highlight some questions in the anti-MET/HGF targeted therapy field that are still waiting for an answer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq33qI6WAqWJ7Vg90H21EOLACvtfcHk0lg7mr8wyLUN0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSmurnL&md5=507f17d762550af451af791c1527d50d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2013.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2013.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DGhiso%26aufirst%3DE.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DTargeting%2520MET%253A%2520why%252C%2520where%2520and%2520how%253F%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2013%26volume%3D13%26spage%3D511%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Schmidt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duh, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choyke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubensky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">AllikMETs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chidambaram, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergerheim, U. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltis, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamarron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernues, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lips, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geil, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orcutt, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stackhouse, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slife, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brauch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niehans, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storkel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerman, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linehan, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zbar, B.</span><span> </span><span class="NLM_article-title">Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">â</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fng0597-68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=9140397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK2sXivFKhsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=68-73&author=L.+Schmidtauthor=F.+M.+Duhauthor=F.+Chenauthor=T.+Kishidaauthor=G.+Glennauthor=P.+Choykeauthor=S.+W.+Schererauthor=Z.+Zhuangauthor=I.+Lubenskyauthor=M.+Deanauthor=R.+AllikMETsauthor=A.+Chidambaramauthor=U.+R.+Bergerheimauthor=J.+T.+Feltisauthor=C.+Casadevallauthor=A.+Zamarronauthor=M.+Bernuesauthor=S.+Richardauthor=C.+J.+Lipsauthor=M.+M.+Waltherauthor=L.+C.+Tsuiauthor=L.+Geilauthor=M.+L.+Orcuttauthor=T.+Stackhouseauthor=J.+Lipanauthor=L.+Slifeauthor=H.+Brauchauthor=J.+Deckerauthor=G.+Niehansauthor=M.+D.+Hughsonauthor=H.+Mochauthor=S.+Storkelauthor=M.+I.+Lermanauthor=W.+M.+Linehanauthor=B.+Zbar&title=Germline+and+somatic+mutations+in+the+tyrosine+kinase+domain+of+the+MET+proto-oncogene+in+papillary+renal+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas</span></div><div class="casAuthors">Schmidt, Laura; Duh, Fuh-Mei; Chen, Fan; Kishida, Takeshi; Glenn, Gladys; Choyke, Peter; Scherer, Stephen W.; Zhuang, Zhenping; Lubensky, Irina; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumors.  The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance.  HPRC is histol. and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8).  Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome.  Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of both copies of the VHL gene by mutation, and/or by hypermethylation.  We found that the HPRC gene was located at chromosome 7q31.1-34 in a 27-centimorgan (cM) interval between D7S496 and D7S1837.  We identified missense mutations located in the tyrosine kinase domain of the MET gene in the germline of affected members of HPRC families and in a subset of sporadic papillary renal carcinomas.  Three mutations in the MET gene are located in codons that are homologous to those in c-kit and RET, proto-oncogenes that are targets of naturally-occurring mutations.  The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm-x_dqJPR-7Vg90H21EOLACvtfcHk0lg7mr8wyLUN0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFKhsbw%253D&md5=7209dbbaa538b418defad117830df3c9</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fng0597-68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0597-68%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DL.%26aulast%3DDuh%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DKishida%26aufirst%3DT.%26aulast%3DGlenn%26aufirst%3DG.%26aulast%3DChoyke%26aufirst%3DP.%26aulast%3DScherer%26aufirst%3DS.%2BW.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DLubensky%26aufirst%3DI.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DAllikMETs%26aufirst%3DR.%26aulast%3DChidambaram%26aufirst%3DA.%26aulast%3DBergerheim%26aufirst%3DU.%2BR.%26aulast%3DFeltis%26aufirst%3DJ.%2BT.%26aulast%3DCasadevall%26aufirst%3DC.%26aulast%3DZamarron%26aufirst%3DA.%26aulast%3DBernues%26aufirst%3DM.%26aulast%3DRichard%26aufirst%3DS.%26aulast%3DLips%26aufirst%3DC.%2BJ.%26aulast%3DWalther%26aufirst%3DM.%2BM.%26aulast%3DTsui%26aufirst%3DL.%2BC.%26aulast%3DGeil%26aufirst%3DL.%26aulast%3DOrcutt%26aufirst%3DM.%2BL.%26aulast%3DStackhouse%26aufirst%3DT.%26aulast%3DLipan%26aufirst%3DJ.%26aulast%3DSlife%26aufirst%3DL.%26aulast%3DBrauch%26aufirst%3DH.%26aulast%3DDecker%26aufirst%3DJ.%26aulast%3DNiehans%26aufirst%3DG.%26aulast%3DHughson%26aufirst%3DM.%2BD.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DStorkel%26aufirst%3DS.%26aulast%3DLerman%26aufirst%3DM.%2BI.%26aulast%3DLinehan%26aufirst%3DW.%2BM.%26aulast%3DZbar%26aufirst%3DB.%26atitle%3DGermline%2520and%2520somatic%2520mutations%2520in%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520MET%2520proto-oncogene%2520in%2520papillary%2520renal%2520carcinomas%26jtitle%3DNat.%2520Genet.%26date%3D1997%26volume%3D16%26spage%3D68%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artigiani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gual, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Different point mutations in the MET oncogene elicit distinct biological properties</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">â</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=399-406&author=S.+Giordanoauthor=A.+Maffeauthor=T.+A.+Williamsauthor=S.+Artigianiauthor=P.+Gualauthor=A.+Bardelliauthor=C.+Basilicoauthor=P.+Michieliauthor=P.+M.+Comoglio&title=Different+point+mutations+in+the+MET+oncogene+elicit+distinct+biological+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DMaffe%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DT.%2BA.%26aulast%3DArtigiani%26aufirst%3DS.%26aulast%3DGual%26aufirst%3DP.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DDifferent%2520point%2520mutations%2520in%2520the%2520MET%2520oncogene%2520elicit%2520distinct%2520biological%2520properties%26jtitle%3DFASEB%2520J.%26date%3D2000%26volume%3D14%26spage%3D399%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Graveel, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">A mouse model of activating MET mutations</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">518</span><span class="NLM_x">â</span> <span class="NLM_lpage">520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=518-520&author=C.+R.+Graveelauthor=C.+A.+Londonauthor=G.+F.+Vande+Woude&title=A+mouse+model+of+activating+MET+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGraveel%26aufirst%3DC.%2BR.%26aulast%3DLondon%26aufirst%3DC.%2BA.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DA%2520mouse%2520model%2520of%2520activating%2520MET%2520mutations%26jtitle%3DCell%2520Cycle%26date%3D2005%26volume%3D4%26spage%3D518%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Ghadjar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank-Liss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simcock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegyi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aebersold, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, Y.</span><span> </span><span class="NLM_article-title">MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers</span> <span class="citation_source-journal">Clin. Exp. Metastasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">â</span> <span class="NLM_lpage">815</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1007%2Fs10585-009-9280-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19639388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWls7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=809-815&author=P.+Ghadjarauthor=W.+Blank-Lissauthor=M.+Simcockauthor=I.+Hegyiauthor=K.+T.+Beerauthor=H.+Mochauthor=D.+M.+Aebersoldauthor=Y.+Zimmer&title=MET+Y1253D-activating+point+mutation+and+development+of+distant+metastasis+in+advanced+head+and+neck+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers</span></div><div class="casAuthors">Ghadjar, Pirus; Blank-Liss, Wieslawa; Simcock, Mathew; Hegyi, Ivan; Beer, Karl T.; Moch, Holger; Aebersold, Daniel M.; Zimmer, Yitzhak</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Metastasis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">809-815</span>CODEN:
                <span class="NLM_cas:coden">CEXMD2</span>;
        ISSN:<span class="NLM_cas:issn">0262-0898</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We investigated if the MET-activating point mutation Y1253D influences clin. outcomes in patients with advanced squamous cell carcinoma of the head and neck (HNSCC).  The study population consisted of 152 HNSCC patients treated by hyperfractionated radiotherapy alone or concomitant with chemotherapy between Sept. 1994 and July 2000.  Tumors were screened for the presence of the MET-activating point mutation Y1253D.  Seventy-eight patients (51%) received radiotherapy alone, 74 patients (49%) underwent radiotherapy concomitant with chemotherapy.  Median patient age was 54 years and median follow-up was 5.5 years.  Distant metastasis-free survival, local relapse-free survival and overall survival were compared with MET Y1253D status.  During follow-up, 29 (19%) patients developed distant metastasis.  MET Y1253D was detected in tumors of 21 out of 152 patients (14%).  Distant metastasis-free survival (P = 0.008) was assocd. with MET Y1253D.  In a multivariate Cox regression model, adjusted for T-category, only presence of MET Y1253D was assocd. with decreased distant metastasis-free survival: hazard ratio = 2.5 (95% confidence interval: 1.1, 5.8).  The obsd. assocn. between MET Y1253D-activating point mutation and decreased distant metastasis-free survival in advanced HNSCC suggests that MET may be a potential target for specific treatment interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmUFtMYBRo1bVg90H21EOLACvtfcHk0lj438-11HsyTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWls7%252FI&md5=cf6c9006cb2ce536bf9869dd23ed93bf</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs10585-009-9280-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10585-009-9280-9%26sid%3Dliteratum%253Aachs%26aulast%3DGhadjar%26aufirst%3DP.%26aulast%3DBlank-Liss%26aufirst%3DW.%26aulast%3DSimcock%26aufirst%3DM.%26aulast%3DHegyi%26aufirst%3DI.%26aulast%3DBeer%26aufirst%3DK.%2BT.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DAebersold%26aufirst%3DD.%2BM.%26aulast%3DZimmer%26aufirst%3DY.%26atitle%3DMET%2520Y1253D-activating%2520point%2520mutation%2520and%2520development%2520of%2520distant%2520metastasis%2520in%2520advanced%2520head%2520and%2520neck%2520cancers%26jtitle%3DClin.%2520Exp.%2520Metastasis%26date%3D2009%26volume%3D26%26spage%3D809%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennacchietti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MaffÃ¨, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamagnone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Mutant MET-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5221</span><span class="NLM_x">â</span> <span class="NLM_lpage">5231</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=5221-5231&author=P.+Michieliauthor=C.+Basilicoauthor=S.+Pennacchiettiauthor=A.+Maff%C3%A8author=L.+Tamagnoneauthor=S.+Giordanoauthor=A.+Bardelliauthor=P.+M.+Comoglio&title=Mutant+MET-mediated+transformation+is+ligand-dependent+and+can+be+inhibited+by+HGF+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DPennacchietti%26aufirst%3DS.%26aulast%3DMaff%25C3%25A8%26aufirst%3DA.%26aulast%3DTamagnone%26aufirst%3DL.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DMutant%2520MET-mediated%2520transformation%2520is%2520ligand-dependent%2520and%2520can%2520be%2520inhibited%2520by%2520HGF%2520antagonists%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D5221%26epage%3D5231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Gumustekin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kargi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulut, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozukizil, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulukus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oztop, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atabey, N.</span><span> </span><span class="NLM_article-title">HGF/MET overexpressions, but not MET mutation, correlates with progression of non-small cell lung cancer</span> <span class="citation_source-journal">Pathol. Oncol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1007%2Fs12253-011-9430-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21779788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVeqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=209-218&author=M.+Gumustekinauthor=A.+Kargiauthor=G.+Bulutauthor=A.+Gozukizilauthor=C.+Ulukusauthor=I.+Oztopauthor=N.+Atabey&title=HGF%2FMET+overexpressions%2C+but+not+MET+mutation%2C+correlates+with+progression+of+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">HGF/c-Met Overexpressions, but not Met Mutation, Correlates with Progression of Non-small Cell Lung Cancer</span></div><div class="casAuthors">Gumustekin, Mukaddes; Kargi, Aydanur; Bulut, Gulay; Gozukizil, Aysim; Ulukus, Cagnur; Oztop, Ilhan; Atabey, Nese</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-218</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hepatocyte Growth Factor (HGF) and its receptor c-Met are suggested to play an important role in progression of solid organ tumors by mediating cell motility, invasion and metastasis.  Overexpression of HGF and c-Met have been shown in non-small-cell lung cancer (NSCLC).  However, their role in tumor progression is not clearly defined.  The aim of this study is to det. the role of HGF/c-Met pathway and its assocn. with invasion related markers and clinicopathol. parameters in NSCLC.  Immunohistochem. anal. was performed on 63 paraffin-embedded NSCLC tumor sections.  The expressions of invasion related markers such as Matrix Metalloproteinases (MMPs) 2 and 9, Tissue Inhibitor Metalloproteinase (TIMP) 1 and 3 and RhoA were also examd.  Co-expression of HGF/c-Met was significantly assocd. with lymph node invasion and TIMP-3 and RhoA overexpressions.  There were pos. correlation between TIMP-3 overexpression and advanced stage and neg. correlation between RhoA overexpression and survival.  DNA sequencing for Met mutations in both nonkinase and tyrosine kinase (TK) domain was established.  A single nucleotide polymorphism (SNP) in sema domain and two SNPs in TK domain of c-Met were found.  There was no statistically significant correlation between the presence of c-Met alterations and clinicopathol. parameters except shorter survival time in cases with two SNPs in TK domain.  These results suggest that HGF/c-Met might exert their effects in tumor progression in assocn. with RhoA and probably with TIMP-3.  The blockade of the HGF/c-Met pathway with RhoA and/or TIMP-3 inhibitors may be an effective therapeutic target for NSCLC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-j4l7V3eLFbVg90H21EOLACvtfcHk0lj438-11HsyTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVeqtbk%253D&md5=ca0c25c427bd55104df0e63060f8886f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs12253-011-9430-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-011-9430-7%26sid%3Dliteratum%253Aachs%26aulast%3DGumustekin%26aufirst%3DM.%26aulast%3DKargi%26aufirst%3DA.%26aulast%3DBulut%26aufirst%3DG.%26aulast%3DGozukizil%26aufirst%3DA.%26aulast%3DUlukus%26aufirst%3DC.%26aulast%3DOztop%26aufirst%3DI.%26aulast%3DAtabey%26aufirst%3DN.%26atitle%3DHGF%252FMET%2520overexpressions%252C%2520but%2520not%2520MET%2520mutation%252C%2520correlates%2520with%2520progression%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2012%26volume%3D18%26spage%3D209%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Peschard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span> </span><span class="NLM_article-title">From Tpr-MET to MET tumorigenesis and tubes</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1276</span><span class="NLM_x">â</span> <span class="NLM_lpage">1285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=1276-1285&author=P.+Peschardauthor=M.+Park&title=From+Tpr-MET+to+MET+tumorigenesis+and+tubes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeschard%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DM.%26atitle%3DFrom%2520Tpr-MET%2520to%2520MET%2520tumorigenesis%2520and%2520tubes%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D1276%26epage%3D1285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Otsuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaRochelle, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottaro, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anver, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlino, G.</span><span> </span><span class="NLM_article-title">MET autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">5157</span><span class="NLM_x">â</span> <span class="NLM_lpage">5167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=5157-5167&author=T.+Otsukaauthor=H.+Takayamaauthor=R.+Sharpauthor=G.+Celliauthor=W.+J.+LaRochelleauthor=D.+P.+Bottaroauthor=N.+Ellmoreauthor=W.+Vieiraauthor=J.+W.+Owensauthor=M.+Anverauthor=G.+Merlino&title=MET+autocrine+activation+induces+development+of+malignant+melanoma+and+acquisition+of+the+metastatic+phenotype"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOtsuka%26aufirst%3DT.%26aulast%3DTakayama%26aufirst%3DH.%26aulast%3DSharp%26aufirst%3DR.%26aulast%3DCelli%26aufirst%3DG.%26aulast%3DLaRochelle%26aufirst%3DW.%2BJ.%26aulast%3DBottaro%26aufirst%3DD.%2BP.%26aulast%3DEllmore%26aufirst%3DN.%26aulast%3DVieira%26aufirst%3DW.%26aulast%3DOwens%26aufirst%3DJ.%2BW.%26aulast%3DAnver%26aufirst%3DM.%26aulast%3DMerlino%26aufirst%3DG.%26atitle%3DMET%2520autocrine%2520activation%2520induces%2520development%2520of%2520malignant%2520melanoma%2520and%2520acquisition%2520of%2520the%2520metastatic%2520phenotype%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D5157%26epage%3D5167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Xie, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worschech, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Giorgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefene, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essenburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeKoning, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâRourke, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marincola, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">570</span><span class="NLM_x">â</span> <span class="NLM_lpage">575</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=570-575&author=Q.+Xieauthor=R.+Bradleyauthor=L.+Kangauthor=J.+Koemanauthor=M.+L.+Asciertoauthor=A.+Worschechauthor=V.+De+Giorgiauthor=E.+Wangauthor=L.+Kefeneauthor=Y.+Suauthor=C.+Essenburgauthor=D.+W.+Kaufmanauthor=T.+DeKoningauthor=M.+A.+Enterauthor=T.+J.+O%E2%80%99Rourkeauthor=F.+M.+Marincolaauthor=G.+F.+Vande+Woude&title=Hepatocyte+growth+factor+%28HGF%29+autocrine+activation+predicts+sensitivity+to+MET+inhibition+in+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DBradley%26aufirst%3DR.%26aulast%3DKang%26aufirst%3DL.%26aulast%3DKoeman%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DM.%2BL.%26aulast%3DWorschech%26aufirst%3DA.%26aulast%3DDe%2BGiorgi%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DKefene%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DEssenburg%26aufirst%3DC.%26aulast%3DKaufman%26aufirst%3DD.%2BW.%26aulast%3DDeKoning%26aufirst%3DT.%26aulast%3DEnter%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DT.%2BJ.%26aulast%3DMarincola%26aufirst%3DF.%2BM.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DHepatocyte%2520growth%2520factor%2520%2528HGF%2529%2520autocrine%2520activation%2520predicts%2520sensitivity%2520to%2520MET%2520inhibition%2520in%2520glioblastoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D570%26epage%3D575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Kentsis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tholouli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valk, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delwel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutok, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licht, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">â</span> <span class="NLM_lpage">1122</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnm.2819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22683780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Ciu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1118-1122&author=A.+Kentsisauthor=C.+Reedauthor=K.+L.+Riceauthor=T.+Sandaauthor=S.+J.+Rodigauthor=E.+Tholouliauthor=A.+Christieauthor=P.+J.+Valkauthor=R.+Delwelauthor=V.+Ngoauthor=J.+L.+Kutokauthor=S.+E.+Dahlbergauthor=L.+A.+Moreauauthor=R.+J.+Byersauthor=J.+G.+Christensenauthor=G.+Vande+Woudeauthor=J.+D.+Lichtauthor=A.+L.+Kungauthor=L.+M.+Staudtauthor=A.+T.+Look&title=Autocrine+activation+of+the+MET+receptor+tyrosine+kinase+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia</span></div><div class="casAuthors">Kentsis, Alex; Reed, Casie; Rice, Kim L.; Sanda, Takaomi; Rodig, Scott J.; Tholouli, Eleni; Christie, Amanda; Valk, Peter J. M.; Delwel, Ruud; Ngo, Vu; Kutok, Jeffery L.; Dahlberg, Suzanne E.; Moreau, Lisa A.; Byers, Richard J.; Christensen, James G.; Woude, George Vande; Licht, Jonathan D.; Kung, Andrew L.; Staudt, Louis M.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1118-1122</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the treatment of acute myeloid leukemia (AML) has improved substantially in the past 3 decades, more than half of all patients develop disease that is refractory to intensive chemotherapy.  Functional genomics approaches offer a means to discover specific mols. mediating the aberrant growth and survival of cancer cells.  Thus, using a loss-of-function RNA interference genomic screen, we identified the aberrant expression of hepatocyte growth factor (HGF) as a crucial element in AML pathogenesis.  We found HGF expression leading to autocrine activation of its receptor tyrosine kinase, MET, in nearly half of the AML cell lines and clin. samples we studied.  Genetic depletion of HGF or MET potently inhibited the growth and survival of HGF-expressing AML cells.  However, leukemic cells treated with the specific MET kinase inhibitor crizotinib developed resistance resulting from compensatory upregulation of HGF expression, leading to the restoration of MET signaling.  In cases of AML where MET is coactivated with other tyrosine kinases, such as fibroblast growth factor receptor 1 (FGFR1), concomitant inhibition of FGFR1 and MET blocked this compensatory HGF upregulation, resulting in sustained logarithmic cell killing both in vitro and in xenograft models in vivo.  These results show a widespread dependence of AML cells on autocrine activation of MET, as well as the key role of compensatory upregulation of HGF expression in maintaining leukemogenic signaling by this receptor.  We anticipate that these findings will lead to the design of addnl. strategies to block adaptive cellular responses that drive compensatory ligand expression as an essential component of the targeted inhibition of oncogenic receptors in human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5q5ejcRZRTLVg90H21EOLACvtfcHk0liAf-tjyVxw5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Ciu7g%253D&md5=c0817d9a114964db126b8e7ab684bd66</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnm.2819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2819%26sid%3Dliteratum%253Aachs%26aulast%3DKentsis%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DC.%26aulast%3DRice%26aufirst%3DK.%2BL.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DTholouli%26aufirst%3DE.%26aulast%3DChristie%26aufirst%3DA.%26aulast%3DValk%26aufirst%3DP.%2BJ.%26aulast%3DDelwel%26aufirst%3DR.%26aulast%3DNgo%26aufirst%3DV.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DMoreau%26aufirst%3DL.%2BA.%26aulast%3DByers%26aufirst%3DR.%2BJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DAutocrine%2520activation%2520of%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D1118%26epage%3D1122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Tokunou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iba, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saitoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirohashi, S.</span><span> </span><span class="NLM_article-title">MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">1451</span><span class="NLM_x">â</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2FS0002-9440%2810%2964096-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=11290563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtVWhtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=1451-1463&author=M.+Tokunouauthor=T.+Nikiauthor=K.+Eguchiauthor=S.+Ibaauthor=H.+Tsudaauthor=T.+Yamadaauthor=Y.+Matsunoauthor=H.+Kondoauthor=Y.+Saitohauthor=H.+Imamuraauthor=S.+Hirohashi&title=MET+expression+in+myofibroblasts%3A+role+in+autocrine+activation+and+prognostic+significance+in+lung+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">c-MET expression in myofibroblasts: Role in autocrine activation and prognostic significance in lung adenocarcinoma</span></div><div class="casAuthors">Tokunou, Masahide; Niki, Toshiro; Eguchi, Keisuke; Iba, Sanae; Tsuda, Hitoshi; Yamada, Tesshi; Matsuno, Yoshihiro; Kondo, Haruhiko; Saitoh, Yukihito; Imamura, Hiroji; Hirohashi, Setsuo</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1451-1463</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Hepatocyte growth factor (HGF) plays important roles in tumor development and progression.  It is currently thought that the main action of HGF is of a paracrine nature: HGF produced by mesenchymal cells acts on epithelial cells that express its receptor c-MET.  In this investigation, we explored the significance of c-MET expression in myofibroblasts, both in culture and in patients with lung adenocarcinoma.  We first showed that human myofibroblasts derived from primary lung cancer expressed c-MET mRNA and protein by reverse transcription-polymerase chain reaction and Western blot anal.  Proliferation of myofibroblasts was stimulated in a dose-dependent manner by exogenously added recombinant human HGF whereas it was inhibited in a dose-dependent manner by neutralizing antibody to HGF.  The addn. of HGF in the culture medium stimulated tyrosine phosphorylation of c-MET.  The c-MET protein was immunohistochem. detected in myofibroblasts in the invasive area of lung adenocarcinoma.  Finally, the prognostic significance of c-MET expression in stromal myofibroblasts was explored in patients with small-sized lung adenocarcinomas.  C-MET-pos. myofibroblasts were obsd. in 69 of 131 cases (53%).  A significant relationship between myofibroblast c-MET expression and shortened patient survival was obsd. in a whole cohort of patients including all pathol. stages (two-sided P = 0.0089 by log-rank test) and in patients with stage IA disease (two-sided P = 0.0019 by log-rank test).  These data suggest that the HGF/c-MET system constitutes an autocrine activation loop in cancer-stromal myofibroblasts.  This autocrine system may play a role in invasion and metastasis of lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYzb_qAZjt0bVg90H21EOLACvtfcHk0liAf-tjyVxw5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtVWhtrY%253D&md5=5c9ef86275b6dab96dc5b60b7786b8e9</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2964096-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252964096-5%26sid%3Dliteratum%253Aachs%26aulast%3DTokunou%26aufirst%3DM.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DEguchi%26aufirst%3DK.%26aulast%3DIba%26aufirst%3DS.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DMatsuno%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DH.%26aulast%3DSaitoh%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DH.%26aulast%3DHirohashi%26aufirst%3DS.%26atitle%3DMET%2520expression%2520in%2520myofibroblasts%253A%2520role%2520in%2520autocrine%2520activation%2520and%2520prognostic%2520significance%2520in%2520lung%2520adenocarcinoma%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2001%26volume%3D158%26spage%3D1451%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Vaupel, P.</span><span> </span><span class="NLM_article-title">The role of hypoxia-induced factors in tumor progression</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=10-17&author=P.+Vaupel&title=The+role+of+hypoxia-induced+factors+in+tumor+progression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVaupel%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520hypoxia-induced%2520factors%2520in%2520tumor%2520progression%26jtitle%3DOncologist%26date%3D2004%26volume%3D9%26spage%3D10%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Hayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minekawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmichi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, Y.</span><span> </span><span class="NLM_article-title">Up-regulation of MET protooncogene product expression through hypoxia-inducible factor-1 alpha is involved in trophoblast invasion under low-oxygen tension</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">4682</span><span class="NLM_x">â</span> <span class="NLM_lpage">4689</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2005&pages=4682-4689&author=M.+Hayashiauthor=M.+Sakataauthor=T.+Takedaauthor=M.+Taharaauthor=T.+Yamamotoauthor=Y.+Okamotoauthor=R.+Minekawaauthor=A.+Isobeauthor=M.+Ohmichiauthor=K.+Tasakaauthor=Y.+Murata&title=Up-regulation+of+MET+protooncogene+product+expression+through+hypoxia-inducible+factor-1+alpha+is+involved+in+trophoblast+invasion+under+low-oxygen+tension"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DSakata%26aufirst%3DM.%26aulast%3DTakeda%26aufirst%3DT.%26aulast%3DTahara%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DMinekawa%26aufirst%3DR.%26aulast%3DIsobe%26aufirst%3DA.%26aulast%3DOhmichi%26aufirst%3DM.%26aulast%3DTasaka%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DY.%26atitle%3DUp-regulation%2520of%2520MET%2520protooncogene%2520product%2520expression%2520through%2520hypoxia-inducible%2520factor-1%2520alpha%2520is%2520involved%2520in%2520trophoblast%2520invasion%2520under%2520low-oxygen%2520tension%26jtitle%3DEndocrinology%26date%3D2005%26volume%3D146%26spage%3D4682%26epage%3D4689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Bhardwaj, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortez, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komaki, R. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, J. W.</span><span> </span><span class="NLM_article-title">Modulation of MET signaling and cellular sensitivity to radiation: potential implications for therapy</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">1768</span><span class="NLM_x">â</span> <span class="NLM_lpage">1775</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2013&pages=1768-1775&author=V.+Bhardwajauthor=T.+Casconeauthor=M.+A.+Cortezauthor=A.+Aminiauthor=J.+Evansauthor=R.+U.+Komakiauthor=J.+V.+Heymachauthor=J.+W.+Welsh&title=Modulation+of+MET+signaling+and+cellular+sensitivity+to+radiation%3A+potential+implications+for+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhardwaj%26aufirst%3DV.%26aulast%3DCascone%26aufirst%3DT.%26aulast%3DCortez%26aufirst%3DM.%2BA.%26aulast%3DAmini%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DKomaki%26aufirst%3DR.%2BU.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DWelsh%26aufirst%3DJ.%2BW.%26atitle%3DModulation%2520of%2520MET%2520signaling%2520and%2520cellular%2520sensitivity%2520to%2520radiation%253A%2520potential%2520implications%2520for%2520therapy%26jtitle%3DCancer%26date%3D2013%26volume%3D119%26spage%3D1768%26epage%3D1775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">De Bacco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luraghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medico, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girolami, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriele, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccaccio, C.</span><span> </span><span class="NLM_article-title">Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">â</span> <span class="NLM_lpage">661</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1093%2Fjnci%2Fdjr093" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=645-661&author=F.+De+Baccoauthor=P.+Luraghiauthor=E.+Medicoauthor=G.+Reatoauthor=F.+Girolamiauthor=T.+Pereraauthor=P.+Gabrieleauthor=P.+M.+Comoglioauthor=C.+Boccaccio&title=Induction+of+MET+by+ionizing+radiation+and+its+role+in+radioresistance+and+invasive+growth+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr093%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBacco%26aufirst%3DF.%26aulast%3DLuraghi%26aufirst%3DP.%26aulast%3DMedico%26aufirst%3DE.%26aulast%3DReato%26aufirst%3DG.%26aulast%3DGirolami%26aufirst%3DF.%26aulast%3DPerera%26aufirst%3DT.%26aulast%3DGabriele%26aufirst%3DP.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DBoccaccio%26aufirst%3DC.%26atitle%3DInduction%2520of%2520MET%2520by%2520ionizing%2520radiation%2520and%2520its%2520role%2520in%2520radioresistance%2520and%2520invasive%2520growth%2520of%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2011%26volume%3D20%26spage%3D645%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Aebersold, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laissue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greiner, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djonov, V.</span><span> </span><span class="NLM_article-title">Involvement of the hepatocyte growth factor/scatter factor receptor MET and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">â</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2F1097-0215%2820010220%2996%3A1%3C41%3A%3AAID-IJC5%3E3.0.CO%3B2-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=11241329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht1WjsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2001&pages=41-54&author=D.+M.+Aebersoldauthor=A.+Kollarauthor=K.+T.+Beerauthor=J.+Laissueauthor=R.+H.+Greinerauthor=V.+Djonov&title=Involvement+of+the+hepatocyte+growth+factor%2Fscatter+factor+receptor+MET+and+of+Bcl-xL+in+the+resistance+of+oropharyngeal+cancer+to+ionizing+radiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-XL in the resistance of oropharyngeal cancer to ionizing radiation</span></div><div class="casAuthors">Aebersold, Daniel M.; Kollar, Attila; Beer, Karl T.; Laissue, Jean; Greiner, Richard H.; Djonov, Valentin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-54</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The activation of cytoplasmic signal transduction pathways by a no. of growth factors and their tyrosine-kinase receptors, including hepatocyte growth factor/scatter factor (HGF/SF) and its receptor c-met, exerts an inhibitory influence on apoptosis induced by ionizing radiation in vitro.  The clin. relevance of the aforementioned ligand-receptor pair, of Bcl-XL, which is targeted by HGF/SF/c-met signaling, and of Bcl-2, was assessed by evaluating their predictive and prognostic impact in a cohort of 97 patients with radically irradiated squamous cell cancers of the oropharynx.  Immunohistochem. expression of c-met and Bcl-XL was correlated with decreased rates of complete remission of the primary tumor in both the univariate (c-met: P = 0.01; Bcl-XL: P = 0.001) and multivariate analyses.  Expression of c-met was, moreover, a significant and independent predictor of impaired local failure-free survival (P = 0.003), disease-free survival (P = 0.003) and overall survival (p = 0.001).  Bcl-2 expression was, on the other hand, assocd. with a favorable outcome, in terms of both local failure-free survival (P = 0.01) and overall survival (P = 0.001).  In accordance with in vitro data, c-met and Bcl-XL appear to be involved in the resistance of oropharyngeal cancers to ionizing radiation, and may therefore represent attractive targets for radiosensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrucBJiW4Yw_bVg90H21EOLACvtfcHk0lgYlTNIt6yI1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht1WjsbY%253D&md5=528bea78ffb195ffe8e3537ab76a07c4</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%2820010220%2996%3A1%3C41%3A%3AAID-IJC5%3E3.0.CO%3B2-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%252820010220%252996%253A1%253C41%253A%253AAID-IJC5%253E3.0.CO%253B2-F%26sid%3Dliteratum%253Aachs%26aulast%3DAebersold%26aufirst%3DD.%2BM.%26aulast%3DKollar%26aufirst%3DA.%26aulast%3DBeer%26aufirst%3DK.%2BT.%26aulast%3DLaissue%26aufirst%3DJ.%26aulast%3DGreiner%26aufirst%3DR.%2BH.%26aulast%3DDjonov%26aufirst%3DV.%26atitle%3DInvolvement%2520of%2520the%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520receptor%2520MET%2520and%2520of%2520Bcl-xL%2520in%2520the%2520resistance%2520of%2520oropharyngeal%2520cancer%2520to%2520ionizing%2520radiation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2001%26volume%3D96%26spage%3D41%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Kim, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Go, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeon, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span> </span><span class="NLM_article-title">Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy</span> <span class="citation_source-journal">Head Neck</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1458</span><span class="NLM_x">â</span> <span class="NLM_lpage">1466</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fhed.21611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21928418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BC3MfksFOksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=1458-1466&author=Y.+J.+Kimauthor=H.+Goauthor=H.+G.+Wuauthor=Y.+K.+Jeonauthor=S.+W.+Parkauthor=S.+H.+Lee&title=Immunohistochemical+study+identifying+prognostic+biomolecular+markers+in+nasopharyngeal+carcinoma+treated+by+radiotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy</span></div><div class="casAuthors">Kim Yeon-Joo; Go Heounjeong; Wu Hong-Gyun; Jeon Yoon Kyung; Park Suk Won; Lee Seung Hee</div><div class="citationInfo"><span class="NLM_cas:title">Head & neck</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1458-66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We evaluated the predictive significance of 14 reported markers using immunohistochemical study in nasopharyngeal carcinoma.  METHODS:  Immunohistochemical stainings were done in 38 patients for Met, cyclooxygenase-2 (COX-2), nm23-H1, epidermal growth factor receptor (EGFR), p63, early growth response factor 1 (Egr1), chromosome segregation 1-like (CSE1L), cathepsin-D (aspartyl protease), C-erbB2, p53, signal transducers and activators of transcription (STAT3/STAT5), CD138 (Syndecan-1), and LIN28 with the usual methods.  RESULTS:  The median follow-up time was 30 months (11-83 months).  High Met and CD138 expression were statistically significant negative prognostic factors on survival.  The expression of Egr1 had a positive prognostic effect on survival.  The combined score of these 3 markers, Met plus CD138 minus Egr1, was a strong prognostic factor.  The median survival curve was distinctly separated in accord with this combined score.  No prognostic value was revealed in COX-2, nm23-H1, EGFR, p63, CSE1L, cathepsin-D, C-erbB2, p53, STAT3, STAT5, and LIN28.  CONCLUSIONS:  The combined score of these markers could be used to stratify biomolecular risk groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXR1WENWHNhS-bLEOO4dYpfW6udTcc2eZxmKn-HR6kZbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfksFOksg%253D%253D&md5=d1e322d2a85e22d9ec65cb5827515c40</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fhed.21611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhed.21611%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DGo%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DH.%2BG.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DPark%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DS.%2BH.%26atitle%3DImmunohistochemical%2520study%2520identifying%2520prognostic%2520biomolecular%2520markers%2520in%2520nasopharyngeal%2520carcinoma%2520treated%2520by%2520radiotherapy%26jtitle%3DHead%2520Neck%26date%3D2011%26volume%3D33%26spage%3D1458%26epage%3D1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Skibinski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skibinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor (HGF) protects MET-expressing Burkittâs lymphoma cell lines from apoptotic death induced by DNA damaging agents</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">â</span> <span class="NLM_lpage">1569</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=1562-1569&author=G.+Skibinskiauthor=A.+Skibinskaauthor=K.+James&title=Hepatocyte+growth+factor+%28HGF%29+protects+MET-expressing+Burkitt%E2%80%99s+lymphoma+cell+lines+from+apoptotic+death+induced+by+DNA+damaging+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkibinski%26aufirst%3DG.%26aulast%3DSkibinska%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DK.%26atitle%3DHepatocyte%2520growth%2520factor%2520%2528HGF%2529%2520protects%2520MET-expressing%2520Burkitt%25E2%2580%2599s%2520lymphoma%2520cell%2520lines%2520from%2520apoptotic%2520death%2520induced%2520by%2520DNA%2520damaging%2520agents%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D1562%26epage%3D1569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Bowers, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abounader, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laterra, J.</span><span> </span><span class="NLM_article-title">Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">4277</span><span class="NLM_x">â</span> <span class="NLM_lpage">4283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=4277-4283&author=D.+C.+Bowersauthor=S.+Fanauthor=K.+A.+Walterauthor=R.+Abounaderauthor=J.+A.+Williamsauthor=E.+M.+Rosenauthor=J.+Laterra&title=Scatter+factor%2Fhepatocyte+growth+factor+protects+against+cytotoxic+death+in+human+glioblastoma+via+phosphatidylinositol+3-kinase-+and+AKT-dependent+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DD.%2BC.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DK.%2BA.%26aulast%3DAbounader%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26aulast%3DRosen%26aufirst%3DE.%2BM.%26aulast%3DLaterra%26aufirst%3DJ.%26atitle%3DScatter%2520factor%252Fhepatocyte%2520growth%2520factor%2520protects%2520against%2520cytotoxic%2520death%2520in%2520human%2520glioblastoma%2520via%2520phosphatidylinositol%25203-kinase-%2520and%2520AKT-dependent%2520pathways%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D4277%26epage%3D4283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Mitamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuragi, N.</span><span> </span><span class="NLM_article-title">Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET</span> <span class="citation_source-journal">Oncogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e40</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e40&author=T.+Mitamuraauthor=H.+Watariauthor=L.+Wangauthor=H.+Kannoauthor=M.+K.+Hassanauthor=M.+Miyazakiauthor=Y.+Katohauthor=T.+Kimuraauthor=M.+Taninoauthor=H.+Nishiharaauthor=S.+Tanakaauthor=N.+Sakuragi&title=Downregulation+of+miRNA-31+induces+taxane+resistance+in+ovarian+cancer+cells+through+increase+of+receptor+tyrosine+kinase+MET"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitamura%26aufirst%3DT.%26aulast%3DWatari%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKanno%26aufirst%3DH.%26aulast%3DHassan%26aufirst%3DM.%2BK.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DKatoh%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DTanino%26aufirst%3DM.%26aulast%3DNishihara%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DSakuragi%26aufirst%3DN.%26atitle%3DDownregulation%2520of%2520miRNA-31%2520induces%2520taxane%2520resistance%2520in%2520ovarian%2520cancer%2520cells%2520through%2520increase%2520of%2520receptor%2520tyrosine%2520kinase%2520MET%26jtitle%3DOncogenesis%26date%3D2013%26volume%3D2%26spage%3De40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Tang, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yam, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A. S.</span><span> </span><span class="NLM_article-title">MET overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">â</span> <span class="NLM_lpage">138</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=128-138&author=M.+K.+Tangauthor=H.+Y.+Zhouauthor=J.+W.+Yamauthor=A.+S.+Wong&title=MET+overexpression+contributes+to+the+acquired+apoptotic+resistance+of+nonadherent+ovarian+cancer+cells+through+a+cross+talk+mediated+by+phosphatidylinositol+3-kinase+and+extracellular+signal-regulated+kinase+1%2F2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DM.%2BK.%26aulast%3DZhou%26aufirst%3DH.%2BY.%26aulast%3DYam%26aufirst%3DJ.%2BW.%26aulast%3DWong%26aufirst%3DA.%2BS.%26atitle%3DMET%2520overexpression%2520contributes%2520to%2520the%2520acquired%2520apoptotic%2520resistance%2520of%2520nonadherent%2520ovarian%2520cancer%2520cells%2520through%2520a%2520cross%2520talk%2520mediated%2520by%2520phosphatidylinositol%25203-kinase%2520and%2520extracellular%2520signal-regulated%2520kinase%25201%252F2%26jtitle%3DNeoplasia%26date%3D2010%26volume%3D12%26spage%3D128%26epage%3D138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Avan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quint, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frampton, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maftouh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelliccioni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuurhuis, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannetti, E.</span><span> </span><span class="NLM_article-title">Enhancement of the antiproliferative activity of gemcitabine by modulation of MET pathway in pancreatic cancer</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">â</span> <span class="NLM_lpage">950</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.2174%2F138161213804547312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22973962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktF2ltb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=940-950&author=A.+Avanauthor=K.+Quintauthor=F.+Nicoliniauthor=N.+Funelauthor=A.+E.+Framptonauthor=M.+Maftouhauthor=S.+Pelliccioniauthor=G.+J.+Schuurhuisauthor=G.+J.+Petersauthor=E.+Giovannetti&title=Enhancement+of+the+antiproliferative+activity+of+gemcitabine+by+modulation+of+MET+pathway+in+pancreatic+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer</span></div><div class="casAuthors">Avan, Amir; Quint, Karl; Nicolini, Francesco; Funel, Niccola; Frampton, Adam E.; Maftouh, Mina; Pelliccioni, Serena; Schuurhuis, Gerrit J.; Peters, Godefridus J.; Giovannetti, Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">940-950</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Pancreatic-ductal-adenocarcinoma (PDAC) is amongst the most lethal malignancies, mainly because of its metastatic spread and multifactorial chemoresistance.  Since c-Met is a marker of pancreatic-cancer-stem-cells (CSC), playing a key role in metastasis and chemoresistance, this study evaluated the therapeutic potential of the novel c-Met/ALK inhibitor crizotinib against PDAC cells, including the Capan-1-gemcitabine-resistant cells (Capan-1-R).  Crizotinib inhibited PDAC cell-growth with IC50 of 1.5 Î¼M in Capan-1-R, and synergistically enhanced the antiproliferative and proapoptotic activity of gemcitabine, as detected by sulforhodamine-B-assay, flow cytometry and combination-index method.  Capan-1-R had higher expression of the CSC markers CD44+/CD133+/CD326+, but their combined expression was significantly reduced by crizotinib, as detected by quant.-RT-PCR and FACS-anal.  Similarly, Capan-1-R cells had significantly higher protein-expression of c-Met (â2-fold), and increased migratory activity, which was reduced by crizotinib (e.g., >50% redn. of cell-migration in Capan-1-R after 8-h exposure, compared to untreated-cells), in assocn. with reduced vimentin expression.  Capan-1-R had also significantly higher mRNA expression of the gemcitabine catabolism-enzyme CDA, potentially explaining the higher CDA activity and statistically significant lower levels of gemcitabine-nucleotides in Capan-1-R compared to Capan-1, as detected by Liq.-chromatog.-mass-spectrometry.  Conversely, crizotinib significantly reduced CDA expression in both Capan-1 and Capan-1-R cells.  In aggregate, these data show the ability of crizotinib to specifically target CSC-like-subpopulations, interfere with cell-proliferation, induce apoptosis, reduce migration and synergistically interact with gemcitabine, supporting further studies on this novel therapeutic approach for PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRVbq6jTSM_bVg90H21EOLACvtfcHk0livO3BSUDtWaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktF2ltb0%253D&md5=2e50057edbbc26d230903ad580c3bc28</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.2174%2F138161213804547312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161213804547312%26sid%3Dliteratum%253Aachs%26aulast%3DAvan%26aufirst%3DA.%26aulast%3DQuint%26aufirst%3DK.%26aulast%3DNicolini%26aufirst%3DF.%26aulast%3DFunel%26aufirst%3DN.%26aulast%3DFrampton%26aufirst%3DA.%2BE.%26aulast%3DMaftouh%26aufirst%3DM.%26aulast%3DPelliccioni%26aufirst%3DS.%26aulast%3DSchuurhuis%26aufirst%3DG.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DGiovannetti%26aufirst%3DE.%26atitle%3DEnhancement%2520of%2520the%2520antiproliferative%2520activity%2520of%2520gemcitabine%2520by%2520modulation%2520of%2520MET%2520pathway%2520in%2520pancreatic%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D940%26epage%3D950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to targeted cancer therapies</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">â</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.2217%2Ffon.12.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22894672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WlsLzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=999-1014&author=M.+R.+Lacknerauthor=T.+R.+Wilsonauthor=J.+Settleman&title=Mechanisms+of+acquired+resistance+to+targeted+cancer+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to targeted cancer therapies</span></div><div class="casAuthors">Lackner, Mark R.; Wilson, Timothy R.; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">999-1014</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Drugs that target genomically defined vulnerabilities in human tumors have now been clin. validated as effective cancer therapies.  However, the relatively rapid acquisition of resistance to such treatments that is obsd. in virtually all cases significantly limits their utility and remains a substantial challenge to the clin. management of advanced cancers.  As mol. mechanisms of resistance have begun to be elucidated, new strategies to overcome or prevent the development of resistance have begun to emerge.  In some cases, specific mutational mechanisms contribute directly to acquired drug resistance, and in other cases it appears that nonmutational and possibly epigenetic mechanisms play a significant role.  This article discusses the various genetic and nongenetic mechanisms of acquired drug resistance that have been reported in the context of rationally targeted' drug therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooztN62IERZrVg90H21EOLACvtfcHk0livO3BSUDtWaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WlsLzK&md5=8a0a8ccb076874d753bfed5ace2ba169</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2217%2Ffon.12.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.12.86%26sid%3Dliteratum%253Aachs%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520targeted%2520cancer%2520therapies%26jtitle%3DFuture%2520Oncol.%26date%3D2012%26volume%3D8%26spage%3D999%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Crespan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucca, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maga, G.</span><span> </span><span class="NLM_article-title">Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2836</span><span class="NLM_x">â</span> <span class="NLM_lpage">2847</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.2174%2F092986711796150513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21651495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2rtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2836-2847&author=E.+Crespanauthor=E.+Zuccaauthor=G.+Maga&title=Overcoming+the+drug+resistance+problem+with+second-generation+tyrosine+kinase+inhibitors%3A+from+enzymology+to+structural+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models</span></div><div class="casAuthors">Crespan, E.; Zucca, E.; Maga, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2836-2847</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation is one of the major pathways used by eukaryotic cells to propagate signals to the final effectors, regulating multiple aspects of the living cell, such as metab., growth, differentiation, adhesion, motility, genome stability and death.  In this context, tyrosine kinases (TKs) play a central role in signal transduction and their overexpression or disregulated activity has been implicated in tumor onset and malignancy progression.  To date, eight TKs inhibitors have been approved by FDA for the treatment of specific tumors.  In spite of their efficacy, insurgence of resistance is a common feature after prolonged administration.  The selective pressure by these drugs, in fact, induces clonal expansion of subsets of cancer cells harboring TKs mutations, leading to decreased inhibition potency.  Alternatively, resistance to TK inhibitors can be acquired through the activation of others, often unrelated, TKs.  For this reason, while stringent target selectivity of TKs inhibitors has been always considered a desirable feature in order to limit toxicity, mols. targeting different TKs have been recently shown to be promising anti-cancer agents as well.  Understanding the mol. mechanisms that confer resistance to TK inhibitors, through a combination of enzymic, structural and cellular studies, is essential in the development of second generation inhibitors active also towards drug resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTAw7AY9OLMbVg90H21EOLACvtfcHk0lioT_jXarSqyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2rtbw%253D&md5=2646df643c23872eda9cbd111268b3ad</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2174%2F092986711796150513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796150513%26sid%3Dliteratum%253Aachs%26aulast%3DCrespan%26aufirst%3DE.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DMaga%26aufirst%3DG.%26atitle%3DOvercoming%2520the%2520drug%2520resistance%2520problem%2520with%2520second-generation%2520tyrosine%2520kinase%2520inhibitors%253A%2520from%2520enzymology%2520to%2520structural%2520models%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2836%26epage%3D2847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Trusolino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertotti, A.</span><span> </span><span class="NLM_article-title">Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">â</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=876-880&author=L.+Trusolinoauthor=A.+Bertotti&title=Compensatory+pathways+in+oncogenic+kinase+signaling+and+resistance+to+targeted+therapies%3A+six+degrees+of+separation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrusolino%26aufirst%3DL.%26aulast%3DBertotti%26aufirst%3DA.%26atitle%3DCompensatory%2520pathways%2520in%2520oncogenic%2520kinase%2520signaling%2520and%2520resistance%2520to%2520targeted%2520therapies%253A%2520six%2520degrees%2520of%2520separation%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D876%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit86b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Logue, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, D. K.</span><span> </span><span class="NLM_article-title">Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=641-650&author=J.+S.+Logueauthor=D.+K.+Morrison&title=Complexity+in+the+signaling+network%3A+insights+from+the+use+of+targeted+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLogue%26aufirst%3DJ.%2BS.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DComplexity%2520in%2520the%2520signaling%2520network%253A%2520insights%2520from%2520the%2520use%2520of%2520targeted%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D641%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltman, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digumarthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosper, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernovsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanuti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Genotyping and histological evolution of lung cancers acquiring resistance to EGFR inhibitors</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">75ra26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87a&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1126%2Fscitranslmed.3002003" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=75ra26&author=L.+V.+Sequistauthor=A.+W.+Waltmanauthor=D.+Dias-Santagataauthor=S.+Digumarthyauthor=A.+B.+Turkeauthor=P.+Fidiasauthor=K.+Bergethonauthor=A.+T.+Shawauthor=S.+Gettingerauthor=A.+K.+Cosperauthor=S.+Akhavanfardauthor=R.+S.+Heistauthor=J.+Temelauthor=J.+G.+Christensenauthor=J.+C.+Wainauthor=T.+J.+Lynchauthor=K.+Vernovskyauthor=E.+J.+Markauthor=M.+Lanutiauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=Genotyping+and+histological+evolution+of+lung+cancers+acquiring+resistance+to+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87a&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002003%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DWaltman%26aufirst%3DA.%2BW.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DCosper%26aufirst%3DA.%2BK.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DTemel%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DVernovsky%26aufirst%3DK.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DLanuti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DGenotyping%2520and%2520histological%2520evolution%2520of%2520lung%2520cancers%2520acquiring%2520resistance%2520to%2520EGFR%2520inhibitors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D75ra26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit87b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">â</span> <span class="NLM_lpage">2247</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87b&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87b&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87b&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87bR"><div class="casContent"><span class="casTitleNuber">87b</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lioT_jXarSqyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit87b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toschi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=77-88&author=A.+B.+Turkeauthor=K.+Zejnullahuauthor=Y.+L.+Wuauthor=Y.+Songauthor=D.+Dias-Santagataauthor=E.+Lifshitsauthor=L.+Toschiauthor=A.+Rogersauthor=T.+Mokauthor=L.+Sequistauthor=N.+I.+Lindemanauthor=C.+Murphyauthor=S.+Akhavanfardauthor=B.+Y.+Yeapauthor=Y.+Xiaoauthor=M.+Capellettiauthor=A.+J.+Iafrateauthor=C.+Leeauthor=J.+G.+Christensenauthor=J.+A.+Engelmanauthor=P.+A.+J%C3%A4nne&title=Preexistence+and+clonal+selection+of+MET+amplification+in+EGFR+mutant+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DRogers%26aufirst%3DA.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DSequist%26aufirst%3DL.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DMurphy%26aufirst%3DC.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPreexistence%2520and%2520clonal%2520selection%2520of%2520MET%2520amplification%2520in%2520EGFR%2520mutant%2520NSCLC%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26spage%3D77%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Yano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuramam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanibuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sone, S.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9479</span><span class="NLM_x">â</span> <span class="NLM_lpage">9487</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9479-9487&author=S.+Yanoauthor=W.+Wangauthor=Q.+Liauthor=K.+Matsumotoauthor=H.+Sakuramamauthor=T.+Nakamuraauthor=H.+Oginoauthor=S.+Kakiuchiauthor=M.+Hanibuchiauthor=Y.+Nishiokaauthor=H.+Ueharaauthor=T.+Mitsudomiauthor=Y.+Yatabeauthor=T.+Nakamuraauthor=S.+Sone&title=Hepatocyte+growth+factor+induces+gefitinib+resistance+of+lung+adenocarcinoma+with+epidermal+growth+factor+receptor-activating+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYano%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DSakuramam%26aufirst%3DH.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DOgino%26aufirst%3DH.%26aulast%3DKakiuchi%26aufirst%3DS.%26aulast%3DHanibuchi%26aufirst%3DM.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DHepatocyte%2520growth%2520factor%2520induces%2520gefitinib%2520resistance%2520of%2520lung%2520adenocarcinoma%2520with%2520epidermal%2520growth%2520factor%2520receptor-activating%2520mutations%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9479%26epage%3D9487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valtorta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siravegna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartore-Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassingena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zecchin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apicella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliardi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galimi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauricella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronesem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, L. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velculescu, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Nicolantonio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siena, S.</span><span> </span><span class="NLM_article-title">Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">â</span> <span class="NLM_lpage">673</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=658-673&author=A.+Bardelliauthor=S.+Corsoauthor=A.+Bertottiauthor=S.+Hoborauthor=E.+Valtortaauthor=G.+Siravegnaauthor=A.+Sartore-Bianchiauthor=E.+Scalaauthor=A.+Cassingenaauthor=D.+Zecchinauthor=M.+Apicellaauthor=G.+Migliardiauthor=F.+Galimiauthor=C.+Lauricellaauthor=C.+Zanonauthor=T.+Pereraauthor=S.+Veronesemauthor=G.+Cortiauthor=A.+Amatuauthor=M.+Gambacortaauthor=L.+A.+Diazauthor=M.+Sausenauthor=V.+E.+Velculescuauthor=P.+Comoglioauthor=L.+Trusolinoauthor=F.+Di+Nicolantonioauthor=S.+Giordanoauthor=S.+Siena&title=Amplification+of+the+MET+receptor+drives+resistance+to+anti-EGFR+therapies+in+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DCorso%26aufirst%3DS.%26aulast%3DBertotti%26aufirst%3DA.%26aulast%3DHobor%26aufirst%3DS.%26aulast%3DValtorta%26aufirst%3DE.%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DScala%26aufirst%3DE.%26aulast%3DCassingena%26aufirst%3DA.%26aulast%3DZecchin%26aufirst%3DD.%26aulast%3DApicella%26aufirst%3DM.%26aulast%3DMigliardi%26aufirst%3DG.%26aulast%3DGalimi%26aufirst%3DF.%26aulast%3DLauricella%26aufirst%3DC.%26aulast%3DZanon%26aufirst%3DC.%26aulast%3DPerera%26aufirst%3DT.%26aulast%3DVeronesem%26aufirst%3DS.%26aulast%3DCorti%26aufirst%3DG.%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DSausen%26aufirst%3DM.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DComoglio%26aufirst%3DP.%26aulast%3DTrusolino%26aufirst%3DL.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DAmplification%2520of%2520the%2520MET%2520receptor%2520drives%2520resistance%2520to%2520anti-EGFR%2520therapies%2520in%2520colorectal%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D658%26epage%3D673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Mohammadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliseenkova, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span> </span><span class="NLM_article-title">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5896</span><span class="NLM_x">â</span> <span class="NLM_lpage">5904</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1093%2Femboj%2F17.20.5896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=9774334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Cmurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=5896-5904&author=M.+Mohammadiauthor=S.+Froumauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=R.+L.+Panekauthor=G.+H.+Luauthor=A.+V.+Eliseenkovaauthor=D.+Greenauthor=J.+Schlessingerauthor=S.+R.+Hubbard&title=Crystal+structure+of+an+angiogenesis+inhibitor+bound+to+the+FGF+receptor+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span></div><div class="casAuthors">Mohammadi, Moosa; Froum, Scott; Hamby, James M.; Schroeder, Mel C.; Panek, Robert L.; Lu, Gina H.; Eliseenkova, Anna V.; Green, David; Schlessinger, Joseph; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5896-5904</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is an essential physiol. process in development, yet also plays a major role in the progression of human diseases such as diabetic retinopathy, atherosclerosis and cancer.  The effects of the most potent angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin and fibroblast growth factor (FGF) are mediated through cell surface receptors that possess intrinsic protein tyrosine kinase activity.  In this report, the authors describe a synthetic compd. of the pyrido[2,3-d]pyrimidine class, designated PD 173074, that selectively inhibits the tyrosine kinase activities of the FGF and VEGF receptors.  The authors show that systemic administration of PD 173074 in mice can effectively block angiogenesis induced by either FGF or VEGF with no apparent toxicity.  To elucidate the determinants of selectivity, the authors have detd. the crystal structure of PD 173074 in complex with the tyrosine kinase domain of FGF receptor 1 at 2.5 Ã resoln.  A high degree of surface complementarity between PD 173074 and the hydrophobic, ATP-binding pocket of FGF receptor 1 underlies the potency and selectivity of this inhibitor.  PD 173074 is thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the treatment of cancer and other diseases whose progression is dependent upon new blood vessel formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4zdEklzyMx7Vg90H21EOLACvtfcHk0lgdlP8QxVNuuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Cmurs%253D&md5=a76b085ddc9d352878a2c6bc9d1cd6ff</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.20.5896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.20.5896%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DFroum%26aufirst%3DS.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520an%2520angiogenesis%2520inhibitor%2520bound%2520to%2520the%2520FGF%2520receptor%2520tyrosine%2520kinase%2520domain%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26spage%3D5896%26epage%3D5904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Paulson, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linklater, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghuis, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">App, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oostendorp, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettinga, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnik, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graveel, C. R.</span><span> </span><span class="NLM_article-title">MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1112</span><span class="NLM_x">â</span> <span class="NLM_lpage">1121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1541-7786.MCR-13-0042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23825050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCgu77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1112-1121&author=A.+K.+Paulsonauthor=E.+S.+Linklaterauthor=B.+D.+Berghuisauthor=C.+A.+Appauthor=L.+D.+Oostendorpauthor=J.+E.+Paulsonauthor=J.+E.+Pettingaauthor=M.+K.+Melnikauthor=G.+F.+Vande+Woudeauthor=C.+R.+Graveel&title=MET+and+ERBB2+are+coexpressed+in+ERBB2%2B+breast+cancers+and+contribute+to+innate+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance</span></div><div class="casAuthors">Paulson, Amanda K.; Linklater, Erik S.; Berghuis, Bree D.; App, Colleen A.; Oostendorp, Leon D.; Paulson, Jayne E.; Pettinga, Jane E.; Melnik, Marianne K.; Vande Woude, George F.; Graveel, Carrie R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1112-1121</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Breast cancer displays significant intratumoral heterogeneity, which has been shown to have a substantial impact on both innate and acquired resistance to tyrosine kinase inhibitors.  The heterogeneous expression of multiple receptor tyrosine kinases (RTK) in cancers supports tumor signaling robustness and plays a significant role in resistance to targeted inhibition.  Recent studies have revealed interactions between the MET receptor and the ERBB receptor family in the therapeutic resistance of several cancers.  In this study, the relationship between MET expression/activity and the expression/activity of the ERBB receptor family in human breast cancer was interrogated.  Importantly, a significant percentage of ERBB2+ tumors coexpressing MET and ERBB2 were obsd. and displayed significant heterogeneity with subpopulations of cells that are MET-/ERBB2+, MET+/ERBB2-, and MET+/ERBB2+.  In a MET+/ERBB2+ breast cancer cell line, MET depletion resulted in increased ERBB2 activation, and conversely, ERBB2 depletion resulted in increased MET activation.  Neither EGFR nor ERBB3 compensated for MET or ERBB2 knockdown.  The loss of either MET or ERBB2 led to a decrease in PI3K/AKT signaling and increased dependency on MAPK.  These data show that a subset of ERBB2+ breast cancers express MET and contain MET+/ERBB2+ subpopulations.  Moreover, anal. of RTK activation during ERBB2 knockdown indicated that MET signaling is a compensatory pathway of resistance.  Implications: ERBB2+ breast cancers with MET+/ERBB2+ subpopulations may have an innate resistance to ERBB2 inhibition and may benefit from combined MET and ERBB2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Y7xfx01AHLVg90H21EOLACvtfcHk0ljuf6H7Agxb3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCgu77K&md5=bbf01aa7c2d26426bc47f52a1c956e9d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-13-0042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-13-0042%26sid%3Dliteratum%253Aachs%26aulast%3DPaulson%26aufirst%3DA.%2BK.%26aulast%3DLinklater%26aufirst%3DE.%2BS.%26aulast%3DBerghuis%26aufirst%3DB.%2BD.%26aulast%3DApp%26aufirst%3DC.%2BA.%26aulast%3DOostendorp%26aufirst%3DL.%2BD.%26aulast%3DPaulson%26aufirst%3DJ.%2BE.%26aulast%3DPettinga%26aufirst%3DJ.%2BE.%26aulast%3DMelnik%26aufirst%3DM.%2BK.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DGraveel%26aufirst%3DC.%2BR.%26atitle%3DMET%2520and%2520ERBB2%2520are%2520coexpressed%2520in%2520ERBB2%252B%2520breast%2520cancers%2520and%2520contribute%2520to%2520innate%2520resistance%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2013%26volume%3D11%26spage%3D1112%26epage%3D1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Harbinski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craig, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanghavi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buness, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatenay-Rivauday, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myer, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graus-Porta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiedt, R.</span><span> </span><span class="NLM_article-title">Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">â</span> <span class="NLM_lpage">959</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=948-959&author=F.+Harbinskiauthor=V.+J.+Craigauthor=S.+Sanghaviauthor=D.+Jefferyauthor=L.+Liuauthor=K.+A.+Sheppardauthor=S.+Wagnerauthor=C.+Stammauthor=A.+Bunessauthor=C.+Chatenay-Rivaudayauthor=Y.+Yaoauthor=F.+Heauthor=C.+X.+Luauthor=V.+Guagnanoauthor=T.+Metzauthor=P.+M.+Finanauthor=F.+Hofmannauthor=W.+R.+Sellersauthor=J.+A.+Porterauthor=V.+E.+Myerauthor=D.+Graus-Portaauthor=C.+J.+Wilsonauthor=A.+Bucklerauthor=R.+Tiedt&title=Rescue+screens+with+secreted+proteins+reveal+compensatory+potential+of+receptor+tyrosine+kinases+in+driving+cancer+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarbinski%26aufirst%3DF.%26aulast%3DCraig%26aufirst%3DV.%2BJ.%26aulast%3DSanghavi%26aufirst%3DS.%26aulast%3DJeffery%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSheppard%26aufirst%3DK.%2BA.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBuness%26aufirst%3DA.%26aulast%3DChatenay-Rivauday%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DC.%2BX.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DMetz%26aufirst%3DT.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DGraus-Porta%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DBuckler%26aufirst%3DA.%26aulast%3DTiedt%26aufirst%3DR.%26atitle%3DRescue%2520screens%2520with%2520secreted%2520proteins%2520reveal%2520compensatory%2520potential%2520of%2520receptor%2520tyrosine%2520kinases%2520in%2520driving%2520cancer%2520growth%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D948%26epage%3D959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Timofeevski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Enzymatic characterization of MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5339</span><span class="NLM_x">â</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900438w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5339-5349&author=S.+L.+Timofeevskiauthor=M.+A.+McTigueauthor=K.+Ryanauthor=J.+Cuiauthor=H.+Y.+Zouauthor=J.+X.+Zhuauthor=F.+Chauauthor=G.+Altonauthor=S.+Karlicekauthor=J.+G.+Christensenauthor=B.+W.+Murray&title=Enzymatic+characterization+of+MET+receptor+tyrosine+kinase+oncogenic+mutants+and+kinetic+studies+with+aminopyridine+and+triazolopyrazine+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=10.1021%2Fbi900438w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900438w%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeevski%26aufirst%3DS.%2BL.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DJ.%2BX.%26aulast%3DChau%26aufirst%3DF.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DEnzymatic%2520characterization%2520of%2520MET%2520receptor%2520tyrosine%2520kinase%2520oncogenic%2520mutants%2520and%2520kinetic%2520studies%2520with%2520aminopyridine%2520and%2520triazolopyrazine%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D5339%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit94b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chiara, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugliese, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Mutations in the MET oncogene unveil a âdual switchâ mechanism controlling tyrosine kinase activity</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">29352</span><span class="NLM_x">â</span> <span class="NLM_lpage">29358</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=29352-29358&author=F.+Chiaraauthor=P.+Michieliauthor=L.+Puglieseauthor=P.+M.+Comoglio&title=Mutations+in+the+MET+oncogene+unveil+a+%E2%80%9Cdual+switch%E2%80%9D+mechanism+controlling+tyrosine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChiara%26aufirst%3DF.%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DPugliese%26aufirst%3DL.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DMutations%2520in%2520the%2520MET%2520oncogene%2520unveil%2520a%2520%25E2%2580%259Cdual%2520switch%25E2%2580%259D%2520mechanism%2520controlling%2520tyrosine%2520kinase%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D29352%26epage%3D29358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Schiering, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor MET and its complex with the microbial alkaloid K-252a</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12654</span><span class="NLM_x">â</span> <span class="NLM_lpage">12659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=R.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+MET+and+its+complex+with+the+microbial+alkaloid+K-252a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520MET%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupka, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizizad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span> </span><span class="NLM_article-title">Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">â</span> <span class="NLM_lpage">3568</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=3563-3568&author=W.+Wangauthor=A.+Marimuthuauthor=J.+Tsaiauthor=A.+Kumarauthor=H.+I.+Krupkaauthor=C.+Zhangauthor=B.+Powellauthor=Y.+Suzukiauthor=H.+Nguyenauthor=M.+Tabrizizadauthor=C.+Luuauthor=B.+L.+West&title=Structural+characterization+of+autoinhibited+c-Met+kinase+produced+by+coexpression+in+bacteria+with+phosphatase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DKrupka%26aufirst%3DH.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DB.%2BL.%26atitle%3DStructural%2520characterization%2520of%2520autoinhibited%2520c-Met%2520kinase%2520produced%2520by%2520coexpression%2520in%2520bacteria%2520with%2520phosphatase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D3563%26epage%3D3568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, W. A.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">746</span><span class="NLM_x">â</span> <span class="NLM_lpage">754</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2F372746a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=7997262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1994&pages=746-754&author=S.+R.+Hubbardauthor=L.+Weiauthor=L.+Ellisauthor=W.+A.+Hendrickson&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+human+insulin+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span></div><div class="casAuthors">Hubbard, Stevan R.; Wei, Lei; Ellis, Leland; Hendrickson, Wayne A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6508</span>),
    <span class="NLM_cas:pages">746-54</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The x-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been detd. by multiwavelength anomalous diffraction phasing and refined to 2.1 Ã resoln.  The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1162, is bound in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp222kk0byoTrVg90H21EOLACvtfcHk0lhIrdMK0qaAIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D&md5=ad60bacc76a642b2957c55ff82274cab</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2F372746a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F372746a0%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520human%2520insulin%2520receptor%26jtitle%3DNature%26date%3D1994%26volume%3D372%26spage%3D746%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Mroczkowski, B.; McTigue, M. A.; Sarup, J.; Murray, B. W.; Hickey, M.; Parge, H.; Zhu, J.</span><span> </span><span class="NLM_article-title">Catalytic Domains of the Human Hepatocyte Growth Factor Receptor Kinase and Material and Methods for Identification Thereof</span>.  EP1243596 A1,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=B.+Mroczkowski&author=M.+A.+McTigue&author=J.+Sarup&author=B.+W.+Murray&author=M.+Hickey&author=H.+Parge&author=J.+Zhu&title=Catalytic+Domains+of+the+Human+Hepatocyte+Growth+Factor+Receptor+Kinase+and+Material+and+Methods+for+Identification+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMroczkowski%26aufirst%3DB.%26atitle%3DCatalytic%2520Domains%2520of%2520the%2520Human%2520Hepatocyte%2520Growth%2520Factor%2520Receptor%2520Kinase%2520and%2520Material%2520and%2520Methods%2520for%2520Identification%2520Thereof%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-DubÃ©, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">â</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">â</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=S.+Sistlaauthor=T.+L.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-RÎ² tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0ljWpDpQjOhyZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DS.%26aulast%3DLuu%26aufirst%3DT.%2BL.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Cui, J.; Zhang, R.; Shen, H.; Chu, J. Y.; Zhang, F.-J.; Koenig, M.; Do, S. H.; Li, X.; Wei, C. C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Preparation of 4-Aryl Substituted Indolinones as Protein Kinase Signal Transduction Modulators for Inhibiting Abnormal Cell Proliferation</span>. PCT Int. Appl. WO0255517,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=R.+Zhang&author=H.+Shen&author=J.+Y.+Chu&author=F.-J.+Zhang&author=M.+Koenig&author=S.+H.+Do&author=X.+Li&author=C.+C.+Wei&author=P.+C.+Tang&title=Preparation+of+4-Aryl+Substituted+Indolinones+as+Protein+Kinase+Signal+Transduction+Modulators+for+Inhibiting+Abnormal+Cell+Proliferation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25204-Aryl%2520Substituted%2520Indolinones%2520as%2520Protein%2520Kinase%2520Signal%2520Transduction%2520Modulators%2520for%2520Inhibiting%2520Abnormal%2520Cell%2520Proliferation%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Cui, J.; Ramphal, Y.; Liang, C.; Sun, L.; Wei, C. C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">5-Aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone Derivatives As Kinase Inhibitors</span>. PCT Int. Appl. WO2002096361 A2,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=Y.+Ramphal&author=C.+Liang&author=L.+Sun&author=C.+C.+Wei&author=P.+C.+Tang&title=5-Aralkylsulfonyl-3-%28pyrrol-2-ylmethylidene%29-2-indolinone+Derivatives+As+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3D5-Aralkylsulfonyl-3-%2528pyrrol-2-ylmethylidene%2529-2-indolinone%2520Derivatives%2520As%2520Kinase%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiewlich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlett, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the MET [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">â</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=14617781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovFCqtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=1085-1092&author=X.+Wangauthor=P.+Leauthor=C.+Liangauthor=J.+Chanauthor=D.+Kiewlichauthor=T.+Millerauthor=D.+Harrisauthor=L.+Sunauthor=A.+Riceauthor=S.+Vasileauthor=R.+A.+Blakeauthor=A.+R.+Howlettauthor=N.+Patelauthor=G.+McMahonauthor=K.+E.+Lipson&title=Potent+and+selective+inhibitors+of+the+MET+%5Bhepatocyte+growth+factor%2Fscatter+factor+%28HGF%2FSF%29+receptor%5D+tyrosine+kinase+block+HGF%2FSF-induced+tumor+cell+growth+and+invasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion</span></div><div class="casAuthors">Wang, Xueyan; Le, Phuong; Liang, Congxin; Chan, Julie; Kiewlich, David; Miller, Todd; Harris, Dave; Sun, Li; Rice, Audie; Vasile, Stefan; Blake, Robert A.; Howlett, Anthony R.; Patel, Neela; McMahon, Gerald; Lipson, Kenneth E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The hepatocyte growth factor/scatter factor (HGF/SF) receptor, Met, mediates various cellular responses on activation with its ligand, including proliferation, survival, motility, invasion, and tubular morphogenesis.  Met expression is frequently up-regulated in sarcomas and carcinomas.  Exptl. evidence suggests that Met activation correlates with poor clin. outcome and the likelihood of metastasis.  Therefore, inhibitors of Met tyrosine kinase may be useful for the treatment of a wide variety of cancers that have spread from the primary site.  We have discovered potent and selective pyrrole-indolinone Met kinase inhibitors and characterized them for their ability to inhibit HGF/SF-induced cellular responses in vitro.  These compds. inhibit HGF/SF-induced receptor phosphorylation in a dose-dependent manner.  They also inhibit the HGF/SF-induced motility and invasion of epithelial and carcinoma cells.  Therefore, these compds. represent a class of prototype small mols. that selectively inhibit the Met kinase and could lead to identification of compds. with potential therapeutic utility in treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVAQRRxT_J1rVg90H21EOLACvtfcHk0ljWpDpQjOhyZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovFCqtL8%253D&md5=3b3141600b15ed4f9c97d86fb7ade81d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DKiewlich%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DRice%26aufirst%3DA.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DHowlett%26aufirst%3DA.%2BR.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520MET%2520%255Bhepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520%2528HGF%252FSF%2529%2520receptor%255D%2520tyrosine%2520kinase%2520block%2520HGF%252FSF-induced%2520tumor%2520cell%2520growth%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D1085%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuruganti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruslim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramphal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of MET kinase inhibits MET-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7345</span><span class="NLM_x">â</span> <span class="NLM_lpage">7355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7345-7355&author=J.+G.+Christensenauthor=R.+Schreckauthor=J.+Burrowsauthor=P.+Kurugantiauthor=E.+Chanauthor=P.+Leauthor=J.+Chenauthor=X.+Wangauthor=L.+Ruslimauthor=R.+Blakeauthor=K.+E.+Lipsonauthor=J.+Ramphalauthor=S.+Doauthor=J.+J.+Cuiauthor=J.+M.+Cherringtonauthor=D.+B.+Mendel&title=A+selective+small+molecule+inhibitor+of+MET+kinase+inhibits+MET-dependent+phenotypes+in+vitro+and+exhibits+cytoreductive+antimutor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DKuruganti%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRuslim%26aufirst%3DL.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DRamphal%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520MET%2520kinase%2520inhibits%2520MET-dependent%2520phenotypes%2520in%2520vitro%2520and%2520exhibits%2520cytoreductive%2520antimutor%2520activity%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7345%26epage%3D7355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and MET, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">â</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+MET%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, â¼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-Î³, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0li_wosz7cu3IA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520MET%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6804</span><span class="NLM_x">â</span> <span class="NLM_lpage">6820</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=6804-6820&author=D.+Zhangauthor=X.+Zhangauthor=J.+Aiauthor=Y.+Zhaiauthor=Z.+Liangauthor=Y.+Wangauthor=Y.+Chenauthor=C.+Liauthor=F.+Zhaoauthor=H.+Jiangauthor=M.+Gengauthor=C.+Luoauthor=H.+Liu&title=Synthesis+and+biological+evaluation+of+2-amino-5-aryl-3-benzylthiopyridine+scaffold+based+potent+c-Met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-amino-5-aryl-3-benzylthiopyridine%2520scaffold%2520based%2520potent%2520c-Met%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D6804%26epage%3D6820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span> </span><span class="NLM_article-title">Aminopyridyl/pyrazinyl spiro[indoline-3,4â²-piperidine]-2-ones as highly selective and efficacious MET/ALK inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">806</span><span class="NLM_x">â</span> <span class="NLM_lpage">810</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml400203d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=806-810&author=J.+Liauthor=N.+Wuauthor=Y.+Tianauthor=J.+Zhangauthor=S.+Wu&title=Aminopyridyl%2Fpyrazinyl+spiro%5Bindoline-3%2C4%E2%80%B2-piperidine%5D-2-ones+as+highly+selective+and+efficacious+MET%2FALK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fml400203d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400203d%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DS.%26atitle%3DAminopyridyl%252Fpyrazinyl%2520spiro%255Bindoline-3%252C4%25E2%2580%25B2-piperidine%255D-2-ones%2520as%2520highly%2520selective%2520and%2520efficacious%2520MET%252FALK%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D806%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Steinig, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.-H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadalbajoo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares-Greco, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertella, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bittner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turton, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokhale, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landfair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span> </span><span class="NLM_article-title">Novel 6-aminofuro[3,2-<i>c</i>]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4381</span><span class="NLM_x">â</span> <span class="NLM_lpage">4387</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4381-4387&author=A.+G.+Steinigauthor=A.-H+Liauthor=J.+Wangauthor=X.+Chenauthor=H.+Dongauthor=C.+Ferraroauthor=M.+Jinauthor=M.+Kadalbajooauthor=A.+Kleinbergauthor=K.+M.+Stolzauthor=P.+A.+Tavares-Grecoauthor=T.+Wangauthor=M.+R.+Albertellaauthor=Y.+Pengauthor=L.+Crewauthor=J.+Kahlerauthor=J.+Kanauthor=R.+Schulzauthor=A.+Cookeauthor=M.+Bittnerauthor=R.+W.+Turtonauthor=M.+Franklinauthor=P.+Gokhaleauthor=D.+Landfairauthor=C.+Mantisauthor=J.+Workmanauthor=R.+Wildauthor=J.+Pachterauthor=D.+Epsteinauthor=M.+J.+Mulvihill&title=Novel+6-aminofuro%5B3%2C2-c%5Dpyridines+as+potent%2C+orally+efficacious+inhibitors+of+cMET+and+RON+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSteinig%26aufirst%3DA.%2BG.%26aulast%3DLi%26aufirst%3DA.-H%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DFerraro%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DM.%26aulast%3DKadalbajoo%26aufirst%3DM.%26aulast%3DKleinberg%26aufirst%3DA.%26aulast%3DStolz%26aufirst%3DK.%2BM.%26aulast%3DTavares-Greco%26aufirst%3DP.%2BA.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlbertella%26aufirst%3DM.%2BR.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DCrew%26aufirst%3DL.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DKan%26aufirst%3DJ.%26aulast%3DSchulz%26aufirst%3DR.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DBittner%26aufirst%3DM.%26aulast%3DTurton%26aufirst%3DR.%2BW.%26aulast%3DFranklin%26aufirst%3DM.%26aulast%3DGokhale%26aufirst%3DP.%26aulast%3DLandfair%26aufirst%3DD.%26aulast%3DMantis%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DJ.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DPachter%26aufirst%3DJ.%26aulast%3DEpstein%26aufirst%3DD.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26atitle%3DNovel%25206-aminofuro%255B3%252C2-c%255Dpyridines%2520as%2520potent%252C%2520orally%2520efficacious%2520inhibitors%2520of%2520cMET%2520and%2520RON%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4381%26epage%3D4387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Nishii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyano, H.</span><span> </span><span class="NLM_article-title">Discovery of 6-benzyloxyquinolines as MET selective kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1405</span><span class="NLM_x">â</span> <span class="NLM_lpage">1409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1405-1409&author=H.+Nishiiauthor=T.+Chibaauthor=K.+Morikamiauthor=T.+A.+Fukamiauthor=H.+Sakamotoauthor=K.+Koauthor=H.+Koyano&title=Discovery+of+6-benzyloxyquinolines+as+MET+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishii%26aufirst%3DH.%26aulast%3DChiba%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DKo%26aufirst%3DK.%26aulast%3DKoyano%26aufirst%3DH.%26atitle%3DDiscovery%2520of%25206-benzyloxyquinolines%2520as%2520MET%2520selective%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1405%26epage%3D1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4920</span><span class="NLM_x">â</span> <span class="NLM_lpage">4931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F0008-5472.CAN-10-3879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21613408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4920-4931&author=C.+M.+Lovlyauthor=J.+M.+Heuckmannauthor=E.+de+Stanchinaauthor=H.+Chenauthor=R.+K.+Thomasauthor=C.+Liangauthor=W.+Pao&title=Insights+into+ALK-driven+cancers+revealed+through+development+of+novel+ALK+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Lovly, Christine M.; Heuckmann, Johannes M.; de Stanchina, Elisa; Chen, Heidi; Thomas, Roman K.; Liang, Chris; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4920-4931</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings.  In this study, we report the identification and biol. characterization of X-376 and X-396, two potent and highly specific ALK small mol. tyrosine kinase inhibitors (TKIs).  In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clin. trials.  Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles.  Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein.  Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations assocd. with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant.  Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin.  Our findings offer preclin. proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.  Cancer Res; 71(14); 4920-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCEJra8njI7Vg90H21EOLACvtfcHk0ljagodO3VFu8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D&md5=000cbd1295c9d9fa6a43027f08c31247</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-3879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-3879%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DInsights%2520into%2520ALK-driven%2520cancers%2520revealed%2520through%2520development%2520of%2520novel%2520ALK%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4920%26epage%3D4931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Novel 5-(benzyloxy)pyridin-2(1<i>H</i>)-one derivatives as potent MET inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">â</span> <span class="NLM_lpage">2413</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2408-2413&author=D.+Zhangauthor=J.+Aiauthor=Z.+Liangauthor=W.+Zhuauthor=X.+Pengauthor=X.+Chenauthor=Y.+Jiauthor=H.+Jiangauthor=C.+Luoauthor=M.+Gengauthor=H.+Liu&title=Novel+5-%28benzyloxy%29pyridin-2%281H%29-one+derivatives+as+potent+MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DNovel%25205-%2528benzyloxy%2529pyridin-2%25281H%2529-one%2520derivatives%2520as%2520potent%2520MET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2408%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Hann, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">KeserÃ¼, G. M.</span><span> </span><span class="NLM_article-title">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">â</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrd3701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22543468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=355-365&author=M.+M.+Hannauthor=G.+M.+Keser%C3%BC&title=Finding+the+sweet+spot%3A+the+role+of+nature+and+nurture+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span></div><div class="casAuthors">Hann, Michael M.; Keserue, Gyoergy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Given its position at the heart of small-mol. drug discovery, medicinal chem. has an important role in tackling the well-known productivity challenges in pharmaceutical research and development.  In recent years, extensive analyses of successful and failed discovery compds. and drug candidates have improved our understanding of the role of physicochem. properties in drug attrition.  Based on the clarified challenges in finding the 'sweet spot' in medicinal chem. programs, we suggest that this goal can be achieved through a combination of first identifying chem. starting points with appropriate 'nature' and then rigorously 'nurturing' them during lead optimization.  Here, we discuss scientific, strategic, organizational and cultural considerations for medicinal chem. practices, with the aim of promoting more effective use of what is already known, as well as a wider appreciation of the risks of pursuing suboptimal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrURciGjB2A3LVg90H21EOLACvtfcHk0li24_yL-ZrIVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D&md5=90170e3f4e69e52bfa38667df380516a</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fnrd3701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3701%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26atitle%3DFinding%2520the%2520sweet%2520spot%253A%2520the%2520role%2520of%2520nature%2520and%2520nurture%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D355%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Tarcsay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">NyÃ­ri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span> </span><span class="NLM_article-title">Impact of lipophilic efficiency on compound quality</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">â</span> <span class="NLM_lpage">1260</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201388p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1252-1260&author=A.+Tarcsayauthor=K.+Ny%C3%ADriauthor=G.+M.+Keseru&title=Impact+of+lipophilic+efficiency+on+compound+quality"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Lipophilic Efficiency on Compound Quality</span></div><div class="casAuthors">Tarcsay, Akos; Nyiri, Kinga; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lipophilic efficiency indexes such as LLE and LELP were suggested to support balanced optimization of potency and ADMET profile.  Here we investigated the performance of LLE and LELP on multiple data sets representing different stages of drug discovery including fragment and HTS hits and leads, development candidates, phase II compds., and launched drugs.  Analyzing their impact on ADME and safety properties and binding thermodn., we found that both LLE and LELP help identifying better quality compds.  LLE is sensible for the development stages but does not prefer fragment-type hits, while LELP has an advantage for this class of compds. and discriminates preferred starting points effectively.  Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE in risk assessment at least on the present data set.  On the basis of the results reported here, monitoring lipophilic efficiency metrics could contribute significantly to compd. quality and might improve the output of medicinal chem. programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB8xs6-5DL7Vg90H21EOLACvtfcHk0li24_yL-ZrIVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D&md5=2536abef781f52806013016971c78bcb</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm201388p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201388p%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DNy%25C3%25ADri%26aufirst%3DK.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DImpact%2520of%2520lipophilic%2520efficiency%2520on%2520compound%2520quality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1252%26epage%3D1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Wager, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekaran, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalobos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Will, Y.</span><span> </span><span class="NLM_article-title">Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">â</span> <span class="NLM_lpage">434</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn100007x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVaqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=420-434&author=T.+T.+Wagerauthor=R.+Y.+Chandrasekaranauthor=X.+Houauthor=M.+D.+Troutmanauthor=P.+R.+Verhoestauthor=A.+Villalobosauthor=Y.+Will&title=Defining+desirable+central+nervous+system+drug+space+through+the+alignment+of+molecular+properties%2C+in+vitro+ADME%2C+and+safety+attributes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes</span></div><div class="casAuthors">Wager, Travis T.; Chandrasekaran, Ramalakshmi Y.; Hou, Xinjun; Troutman, Matthew D.; Verhoest, Patrick R.; Villalobos, Anabella; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">420-434</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of our effort to increase survival of drug candidates and to move our medicinal chem. design to higher probability space for success in the Neuroscience therapeutic area, we embarked on a detailed study of the property space for a collection of central nervous system (CNS) mols.  We carried out a thorough anal. of properties for 119 marketed CNS drugs and a set of 108 Pfizer CNS candidates.  In particular, we focused on understanding the relationships between physicochem. properties, in vitro ADME (absorption, distribution, metab., and elimination) attributes, primary pharmacol. binding efficiencies, and in vitro safety data for these two sets of compds.  This scholarship provides guidance for the design of CNS mols. in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEMBo2f34BrVg90H21EOLACvtfcHk0li24_yL-ZrIVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVaqtbk%253D&md5=85716be86290fd85e93c6b8d5621683c</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fcn100007x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100007x%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DChandrasekaran%26aufirst%3DR.%2BY.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DDefining%2520desirable%2520central%2520nervous%2520system%2520drug%2520space%2520through%2520the%2520alignment%2520of%2520molecular%2520properties%252C%2520in%2520vitro%2520ADME%252C%2520and%2520safety%2520attributes%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D420%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-DubÃ©, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8091</span><span class="NLM_x">â</span> <span class="NLM_lpage">8109</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300967g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8091-8109&author=J.+J.+Cuiauthor=M.+McTigueauthor=M.+Nambuauthor=M.+Tran-Dub%C3%A9author=M.+Pairishauthor=H.+Shenauthor=L.+Jiaauthor=H.+Chengauthor=J.+Hoffmanauthor=P.+Leauthor=M.+Jalaieauthor=G.+H.+Goetzauthor=K.+Ryanauthor=N.+Grodskyauthor=Y.+L.+Dengauthor=M.+Parkerauthor=S.+Timofeevskiauthor=B.+W.+Murrayauthor=S.+Yamazakiauthor=S.+Aguirreauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Discovery+of+a+novel+class+of+exquisitely+selective+mesenchymal-epithelial+transition+factor+%28MET%29+protein+kinase+inhibitors+and+identification+of+the+clinical+candidate+2-%284-%281-%28quinolin-6-ylmethyl%29-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-b%5Dpyrazin-6-yl%29-1H-pyrazol-1-yl%29ethanol+%28PF-04217903%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%2BH.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520exquisitely%2520selective%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528MET%2529%2520protein%2520kinase%2520inhibitors%2520and%2520identification%2520of%2520the%2520clinical%2520candidate%25202-%25284-%25281-%2528quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2520%2528PF-04217903%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8091%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Koenig, M.; Cui, J.; Wei, C. C.; Do, S. H.; Zhang, F.-J.; Vojkovsky, T.; Ramphal, J.; Yang, G.; Mattson, M.; Nelson, C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Indolinone Hydrazides as MET Inhibitors</span>. PCT Int. Appl. WO2005005378,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Koenig&author=J.+Cui&author=C.+C.+Wei&author=S.+H.+Do&author=F.-J.+Zhang&author=T.+Vojkovsky&author=J.+Ramphal&author=G.+Yang&author=M.+Mattson&author=C.+Nelson&author=P.+C.+Tang&title=Indolinone+Hydrazides+as+MET+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoenig%26aufirst%3DM.%26atitle%3DIndolinone%2520Hydrazides%2520as%2520MET%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Vojkovsky, T.; Koenig, M.; Zhang, F.-J.; Cui, J.</span><span> </span><span class="NLM_article-title">Tetracyclic Compounds as MET Inhibitors</span>. PCT Int. Appl. WO2005004808,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Vojkovsky&author=M.+Koenig&author=F.-J.+Zhang&author=J.+Cui&title=Tetracyclic+Compounds+as+MET+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVojkovsky%26aufirst%3DT.%26atitle%3DTetracyclic%2520Compounds%2520as%2520MET%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Zhang, F.-J.; Vojkovsky, T.; Huang, P.; Liang, C.; Do, S. H.; Koenig, M.; Cui, J.</span><span> </span><span class="NLM_article-title">Preparation of Triazolotriazines as MET Modulators for Treating Cancer</span>. PCT Int. Appl. WO2005010005,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=F.-J.+Zhang&author=T.+Vojkovsky&author=P.+Huang&author=C.+Liang&author=S.+H.+Do&author=M.+Koenig&author=J.+Cui&title=Preparation+of+Triazolotriazines+as+MET+Modulators+for+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.-J.%26atitle%3DPreparation%2520of%2520Triazolotriazines%2520as%2520MET%2520Modulators%2520for%2520Treating%2520Cancer%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Cui, J.; Botrous, I.</span><span> </span><span class="NLM_article-title">Arylmethyl Triazolo and Imidazopyrazines as MET Inhibitors</span>. PCT Int. Appl. WO2005004607,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+Cui&author=I.+Botrous&title=Arylmethyl+Triazolo+and+Imidazopyrazines+as+MET+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DArylmethyl%2520Triazolo%2520and%2520Imidazopyrazines%2520as%2520MET%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-DubÃ©, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Lessons from (<i>S</i>)-6-(1-(6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6651</span><span class="NLM_x">â</span> <span class="NLM_lpage">6665</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400926x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6651-6665&author=J.+J.+Cuiauthor=H.+Shenauthor=M.+Tran-Dub%C3%A9author=M.+Nambuauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=S.+Yamazakiauthor=S.+Aguirreauthor=M.+Parkerauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Lessons+from+%28S%29-6-%281-%286-%281-methyl-1H-pyrazol-4-yl%29-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-b%5Dpyridazin-3-yl%29ethyl%29quinoline+%28PF-04254644%29%2C+an+inhibitor+of+receptor+tyrosine+kinase+c-Met+with+high+protein+kinase+selectivity+but+broad+phosphodiesterase+family+inhibition+leading+to+myocardial+degeneration+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fjm400926x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400926x%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DLessons%2520from%2520%2528S%2529-6-%25281-%25286-%25281-methyl-1H-pyrazol-4-yl%2529-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-b%255Dpyridazin-3-yl%2529ethyl%2529quinoline%2520%2528PF-04254644%2529%252C%2520an%2520inhibitor%2520of%2520receptor%2520tyrosine%2520kinase%2520c-Met%2520with%2520high%2520protein%2520kinase%2520selectivity%2520but%2520broad%2520phosphodiesterase%2520family%2520inhibition%2520leading%2520to%2520myocardial%2520degeneration%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6651%26epage%3D6665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Aguirre, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collette, W.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobrowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasi, E. R.</span><span> </span><span class="NLM_article-title">Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">â</span> <span class="NLM_lpage">428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1177%2F0192623310364027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20231546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1Ontbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=416-428&author=S.+A.+Aguirreauthor=J.+R.+Heyenauthor=W.+Colletteauthor=W.+Bobrowskiauthor=E.+R.+Blasi&title=Cardiovascular+effects+in+rats+following+exposure+to+a+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Aguirre, Shirley A.; Heyen, Jonathan R.; Collette, Walter, III; Bobrowski, Walter; Blasi, Eileen R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">416-428</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase receptor (RTK) signaling pathway, mesenchymal-epithelial transition factor (c-Met)/hepatocyte growth factor receptor (HGFR), has been implicated in oncogenesis and is a target of interest in cancer therapy.  PF-04254644 is a potent and selective inhibitor of c-Met/HGFR.  Wide ligand binding profiling of PF-04254644 revealed a potentially significant interaction with phosphodiesterase (PDE) 3, and follow-up PDE enzyme activity assays confirmed PF-04254644 as a potent inhibitor of PDE3 as well as other PDEs (1, 2, 5, 10, and 11).  Clin. observations, lab., and echocardiog. parameters were recorded in Sprague-Dawley (SD) rats that received PF-04254644 oral dosing for up to seven consecutive days.  Toxicol. evaluations revealed myocardial degeneration as an adverse event at all tested doses.  Echocardiog. evaluations revealed an increase in heart rate (HR) and contractility after the first dose with PF-04254644 and myocardial fibrosis correlated with decreased cardiac function after repeat dosing.  A study in telemetry-instrumented rats substantiated that PF-04254644 induced a sustained increased HR and decreased contractility after six days of treatment.  Data suggest that the decreased cardiac function and cardiotoxicity are likely due to inhibition of multiple PDEs by PF-04254644.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_6wrzHn8abVg90H21EOLACvtfcHk0ljPBUbsCVTT-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1Ontbc%253D&md5=59dc667b0b8436e87cb5b4ae1ec56778</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1177%2F0192623310364027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623310364027%26sid%3Dliteratum%253Aachs%26aulast%3DAguirre%26aufirst%3DS.%2BA.%26aulast%3DHeyen%26aufirst%3DJ.%2BR.%26aulast%3DCollette%26aufirst%3DW.%26aulast%3DBobrowski%26aufirst%3DW.%26aulast%3DBlasi%26aufirst%3DE.%2BR.%26atitle%3DCardiovascular%2520effects%2520in%2520rats%2520following%2520exposure%2520to%2520a%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DToxicol.%2520Pathol.%26date%3D2010%26volume%3D38%26spage%3D416%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirakawa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition</span> <span class="citation_source-journal">J. Appl. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1008</span><span class="NLM_x">â</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fjat.2801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22936366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yks7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=1008-1020&author=W.+Huauthor=B.+Hirakawaauthor=B.+Jessenauthor=M.+Leeauthor=S.+A.+Aguirre&title=Tyrosine+kinase+inhibitor-induced+myocardial+degeneration+in+rats+through+off-target+phosphodiesterase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition</span></div><div class="casAuthors">Hu, Wenyue; Hirakawa, Brad; Jessen, Bart; Lee, Michelle; Aguirre, Shirley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1008-1020</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">PF-04254644 is a selective kinase inhibitor of mesenchymal epithelial transition factor/hepatocyte growth factor receptor with known off-target inhibitory activity against the phosphodiesterase (PDE) family.  Rats given repeated oral doses of PF-04254644 developed a mild to moderate myocardial degeneration accompanied by sustained increase in heart rate and contractility.  Investigative studies were conducted to delineate the mechanisms of toxicity.  Microarray anal. of Sprague-Dawley rat hearts in a 6 day repeat dose study with PF-04254644 or milrinone, a selective PDE3 inhibitor, revealed similar perturbation of the cyclic adenosine monophosphate (c-AMP) pathway.  PDE inhibition and activation of c-AMP were further substantiated using PDE3B immunofluorescence staining and through a c-AMP response element reporter gene assay.  The intracellular calcium and oxidative stress signaling pathways were more perturbed by treatment with PF-04254644 than milrinone.  The rat cardiomyocytes calcium assay found a dose-dependent increase in intracellular calcium with PF-04254644 treatment.  These data suggest that cardiotoxicity of PF-04254644 was probably due to activation of c-AMP signaling, and possibly subsequent disruption of intracellular calcium and oxidative stress signaling pathways.  The greater response with PF-04254644 as compared with milrinone in gene expression and micro- and ultrastructural changes is probably due to the broader panel of PDEs inhibition.  Copyright Â© 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3XR4RRu0a4rVg90H21EOLACvtfcHk0lhoMmcCl01u7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yks7bM&md5=5565a0333f18d96b4a9524f5decc6425</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fjat.2801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.2801%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHirakawa%26aufirst%3DB.%26aulast%3DJessen%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DAguirre%26aufirst%3DS.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitor-induced%2520myocardial%2520degeneration%2520in%2520rats%2520through%2520off-target%2520phosphodiesterase%2520inhibition%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2012%26volume%3D32%26spage%3D1008%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Perera, T.; Lavrijssen, T.; Janssens, B.; Geerts, T.; King, P.; Mevellec, L.; Cummings, M. D.; Lu, T.; Johnson, D.; Page, M.</span><span> </span><span class="NLM_article-title">JNJ-38877605: A Selective MET Kinase Inhibitor Inducing Regression of MET-Driven Tumor Models</span>. Presented at the 99th AACR Annual Meeting; San Diego, CA, Apr 12â16,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>No. 4837.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+Perera&author=T.+Lavrijssen&author=B.+Janssens&author=T.+Geerts&author=P.+King&author=L.+Mevellec&author=M.+D.+Cummings&author=T.+Lu&author=D.+Johnson&author=M.+Page&title=JNJ-38877605%3A+A+Selective+MET+Kinase+Inhibitor+Inducing+Regression+of+MET-Driven+Tumor+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%26atitle%3DJNJ-38877605%253A%2520A%2520Selective%2520MET%2520Kinase%2520Inhibitor%2520Inducing%2520Regression%2520of%2520MET-Driven%2520Tumor%2520Models%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bounaud, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huser, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felce, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froning, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterman, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubol, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessert, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwinn, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leon, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emtage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burley, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, S. H.</span><span> </span><span class="NLM_article-title">SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3181</span><span class="NLM_x">â</span> <span class="NLM_lpage">3190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1535-7163.MCT-09-0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19934279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3181-3190&author=S.+G.+Buchananauthor=J.+Hendleauthor=P.+S.+Leeauthor=C.+R.+Smithauthor=P.+Y.+Bounaudauthor=K.+A.+Jessenauthor=C.+M.+Tangauthor=N.+H.+Huserauthor=J.+D.+Felceauthor=K.+J.+Froningauthor=M.+C.+Petermanauthor=B.+E.+Aubolauthor=S.+F.+Gessertauthor=J.+M.+Sauderauthor=K.+D.+Schwinnauthor=M.+Russellauthor=I.+A.+Rooneyauthor=J.+Adamsauthor=B.+C.+Leonauthor=T.+H.+Doauthor=J.+M.+Blaneyauthor=P.+A.+Sprengelerauthor=D.+A.+Thompsonauthor=L.+Smythauthor=L.+A.+Pelletierauthor=S.+Atwellauthor=K.+Holmeauthor=S.+R.+Wassermanauthor=S.+Emtageauthor=S.+K.+Burleyauthor=S.+H.+Reich&title=SGX523+is+an+exquisitely+selective%2C+ATP-competitive+inhibitor+of+the+MET+receptor+tyrosine+kinase+with+antitumor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</span></div><div class="casAuthors">Buchanan, Sean G.; Hendle, Jorg; Lee, Patrick S.; Smith, Christopher R.; Bounaud, Pierre-Yves; Jessen, Katti A.; Tang, Crystal M.; Huser, Nanni H.; Felce, Jeremy D.; Froning, Karen J.; Peterman, Marshall C.; Aubol, Brandon E.; Gessert, Steve F.; Sauder, J. Michael; Schwinn, Kenneth D.; Russell, Marijane; Rooney, Isabelle A.; Adams, Jason; Leon, Barbara C.; Do, Tuan H.; Blaney, Jeff M.; Sprengeler, Paul A.; Thompson, Devon A.; Smyth, Lydia; Pelletier, Laura A.; Atwell, Shane; Holme, Kevin; Wasserman, Stephen R.; Emtage, Spencer; Burley, Stephen K.; Reich, Siegfried H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3181-3190</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics.  Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers.  In other cancers, such as glioblastoma, autocrine activation of MET has been demonstrated.  Several classes of ATP-competitive inhibitor have been described, which inhibit MET but also other kinases.  Here, we describe SGX523, a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET.  SGX523 potently inhibited MET with an IC50 of 4 nmol/L and is >1000-fold selective vs. the >200-fold selectivity of other protein kinases tested in biochem. assays.  Crystallog. study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the selectivity.  SGX523 inhibited MET-mediated signaling, cell proliferation, and cell migration at nanomolar concns. but had no effect on signaling dependent on other protein kinases, including the closely related RON, even at micromolar concns.  SGX523 inhibition of MET in vivo was assocd. with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers, confirming the dependence of these tumors on MET catalytic activity.  Our results show that SGX523 is the most selective inhibitor of MET catalytic activity described to date and is thus a useful tool to investigate the role of MET kinase in cancer without the confounding effects of promiscuous protein kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplt9w6z--VQ7Vg90H21EOLACvtfcHk0lhoMmcCl01u7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbzI&md5=7410ae811f0bf2d3298691ed34d35878</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0477%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DHendle%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DBounaud%26aufirst%3DP.%2BY.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DTang%26aufirst%3DC.%2BM.%26aulast%3DHuser%26aufirst%3DN.%2BH.%26aulast%3DFelce%26aufirst%3DJ.%2BD.%26aulast%3DFroning%26aufirst%3DK.%2BJ.%26aulast%3DPeterman%26aufirst%3DM.%2BC.%26aulast%3DAubol%26aufirst%3DB.%2BE.%26aulast%3DGessert%26aufirst%3DS.%2BF.%26aulast%3DSauder%26aufirst%3DJ.%2BM.%26aulast%3DSchwinn%26aufirst%3DK.%2BD.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DRooney%26aufirst%3DI.%2BA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DLeon%26aufirst%3DB.%2BC.%26aulast%3DDo%26aufirst%3DT.%2BH.%26aulast%3DBlaney%26aufirst%3DJ.%2BM.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DSmyth%26aufirst%3DL.%26aulast%3DPelletier%26aufirst%3DL.%2BA.%26aulast%3DAtwell%26aufirst%3DS.%26aulast%3DHolme%26aufirst%3DK.%26aulast%3DWasserman%26aufirst%3DS.%2BR.%26aulast%3DEmtage%26aufirst%3DS.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DReich%26aufirst%3DS.%2BH.%26atitle%3DSGX523%2520is%2520an%2520exquisitely%2520selective%252C%2520ATP-competitive%2520inhibitor%2520of%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3181%26epage%3D3190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Tiedt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenkolbe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleton, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepfer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buck, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddy, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haasen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span> </span><span class="NLM_article-title">A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">5255</span><span class="NLM_x">â</span> <span class="NLM_lpage">5264</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=5255-5264&author=R.+Tiedtauthor=E.+Degenkolbeauthor=P.+Furetauthor=B.+A.+Appletonauthor=S.+Wagnerauthor=J.+Schoepferauthor=E.+Buckauthor=D.+A.+Ruddyauthor=J.+E.+Monahanauthor=M.+D.+Jonesauthor=J.+Blankauthor=D.+Haasenauthor=P.+Drueckesauthor=M.+Wartmannauthor=C.+McCarthyauthor=W.+R.+Sellersauthor=F.+Hofmann&title=A+drug+resistance+screen+using+a+selective+MET+inhibitor+reveals+a+spectrum+of+mutations+that+partially+overlap+with+activating+mutations+found+in+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DDegenkolbe%26aufirst%3DE.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DRuddy%26aufirst%3DD.%2BA.%26aulast%3DMonahan%26aufirst%3DJ.%2BE.%26aulast%3DJones%26aufirst%3DM.%2BD.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DHaasen%26aufirst%3DD.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26atitle%3DA%2520drug%2520resistance%2520screen%2520using%2520a%2520selective%2520MET%2520inhibitor%2520reveals%2520a%2520spectrum%2520of%2520mutations%2520that%2520partially%2520overlap%2520with%2520activating%2520mutations%2520found%2520in%2520cancer%2520patients%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D5255%26epage%3D5264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marando, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblish, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behshad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span> </span><span class="NLM_article-title">A novel kinase inhibitor, INCB28060, blocks MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7127</span><span class="NLM_x">â</span> <span class="NLM_lpage">7138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-11-1157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21918175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7127-7138&author=X.+Liuauthor=Q.+Wangauthor=G.+Yangauthor=C.+Marandoauthor=H.+K.+Koblishauthor=L.+M.+Hallauthor=J.+S.+Fridmanauthor=E.+Behshadauthor=R.+Wynnauthor=Y.+Liauthor=J.+Boerauthor=S.+Diamondauthor=C.+Heauthor=M.+Xuauthor=J.+Zhuoauthor=W.+Yaoauthor=R.+C.+Newtonauthor=P.+A.+Scherle&title=A+novel+kinase+inhibitor%2C+INCB28060%2C+blocks+MET-dependent+signaling%2C+neoplastic+activities%2C+and+cross-talk+with+EGFR+and+HER-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3</span></div><div class="casAuthors">Liu, Xiangdong; Wang, Qian; Yang, Gengjie; Marando, Cindy; Koblish, Holly K.; Hall, Leslie M.; Fridman, Jordan S.; Behshad, Elham; Wynn, Richard; Li, Yu; Boer, Jason; Diamond, Sharon; He, Chunhong; Xu, Meizhong; Zhuo, Jincong; Yao, Wenqing; Newton, Robert C.; Scherle, Peggy A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7127-7138</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The c-MET receptor tyrosine kinase plays important roles in the formation, progression, and dissemination of human cancer and presents an attractive therapeutic target.  This study describes the preclin. characterization of INCB28060, a novel inhibitor of c-MET kinase.  Exptl. Design: Studies were conducted using a series of in vitro and in vivo biochem. and biol. expts.  RESULTS: INCB28060 exhibits picomolar enzymic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases.  This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines.  As a result, INCB28060 potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro.  Oral dosing of INCB28060 results in time- and dose-dependent inhibition of c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models, and the inhibitor is well tolerated at doses that achieve complete tumor inhibition.  In a further exploration of potential interactions between c-MET and other signaling pathways, we found that activated c-MET pos. regulates the activity of epidermal growth factor receptors (EGFR) and HER-3, as well as expression of their ligands.  These effects are reversed with INCB28060 treatment.  Finally, we confirmed that circulating hepatocyte growth factor levels are significantly elevated in patients with various cancers.  CONCLUSIONS: Activated c-MET has pleiotropic effects on multiple cancer-promoting signaling pathways and may play a crit. role in driving tumor cell growth and survival.  INCB28060 is a potent and selective c-MET kinase inhibitor that may have therapeutic potential in cancer treatment.  Clin Cancer Res; 17(22); 7127-38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqqT6dM1mGprVg90H21EOLACvtfcHk0liWXqIrdKXuLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7nK&md5=c272514704702cb5cbcc9e405bea3c53</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1157%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMarando%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DHall%26aufirst%3DL.%2BM.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBehshad%26aufirst%3DE.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZhuo%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520kinase%2520inhibitor%252C%2520INCB28060%252C%2520blocks%2520MET-dependent%2520signaling%252C%2520neoplastic%2520activities%252C%2520and%2520cross-talk%2520with%2520EGFR%2520and%2520HER-3%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7127%26epage%3D7138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridrich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimanovich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span> </span><span class="NLM_article-title">Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the MET kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2879</span><span class="NLM_x">â</span> <span class="NLM_lpage">2882</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800043g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2879-2882&author=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=D.+Bauerauthor=L.+Berryauthor=C.+Bodeauthor=A.+A.+Boezioauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=C.+Fridrichauthor=S.+Hiraiauthor=D.+Hoffmanauthor=J.+F.+Larrowauthor=P.+Kaplan-Lefkoauthor=J.+Linauthor=J.+Lohmanauthor=A.+M.+Longauthor=J.+Moriguchiauthor=A.+O%E2%80%99Connorauthor=M.+H.+Potashmanauthor=M.+Reeseauthor=K.+Rexauthor=A.+Siegmundauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+Bellon&title=Discovery+and+optimization+of+triazolopyridazines+as+potent+and+selective+inhibitors+of+the+MET+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm800043g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800043g%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMoriguchi%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DA.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DReese%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520triazolopyridazines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520MET%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2879%26epage%3D2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santostefano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimanovich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span> </span><span class="NLM_article-title">Discovery and optimization of potent and selective triazolopyridazine series of MET inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6307</span><span class="NLM_x">â</span> <span class="NLM_lpage">6312</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6307-6312&author=A.+A.+Boezioauthor=L.+Berryauthor=B.+K.+Albrechtauthor=D.+Bauerauthor=S.+F.+Bellonauthor=C.+Bodeauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=M.+Fangauthor=S.+Hiraiauthor=P.+Kaplan-Lefkoauthor=J.+F.+Larrowauthor=M.+H.+Linauthor=J.+Lohmanauthor=M.+H.+Potashmanauthor=Y.+Quauthor=K.+Rexauthor=M.+Santostefanoauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+potent+and+selective+triazolopyridazine+series+of+MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DFang%26aufirst%3DM.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSantostefano%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520potent%2520and%2520selective%2520triazolopyridazine%2520series%2520of%2520MET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6307%26epage%3D6312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Bode, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span> </span><span class="NLM_article-title">Discovery and optimization of a potent and selective triazolopyridinone series of MET inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4089</span><span class="NLM_x">â</span> <span class="NLM_lpage">4093</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4089-4093&author=C.+M.+Bodeauthor=A.+A.+Boezioauthor=B.+K.+Albrechtauthor=S.+F.+Bellonauthor=L.+Berryauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=I.+Dussaultauthor=R.+T.+Lewisauthor=M.+H.+Linauthor=K.+Rexauthor=D.+A.+Whittingtonauthor=Y.+Yangauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+a+potent+and+selective+triazolopyridinone+series+of+MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520potent%2520and%2520selective%2520triazolopyridinone%2520series%2520of%2520MET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4089%26epage%3D4093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Bladt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friese-Hamim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knuehl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fittschen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GrÃ¤dler, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyring, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaehrling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pehl, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stieber, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaukat, A.</span><span> </span><span class="NLM_article-title">EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective MET inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2941</span><span class="NLM_x">â</span> <span class="NLM_lpage">2951</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-12-3247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23553846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12ju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2941-2951&author=F.+Bladtauthor=B.+Fadenauthor=M.+Friese-Hamimauthor=C.+Knuehlauthor=C.+Wilmauthor=C.+Fittschenauthor=U.+Gr%C3%A4dlerauthor=M.+Meyringauthor=D.+Dorschauthor=F.+Jaehrlingauthor=U.+Pehlauthor=F.+Stieberauthor=O.+Schadtauthor=A.+Blaukat&title=EMD+1214063+and+EMD+1204831+constitute+a+new+class+of+potent+and+highly+selective+MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors</span></div><div class="casAuthors">Bladt, Friedhelm; Faden, Bettina; Friese-Hamim, Manja; Knuehl, Christine; Wilm, Claudia; Fittschen, Claus; Graedler, Ulrich; Meyring, Michael; Dorsch, Dieter; Jaehrling, Frank; Pehl, Ulrich; Stieber, Frank; Schadt, Oliver; Blaukat, Andree</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2941-2951</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The mesenchymal-epithelial transition factor (c-Met) receptor, also known as hepatocyte growth factor receptor (HGFR), controls morphogenesis, a process that is physiol. required for embryonic development and tissue repair.  Aberrant c-Met activation is assocd. with a variety of human malignancies including cancers of the lung, kidney, stomach, liver, and brain.  In this study, we investigated the properties of two novel compds. developed to selectively inhibit the c-Met receptor in antitumor therapeutic interventions.  Exptl. Design: The pharmacol. properties, c-Met inhibitory activity, and antitumor effects of EMD 1214063 and EMD 1204831 were investigated in vitro and in vivo, using human cancer cell lines and mouse xenograft models.  Results: EMD 1214063 and EMD 1204831 selectively suppressed the c-Met receptor tyrosine kinase activity.  Their inhibitory activity was potent [inhibitory 50% concn. (IC50), 3 nmol/L and 9 nmol/L, resp.] and highly selective, when compared with their effect on a panel of 242 human kinases.  Both EMD 1214063 and EMD 1204831 inhibited c-Met phosphorylation and downstream signaling in a dose-dependent fashion, but differed in the duration of their inhibitory activity.  In murine xenograft models, both compds. induced regression of human tumors, regardless of whether c-Met activation was HGF dependent or independent.  Both drugs were well tolerated and induced no substantial wt. loss after more than 3 wk of treatment.  Conclusions: Our results indicate selective c-Met inhibition by EMD 1214063 and EMD 1204831 and strongly support clin. testing of these compds. in the context of molecularly targeted anticancer strategies.  Clin Cancer Res; 19(11); 2941-51. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP2ZWzE5rC6LVg90H21EOLACvtfcHk0ljnpuQtKjd2Sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12ju78%253D&md5=a1d24bf9fdaea35808c7468a6e7d197f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3247%26sid%3Dliteratum%253Aachs%26aulast%3DBladt%26aufirst%3DF.%26aulast%3DFaden%26aufirst%3DB.%26aulast%3DFriese-Hamim%26aufirst%3DM.%26aulast%3DKnuehl%26aufirst%3DC.%26aulast%3DWilm%26aufirst%3DC.%26aulast%3DFittschen%26aufirst%3DC.%26aulast%3DGr%25C3%25A4dler%26aufirst%3DU.%26aulast%3DMeyring%26aufirst%3DM.%26aulast%3DDorsch%26aufirst%3DD.%26aulast%3DJaehrling%26aufirst%3DF.%26aulast%3DPehl%26aufirst%3DU.%26aulast%3DStieber%26aufirst%3DF.%26aulast%3DSchadt%26aufirst%3DO.%26aulast%3DBlaukat%26aufirst%3DA.%26atitle%3DEMD%25201214063%2520and%2520EMD%25201204831%2520constitute%2520a%2520new%2520class%2520of%2520potent%2520and%2520highly%2520selective%2520MET%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2941%26epage%3D2951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fclinicaltrials.gov."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, P.</span><span> </span><span class="NLM_article-title">Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1575</span><span class="NLM_x">â</span> <span class="NLM_lpage">1587</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1575-1587&author=D.+Dalvieauthor=H.+Sunauthor=C.+Xiangauthor=Q.+Huauthor=Y.+Jiangauthor=P.+Kang&title=Effect+of+structural+variation+on+aldehyde+oxidase-catalyzed+oxidation+of+zoniporide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXiang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DP.%26atitle%3DEffect%2520of%2520structural%2520variation%2520on%2520aldehyde%2520oxidase-catalyzed%2520oxidation%2520of%2520zoniporide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1575%26epage%3D1587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R. K.</span><span> </span><span class="NLM_article-title">Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">369</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=363-369&author=J.+R.+Infanteauthor=T.+Ruggauthor=M.+Gordonauthor=I.+Rooneyauthor=L.+Rosenauthor=K.+Zehauthor=R.+Liuauthor=H.+A.+Burrisauthor=R.+K.+Ramanathan&title=Unexpected+renal+toxicity+associated+with+SGX523%2C+a+small+molecule+inhibitor+of+MET"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DRugg%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DRooney%26aufirst%3DI.%26aulast%3DRosen%26aufirst%3DL.%26aulast%3DZeh%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DUnexpected%2520renal%2520toxicity%2520associated%2520with%2520SGX523%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520MET%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D363%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maduskuie, T. P.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falahatpisheh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span> </span><span class="NLM_article-title">Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1277</span><span class="NLM_x">â</span> <span class="NLM_lpage">1285</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1124%2Fdmd.110.032375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20421447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWktrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1277-1285&author=S.+Diamondauthor=J.+Boerauthor=T.+P.+Maduskuieauthor=N.+Falahatpishehauthor=Y.+Liauthor=S.+Yeleswaram&title=Species-specific+metabolism+of+SGX523+by+aldehyde+oxidase+and+the+toxicological+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications</span></div><div class="casAuthors">Diamond, Sharon; Boer, Jason; Maduskuie, Thomas P., Jr.; Falahatpisheh, Nikoo; Li, Yu; Yeleswaram, Swamy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1277-1285</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">An investigation was conducted to follow up on the apparent species-dependent toxicity reported for 6-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio]quinoline (SGX523), a mesenchymal-epithelial transition factor (c-MET) inhibitor that entered clin. development for the treatment of solid tumors.  Patients treated with SGX523 exhibited compromised renal function presumably resulting from crystal deposits in renal tubules.  Our independent metabolite profiling of SGX523 indicates that a major NADPH-independent, late-eluting metabolite [6-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)quinolin-2(1H)-one (M11)] was generated by monkey and human liver S-9, and to a lesser extent by rat S-9, whereas M11 was absent in dog S-9 incubations.  We confirmed the identity of M11 as 2-quinolinone-SGX523.  Expts. with various molybdenum hydroxylase inhibitors showed that aldehyde oxidase (AO), and not xanthine oxidase, metabolized SGX523 to M11 in monkey and human liver cytosol.  In addn., the oxygen incorporated into M11 was derived from water rather than atm. oxygen, corroborating M11 formation via AO.  After oral dosing in monkeys, metabolite profiling of plasma and urine showed that SGX523 was indeed metabolized to M11 and its N-demethyl analog (M8).  In urine, M11 levels were â¼70-fold greater than that of SGX523, and the soly. of M11 in urine was only 3% of that of SGX523.  In summary, SGX523 is metabolized by AO in a species-specific manner to a markedly less-sol. metabolite, M11.  We propose that M11 is likely involved in the obsd. obstructive nephropathy reported in clin. studies.  Moreover, this study illustrates the need to conduct thorough metabolic evaluations early in drug development to select the most relevant nonclin. species for toxicol. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryx8buDjc41LVg90H21EOLACvtfcHk0lgUTQcU2Td1tA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWktrjM&md5=27450436ad7a69d72d4cc8ae9860ccd9</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032375%26sid%3Dliteratum%253Aachs%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DMaduskuie%26aufirst%3DT.%2BP.%26aulast%3DFalahatpisheh%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYeleswaram%26aufirst%3DS.%26atitle%3DSpecies-specific%2520metabolism%2520of%2520SGX523%2520by%2520aldehyde%2520oxidase%2520and%2520the%2520toxicological%2520implications%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1277%26epage%3D1285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Fujiwara, Y.; Miwa, A.; Nakamura, K.; Nishitoba, T.; Osawa, T.; Senga, T.</span><span> </span><span class="NLM_article-title">Quinoline Derivative and Quinazoline Derivative Inhibiting Self-Phosphorylation of Hepatocytus Proliferator Receptor, and Medicinal Composition Containing the Same</span>. PCT Int. Appl. WO2003000660,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=Y.+Fujiwara&author=A.+Miwa&author=K.+Nakamura&author=T.+Nishitoba&author=T.+Osawa&author=T.+Senga&title=Quinoline+Derivative+and+Quinazoline+Derivative+Inhibiting+Self-Phosphorylation+of+Hepatocytus+Proliferator+Receptor%2C+and+Medicinal+Composition+Containing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DY.%26atitle%3DQuinoline%2520Derivative%2520and%2520Quinazoline%2520Derivative%2520Inhibiting%2520Self-Phosphorylation%2520of%2520Hepatocytus%2520Proliferator%2520Receptor%252C%2520and%2520Medicinal%2520Composition%2520Containing%2520the%2520Same%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Elisei, R.; Schlumberger, M. J.; MÃ¼ller, S. P.; SchÃ¶ffski, P.; Brose, M. S.; Shah, M. H.; Licitra, L.; Jarzab, B.; Medvedev, V.; Kreissl, M. C.; Niederle, B.; Cohen, E. E.; Wirth, L. J.; Ali, H.; Hessel, C.; Yaron, Y.; Ball, D.; Nelkin, B.; Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span> [Online early access]. DOI: <span class="refDoi">Â DOI: 10.1200/JCO.2012.48.4659</span> . Published Online: Sep 3,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=24002501" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Elisei&author=M.+J.+Schlumberger&author=S.+P.+M%C3%BCller&author=P.+Sch%C3%B6ffski&author=M.+S.+Brose&author=M.+H.+Shah&author=L.+Licitra&author=B.+Jarzab&author=V.+Medvedev&author=M.+C.+Kreissl&author=B.+Niederle&author=E.+E.+Cohen&author=L.+J.+Wirth&author=H.+Ali&author=C.+Hessel&author=Y.+Yaron&author=D.+Ball&author=B.+Nelkin&author=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26doi%3D10.1200%2FJCO.2012.48.4659%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2298</span><span class="NLM_x">â</span> <span class="NLM_lpage">2308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0lgUTQcU2Td1tA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">â</span> <span class="NLM_lpage">8016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tohyama, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funasaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirotori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obaishi, H.</span><span> </span><span class="NLM_article-title">E7050: a dual MET and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">â</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1111%2Fj.1349-7006.2009.01343.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19832844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVOisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2010&pages=210-215&author=T.+Nakagawaauthor=O.+Tohyamaauthor=A.+Yamaguchiauthor=T.+Matsushimaauthor=K.+Takahashiauthor=S.+Funasakaauthor=S.+Shirotoriauthor=M.+Asadaauthor=H.+Obaishi&title=E7050%3A+a+dual+MET+and+VEGFR-2+tyrosine+kinase+inhibitor+promotes+tumor+regression+and+prolongs+survival+in+mouse+xenograft+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models</span></div><div class="casAuthors">Nakagawa, Takayuki; Tohyama, Osamu; Yamaguchi, Atsumi; Matsushima, Tomohiro; Takahashi, Keiko; Funasaka, Setsuo; Shirotori, Shuji; Asada, Makoto; Obaishi, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">C-Met is the cellular receptor for hepatocyte growth factor (HGF) and is known to be dysregulated in various types of human cancers.  Activation of the HGF/c-Met pathway causes tumor progression, invasion, and metastasis.  Vascular endothelial growth factor (VEGF) is also known as a key mol. in tumor progression through the induction of tumor angiogenesis.  Because of their key roles in tumor progression, these pathways provide attractive targets for therapeutic intervention.  We have generated a novel, orally active, small mol. compd., E7050, which inhibits both c-Met and vascular endothelial growth factor receptor (VEGFR)-2.  In vitro studies indicate that E7050 potently inhibits phosphorylation of both c-Met and VEGFR-2.  E7050 also potently represses the growth of both c-met amplified tumor cells and endothelial cells stimulated with either HGF or VEGF.  In vivo studies using E7050 showed inhibition of the phosphorylation of c-Met and VEGFR-2 in tumors, and strong inhibition of tumor growth and tumor angiogenesis in xenograft models.  Treatment of some tumor lines contg. c-met amplifications with high doses of E7050 (50-200 mg/kg) induced tumor regression and disappearance.  In a peritoneal dissemination model, E7050 showed an antitumor effect against peritoneal tumors as well as a significant prolongation of lifespan in treated mice.  Our results indicate that E7050 is a potent inhibitor of c-Met and VEGFR-2 and has therapeutic potential for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd7smhBTumtLVg90H21EOLACvtfcHk0lgdDDhLR9PKRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVOisA%253D%253D&md5=e8ce73fa1262f767cea173f0561d8e35</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2009.01343.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2009.01343.x%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DTohyama%26aufirst%3DO.%26aulast%3DYamaguchi%26aufirst%3DA.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DFunasaka%26aufirst%3DS.%26aulast%3DShirotori%26aufirst%3DS.%26aulast%3DAsada%26aufirst%3DM.%26aulast%3DObaishi%26aufirst%3DH.%26atitle%3DE7050%253A%2520a%2520dual%2520MET%2520and%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitor%2520promotes%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DCancer%2520Sci.%26date%3D2010%26volume%3D101%26spage%3D210%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Bonfils, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroun, C. R.</span><span> </span><span class="NLM_article-title">The combination of MGCD265, a MET/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">8 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">1790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1790&issue=8+Suppl.&author=C.+Bonfilsauthor=N.+Beaulieuauthor=M.+Fournelauthor=H.+Ste-Croixauthor=J.+M.+Bestermanauthor=C.+R.+Maroun&title=The+combination+of+MGCD265%2C+a+MET%2FVEGFR+inhibitor+in+clinical+development%2C+and+erlotinib+potently+inhibits+tumor+growth+by+altering+multiple+pathways+including+glycolysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26atitle%3DThe%2520combination%2520of%2520MGCD265%252C%2520a%2520MET%252FVEGFR%2520inhibitor%2520in%2520clinical%2520development%252C%2520and%2520erlotinib%2520potently%2520inhibits%2520tumor%2520growth%2520by%2520altering%2520multiple%2520pathways%2520including%2520glycolysis%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3D8%2520Suppl%26spage%3D1790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fellows, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAngelo, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span> </span><span class="NLM_article-title">Structure-based design of novel class II MET inhibitors: 1. Identification of pyrazolone-based derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1858</span><span class="NLM_x">â</span> <span class="NLM_lpage">1867</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201330u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1858-1867&author=M.+H.+Normanauthor=L.+Liuauthor=M.+Leeauthor=N.+Xiauthor=I.+Fellowsauthor=N.+D.+D%E2%80%99Angeloauthor=C.+Dominguezauthor=K.+Rexauthor=S.+F.+Bellonauthor=T.+S.+Kimauthor=I.+Dussault&title=Structure-based+design+of+novel+class+II+MET+inhibitors%3A+1.+Identification+of+pyrazolone-based+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm201330u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201330u%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DFellows%26aufirst%3DI.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DKim%26aufirst%3DT.%2BS.%26aulast%3DDussault%26aufirst%3DI.%26atitle%3DStructure-based%2520design%2520of%2520novel%2520class%2520II%2520MET%2520inhibitors%253A%25201.%2520Identification%2520of%2520pyrazolone-based%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1858%26epage%3D1867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimanovich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. S.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally bioavailable MET inhibitor: 1-(2-hydroxy-2-methylpropyl)-<i>N</i>-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazole-4-carboxamide (AMG 458)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3688</span><span class="NLM_x">â</span> <span class="NLM_lpage">3691</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800401t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3688-3691&author=L.+Liuauthor=A.+Siegmundauthor=N.+Xiauthor=P.+Kaplan-Lefkoauthor=K.+Rexauthor=A.+Chenauthor=J.+Linauthor=J.+Moriguchiauthor=L.+Berryauthor=L.+Huangauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+F.+Bellonauthor=M.+Leeauthor=R.+Shimanovichauthor=A.+Bakauthor=C.+Dominguezauthor=M.+H.+Normanauthor=J.+C.+Harmangeauthor=I.+Dussaultauthor=T.+S.+Kim&title=Discovery+of+a+potent%2C+selective%2C+and+orally+bioavailable+MET+inhibitor%3A+1-%282-hydroxy-2-methylpropyl%29-N-%285-%287-methoxyquinolin-4-yloxy%29pyridin-2-yl%29-5-methyl-3-oxo-2-phenyl-2%2C3-dihydro-1H-pyrazole-4-carboxamide+%28AMG+458%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142a&amp;dbid=16384&amp;doi=10.1021%2Fjm800401t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800401t%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoriguchi%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DBak%26aufirst%3DA.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DT.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520MET%2520inhibitor%253A%25201-%25282-hydroxy-2-methylpropyl%2529-N-%25285-%25287-methoxyquinolin-4-yloxy%2529pyridin-2-yl%2529-5-methyl-3-oxo-2-phenyl-2%252C3-dihydro-1H-pyrazole-4-carboxamide%2520%2528AMG%2520458%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3688%26epage%3D3691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit142b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAngelo, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span> </span><span class="NLM_article-title">Structure-based design of novel class II MET inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1868</span><span class="NLM_x">â</span> <span class="NLM_lpage">1897</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201331s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1868-1897&author=L.+Liuauthor=M.+H.+Normanauthor=M.+Leeauthor=N.+Xiauthor=A.+Siegmundauthor=A.+A.+Boezioauthor=S.+Bookerauthor=D.+Choquetteauthor=N.+D.+D%E2%80%99Angeloauthor=J.+Germainauthor=K.+Yangauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+F.+Bellonauthor=D.+A.+Whittingtonauthor=J.+C.+Harmangeauthor=C.+Dominguezauthor=T.+S.+Kimauthor=I.+Dussault&title=Structure-based+design+of+novel+class+II+MET+inhibitors%3A+2.+SAR+and+kinase+selectivity+profiles+of+the+pyrazolone+series"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142b&amp;dbid=16384&amp;doi=10.1021%2Fjm201331s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201331s%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBooker%26aufirst%3DS.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DT.%2BS.%26aulast%3DDussault%26aufirst%3DI.%26atitle%3DStructure-based%2520design%2520of%2520novel%2520class%2520II%2520MET%2520inhibitors%253A%25202.%2520SAR%2520and%2520kinase%2520selectivity%2520profiles%2520of%2520the%2520pyrazolone%2520series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1868%26epage%3D1897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the MET kinase superfamily</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">â</span> <span class="NLM_lpage">1254</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801586s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1251-1254&author=G.+M.+Schroederauthor=Y.+Anauthor=Z.+W.+Caiauthor=X.+T.+Chenauthor=C.+Clarkauthor=L.+A.+Corneliusauthor=J.+Daiauthor=J.+Gullo-Brownauthor=A.+Guptaauthor=B.+Henleyauthor=J.+T.+Huntauthor=R.+Jeyaseelanauthor=A.+Kamathauthor=K.+Kimauthor=J.+Lippyauthor=L.+J.+Lombardoauthor=V.+Manneauthor=S.+Oppenheimerauthor=J.+S.+Sackauthor=R.+J.+Schmidtauthor=G.+Shenauthor=K.+Stefanskiauthor=J.+S.+Tokarskiauthor=G.+L.+Trainorauthor=B.+S.+Wautletauthor=D.+Weiauthor=D.+K.+Williamsauthor=Y.+Zhangauthor=Y.+Zhangauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+N-%284-%282-amino-3-chloropyridin-4-yloxy%29-3-fluorophenyl%29-4-ethoxy-1-%284-fluorophenyl%29-2-oxo-1%2C2-dihydropyridine-3-carboxamide+%28BMS-777607%29%2C+a+selective+and+orally+efficacious+inhibitor+of+the+MET+kinase+superfamily"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm801586s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801586s%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25284-%25282-amino-3-chloropyridin-4-yloxy%2529-3-fluorophenyl%2529-4-ethoxy-1-%25284-fluorophenyl%2529-2-oxo-1%252C2-dihydropyridine-3-carboxamide%2520%2528BMS-777607%2529%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520the%2520MET%2520kinase%2520superfamily%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1251%26epage%3D1254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Hurley, L. H.; Mahadevan, D.; Han, H.; Bearss, D. J.; Vankayalapati, H.; Bashyam, S.; Munoz, R. M.; Warner, S. L.; Della Croce, K.; Von Hoff, D. D.; Grand, C. L.; Welsh, J.</span><span> </span><span class="NLM_article-title">Preparation of Fused Pyrimidines as Therapeutic Protein Kinase Inhibitors</span>. US2008/0051414,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=L.+H.+Hurley&author=D.+Mahadevan&author=H.+Han&author=D.+J.+Bearss&author=H.+Vankayalapati&author=S.+Bashyam&author=R.+M.+Munoz&author=S.+L.+Warner&author=K.+Della+Croce&author=D.+D.+Von+Hoff&author=C.+L.+Grand&author=J.+Welsh&title=Preparation+of+Fused+Pyrimidines+as+Therapeutic+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHurley%26aufirst%3DL.%2BH.%26atitle%3DPreparation%2520of%2520Fused%2520Pyrimidines%2520as%2520Therapeutic%2520Protein%2520Kinase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Baxter, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuffey, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauser, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuchtern, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inloes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, S. M.</span><span> </span><span class="NLM_article-title">Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">â</span> <span class="NLM_lpage">812</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1007%2Fs00280-010-1380-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20563581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVemsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=809-812&author=P.+A.+Baxterauthor=P.+A.+Thompsonauthor=L.+M.+McGuffeyauthor=B.+W.+Gibsonauthor=R.+C.+Dauserauthor=J.+G.+Nuchternauthor=C.+Shiauthor=R.+Inloesauthor=G.+Choyauthor=S.+Redkarauthor=S.+M.+Blaney&title=Plasma+and+cerebrospinal+fluid+pharmacokinetics+of+MP470+in+non-human+primates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates</span></div><div class="casAuthors">Baxter, P. A.; Thompson, P. A.; McGuffey, L. M.; Gibson, B. W.; Dauser, R. C.; Nuchtern, J. G.; Shi, C.; Inloes, R.; Choy, G.; Redkar, S.; Blaney, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">809-812</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: MP470 is a multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRÎ±, Flt3, c-Met and c-Ret that is being evaluated as an anticancer agent.  The plasma and cerebrospinal fluid (CSF) pharmacokinetics of MP470 were studied in a non-human primate model that is highly predictive of CSF penetration in humans.  Methods: Oral MP470, 300 mg, was administered to four non-human primates.  Serial samples of blood were collected from four animals and CSF samples from three animals for pharmacokinetic studies.  Plasma and CSF concns. were measured using an LC-MS/MS assay.  Both model-independent and model-dependent methods were used to analyze the pharmacokinetic data.  Results: Following a one-time oral dose of 300 mg, the MP470 plasma area under the curve (AUC) was 1,690 Â± 821 nM h (mean Â± SD).  The half-life of MP470 in the plasma was 11.0 Â± 3.4 h.  There was no measurable MP470 in the CSF.  Conclusions: Although CSF penetration is minimal, MP470 has demonstrated potent activity against cancer cell lines in vitro and in vivo, and further clin. investigation is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD1mRQVSgLB7Vg90H21EOLACvtfcHk0lhhvIYMJUpWpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVemsro%253D&md5=ac917f160193bbf661629032ee7889a7</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs00280-010-1380-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-010-1380-3%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DP.%2BA.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DMcGuffey%26aufirst%3DL.%2BM.%26aulast%3DGibson%26aufirst%3DB.%2BW.%26aulast%3DDauser%26aufirst%3DR.%2BC.%26aulast%3DNuchtern%26aufirst%3DJ.%2BG.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DInloes%26aufirst%3DR.%26aulast%3DChoy%26aufirst%3DG.%26aulast%3DRedkar%26aufirst%3DS.%26aulast%3DBlaney%26aufirst%3DS.%2BM.%26atitle%3DPlasma%2520and%2520cerebrospinal%2520fluid%2520pharmacokinetics%2520of%2520MP470%2520in%2520non-human%2520primates%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D67%26spage%3D809%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Pan, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariv, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span> </span><span class="NLM_article-title">MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated MET receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1524</span><span class="NLM_x">â</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1524-1533&author=B.+S.+Panauthor=G.+K.+Chanauthor=M.+Chenardauthor=A.+Chiauthor=L.+J.+Davisauthor=S.+V.+Deshmukhauthor=J.+B.+Gibbsauthor=S.+Gilauthor=G.+Hangauthor=H.+Hatchauthor=J.+P.+Jewellauthor=I.+Karivauthor=J.+D.+Katzauthor=K.+Kuniiauthor=W.+Luauthor=B.+A.+Lutterbachauthor=C.+P.+Paweletzauthor=X.+Quauthor=J.+F.+Reillyauthor=A.+A.+Szewczakauthor=Q.+Zengauthor=N.+E.+Kohlauthor=C.+J.+Dinsmore&title=MK-2461%2C+a+novel+multitargeted+kinase+inhibitor%2C+preferentially+inhibits+the+activated+MET+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DB.%2BS.%26aulast%3DChan%26aufirst%3DG.%2BK.%26aulast%3DChenard%26aufirst%3DM.%26aulast%3DChi%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DL.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DGibbs%26aufirst%3DJ.%2BB.%26aulast%3DGil%26aufirst%3DS.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26atitle%3DMK-2461%252C%2520a%2520novel%2520multitargeted%2520kinase%2520inhibitor%252C%2520preferentially%2520inhibits%2520the%2520activated%2520MET%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1524%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leggett, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. J.</span><span> </span><span class="NLM_article-title">ARQ 197, a novel and selective inhibitor of the human MET receptor tyrosine kinase with antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">â</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.+R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+novel+and+selective+inhibitor+of+the+human+MET+receptor+tyrosine+kinase+with+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0ljDfgzpIMBNFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BR.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520the%2520human%2520MET%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh-hara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span> </span><span class="NLM_article-title">Cytotoxic activity of tivantinib (ARQ 197) is not due solely to MET inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">3087</span><span class="NLM_x">â</span> <span class="NLM_lpage">3096</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=3087-3096&author=R.+Katayamaauthor=A.+Aoyamaauthor=T.+Yamoriauthor=J.+Qiauthor=T.+Oh-haraauthor=Y.+Songauthor=J.+A.+Engelmanauthor=N.+Fujita&title=Cytotoxic+activity+of+tivantinib+%28ARQ+197%29+is+not+due+solely+to+MET+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DAoyama%26aufirst%3DA.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DOh-hara%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DFujita%26aufirst%3DN.%26atitle%3DCytotoxic%2520activity%2520of%2520tivantinib%2520%2528ARQ%2520197%2529%2520is%2520not%2520due%2520solely%2520to%2520MET%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D3087%26epage%3D3096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennacchietti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigna, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiriaco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arena, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdembri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span> </span><span class="NLM_article-title">Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2381</span><span class="NLM_x">â</span> <span class="NLM_lpage">2392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-12-3459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23532890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWrurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2381-2392&author=C.+Basilicoauthor=S.+Pennacchiettiauthor=E.+Vignaauthor=C.+Chiriacoauthor=S.+Arenaauthor=A.+Bardelliauthor=D.+Valdembriauthor=G.+Seriniauthor=P.+Michieli&title=Tivantinib+%28ARQ197%29+displays+cytotoxic+activity+that+is+independent+of+its+ability+to+bind+MET"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET</span></div><div class="casAuthors">Basilico, Cristina; Pennacchietti, Selma; Vigna, Elisa; Chiriaco, Cristina; Arena, Sabrina; Bardelli, Alberto; Valdembri, Donatella; Serini, Guido; Michieli, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2381-2392</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: MET, the high-affinity receptor for hepatocyte growth factor, is frequently deregulated in human cancer.  Tivantinib (ARQ197; Arqule), a staurosporine deriv. that binds to the dephosphorylated MET kinase in vitro, is being tested clin. as a highly selective MET inhibitor.  However, the mechanism of action of tivantinib is still unclear.  The activity of tivantinib was analyzed in multiple cellular models, including: cells displaying c-MET gene amplification, strictly addicted' to MET signaling; cells with normal c-MET gene copy no., not dependent on MET for growth; cells not expressing MET; somatic knockout cells in which the ATP-binding cleft of MET, where tivantinib binds, was deleted by homologous recombination; and a cell system poisoned' by MET kinase hyperactivation, where cells die unless cultured in the presence of a specific MET inhibitor.  Tivantinib displayed cytotoxic activity independently of c-MET gene copy no. and regardless of the presence or absence of MET.  In both wild-type and isogenic knockout cells, tivantinib perturbed microtubule dynamics, induced G2/M arrest, and promoted apoptosis.  Tivantinib did not rescue survival of cells poisoned' by MET kinase hyperactivation, but further incremented cell death.  In all cell models analyzed, tivantinib did not inhibit HGF-dependent or -independent MET tyrosine autophosphorylation.  We conclude that tivantinib displays cytotoxic activity via mol. mechanisms that are independent from its ability to bind MET.  This notion has a relevant impact on the interpretation of clin. results, on the design of future clin. trials, and on the selection of patients receiving tivantinib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0izNZX9sR77Vg90H21EOLACvtfcHk0lj1HA-rRwvcMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWrurY%253D&md5=42642dc65760984e663edcae9f819a9a</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3459%26sid%3Dliteratum%253Aachs%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DPennacchietti%26aufirst%3DS.%26aulast%3DVigna%26aufirst%3DE.%26aulast%3DChiriaco%26aufirst%3DC.%26aulast%3DArena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DValdembri%26aufirst%3DD.%26aulast%3DSerini%26aufirst%3DG.%26aulast%3DMichieli%26aufirst%3DP.%26atitle%3DTivantinib%2520%2528ARQ197%2529%2520displays%2520cytotoxic%2520activity%2520that%2520is%2520independent%2520of%2520its%2520ability%2520to%2520bind%2520MET%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2381%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Peters, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">MET: a promising anticancer therapeutic target</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150a&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrclinonc.2012.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150a&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOrtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=314-326&author=S.+Petersauthor=A.+A.+Adjei&title=MET%3A+a+promising+anticancer+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150aR"><div class="casContent"><span class="casTitleNuber">150a</span><div class="casTitle"><span class="NLM_cas:atitle">MET: a promising anticancer therapeutic target</span></div><div class="casAuthors">Peters, Solange; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">314-326</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Targeting the MET pathway is an increasingly attractive anticancer strategy.  In this Review, this pathway is viewed from the clin. perspective, assessing the available agents in terms of efficacy and toxicity and looking forward to biomarker-driven application in the clinic.  The MET pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination.  Abnormalities in MET signalling have been reported to correlate with poor clin. outcomes and drug resistance in patients with cancer.  Thus, MET has emerged as an attractive target for cancer therapy.  Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clin. trials.  In general, initial results from these studies indicate only a modest benefit in unselected populations.  In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1VV_hiW_CLVg90H21EOLACvtfcHk0lj1HA-rRwvcMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOrtL0%253D&md5=db84521545ee290e245a5b541b103ff1</span></div><a href="/servlet/linkout?suffix=cit150a&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.71%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DMET%253A%2520a%2520promising%2520anticancer%2520therapeutic%2520target%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D314%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit150b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Robinson, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A. B.</span><span> </span><span class="NLM_article-title">The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">122</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=115-122&author=K.+W.+Robinsonauthor=A.+B.+Sandler&title=The+role+of+MET+receptor+tyrosine+kinase+in+non-small+cell+lung+cancer+and+clinical+development+of+targeted+anti-MET+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DK.%2BW.%26aulast%3DSandler%26aufirst%3DA.%2BB.%26atitle%3DThe%2520role%2520of%2520MET%2520receptor%2520tyrosine%2520kinase%2520in%2520non-small%2520cell%2520lung%2520cancer%2520and%2520clinical%2520development%2520of%2520targeted%2520anti-MET%2520agents%26jtitle%3DOncologist%26date%3D2013%26volume%3D18%26spage%3D115%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeesh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nallasura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lader, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarbaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Functional expression and mutations of MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">â</span> <span class="NLM_lpage">1488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1479-1488&author=P.+C.+Maauthor=R.+Jagadeeswaranauthor=S.+Jagadeeshauthor=M.+S.+Tretiakovaauthor=V.+Nallasuraauthor=E.+A.+Foxauthor=M.+Hansenauthor=E.+Schaeferauthor=K.+Naokiauthor=A.+Laderauthor=W.+Richardsauthor=D.+Sugarbakerauthor=A.+N.+Husainauthor=J.+G.+Christensenauthor=R.+Salgia&title=Functional+expression+and+mutations+of+MET+and+its+therapeutic+inhibition+with+SU11274+and+small+interfering+RNA+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DJagadeesh%26aufirst%3DS.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DNallasura%26aufirst%3DV.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DSchaefer%26aufirst%3DE.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DLader%26aufirst%3DA.%26aulast%3DRichards%26aufirst%3DW.%26aulast%3DSugarbaker%26aufirst%3DD.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DFunctional%2520expression%2520and%2520mutations%2520of%2520MET%2520and%2520its%2520therapeutic%2520inhibition%2520with%2520SU11274%2520and%2520small%2520interfering%2520RNA%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D1479%26epage%3D1488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skokan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajapathy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felicioni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Grammastro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciarrotta, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttitta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Incarbone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toschi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finocchiaro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Destro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terracciano, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roncalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alloisio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span> </span><span class="NLM_article-title">Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1667</span><span class="NLM_x">â</span> <span class="NLM_lpage">1674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2008.19.1635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19255323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BD1M3ktlKruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=1667-1674&author=F.+Cappuzzoauthor=A.+Marchettiauthor=M.+Skokanauthor=E.+Rossiauthor=S.+Gajapathyauthor=L.+Felicioniauthor=M.+Del+Grammastroauthor=M.+G.+Sciarrottaauthor=F.+Buttittaauthor=M.+Incarboneauthor=L.+Toschiauthor=G.+Finocchiaroauthor=A.+Destroauthor=L.+Terraccianoauthor=M.+Roncalliauthor=M.+Alloisioauthor=A.+Santoroauthor=M.+Varella-Garcia&title=Increased+MET+gene+copy+number+negatively+affects+survival+of+surgically+resected+non-small-cell+lung+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients</span></div><div class="casAuthors">Cappuzzo Federico; Marchetti Antonio; Skokan Margaret; Rossi Elisa; Gajapathy Sujatha; Felicioni Lara; Del Grammastro Maela; Sciarrotta Maria Grazia; Buttitta Fiamma; Incarbone Matteo; Toschi Luca; Finocchiaro Giovanna; Destro Annarita; Terracciano Luigi; Roncalli Massimo; Alloisio Marco; Santoro Armando; Varella-Garcia Marileila</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1667-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To investigate the prognostic role of genomic gain for MET and epidermal growth factor receptor (EGFR) genes in surgically resected non-small-cell lung cancer (NSCLC).  PATIENTS AND METHODS:  This retrospective study included 447 NSCLC patients with available tumor tissue from primary lung tumor and survival data.  EGFR and MET status was evaluated by fluorescent in situ hybridization (FISH) in tissue microarray sections.  RESULTS:  EGFR FISH results were obtained in 376 cases.  EGFR gene amplification and high polysomy (EGFR FISH+) were observed in 10.4% and 32.4% of cases, respectively.  EGFR FISH-positive patients had a nonsignificant shorter survival than EGFR FISH-negative patients (P = .4).  Activating EGFR mutations were detected in 9.7% of 144 stage I-II disease with no impact on survival.  MET FISH analysis was performed in 435 cases.  High MET gene copy number (mean > or = 5 copies/cell) was observed in 48 cases (MET+, 11.1%), including 18 cases with true gene amplification (4.1%).  MET+ status was associated with advanced stage (P = .01), with grade 3 (P = .016) and with EGFR FISH+ result (P < .0001).  No patient with activating EGFR mutation resulted MET+.  In the whole population, MET-positive patients had shorter survival than MET-negative patients (P = .005).  Multivariable model confirmed that MET-negative patients had a significant reduction in the risk of death than MET-positive patients (hazard ratio, 0.66; P = .04).  CONCLUSION:  MET increased gene copy number is an independent negative prognostic factor in surgically resected NSCLC.  EGFR gene gain does not impact survival after resection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnc5G-Os6-WzdblLE_E9PWfW6udTcc2easLvYTc4Uzorntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3ktlKruw%253D%253D&md5=41bfbb70eb8a9e4ffd2964caf68e2511</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.1635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.1635%26sid%3Dliteratum%253Aachs%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMarchetti%26aufirst%3DA.%26aulast%3DSkokan%26aufirst%3DM.%26aulast%3DRossi%26aufirst%3DE.%26aulast%3DGajapathy%26aufirst%3DS.%26aulast%3DFelicioni%26aufirst%3DL.%26aulast%3DDel%2BGrammastro%26aufirst%3DM.%26aulast%3DSciarrotta%26aufirst%3DM.%2BG.%26aulast%3DButtitta%26aufirst%3DF.%26aulast%3DIncarbone%26aufirst%3DM.%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DFinocchiaro%26aufirst%3DG.%26aulast%3DDestro%26aufirst%3DA.%26aulast%3DTerracciano%26aufirst%3DL.%26aulast%3DRoncalli%26aufirst%3DM.%26aulast%3DAlloisio%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26atitle%3DIncreased%2520MET%2520gene%2520copy%2520number%2520negatively%2520affects%2520survival%2520of%2520surgically%2520resected%2520non-small-cell%2520lung%2520cancer%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D1667%26epage%3D1674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Sadiq, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">MET as a possible target for non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">â</span> <span class="NLM_lpage">1096</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2012.43.9422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23401458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2mtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1089-1096&author=A.+A.+Sadiqauthor=R.+Salgia&title=MET+as+a+possible+target+for+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">MET as a possible target for non-small-cell lung cancer</span></div><div class="casAuthors">Sadiq, Ahad A.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1089-1096</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Lung cancer is a heterogeneous group of disorders that is now being subdivided into mol. subtypes with dedicated targeted therapies.  The MET receptor tyrosine kinase has been identified as aberrantly overexpressed, potentially having activating mutations, and amplified in certain subsets of lung cancers.  The ligand hepatocyte growth factor (HGF) can also be overexpressed in lung cancer or expressed in stroma, and both the MET receptor and the HGF ligand can be targets for therapeutics, esp. in lung cancer.  Activation of MET leads to a plethora of biochem. and biol. changes both in normal and cancerous cells.  Preclinically, it has been shown that silencing or inactivating MET leads to decreased viability of cancer cells.  There are a no. of compds. against MET/HGF in clin. trials that have been shown to be active in lung cancers.  This review will summarize the biol. of MET as well as its therapeutic inhibition in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT3C3GIW14j7Vg90H21EOLACvtfcHk0lhtAelJtwLW6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2mtbc%253D&md5=38e65a5dc6c8819995f38e596d230a27</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.9422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.9422%26sid%3Dliteratum%253Aachs%26aulast%3DSadiq%26aufirst%3DA.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DMET%2520as%2520a%2520possible%2520target%2520for%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1089%26epage%3D1096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Tanizaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takezawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1624</span><span class="NLM_x">â</span> <span class="NLM_lpage">1631</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1097%2FJTO.0b013e31822591e9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21716144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BC3MfjsFymtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1624-1631&author=J.+Tanizakiauthor=I.+Okamotoauthor=K.+Okamotoauthor=K.+Takezawaauthor=K.+Kuwataauthor=H.+Yamaguchiauthor=K.+Nakagawa&title=MET+tyrosine+kinase+inhibitor+crizotinib+%28PF-02341066%29+shows+differential+antitumor+effects+in+non-small+cell+lung+cancer+according+to+MET+alterations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations</span></div><div class="casAuthors">Tanizaki Junko; Okamoto Isamu; Okamoto Kunio; Takezawa Ken; Kuwata Kiyoko; Yamaguchi Haruka; Nakagawa Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1624-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Tyrosine kinase inhibitors (TKIs) targeted to MET are undergoing clinical trials in patients with solid tumors, but the precise mechanism of the antitumor activity of these drugs remains unclear.  We examined the antitumor action of the MET-TKI crizotinib (PF-02341066) in lung cancer cells that are positive or negative for MET amplification or mutation.  METHODS:  The antitumor action of crizotinib was evaluated on the basis of signal transduction, cell proliferation, apoptosis, and progression of tumor xenografts.  RESULTS:  Inhibition of MET signaling by crizotinib or by RNA interference-mediated MET depletion resulted in the induction of apoptosis accompanied by inhibition of AKT and extracellular signal-regulated kinase phosphorylation in lung cancer cells with MET amplification but not in cells with a MET mutation or in those without amplification or mutation of MET.  These results suggest that MET signaling is essential for the survival of cells with MET amplification but not for that of cells without this genetic change, including those with a MET mutation.  Crizotinib up-regulated the expression of BIM, a proapoptotic member of the Bcl-2 family, and down-regulated that of survivin, a member of the inhibitor of apoptosis protein family, in cells with MET amplification.  Forced depletion of BIM and expression of survivin each inhibited crizotinib-induced apoptosis, suggesting that both up-regulation of BIM and down-regulation of survivin contribute to the proapoptotic effect of crizotinib.  CONCLUSIONS:  Crizotinib shows a marked antitumor action in MET amplification-positive lung cancer cells but not in cells without MET amplification, including those with a MET mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8hMQlXKWgvS86Js-BCLiifW6udTcc2eZ47ZmsSiXwdrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfjsFymtA%253D%253D&md5=69a87a8667cd239d19735f3fcb3feddc</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31822591e9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31822591e9%26sid%3Dliteratum%253Aachs%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DKuwata%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DMET%2520tyrosine%2520kinase%2520inhibitor%2520crizotinib%2520%2528PF-02341066%2529%2520shows%2520differential%2520antitumor%2520effects%2520in%2520non-small%2520cell%2520lung%2520cancer%2520according%2520to%2520MET%2520alterations%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D1624%26epage%3D1631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">â</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1097%2FJTO.0b013e31821528d3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21623265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=942-946&author=S.-H.+I.+Ouauthor=E.+L.+Kwakauthor=C.+Siwak-Tappauthor=J.+Dyauthor=K.+Bergethonauthor=J.+W.+Clarkauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=R.+G.+Makiauthor=Y.-J.+Bangauthor=D.-W.+Kimauthor=J.+Christensenauthor=W.+Tanauthor=K.+D.+Wilnerauthor=R.+Salgiaauthor=A.+J.+Iafrate&title=Activity+of+crizotinib+%28PF02341066%29%2C+a+dual+mesenchymal-epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor%2C+in+a+non-small+cell+lung+cancer+patient+with+de+novo+MET+amplification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Kwak Eunice L; Siwak-Tapp Christina; Dy Joni; Bergethon Kristin; Clark Jeffrey W; Camidge D Ross; Solomon Benjamin J; Maki Robert G; Bang Yung-Jue; Kim Dong-Wan; Christensen James; Tan Weiwei; Wilner Keith D; Salgia Ravi; Iafrate A John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is a dual MET and ALK inhibitor.  Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC).  Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1REpDHXMT37jnyZkbE8yXfW6udTcc2eZ47ZmsSiXwdrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D&md5=920657051f20d097e6cd1d83b0aa7e10</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31821528d3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31821528d3%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DDy%26aufirst%3DJ.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DActivity%2520of%2520crizotinib%2520%2528PF02341066%2529%252C%2520a%2520dual%2520mesenchymal-epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%252C%2520in%2520a%2520non-small%2520cell%2520lung%2520cancer%2520patient%2520with%2520de%2520novo%2520MET%2520amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Spigel, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramlau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldschmidt, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement-Duchene, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlesi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlov, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertheim, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A. C.</span><span> </span><span class="NLM_article-title">Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">7505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=7505&author=D.+R.+Spigelauthor=T.+J.+Ervinauthor=R.+Ramlauauthor=D.+B.+Danielauthor=J.+H.+Goldschmidtauthor=G.+R.+Blumenscheinauthor=M.+J.+Krzakowskiauthor=G.+Robinetauthor=C.+Clement-Ducheneauthor=F.+Barlesiauthor=R.+Govindanauthor=T.+Patelauthor=S.+V.+Orlovauthor=M.+S.+Wertheimauthor=J.+Zhaauthor=A.+Panditaauthor=W.+Yuauthor=R.+L.+Yauchauthor=P.+H.+Patelauthor=A.+C.+Peterson&title=Final+efficacy+results+from+OAM4558g%2C+a+randomized+phase+II+study+evaluating+MetMAb+or+placebo+in+combination+with+erlotinib+in+advanced+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DErvin%26aufirst%3DT.%2BJ.%26aulast%3DRamlau%26aufirst%3DR.%26aulast%3DDaniel%26aufirst%3DD.%2BB.%26aulast%3DGoldschmidt%26aufirst%3DJ.%2BH.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DKrzakowski%26aufirst%3DM.%2BJ.%26aulast%3DRobinet%26aufirst%3DG.%26aulast%3DClement-Duchene%26aufirst%3DC.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DT.%26aulast%3DOrlov%26aufirst%3DS.%2BV.%26aulast%3DWertheim%26aufirst%3DM.%2BS.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DPandita%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DPatel%26aufirst%3DP.%2BH.%26aulast%3DPeterson%26aufirst%3DA.%2BC.%26atitle%3DFinal%2520efficacy%2520results%2520from%2520OAM4558g%252C%2520a%2520randomized%2520phase%2520II%2520study%2520evaluating%2520MetMAb%2520or%2520placebo%2520in%2520combination%2520with%2520erlotinib%2520in%2520advanced%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D7505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Ou, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argiris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usari, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, F.</span><span> </span><span class="NLM_article-title">Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2610</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2610&author=S.+I.+Ouauthor=R.+Govindanauthor=K.+D.+Eatonauthor=G.+A.+Ottersonauthor=M.+Gutierrezauthor=A.+C.+Mitaauthor=A.+Argirisauthor=N.+Bregaauthor=T.+Usariauthor=W.+Tanauthor=S.+N.+Hoauthor=F.+Robert&title=Phase+I%2FII+dose-finding+study+of+crizotinib+%28CRIZ%29+in+combination+with+erlotinib+%28E%29+in+patients+%28pts%29+with+advanced+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DEaton%26aufirst%3DK.%2BD.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DArgiris%26aufirst%3DA.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DHo%26aufirst%3DS.%2BN.%26aulast%3DRobert%26aufirst%3DF.%26atitle%3DPhase%2520I%252FII%2520dose-finding%2520study%2520of%2520crizotinib%2520%2528CRIZ%2529%2520in%2520combination%2520with%2520erlotinib%2520%2528E%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D2610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Ferlay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, D. M.</span><span> </span><span class="NLM_article-title">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">2893</span><span class="NLM_x">â</span> <span class="NLM_lpage">2917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fijc.25516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21351269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWhs7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=2893-2917&author=J.+Ferlayauthor=H.+R.+Shinauthor=F.+Brayauthor=D.+Formanauthor=C.+Mathersauthor=D.+M.+Parkin&title=Estimates+of+worldwide+burden+of+cancer+in+2008%3A+GLOBOCAN+2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</span></div><div class="casAuthors">Ferlay, Jacques; Shin, Hai-Rim; Bray, Freddie; Forman, David; Mathers, Colin; Parkin, Donald Maxwell</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2893-2917</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Ests. of the worldwide incidence and mortality from 27 cancers in 2008 have been prepd. for 182 countries as part of the GLOBOCAN series published by the International Agency for Research on Cancer.  In this article, we present the results for 20 world regions, summarizing the global patterns for the eight most common cancers.  Overall, an estd. 12.7 million new cancer cases and 7.6 million cancer deaths occur in 2008, with 56% of new cancer cases and 63% of the cancer deaths occurring in the less developed regions of the world.  The most commonly diagnosed cancers worldwide are lung (1.61 million, 12.7% of the total), breast (1.38 million, 10.9%) and colorectal cancers (1.23 million, 9.7%).  The most common causes of cancer death are lung cancer (1.38 million, 18.2% of the total), stomach cancer (738,000 deaths, 9.7%) and liver cancer (696,000 deaths, 9.2%).  Cancer is neither rare anywhere in the world, nor mainly confined to high-resource countries.  Striking differences in the patterns of cancer from region to region are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNEfa8G4I-C7Vg90H21EOLACvtfcHk0lheuXoSl6wAKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWhs7fO&md5=986c00d4fc94238145c1d56b8dfc4840</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fijc.25516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25516%26sid%3Dliteratum%253Aachs%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DH.%2BR.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DForman%26aufirst%3DD.%26aulast%3DMathers%26aufirst%3DC.%26aulast%3DParkin%26aufirst%3DD.%2BM.%26atitle%3DEstimates%2520of%2520worldwide%2520burden%2520of%2520cancer%2520in%25202008%253A%2520GLOBOCAN%25202008%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D127%26spage%3D2893%26epage%3D2917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Goyal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzumdar, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span> </span><span class="NLM_article-title">Targeting the HGF/c-MET pathway in hepatocellular carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2310</span><span class="NLM_x">â</span> <span class="NLM_lpage">2318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-12-2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23388504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWrtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2310-2318&author=L.+Goyalauthor=M.+D.+Muzumdarauthor=A.+X.+Zhu&title=Targeting+the+HGF%2Fc-MET+pathway+in+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma</span></div><div class="casAuthors">Goyal, Lipika; Muzumdar, Mandar D.; Zhu, Andrew X.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2310-2318</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and mortality worldwide.  Despite improvements in local therapies, including surgical resection, liver transplantation, and transarterial embolization, the prognosis remains poor for the majority of patients who develop recurrence or present with advanced disease.  Systemic therapy with the tyrosine kinase inhibitor sorafenib represents a milestone in advanced HCC but provides a limited survival benefit.  Ongoing efforts to study hepatocarcinogenesis have identified an important role for c-MET signaling in the promotion of tumor growth, angiogenesis, and metastasis.  In this review, we summarize the preclin. data from human tissue, cell lines, and animal models that implicate c-MET in the pathogenesis of HCC.  We also evaluate potential biomarkers that may est. prognosis or predict response to c-MET inhibitors for more rational clin. trial design.  Finally, we discuss the latest clin. trials of c-MET inhibitors in advanced HCC.  Clin Cancer Res; 19(9); 2310-8. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq72oTEvzdBqbVg90H21EOLACvtfcHk0lheuXoSl6wAKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWrtb8%253D&md5=1b73508518b06dfa8dc4297e0cf0f22d</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2791%26sid%3Dliteratum%253Aachs%26aulast%3DGoyal%26aufirst%3DL.%26aulast%3DMuzumdar%26aufirst%3DM.%2BD.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26atitle%3DTargeting%2520the%2520HGF%252Fc-MET%2520pathway%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2310%26epage%3D2318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Park, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Na, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zbar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span> </span><span class="NLM_article-title">Somatic mutations in the kinase domain of the MET/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=307-310&author=W.+S.+Parkauthor=S.+M.+Dongauthor=S.+Y.+Kimauthor=E.+Y.+Naauthor=M.+S.+Shinauthor=J.+H.+Piauthor=B.+J+Kimauthor=J.+H.+Baeauthor=Y.+K.+Hongauthor=K.+S.+Leeauthor=S.+H.+Leeauthor=N.+J.+Yooauthor=J.+J.+Jangauthor=S.+Packauthor=Z.+Zhuangauthor=L.+Schmidtauthor=B.+Zbarauthor=J.+Y.+Lee&title=Somatic+mutations+in+the+kinase+domain+of+the+MET%2Fhepatocyte+growth+factor+receptor+gene+in+childhood+hepatocellular+carcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DW.%2BS.%26aulast%3DDong%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DNa%26aufirst%3DE.%2BY.%26aulast%3DShin%26aufirst%3DM.%2BS.%26aulast%3DPi%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DB.%2BJ%26aulast%3DBae%26aufirst%3DJ.%2BH.%26aulast%3DHong%26aufirst%3DY.%2BK.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DYoo%26aufirst%3DN.%2BJ.%26aulast%3DJang%26aufirst%3DJ.%2BJ.%26aulast%3DPack%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DSchmidt%26aufirst%3DL.%26aulast%3DZbar%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26atitle%3DSomatic%2520mutations%2520in%2520the%2520kinase%2520domain%2520of%2520the%2520MET%252Fhepatocyte%2520growth%2520factor%2520receptor%2520gene%2520in%2520childhood%2520hepatocellular%2520carcinomas%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D307%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Sennino, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, D. M.</span><span> </span><span class="NLM_article-title">Controlling escape from angiogenesis inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">â</span> <span class="NLM_lpage">709</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc3366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23001349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlyltbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=699-709&author=B.+Senninoauthor=D.+M.+McDonald&title=Controlling+escape+from+angiogenesis+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling escape from angiogenesis inhibitors</span></div><div class="casAuthors">Sennino, Barbara; McDonald, Donald M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">699-709</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Selective inhibition of vascular endothelial growth factor (VEGF) increases the efficacy of chemotherapy and has beneficial effects on multiple advanced cancers, but response is often limited and the disease eventually progresses.  Changes in the tumor microenvironment - hypoxia among them - that result from vascular pruning, suppressed angiogenesis and other consequences of VEGF inhibition can promote escape and tumor progression.  New therapeutic approaches that target pathways that are involved in the escape mechanisms add the benefits of blocking tumor progression to those of slowing tumor growth by inhibiting angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB0CTfbTo7k7Vg90H21EOLACvtfcHk0lgwiPa0ayfLwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlyltbvL&md5=a08b3fba4193491e932863b8c7e8aacc</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fnrc3366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3366%26sid%3Dliteratum%253Aachs%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DMcDonald%26aufirst%3DD.%2BM.%26atitle%3DControlling%2520escape%2520from%2520angiogenesis%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D699%26epage%3D709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Rimassa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borbath, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvagni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Laethem, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Vlierberghe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolligs, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barahona, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasbarrini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lencioni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbadessa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span> </span><span class="NLM_article-title">Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4006</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=4006&author=L.+Rimassaauthor=C.+Portaauthor=I.+Borbathauthor=B.+Danieleauthor=S.+Salvagniauthor=J.+L.+Van+Laethemauthor=H.+Van+Vlierbergheauthor=J.+Trojanauthor=F.+Kolligsauthor=A.+Weissauthor=N.+Barahonaauthor=A.+Gasbarriniauthor=M.+Lencioniauthor=A.+Pandeauthor=M.+Lamarauthor=Y.+Chenauthor=G.+Abbadessaauthor=B.+Schwartzauthor=A.+Santoro&title=Tivantinib+%28ARQ+197%29+versus+placebo+in+patients+%28Pts%29+with+hepatocellular+carcinoma+%28HCC%29+who+failed+one+systemic+therapy%3A+results+of+a+randomized+controlled+phase+II+trial+%28RCT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRimassa%26aufirst%3DL.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBorbath%26aufirst%3DI.%26aulast%3DDaniele%26aufirst%3DB.%26aulast%3DSalvagni%26aufirst%3DS.%26aulast%3DVan%2BLaethem%26aufirst%3DJ.%2BL.%26aulast%3DVan%2BVlierberghe%26aufirst%3DH.%26aulast%3DTrojan%26aufirst%3DJ.%26aulast%3DKolligs%26aufirst%3DF.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DBarahona%26aufirst%3DN.%26aulast%3DGasbarrini%26aufirst%3DA.%26aulast%3DLencioni%26aufirst%3DM.%26aulast%3DPande%26aufirst%3DA.%26aulast%3DLamar%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DAbbadessa%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSantoro%26aufirst%3DA.%26atitle%3DTivantinib%2520%2528ARQ%2520197%2529%2520versus%2520placebo%2520in%2520patients%2520%2528Pts%2529%2520with%2520hepatocellular%2520carcinoma%2520%2528HCC%2529%2520who%2520failed%2520one%2520systemic%2520therapy%253A%2520results%2520of%2520a%2520randomized%2520controlled%2520phase%2520II%2520trial%2520%2528RCT%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D4006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Verslype, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohn, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramies, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span> </span><span class="NLM_article-title">Activity of cabozantinib (XL 184) in hepatocellular carcinoma patients (pts): results from a phase II randomized discontinuation trial (RDT)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=4007&author=C.+Verslypeauthor=A.+L.+Cohnauthor=R.+K.+Kelleyauthor=T.-S.+Yangauthor=W.-C.+Suauthor=D.+A.+Ramiesauthor=Y.+Leeauthor=X.+Shenauthor=E.+Van+Cutsem&title=Activity+of+cabozantinib+%28XL+184%29+in+hepatocellular+carcinoma+patients+%28pts%29%3A+results+from+a+phase+II+randomized+discontinuation+trial+%28RDT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerslype%26aufirst%3DC.%26aulast%3DCohn%26aufirst%3DA.%2BL.%26aulast%3DKelley%26aufirst%3DR.%2BK.%26aulast%3DYang%26aufirst%3DT.-S.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DRamies%26aufirst%3DD.%2BA.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26atitle%3DActivity%2520of%2520cabozantinib%2520%2528XL%2520184%2529%2520in%2520hepatocellular%2520carcinoma%2520patients%2520%2528pts%2529%253A%2520results%2520from%2520a%2520phase%2520II%2520randomized%2520discontinuation%2520trial%2520%2528RDT%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D4007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">SchÃ¶ffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonasch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagawa, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma</span> <span class="citation_source-journal">BJU Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">â</span> <span class="NLM_lpage">686</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21156020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GgtbfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=679-686&author=P.+Sch%C3%B6ffskiauthor=J.+A.+Garciaauthor=W.+M.+Stadlerauthor=T.+Gilauthor=E.+Jonaschauthor=S.+T.+Tagawaauthor=M.+Smittauthor=X.+Yangauthor=K.+S.+Olinerauthor=A.+Andersonauthor=M.+Zhuauthor=F.+Kabbinavar&title=A+phase+II+study+of+the+efficacy+and+safety+of+AMG+102+in+patients+with+metastatic+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma</span></div><div class="casAuthors">Schoffski, Patrick; Garcia, Jorge A.; Stadler, Walter M.; Gil, Thierry; Jonasch, Eric; Tagawa, Scott T.; Smitt, Melanie; Yang, Xinqun; Oliner, Kelly S.; Anderson, Abraham; Zhu, Min; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-686</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy and safety of single-agent AMG 102, an investigational, fully human monoclonal antibody to hepatocyte growth factor/scatter factor (HGF/SF), in renal cell carcinoma (RCC).  Patients and Methods: This open-label phase II study included patients â¥18 years old with histol. confirmed, advanced or metastatic RCC (mRCC) and Eastern Cooperative Oncol. Group performance status 0 to 2.  AMG 102 was administered i.v. at 10 or 20 mg/kg once every 2 wk.  A two-stage design was used at each dose level and the primary endpoint was objective best confirmed response (by Response Evaluation Criteria in Solid Tumors) at any time.  Results: Sixty-one patients with mRCC enrolled and received AMG 102 (40 at 10 mg/kg; 21 at 20 mg/kg).  Overall, 70.5% were men, median age was 59 years (range, 39 to 84 years), and 92% had received previous anti-vascular endothelial growth factor therapy.  RCC histologies were: clear cell (75.4%), papillary (11.5%), chromophobe (4.9%) and unclassified (8.2%).  One confirmed partial response occurred at 10 mg/kg, maintained for over 2.5 years; 26 patients (43%) had stable disease, 10 (16%) for â¥32 wk.  The median profression-free survival was 3.7 mo at 10 mg/kg and 2.0 mo at 20 mg/kg.  The commonest adverse events were edema (45.9%), fatigue (37.7%) and nausea (27.9%).  Grade 3 or 4 adverse events occurred in 33% of patients, the most common being edema (9.8%).  Baseline levels of plasma HGF/SF and sol. c-Met as well as archival-tumor c-Met did not correlate with measures of efficacy.  Conclusion: Single-agent AMG 102 was tolerable, but it is unclear if AMG 102 was growth inhibitory in this population of patients with mRCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp923Wc40CHhLVg90H21EOLACvtfcHk0liDplBFhFhWyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GgtbfM&md5=368f1a948f5cd1a64b57c9b3368d9477</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DGarcia%26aufirst%3DJ.%2BA.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DGil%26aufirst%3DT.%26aulast%3DJonasch%26aufirst%3DE.%26aulast%3DTagawa%26aufirst%3DS.%2BT.%26aulast%3DSmitt%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DOliner%26aufirst%3DK.%2BS.%26aulast%3DAnderson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520AMG%2520102%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DBJU%2520Int.%26date%3D2011%26volume%3D108%26spage%3D679%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Diamond, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanteti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ching, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lira, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenmakers, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">e254</span><span class="NLM_x">â</span> <span class="NLM_lpage">258</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=e254-258&author=J.+R.+Diamondauthor=R.+Salgiaauthor=M.+Varella-Garciaauthor=R.+Kantetiauthor=P.+M.+LoRussoauthor=J.+W.+Clarkauthor=L.+G.+Xuauthor=K.+Wilnerauthor=S.+G.+Eckhardtauthor=K.+A.+Chingauthor=M.+E.+Liraauthor=E.+F.+Schoenmakersauthor=J.+G.+Christensenauthor=D.+R.+Camidge&title=Initial+clinical+sensitivity+and+acquired+resistance+to+MET+inhibition+in+MET-mutated+papillary+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DL.%2BG.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DChing%26aufirst%3DK.%2BA.%26aulast%3DLira%26aufirst%3DM.%2BE.%26aulast%3DSchoenmakers%26aufirst%3DE.%2BF.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DInitial%2520clinical%2520sensitivity%2520and%2520acquired%2520resistance%2520to%2520MET%2520inhibition%2520in%2520MET-mutated%2520papillary%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3De254%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaishampayan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harzstark, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottesen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubscher, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottaro, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linehan, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, R.</span><span> </span><span class="NLM_article-title">Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">â</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2012.43.3383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23213094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2gsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=181-186&author=T.+K.+Choueiriauthor=U.+Vaishampayanauthor=J.+E.+Rosenbergauthor=T.+F.+Loganauthor=A.+L.+Harzstarkauthor=R.+M.+Bukowskiauthor=B.+I.+Riniauthor=S.+Srinivasauthor=M.+N.+Steinauthor=L.+M.+Adamsauthor=L.+H.+Ottesenauthor=K.+H.+Laubscherauthor=L.+Shermanauthor=D.+F.+McDermottauthor=N.+B.+Haasauthor=K.+T.+Flahertyauthor=R.+Rossauthor=P.+Eisenbergauthor=P.+S.+Meltzerauthor=M.+J.+Merinoauthor=D.+P.+Bottaroauthor=W.+M.+Linehanauthor=R.+Srinivasan&title=Phase+II+and+biomarker+study+of+the+dual+MET%2FVEGFR2+inhibitor+foretinib+in+patients+with+papillary+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma</span></div><div class="casAuthors">Choueiri, Toni K.; Vaishampayan, Ulka; Rosenberg, Jonathan E.; Logan, Theodore F.; Harzstark, Andrea L.; Bukowski, Ronald M.; Rini, Brian I.; Srinivas, Sandy; Stein, Mark N.; Adams, Laurel M.; Ottesen, Lone H.; Laubscher, Kevin H.; Sherman, Laurie; McDermott, David F.; Haas, Naomi B.; Flaherty, Keith T.; Ross, Robert; Eisenberg, Peter; Meltzer, Paul S.; Merino, Maria J.; Bottaro, Donald P.; Linehan, W. Marston; Srinivasan, Ramaprasad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-186</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors.  Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC).  We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC.  Patients and Methods: Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm).  Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET[7q31] amplification, or gain of chromosome 7).  The primary end point was overall response rate (ORR).  Results: Overall, 74 patients were enrolled, with 37 in each dosing cohort.  ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 mo, and median overall survival was not reached.  The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, resp.).  The most frequent adverse events of any grade assocd. with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli.  Conclusion: Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6QX38hu-PlLVg90H21EOLACvtfcHk0liDplBFhFhWyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2gsrs%253D&md5=4933edf67e1dfc4867a9672ce526c94b</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.3383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.3383%26sid%3Dliteratum%253Aachs%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DVaishampayan%26aufirst%3DU.%26aulast%3DRosenberg%26aufirst%3DJ.%2BE.%26aulast%3DLogan%26aufirst%3DT.%2BF.%26aulast%3DHarzstark%26aufirst%3DA.%2BL.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DSrinivas%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DM.%2BN.%26aulast%3DAdams%26aufirst%3DL.%2BM.%26aulast%3DOttesen%26aufirst%3DL.%2BH.%26aulast%3DLaubscher%26aufirst%3DK.%2BH.%26aulast%3DSherman%26aufirst%3DL.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DHaas%26aufirst%3DN.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DEisenberg%26aufirst%3DP.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DMerino%26aufirst%3DM.%2BJ.%26aulast%3DBottaro%26aufirst%3DD.%2BP.%26aulast%3DLinehan%26aufirst%3DW.%2BM.%26aulast%3DSrinivasan%26aufirst%3DR.%26atitle%3DPhase%2520II%2520and%2520biomarker%2520study%2520of%2520the%2520dual%2520MET%252FVEGFR2%2520inhibitor%2520foretinib%2520in%2520patients%2520with%2520papillary%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D181%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Graziano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluccio, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canestrari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâEmidio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catalano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sisti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligorio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rulli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Oto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zingaretti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Nictolis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnani, M.</span><span> </span><span class="NLM_article-title">Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4789</span><span class="NLM_x">â</span> <span class="NLM_lpage">4795</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2011.36.7706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22042954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslygs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4789-4795&author=F.+Grazianoauthor=N.+Galluccioauthor=P.+Lorenziniauthor=A.+Ruzzoauthor=E.+Canestrariauthor=S.+D%E2%80%99Emidioauthor=V.+Catalanoauthor=V.+Sistiauthor=C.+Ligorioauthor=F.+Andreoniauthor=E.+Rulliauthor=E.+Di+Otoauthor=G.+Fiorentiniauthor=C.+Zingarettiauthor=M.+De+Nictolisauthor=F.+Cappuzzoauthor=M.+Magnani&title=Genetic+activation+of+the+MET+pathway+and+prognosis+of+patients+with+high-risk%2C+radically+resected+gastric+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer</span></div><div class="casAuthors">Graziano, Francesco; Galluccio, Nadia; Lorenzini, Paola; Ruzzo, Annamaria; Canestrari, Emanuele; D'Emidio, Silvia; Catalano, Vincenzo; Sisti, Valerio; Ligorio, Claudia; Andreoni, Francesca; Rulli, Eliana; Di Oto, Enrico; Fiorentini, Giammaria; Zingaretti, Costantino; De Nictolis, Michele; Cappuzzo, Federico; Magnani, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4789-4795</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose To investigate whether prognosis of patients with high-risk gastric cancer may depend on MET copy no. gain (CNG) or an activating truncation within a deoxyadenosine tract element (DATE) in the promoter region of the MET ligand HGF.  Patients and Methods A single-institution cohort of 230 patients with stage II/III gastric cancer was studied.  Formalin-fixed paraffin-embedded tumor specimens were used for DNA extn.  Quant. polymerase chain reaction (qPCR) for MET CNG and sequencing for HGF DATE truncation (< 25 deoxyadenosines instead of 30) were used.  Results were analyzed for assocn. with disease-free survival (DFS) and overall survival (OS).  To assess the reliability of the qPCR measurement, a random sample of cases was reanalyzed using an alternative assay (fluorescent in situ hybridization [FISH]) with calcn. of the intracorrelation coeff. (ICC).  Results In 216 assessable patients, MET CNG five or more copies and homozygous HGF-truncated DATE occurred in 21 patients (10%) and 30 patients (13%), resp.  Patients with MET CNG five or more copies (MET-pos.) showed significantly worse prognosis with multivariate hazard ratio (HR) of 3.02 (95% CI, 1.71 to 5.33; P < .001) for DFS and multivariate HR of 2.91 (95% CI, 1.65 to 5.11; P < .001) for OS.  The agreement between qPCR and FISH was high, with ICC = 0.9% (95% CI, 0.81 % to 0.95%; the closer the ICC is to 1, the greater is the agreement).  HGF-truncated DATE did not show relevant prognostic effect.  Conclusion In this study, qPCR revealed approx. 10% of white patients with gastric cancer harboring MET CNG of five or more copies.  This marker was significantly assocd. with unfavorable prognosis.  This information is relevant to the current clin. development of anti-MET compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ29BNpIYeJLVg90H21EOLACvtfcHk0lirwyOfSK11jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslygs74%253D&md5=cf758969ea3570bac488f9e1f723f450</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.36.7706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.36.7706%26sid%3Dliteratum%253Aachs%26aulast%3DGraziano%26aufirst%3DF.%26aulast%3DGalluccio%26aufirst%3DN.%26aulast%3DLorenzini%26aufirst%3DP.%26aulast%3DRuzzo%26aufirst%3DA.%26aulast%3DCanestrari%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Emidio%26aufirst%3DS.%26aulast%3DCatalano%26aufirst%3DV.%26aulast%3DSisti%26aufirst%3DV.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DAndreoni%26aufirst%3DF.%26aulast%3DRulli%26aufirst%3DE.%26aulast%3DDi%2BOto%26aufirst%3DE.%26aulast%3DFiorentini%26aufirst%3DG.%26aulast%3DZingaretti%26aufirst%3DC.%26aulast%3DDe%2BNictolis%26aufirst%3DM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMagnani%26aufirst%3DM.%26atitle%3DGenetic%2520activation%2520of%2520the%2520MET%2520pathway%2520and%2520prognosis%2520of%2520patients%2520with%2520high-risk%252C%2520radically%2520resected%2520gastric%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D4789%26epage%3D4795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Catenacci, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegde, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Durable complete response of metastatic gastric cancer with anti-MET therapy followed by resistance at recurrence</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">â</span> <span class="NLM_lpage">579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=573-579&author=D.+V.+Catenacciauthor=L.+Hendersonauthor=S.+Y.+Xiaoauthor=P.+Patelauthor=R.+L.+Yauchauthor=P.+Hegdeauthor=J.+Zhaauthor=A.+Panditaauthor=A.+Petersonauthor=R.+Salgia&title=Durable+complete+response+of+metastatic+gastric+cancer+with+anti-MET+therapy+followed+by+resistance+at+recurrence"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%26aulast%3DHenderson%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DS.%2BY.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DHegde%26aufirst%3DP.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DPandita%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DDurable%2520complete%2520response%2520of%2520metastatic%2520gastric%2520cancer%2520with%2520anti-MET%2520therapy%2520followed%2520by%2520resistance%2520at%2520recurrence%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D573%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Lennerz, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackerman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauwers, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4803</span><span class="NLM_x">â</span> <span class="NLM_lpage">4810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2011.35.4928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22042947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslygs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4803-4810&author=J.+K.+Lennerzauthor=E.+L.+Kwakauthor=A.+Ackermanauthor=M.+Michaelauthor=S.+B.+Foxauthor=K.+Bergethonauthor=G.+Y.+Lauwersauthor=J.+G.+Christensenauthor=K.+D.+Wilnerauthor=D.+A.+Haberauthor=R.+Salgiaauthor=Y.+J.+Bangauthor=J.+W.+Clarkauthor=B.+J.+Solomonauthor=A.+J.+Iafrate&title=MET+amplification+identifies+a+small+and+aggressive+subgroup+of+esophagogastric+adenocarcinoma+with+evidence+of+responsiveness+to+crizotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib</span></div><div class="casAuthors">Lennerz, Jochen K.; Kwak, Eunice L.; Ackerman, Allison; Michael, Michael; Fox, Stephen B.; Bergethon, Kristin; Lauwers, Gregory Y.; Christensen, James G.; Wilner, Keith D.; Haber, Daniel A.; Salgia, Ravi; Bang, Yung-Jue; Clark, Jeffrey W.; Solomon, Benjamin J.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4803-4810</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a mol. marker for targeted therapy.  We examd. a GEC cohort with follow-up and reported the clin. response of four addnl. patients with MET-amplified tumors to the small mol. inhibitor crizotinib as part of an expanded phase 1 cohort study.  Patients and Methods: From 2007 to 2009, patients with GEC were genetically screened as a consecutive series of 489 tumors (stages 0, I, and II, 39%; III, 25%; IV, 36%; n = 222 esophageal, including n = 21 squamous carcinomas).  MET, EGFR, and HER2 amplification status was assessed by using fluorescence in situ hybridization.  Results: Ten (2%) of 489 patients screened harbored MET amplification; 23 (4.7%) harbored EGFR amplification; 45 (8.9%) harbored HER2 amplification; and 411 (84%) were wild type for all three genes (ie, neg.).  MET-amplified tumors were typically high-grade adenocarcinomas that presented at advanced stages (5%; n = 4 of 80).  EGFR-amplified tumors showed the highest fraction of squamous cell carcinoma (17%; n = 4 of 23).  HER2, MET, and EGFR amplification were, with one exception (MET and EGFR pos.), mutually exclusive events.  Survival anal. in patients with stages III and IV disease showed substantially shorter median survival in MET/EGFR-amplified groups, with a rank order for all groups by median survival (from most to least aggressive): MET (7.1 mo; P < .001) less than EGFR (11.2 mo; P = .16) less than HER2 (16.9 mo; P = .89) when compared with the neg. group (16.2 mo).  Two of four patients with MET-amplified tumors treated with crizotinib experienced tumor shrinkage (-30% and -16%) and experienced progression after 3.7 and 3.5 mo.  Conclusion MET amplification defines a small and aggressive subset of GEC with indications of transient sensitivity to the targeted MET inhibitor crizotinib (PF-02341066).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvuLInpDQR7Vg90H21EOLACvtfcHk0lirwyOfSK11jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslygs7w%253D&md5=c98cb00019310228b39247e23c18d5c4</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.4928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.4928%26sid%3Dliteratum%253Aachs%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DAckerman%26aufirst%3DA.%26aulast%3DMichael%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DS.%2BB.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DLauwers%26aufirst%3DG.%2BY.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DMET%2520amplification%2520identifies%2520a%2520small%2520and%2520aggressive%2520subgroup%2520of%2520esophagogastric%2520adenocarcinoma%2520with%2520evidence%2520of%2520responsiveness%2520to%2520crizotinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D4803%26epage%3D4810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Dunn, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinne, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wykosky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quayle, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwalla, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chheda, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligon, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furnari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavenee, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depinho, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span> </span><span class="NLM_article-title">Emerging insights into the molecular and cellular basis of glioblastoma</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">â</span> <span class="NLM_lpage">784</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=756-784&author=G.+P.+Dunnauthor=M.+L.+Rinneauthor=J.+Wykoskyauthor=G.+Genoveseauthor=S.+N.+Quayleauthor=I.+F.+Dunnauthor=P.+K.+Agarwallaauthor=M.+G.+Chhedaauthor=B.+Camposauthor=A.+Wangauthor=C.+Brennanauthor=K.+L.+Ligonauthor=F.+Furnariauthor=W.+K.+Caveneeauthor=R.+A.+Depinhoauthor=L.+Chinauthor=W.+C.+Hahn&title=Emerging+insights+into+the+molecular+and+cellular+basis+of+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DG.%2BP.%26aulast%3DRinne%26aufirst%3DM.%2BL.%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DGenovese%26aufirst%3DG.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DDunn%26aufirst%3DI.%2BF.%26aulast%3DAgarwalla%26aufirst%3DP.%2BK.%26aulast%3DChheda%26aufirst%3DM.%2BG.%26aulast%3DCampos%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DLigon%26aufirst%3DK.%2BL.%26aulast%3DFurnari%26aufirst%3DF.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26aulast%3DDepinho%26aufirst%3DR.%2BA.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26atitle%3DEmerging%2520insights%2520into%2520the%2520molecular%2520and%2520cellular%2520basis%2520of%2520glioblastoma%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D756%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raizer, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laterra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reardon, D. A.</span><span> </span><span class="NLM_article-title">A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma</span> <span class="citation_source-journal">Neuro-Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">â</span> <span class="NLM_lpage">446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=437-446&author=P.+Y.+Wenauthor=D.+Schiffauthor=T.+F.+Cloughesyauthor=J.+J.+Raizerauthor=J.+Laterraauthor=M.+Smittauthor=M.+Wolfauthor=K.+S.+Olinerauthor=A.+Andersonauthor=M.+Zhuauthor=E.+Lohauthor=D.+A.+Reardon&title=A+phase+II+study+evaluating+the+efficacy+and+safety+of+AMG+102+%28rilotumumab%29+in+patients+with+recurrent+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DSchiff%26aufirst%3DD.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DRaizer%26aufirst%3DJ.%2BJ.%26aulast%3DLaterra%26aufirst%3DJ.%26aulast%3DSmitt%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DOliner%26aufirst%3DK.%2BS.%26aulast%3DAnderson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DLoh%26aufirst%3DE.%26aulast%3DReardon%26aufirst%3DD.%2BA.%26atitle%3DA%2520phase%2520II%2520study%2520evaluating%2520the%2520efficacy%2520and%2520safety%2520of%2520AMG%2520102%2520%2528rilotumumab%2529%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%26jtitle%3DNeuro-Oncology%26date%3D2011%26volume%3D13%26spage%3D437%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Chi, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymalâepithelial transition inhibitor</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">e30</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=e30-33&author=A.+S.+Chiauthor=T.+T.+Batchelorauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=D.+L.+Wangauthor=K.+D.+Wilnerauthor=D.+N.+Louisauthor=A.+J.+Iafrate&title=Rapid+radiographic+and+clinical+improvement+after+treatment+of+a+MET-amplified+recurrent+glioblastoma+with+a+mesenchymal%E2%80%93epithelial+transition+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DA.%2BS.%26aulast%3DBatchelor%26aufirst%3DT.%2BT.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DWang%26aufirst%3DD.%2BL.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DRapid%2520radiographic%2520and%2520clinical%2520improvement%2520after%2520treatment%2520of%2520a%2520MET-amplified%2520recurrent%2520glioblastoma%2520with%2520a%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520inhibitor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3De30%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Seiwert, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faoro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janamanchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nallasura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Dinali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanteti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingen, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3021</span><span class="NLM_x">â</span> <span class="NLM_lpage">3031</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3021-3031&author=T.+Y.+Seiwertauthor=R.+Jagadeeswaranauthor=L.+Faoroauthor=V.+Janamanchiauthor=V.+Nallasuraauthor=M.+El+Dinaliauthor=S.+Yalaauthor=R.+Kantetiauthor=E.+E.+Cohenauthor=M.+W.+Lingenauthor=L.+Martinauthor=S.+Krishnaswamyauthor=A.+Klein-Szantoauthor=J.+G.+Christensenauthor=E.+E.+Vokesauthor=R.+Salgia&title=The+MET+receptor+tyrosine+kinase+is+a+potential+novel+therapeutic+target+for+head+and+neck+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeiwert%26aufirst%3DT.%2BY.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DFaoro%26aufirst%3DL.%26aulast%3DJanamanchi%26aufirst%3DV.%26aulast%3DNallasura%26aufirst%3DV.%26aulast%3DEl%2BDinali%26aufirst%3DM.%26aulast%3DYala%26aufirst%3DS.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DLingen%26aufirst%3DM.%2BW.%26aulast%3DMartin%26aufirst%3DL.%26aulast%3DKrishnaswamy%26aufirst%3DS.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DThe%2520MET%2520receptor%2520tyrosine%2520kinase%2520is%2520a%2520potential%2520novel%2520therapeutic%2520target%2520for%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D3021%26epage%3D3031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggiora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortesina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1547</span><span class="NLM_x">â</span> <span class="NLM_lpage">1555</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=1547-1555&author=M.+F.+Di+Renzoauthor=M.+Oliveroauthor=T.+Martoneauthor=A.+Maffeauthor=P.+Maggioraauthor=A.+D.+Stefaniauthor=G.+Valenteauthor=S.+Giordanoauthor=G.+Cortesinaauthor=P.+M.+Comoglio&title=Somatic+mutations+of+the+MET+oncogene+are+selected+during+metastatic+spread+of+human+HNSC+carcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26aulast%3DOlivero%26aufirst%3DM.%26aulast%3DMartone%26aufirst%3DT.%26aulast%3DMaffe%26aufirst%3DA.%26aulast%3DMaggiora%26aufirst%3DP.%26aulast%3DStefani%26aufirst%3DA.%2BD.%26aulast%3DValente%26aufirst%3DG.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DCortesina%26aufirst%3DG.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DSomatic%2520mutations%2520of%2520the%2520MET%2520oncogene%2520are%2520selected%2520during%2520metastatic%2520spread%2520of%2520human%2520HNSC%2520carcinomas%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D1547%26epage%3D1555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Hansen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor targeting in head and neck cancer: Have we been just skimming the surface?</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1381</span><span class="NLM_x">â</span> <span class="NLM_lpage">1383</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2012.47.9220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23460713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12rtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1381-1383&author=A.+R.+Hansenauthor=L.+L.+Siu&title=Epidermal+growth+factor+receptor+targeting+in+head+and+neck+cancer%3A+Have+we+been+just+skimming+the+surface%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface?</span></div><div class="casAuthors">Hansen, Aaron R.; Siu, Lillian L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1381-1383</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The research of Martins et al. (2013) entitled, 'Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial' and Argiris et al. (2013) entitled, 'Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern Cooperative Oncol. Group trial' is reviewed with commentary and refs.  Martins et al. assessed the effect of the addn. of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib to std. cisplatin-based chemoradiotherapy on complete response rate (CRR) and progression-free survival (PFS).  They noted the lack of benefit of combining anti-EGFR therapy with concurrent chemoradiotherapy as a chemoadditive strategy in unselected patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).  On the other hand, Argiris et al. examd. the addn. of another EGFR TKI, gefitinib, to palliative chemotherapy in patients with recurrent or metastatic (RM) SCCHN.  Although Argiris et al.'s study was not designed to specifically address the suitability of gefitinib and docetaxel after combination cetuximab plus chemotherapy treatment, the history of prior chemotherapy did not impact outcome on the basis of subgroup evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFNSVOfuZa77Vg90H21EOLACvtfcHk0lh4oU7yug6LsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12rtbg%253D&md5=125e30e5c441f7a39737b341048375fc</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.47.9220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.47.9220%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DA.%2BR.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520targeting%2520in%2520head%2520and%2520neck%2520cancer%253A%2520Have%2520we%2520been%2520just%2520skimming%2520the%2520surface%253F%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1381%26epage%3D1383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stabile, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubish, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gooding, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandis, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegfried, J. M.</span><span> </span><span class="NLM_article-title">Dual blockade of EGFR and MET abrogates redundant signaling and proliferation in head and neck carcinoma cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4425</span><span class="NLM_x">â</span> <span class="NLM_lpage">4438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-10-3339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21622718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1SmtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4425-4438&author=H.+Xuauthor=L.+P.+Stabileauthor=C.+T.+Gubishauthor=W.+E.+Goodingauthor=J.+R.+Grandisauthor=J.+M.+Siegfried&title=Dual+blockade+of+EGFR+and+MET+abrogates+redundant+signaling+and+proliferation+in+head+and+neck+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells</span></div><div class="casAuthors">Xu, Hai; Stabile, Laura P.; Gubish, Christopher T.; Gooding, William E.; Grandis, Jennifer R.; Siegfried, Jill M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4425-4438</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Head and neck squamous cell carcinoma (HNSCC) is usually fatal, and innovative approaches targeting growth pathways are necessary to effectively treat this disease.  Both the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor (HGF)/c-Met pathways are overexpressed in HNSCC and initiate similar downstream signaling pathways.  C-Met may act in consort with EGFR and/or be activated as a compensatory pathway in the presence of EGFR blockade.  Expression levels of EGFR and c-Met were detd. by Western anal. in HNSCC cell lines and correlated with antitumor responses to inhibitors of these pathways.  Combining the c-Met inhibitor PF2341066 with the EGFR inhibitor gefitinib abrogated HNSCC cell proliferation, invasion, and wound healing significantly more than inhibition of each pathway alone in HNSCC cell lines.  When both HGF and the EGFR ligand, TGF-Î±, were present in vitro, P-AKT and P-MAPK expression were maximally inhibited by targeting both EGFR and c-Met pathways, suggesting that c-Met or EGFR can compensate when phosphorylation of the other receptor is inhibited.  We also showed that TGF-Î± can induce phosphorylation of c-Met over sixfold by 8 h in the absence of HGF, supporting a ligand-independent mechanism.  Combined targeting of c-Met and EGFR resulted in an enhanced inhibition of tumor vols. accompanied by a decreased no. of proliferating cells and increased apoptosis compared with single agent treatment in vivo.  Together, these results suggest that dual blockade of c-Met and EGFR may be a promising clin. therapeutic strategy for treating HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooC0GvK87aX7Vg90H21EOLACvtfcHk0lh6_15aMk8m0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1SmtL0%253D&md5=d3a3a65e764c90f92214b4666e52228f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3339%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DStabile%26aufirst%3DL.%2BP.%26aulast%3DGubish%26aufirst%3DC.%2BT.%26aulast%3DGooding%26aufirst%3DW.%2BE.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26aulast%3DSiegfried%26aufirst%3DJ.%2BM.%26atitle%3DDual%2520blockade%2520of%2520EGFR%2520and%2520MET%2520abrogates%2520redundant%2520signaling%2520and%2520proliferation%2520in%2520head%2520and%2520neck%2520carcinoma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4425%26epage%3D4438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarantopoulos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallender, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keer, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G.,  Jr.</span><span> </span><span class="NLM_article-title">Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">â</span> <span class="NLM_lpage">424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=417-424&author=T.+Seiwertauthor=J.+Sarantopoulosauthor=H.+Kallenderauthor=S.+McCallumauthor=H.+N.+Keerauthor=G.+Blumenschein&title=Phase+II+trial+of+single-agent+foretinib+%28GSK1363089%29+in+patients+with+recurrent+or+metastatic+squamous+cell+carcinoma+of+the+head+and+neck"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26aulast%3DKallender%26aufirst%3DH.%26aulast%3DMcCallum%26aufirst%3DS.%26aulast%3DKeer%26aufirst%3DH.%2BN.%26aulast%3DBlumenschein%26aufirst%3DG.%26atitle%3DPhase%2520II%2520trial%2520of%2520single-agent%2520foretinib%2520%2528GSK1363089%2529%2520in%2520patients%2520with%2520recurrent%2520or%2520metastatic%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D417%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86a','cit86b'],'ref87':['cit87a','cit87b'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94a','cit94b'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142a','cit142b'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150a','cit150b'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 132 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tianhui Shi, Jialing Hu, Wenxiao Wang, Qunying Jiang, Zhen Xu, Shuyi Yu, Fuan Wang, <span class="NLM_string-name hlFld-ContribAuthor">Xiaoqing Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Multiple Blockades of the HGF/Met Signaling Pathway for Metastasis Suppression Using Nanoinhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2021,</strong> <em>13 </em>
                                    (26)
                                     , 30350-30358. <a href="https://doi.org/10.1021/acsami.1c07010" title="DOI URL">https://doi.org/10.1021/acsami.1c07010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.1c07010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.1c07010%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DMultiple%252BBlockades%252Bof%252Bthe%252BHGF%25252FMet%252BSignaling%252BPathway%252Bfor%252BMetastasis%252BSuppression%252BUsing%252BNanoinhibitors%26aulast%3DShi%26aufirst%3DTianhui%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D16042021%26date%3D14062021%26date%3D24062021%26volume%3D13%26issue%3D26%26spage%3D30350%26epage%3D30358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qing Tang, Alex M. Aronov, David D. Deininger, Simon Giroux, David J. Lauffer, Pan Li, Jianglin Liang, Kira McGinty, Steven Ronkin, Rebecca Swett, Nathan Waal, Diane Boucher, Pamella J. Ford, <span class="NLM_string-name hlFld-ContribAuthor">Cameron S. Moody</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 955-960. <a href="https://doi.org/10.1021/acsmedchemlett.1c00094" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00094%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%25252C%252BSelective%252BTriazolothiadiazole-Containing%252Bc-Met%252BInhibitors%26aulast%3DTang%26aufirst%3DQing%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18022021%26date%3D11052021%26date%3D24052021%26volume%3D12%26issue%3D6%26spage%3D955%26epage%3D960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chaosheng Luo, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey S. Bandar</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Defluoroallylation of Trifluoromethylarenes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (36)
                                     , 14120-14125. <a href="https://doi.org/10.1021/jacs.9b07766" title="DOI URL">https://doi.org/10.1021/jacs.9b07766</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b07766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b07766%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DSelective%252BDefluoroallylation%252Bof%252BTrifluoromethylarenes%26aulast%3DLuo%26aufirst%3DChaosheng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20072019%26date%3D28082019%26date%3D22082019%26volume%3D141%26issue%3D36%26spage%3D14120%26epage%3D14125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vishnu
C. Damalanka, Zhenfu Han, Partha Karmakar, Anthony J. OâDonoghue, Florencia La Greca, Tommy Kim, Shishir M. Pant, Jonathan Helander, Juha KlefstrÃ¶m, Charles S. Craik, <span class="NLM_string-name hlFld-ContribAuthor">James W. Janetka</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 480-490. <a href="https://doi.org/10.1021/acs.jmedchem.8b01536" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01536</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01536%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSelective%252BMatriptase%252Band%252BHepsin%252BSerine%252BProtease%252BInhibitors%25253A%252BUseful%252BChemical%252BTools%252Bfor%252BCancer%252BCell%252BBiology%26aulast%3DDamalanka%26aufirst%3DVishnu%2BC.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D02102018%26date%3D04012019%26date%3D20122018%26volume%3D62%26issue%3D2%26spage%3D480%26epage%3D490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhengsheng Zhan, Xia Peng, Yiming Sun, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2018,</strong> <em>31 </em>
                                    (11)
                                     , 1213-1218. <a href="https://doi.org/10.1021/acs.chemrestox.8b00191" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.8b00191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.8b00191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.8b00191%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DEvaluation%252Bof%252BDeuterium-Labeled%252BJNJ38877605%25253A%252BPharmacokinetic%25252C%252BMetabolic%25252C%252Band%252Bin%252BVivo%252BAntitumor%252BProfiles%26aulast%3DZhan%26aufirst%3DZhengsheng%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18072018%26date%3D16102018%26date%3D04102018%26volume%3D31%26issue%3D11%26spage%3D1213%26epage%3D1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Li  Xie</span>, <span class="hlFld-ContribAuthor ">Lei  Xie</span>, and <span class="hlFld-ContribAuthor ">Philip E.  Bourne</span>  . </span><span class="cited-content_cbyCitation_article-title">Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (9)
                                     , 4326-4341. <a href="https://doi.org/10.1021/acs.jmedchem.5b02041" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b02041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b02041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b02041%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDelineation%252Bof%252BPolypharmacology%252Bacross%252Bthe%252BHuman%252BStructural%252BKinome%252BUsing%252Ba%252BFunctional%252BSite%252BInteraction%252BFingerprint%252BApproach%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D31122015%26date%3D17032016%26date%3D12052016%26date%3D01032016%26volume%3D59%26issue%3D9%26spage%3D4326%26epage%3D4341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel H.  Myers</span>, <span class="hlFld-ContribAuthor ">Valerie G.  Brunton</span>, and <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>  . </span><span class="cited-content_cbyCitation_article-title">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (8)
                                     , 3593-3608. <a href="https://doi.org/10.1021/acs.jmedchem.5b01273" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAXL%252BInhibitors%252Bin%252BCancer%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DMyers%26aufirst%3DSamuel%2BH.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D14082015%26date%3D20112015%26date%3D28042016%26date%3D10112015%26volume%3D59%26issue%3D8%26spage%3D3593%26epage%3D3608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandro A.  Boezio</span>, <span class="hlFld-ContribAuthor ">Katrina W.  Copeland</span>, <span class="hlFld-ContribAuthor ">Karen  Rex</span>, <span class="hlFld-ContribAuthor ">Brian  K. Albrecht</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Steven F.  Bellon</span>, <span class="hlFld-ContribAuthor ">Christiane  Boezio</span>, <span class="hlFld-ContribAuthor ">Martin A.  Broome</span>, <span class="hlFld-ContribAuthor ">Deborah  Choquette</span>, <span class="hlFld-ContribAuthor ">Angela  Coxon</span>, <span class="hlFld-ContribAuthor ">Isabelle  Dussault</span>, <span class="hlFld-ContribAuthor ">Satoko  Hirai</span>, <span class="hlFld-ContribAuthor ">Richard  Lewis</span>, <span class="hlFld-ContribAuthor ">Min-Hwa Jasmine  Lin</span>, <span class="hlFld-ContribAuthor ">Julia  Lohman</span>, <span class="hlFld-ContribAuthor ">Jingzhou  Liu</span>, <span class="hlFld-ContribAuthor ">Emily A.  Peterson</span>, <span class="hlFld-ContribAuthor ">Michele  Potashman</span>, <span class="hlFld-ContribAuthor ">Roman  Shimanovich</span>, <span class="hlFld-ContribAuthor ">Yohannes  Teffera</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Whittington</span>, <span class="hlFld-ContribAuthor ">Karina R.  Vaida</span>, and <span class="hlFld-ContribAuthor ">Jean-Christophe  Harmange</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (6)
                                     , 2328-2342. <a href="https://doi.org/10.1021/acs.jmedchem.5b01716" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01716%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%252529-6-%2525281-%2525288-Fluoro-6-%2525281-methyl-1H-pyrazol-4-yl%252529-%25255B1%25252C2%25252C4%25255Dtriazolo%25255B4%25252C3-a%25255Dpyridin-3-yl%252529ethyl%252529-3-%2525282-methoxyethoxy%252529-1%25252C6-naphthyridin-5%2525286H%252529-one%252B%252528AMG%252B337%252529%25252C%252Ba%252BPotent%252Band%252BSelective%252BInhibitor%252Bof%252BMET%252Bwith%252BHigh%252BUnbound%252BTarget%252BCoverage%252Band%252BRobust%252BIn%252BVivo%252BAntitumor%252BActivity%26aulast%3DBoezio%26aufirst%3DAlessandro%2BA.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D04112015%26date%3D11022016%26date%3D24032016%26date%3D26012016%26volume%3D59%26issue%3D6%26spage%3D2328%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emily A.  Peterson</span>, <span class="hlFld-ContribAuthor ">Yohannes  Teffera</span>, <span class="hlFld-ContribAuthor ">Brian K.  Albrecht</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Steven F.  Bellon</span>, <span class="hlFld-ContribAuthor ">Alessandro  Boezio</span>, <span class="hlFld-ContribAuthor ">Christiane  Boezio</span>, <span class="hlFld-ContribAuthor ">Martin A.  Broome</span>, <span class="hlFld-ContribAuthor ">Deborah  Choquette</span>, <span class="hlFld-ContribAuthor ">Katrina W.  Copeland</span>, <span class="hlFld-ContribAuthor ">Isabelle  Dussault</span>, <span class="hlFld-ContribAuthor ">Richard  Lewis</span>, <span class="hlFld-ContribAuthor ">Min-Hwa Jasmine  Lin</span>, <span class="hlFld-ContribAuthor ">Julia  Lohman</span>, <span class="hlFld-ContribAuthor ">Jingzhou  Liu</span>, <span class="hlFld-ContribAuthor ">Michele  Potashman</span>, <span class="hlFld-ContribAuthor ">Karen  Rex</span>, <span class="hlFld-ContribAuthor ">Roman  Shimanovich</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Whittington</span>, <span class="hlFld-ContribAuthor ">Karina R.  Vaida</span>, and <span class="hlFld-ContribAuthor ">Jean-Christophe  Harmange</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (5)
                                     , 2417-2430. <a href="https://doi.org/10.1021/jm501913a" title="DOI URL">https://doi.org/10.1021/jm501913a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501913a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501913a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252B8-Fluorotriazolopyridine%252Bc-Met%252BInhibitors%26aulast%3DPeterson%26aufirst%3DEmily%2BA.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D10122014%26date%3D03032015%26date%3D12032015%26date%3D20022015%26volume%3D58%26issue%3D5%26spage%3D2417%26epage%3D2430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuchi  Ma</span>, <span class="hlFld-ContribAuthor ">Guangqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Danqi  Chen</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Yue-Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Jin  Liang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Bing  Xiong</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Optimization of a Series of 1-Sulfonylpyrazolo[4,3-b]pyridines as Selective c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (5)
                                     , 2513-2529. <a href="https://doi.org/10.1021/jm502018y" title="DOI URL">https://doi.org/10.1021/jm502018y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm502018y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm502018y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BOptimization%252Bof%252Ba%252BSeries%252Bof%252B1-Sulfonylpyrazolo%25255B4%25252C3-b%25255Dpyridines%252Bas%252BSelective%252Bc-Met%252BInhibitors%26aulast%3DMa%26aufirst%3DYuchi%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D30122014%26date%3D25022015%26date%3D12032015%26date%3D10022015%26volume%3D58%26issue%3D5%26spage%3D2513%26epage%3D2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Jin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Shihe  Hu</span>, <span class="hlFld-ContribAuthor ">Huifang  Li</span>, <span class="hlFld-ContribAuthor ">Jinxing  Xu</span>, <span class="hlFld-ContribAuthor ">Yaning  Hu</span>, <span class="hlFld-ContribAuthor ">Xiao  Xiong</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, and <span class="hlFld-ContribAuthor ">Tao  Lu</span>  . </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling of Exquisitely Selective c-Met Inhibitors through 3D-QSAR and Molecular Dynamics Simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (9)
                                     , 2544-2554. <a href="https://doi.org/10.1021/ci500268s" title="DOI URL">https://doi.org/10.1021/ci500268s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500268s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500268s%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMolecular%252BModeling%252Bof%252BExquisitely%252BSelective%252Bc-Met%252BInhibitors%252Bthrough%252B3D-QSAR%252Band%252BMolecular%252BDynamics%252BSimulations%26aulast%3DYuan%26aufirst%3DHaoliang%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D05052014%26date%3D09092014%26date%3D22092014%26date%3D02092014%26volume%3D54%26issue%3D9%26spage%3D2544%26epage%3D2554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minke  Shi</span>, <span class="hlFld-ContribAuthor ">Jing  Ma</span>, <span class="hlFld-ContribAuthor ">Meilin  Feng</span>, <span class="hlFld-ContribAuthor ">Lei  Liang</span>, <span class="hlFld-ContribAuthor ">Hongyuan  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenghua  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study. </span><span class="cited-content_cbyCitation_journal-name">Cancer Genetics</span><span> <strong>2021,</strong> <em>256-257 </em>, 62-67. <a href="https://doi.org/10.1016/j.cancergen.2021.04.005" title="DOI URL">https://doi.org/10.1016/j.cancergen.2021.04.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cancergen.2021.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cancergen.2021.04.005%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Genetics%26atitle%3DNovel%252BMET%252Bexon%252B14%252Bskipping%252Banalogs%252Bcharacterized%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bpatients%25253A%252BA%252Bcase%252Bstudy%26aulast%3DShi%26aufirst%3DMinke%26date%3D2021%26volume%3D256-257%26spage%3D62%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuâjuan  Feng</span>, <span class="hlFld-ContribAuthor ">YuâLin  Ren</span>, <span class="hlFld-ContribAuthor ">LiâMing  Zhao</span>, <span class="hlFld-ContribAuthor ">GuoâQiang  Xue</span>, <span class="hlFld-ContribAuthor ">WenâHao  Yu</span>, <span class="hlFld-ContribAuthor ">JiaâQi  Yang</span>, <span class="hlFld-ContribAuthor ">JunâWei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel
              Î±âAcyloxycarboxamideâBased
              Derivatives as
              câMet
              Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2021,</strong> <em>39 </em>
                                    (8)
                                     , 2241-2250. <a href="https://doi.org/10.1002/cjoc.202100106" title="DOI URL">https://doi.org/10.1002/cjoc.202100106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.202100106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.202100106%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252B%2525CE%2525B1%2525E2%252580%252590Acyloxycarboxamide%2525E2%252580%252590Based%252BDerivatives%252Bas%252Bc%2525E2%252580%252590Met%252BInhibitors%26aulast%3DFeng%26aufirst%3DYu%25E2%2580%2590juan%26date%3D2021%26date%3D2021%26volume%3D39%26issue%3D8%26spage%3D2241%26epage%3D2250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philippe  Aftimos</span>, <span class="hlFld-ContribAuthor ">Christian  Rolfo</span>, <span class="hlFld-ContribAuthor ">Sylvie  Rottey</span>, <span class="hlFld-ContribAuthor ">Philippe  BarthÃ©lÃ©my</span>, <span class="hlFld-ContribAuthor ">Christophe  Borg</span>, <span class="hlFld-ContribAuthor ">Keunchil  Park</span>, <span class="hlFld-ContribAuthor ">Do-Youn  Oh</span>, <span class="hlFld-ContribAuthor ">Sang-We  Kim</span>, <span class="hlFld-ContribAuthor ">Natalie  De Jonge</span>, <span class="hlFld-ContribAuthor ">ValÃ©rie  Hanssens</span>, <span class="hlFld-ContribAuthor ">Karen  Zwanenpoel</span>, <span class="hlFld-ContribAuthor ">Carla  Molthoff</span>, <span class="hlFld-ContribAuthor ">DaniÃ«lle  Vugts</span>, <span class="hlFld-ContribAuthor ">Torsten  Dreier</span>, <span class="hlFld-ContribAuthor ">Peter  Verheesen</span>, <span class="hlFld-ContribAuthor ">Guus A.M.S.  van Dongen</span>, <span class="hlFld-ContribAuthor ">Julie  Jacobs</span>, <span class="hlFld-ContribAuthor ">Luc  Van Rompaey</span>, <span class="hlFld-ContribAuthor ">Anna  Hultberg</span>, <span class="hlFld-ContribAuthor ">Paolo  Michieli</span>, <span class="hlFld-ContribAuthor ">Patrick  Pauwels</span>, <span class="hlFld-ContribAuthor ">Samson  Fung</span>, <span class="hlFld-ContribAuthor ">Alain  Thibault</span>, <span class="hlFld-ContribAuthor ">Hans  de Haard</span>, <span class="hlFld-ContribAuthor ">Nicolas  Leupin</span>, <span class="hlFld-ContribAuthor ">Ahmad  Awada</span>. </span><span class="cited-content_cbyCitation_article-title">The NHanceÂ® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2021,</strong> <em>9 </em>
                                    (6)
                                     , 665. <a href="https://doi.org/10.3390/biomedicines9060665" title="DOI URL">https://doi.org/10.3390/biomedicines9060665</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines9060665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines9060665%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DThe%252BNHance%2525C2%2525AE%252BMutation-Equipped%252BAnti-MET%252BAntibody%252BARGX-111%252BDisplays%252BIncreased%252BTissue%252BPenetration%252Band%252BAnti-Tumor%252BActivity%252Bin%252BAdvanced%252BCancer%252BPatients%26aulast%3DAftimos%26aufirst%3DPhilippe%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D6%26spage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuting  Guo</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Yitong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhengsheng  Zhan</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of triazolotriazine derivatives as c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>25 </em>
                                    (2)
                                     , 839-846. <a href="https://doi.org/10.1007/s11030-020-10067-5" title="DOI URL">https://doi.org/10.1007/s11030-020-10067-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10067-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10067-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Bof%252Btriazolotriazine%252Bderivatives%252Bas%252Bc-Met%252Binhibitors%26aulast%3DGuo%26aufirst%3DYuting%26date%3D2021%26date%3D2020%26volume%3D25%26issue%3D2%26spage%3D839%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianqing  Zhang</span>, <span class="hlFld-ContribAuthor ">Pengqin  Chen</span>, <span class="hlFld-ContribAuthor ">Yongli  Duan</span>, <span class="hlFld-ContribAuthor ">Hehua  Xiong</span>, <span class="hlFld-ContribAuthor ">Hongmin  Li</span>, <span class="hlFld-ContribAuthor ">Yao  Zeng</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>, <span class="hlFld-ContribAuthor ">Qidong  Tang</span>, <span class="hlFld-ContribAuthor ">Di  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113273. <a href="https://doi.org/10.1016/j.ejmech.2021.113273" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113273%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bcontaining%252B1%25252C8-naphthyridine-4-one%252Bfragment%26aulast%3DZhang%26aufirst%3DJianqing%26date%3D2021%26volume%3D215%26spage%3D113273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junâich  Mori</span>, <span class="hlFld-ContribAuthor ">Keishi  Adachi</span>, <span class="hlFld-ContribAuthor ">Yukimi  Sakoda</span>, <span class="hlFld-ContribAuthor ">Takahiro  Sasaki</span>, <span class="hlFld-ContribAuthor ">Shunsuke  Goto</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Yoji  Nagashima</span>, <span class="hlFld-ContribAuthor ">Hideyasu  Matsuyama</span>, <span class="hlFld-ContribAuthor ">Koji  Tamada</span>. </span><span class="cited-content_cbyCitation_article-title">Antiâtumor efficacy of human antiâcâmet CARâT cells against papillary renal cell carcinoma in an orthotopic model. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2021,</strong> <em>112 </em>
                                    (4)
                                     , 1417-1428. <a href="https://doi.org/10.1111/cas.14835" title="DOI URL">https://doi.org/10.1111/cas.14835</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.14835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.14835%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DAnti%2525E2%252580%252590tumor%252Befficacy%252Bof%252Bhuman%252Banti%2525E2%252580%252590c%2525E2%252580%252590met%252BCAR%2525E2%252580%252590T%252Bcells%252Bagainst%252Bpapillary%252Brenal%252Bcell%252Bcarcinoma%252Bin%252Ban%252Borthotopic%252Bmodel%26aulast%3DMori%26aufirst%3DJun%25E2%2580%2590ich%26date%3D2021%26date%3D2021%26volume%3D112%26issue%3D4%26spage%3D1417%26epage%3D1428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meet  Patel</span>, <span class="hlFld-ContribAuthor ">Adam  Eckburg</span>, <span class="hlFld-ContribAuthor ">Shahina  Gantiwala</span>, <span class="hlFld-ContribAuthor ">Zachary  Hart</span>, <span class="hlFld-ContribAuthor ">Joshua  Dein</span>, <span class="hlFld-ContribAuthor ">Katie  Lam</span>, <span class="hlFld-ContribAuthor ">Neelu  Puri</span>. </span><span class="cited-content_cbyCitation_article-title">Resistance to Molecularly Targeted Therapies in Melanoma. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 1115. <a href="https://doi.org/10.3390/cancers13051115" title="DOI URL">https://doi.org/10.3390/cancers13051115</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13051115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13051115%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DResistance%252Bto%252BMolecularly%252BTargeted%252BTherapies%252Bin%252BMelanoma%26aulast%3DPatel%26aufirst%3DMeet%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raju Suresh  Kumar</span>, <span class="hlFld-ContribAuthor ">Abdulrahman I.  Almansour</span>, <span class="hlFld-ContribAuthor ">Natarajan  Arumugam</span>, <span class="hlFld-ContribAuthor ">D.  Kotresha</span>, <span class="hlFld-ContribAuthor ">J. Carlos  MenÃ©ndez</span>, <span class="hlFld-ContribAuthor ">Raju Ranjith  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Ionic liquid mediated synthesis and
              in vitro
              mechanistic exploration of polycyclic cageâlike heterocyclic hybrid. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2021,</strong> <em>58 </em>
                                    (2)
                                     , 580-588. <a href="https://doi.org/10.1002/jhet.4197" title="DOI URL">https://doi.org/10.1002/jhet.4197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4197%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DIonic%252Bliquid%252Bmediated%252Bsynthesis%252Band%252Bin%252Bvitro%252Bmechanistic%252Bexploration%252Bof%252Bpolycyclic%252Bcage%2525E2%252580%252590like%252Bheterocyclic%252Bhybrid%26aulast%3DKumar%26aufirst%3DRaju%2BSuresh%26date%3D2021%26date%3D2020%26volume%3D58%26issue%3D2%26spage%3D580%26epage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianqing  Zhang</span>, <span class="hlFld-ContribAuthor ">Hehua  Xiong</span>, <span class="hlFld-ContribAuthor ">Feiyi  Yang</span>, <span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Ting  Chen</span>, <span class="hlFld-ContribAuthor ">Dongxue  Fu</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Qidong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 4-(pyrrolo[2,3-d]pyrimidine-4-yloxy)benzamide derivatives as potential antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>33 </em>, 127740. <a href="https://doi.org/10.1016/j.bmcl.2020.127740" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127740</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127740%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B4-%252528pyrrolo%25255B2%25252C3-d%25255Dpyrimidine-4-yloxy%252529benzamide%252Bderivatives%252Bas%252Bpotential%252Bantitumor%252Bagents%26aulast%3DZhang%26aufirst%3DJianqing%26date%3D2021%26volume%3D33%26spage%3D127740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuting  Zhou</span>, <span class="hlFld-ContribAuthor ">Xingwei  Xu</span>, <span class="hlFld-ContribAuthor ">Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Huan  He</span>, <span class="hlFld-ContribAuthor ">Baohui  Qi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>106 </em>, 104511. <a href="https://doi.org/10.1016/j.bioorg.2020.104511" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104511%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-%252528%2525284-%2525284-%2525283-%2525282-%2525282%25252C6-difluorophenyl%252529-4-oxothiazolidin-3-yl%252529ureido%252529-2-fluorophenoxy%252529-6-methoxyquinolin-7-yl%252529oxy%252529-N%25252CN-diethylpiperidine-1-carboxamide%252Bas%252Bkinase%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Bcolorectal%252Bcancer%26aulast%3DZhou%26aufirst%3DYuting%26date%3D2021%26volume%3D106%26spage%3D104511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qianwen  Ye</span>, <span class="hlFld-ContribAuthor ">Chenggong  Fu</span>, <span class="hlFld-ContribAuthor ">Jiazhong  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (1)
                                     , 52. <a href="https://doi.org/10.3390/molecules26010052" title="DOI URL">https://doi.org/10.3390/molecules26010052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26010052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26010052%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DStudying%252Bthe%252BBinding%252BModes%252Bof%252BNovel%252B2-Aminopyridine%252BDerivatives%252Bas%252BEffective%252Band%252BSelective%252Bc-Met%252BKinase%252BType%252B1%252BInhibitors%252BUsing%252BMolecular%252BModeling%252BApproaches%26aulast%3DYe%26aufirst%3DQianwen%26date%3D2021%26date%3D2020%26volume%3D26%26issue%3D1%26spage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuhong  Dong</span>, <span class="hlFld-ContribAuthor ">Hao  Hu</span>, <span class="hlFld-ContribAuthor ">Yuwei  Sun</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (23)
                                     , 127610. <a href="https://doi.org/10.1016/j.bmcl.2020.127610" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127610%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bc-Met%25252FHDAC%252Bdual%252Binhibitors%26aulast%3DDong%26aufirst%3DYuhong%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin-Sheng  Zhuo</span>, <span class="hlFld-ContribAuthor ">Feng-Xu  Wu</span>, <span class="hlFld-ContribAuthor ">Ming-Shu  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-Chuang  Xu</span>, <span class="hlFld-ContribAuthor ">Fan-Peng  Yang</span>, <span class="hlFld-ContribAuthor ">Yan-Guang  Tian</span>, <span class="hlFld-ContribAuthor ">Xing-E.  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhi-Hui  Ming</span>, <span class="hlFld-ContribAuthor ">Xiao-Lei  Zhu</span>, <span class="hlFld-ContribAuthor ">Ge-Fei  Hao</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Structureâactivity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112785. <a href="https://doi.org/10.1016/j.ejmech.2020.112785" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112785</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112785%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593activity%252Brelationship%252Bstudy%252Bof%252Bnovel%252Bquinazoline-based%252B1%25252C6-naphthyridinones%252Bas%252BMET%252Binhibitors%252Bwith%252Bpotent%252Bantitumor%252Befficacy%26aulast%3DZhuo%26aufirst%3DLin-Sheng%26date%3D2020%26volume%3D208%26spage%3D112785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guolin  Luo</span>, <span class="hlFld-ContribAuthor ">Yanxia  Ma</span>, <span class="hlFld-ContribAuthor ">Xintong  Liang</span>, <span class="hlFld-ContribAuthor ">Guoquan  Xie</span>, <span class="hlFld-ContribAuthor ">Yingqi  Luo</span>, <span class="hlFld-ContribAuthor ">Dailong  Zha</span>, <span class="hlFld-ContribAuthor ">Sheng  Wang</span>, <span class="hlFld-ContribAuthor ">Lihong  Yu</span>, <span class="hlFld-ContribAuthor ">Xuehua  Zheng</span>, <span class="hlFld-ContribAuthor ">Wenhao  Wu</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104356. <a href="https://doi.org/10.1016/j.bioorg.2020.104356" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104356</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104356%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bevaluation%252Bof%252Bnovel%252B5-methylpyrazolo%25255B1%25252C5-a%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotential%252Bc-Met%252Binhibitors%26aulast%3DLuo%26aufirst%3DGuolin%26date%3D2020%26volume%3D104%26spage%3D104356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiyan  Yang</span>, <span class="hlFld-ContribAuthor ">Zhen  Zhou</span>, <span class="hlFld-ContribAuthor ">Li  Lin</span>, <span class="hlFld-ContribAuthor ">Mingxia  Yang</span>, <span class="hlFld-ContribAuthor ">Chong  Li</span>, <span class="hlFld-ContribAuthor ">Ziming  Li</span>, <span class="hlFld-ContribAuthor ">Xinmin  Yu</span>, <span class="hlFld-ContribAuthor ">Analyn  Lizaso</span>, <span class="hlFld-ContribAuthor ">Han  Han-Zhang</span>, <span class="hlFld-ContribAuthor ">Bing  Li</span>, <span class="hlFld-ContribAuthor ">Jianxing  Xiang</span>, <span class="hlFld-ContribAuthor ">Xinru  Mao</span>, <span class="hlFld-ContribAuthor ">Qinqin  Xu</span>, <span class="hlFld-ContribAuthor ">Yongchang  Zhang</span>, <span class="hlFld-ContribAuthor ">Nong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers. </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer</span><span> <strong>2020,</strong> <em>148 </em>, 113-121. <a href="https://doi.org/10.1016/j.lungcan.2020.08.009" title="DOI URL">https://doi.org/10.1016/j.lungcan.2020.08.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lungcan.2020.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lungcan.2020.08.009%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%26atitle%3DCharacterization%252Bof%252BMET%252Bexon%252B14%252Balteration%252Band%252Bassociation%252Bwith%252Bclinical%252Boutcomes%252Bof%252Bcrizotinib%252Bin%252BChinese%252Blung%252Bcancers%26aulast%3DYang%26aufirst%3DHaiyan%26date%3D2020%26volume%3D148%26spage%3D113%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth Qian Xu  Mulcahy</span>, <span class="hlFld-ContribAuthor ">Rossymar Rivera  ColÏn</span>, <span class="hlFld-ContribAuthor ">Roger  Abounader</span>. </span><span class="cited-content_cbyCitation_article-title">HGF/MET Signaling in Malignant Brain Tumors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (20)
                                     , 7546. <a href="https://doi.org/10.3390/ijms21207546" title="DOI URL">https://doi.org/10.3390/ijms21207546</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21207546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21207546%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DHGF%25252FMET%252BSignaling%252Bin%252BMalignant%252BBrain%252BTumors%26aulast%3DMulcahy%26aufirst%3DElizabeth%2BQian%2BXu%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D20%26spage%3D7546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Somayeh  Pirhadi</span>, <span class="hlFld-ContribAuthor ">Tahereh  Damghani</span>, <span class="hlFld-ContribAuthor ">Mohammad Sadegh  Avestan</span>, <span class="hlFld-ContribAuthor ">Shahrzad  Sharifi</span>. </span><span class="cited-content_cbyCitation_article-title">Dual potent c-Met and ALK inhibitors: from common feature pharmacophore modeling to structure based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2020,</strong> <em>40 </em>
                                    (4)
                                     , 357-364. <a href="https://doi.org/10.1080/10799893.2020.1735418" title="DOI URL">https://doi.org/10.1080/10799893.2020.1735418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2020.1735418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2020.1735418%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DDual%252Bpotent%252Bc-Met%252Band%252BALK%252Binhibitors%25253A%252Bfrom%252Bcommon%252Bfeature%252Bpharmacophore%252Bmodeling%252Bto%252Bstructure%252Bbased%252Bvirtual%252Bscreening%26aulast%3DPirhadi%26aufirst%3DSomayeh%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D4%26spage%3D357%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toshio  Fujino</span>, <span class="hlFld-ContribAuthor ">Kenichi  Suda</span>, <span class="hlFld-ContribAuthor ">Tetsuya  Mitsudomi</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Emerging Drugs</span><span> <strong>2020,</strong> <em>25 </em>
                                    (3)
                                     , 229-249. <a href="https://doi.org/10.1080/14728214.2020.1791821" title="DOI URL">https://doi.org/10.1080/14728214.2020.1791821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728214.2020.1791821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728214.2020.1791821%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Emerging%2520Drugs%26atitle%3DEmerging%252BMET%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DFujino%26aufirst%3DToshio%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D3%26spage%3D229%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fengxu  Wu</span>, <span class="hlFld-ContribAuthor ">Linsheng  Zhuo</span>, <span class="hlFld-ContribAuthor ">Fan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Gefei  Hao</span>, <span class="hlFld-ContribAuthor ">Guangfu  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Auto In Silico Ligand Directing Evolution to Facilitate the Rapid and Efficient Discovery of Drug Lead. </span><span class="cited-content_cbyCitation_journal-name">iScience</span><span> <strong>2020,</strong> <em>23 </em>
                                    (6)
                                     , 101179. <a href="https://doi.org/10.1016/j.isci.2020.101179" title="DOI URL">https://doi.org/10.1016/j.isci.2020.101179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.isci.2020.101179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.isci.2020.101179%26sid%3Dliteratum%253Aachs%26jtitle%3DiScience%26atitle%3DAuto%252BIn%252BSilico%252BLigand%252BDirecting%252BEvolution%252Bto%252BFacilitate%252Bthe%252BRapid%252Band%252BEfficient%252BDiscovery%252Bof%252BDrug%252BLead%26aulast%3DWu%26aufirst%3DFengxu%26date%3D2020%26volume%3D23%26issue%3D6%26spage%3D101179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">YuâQin  Mao</span>, <span class="hlFld-ContribAuthor ">SanâFeng  Han</span>, <span class="hlFld-ContribAuthor ">ShiâLong  Zhang</span>, <span class="hlFld-ContribAuthor ">ZhengâYan  Zhang</span>, <span class="hlFld-ContribAuthor ">ChaoâYue  Kong</span>, <span class="hlFld-ContribAuthor ">HuiâLing  Chen</span>, <span class="hlFld-ContribAuthor ">ZhanâMing  Li</span>, <span class="hlFld-ContribAuthor ">PeiâRan  Cai</span>, <span class="hlFld-ContribAuthor ">Bing  Han</span>, <span class="hlFld-ContribAuthor ">LiâShun  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">An approach using
              Caenorhabditis elegans
              screening novel targets to suppress tumour cell proliferation. </span><span class="cited-content_cbyCitation_journal-name">Cell Proliferation</span><span> <strong>2020,</strong> <em>53 </em>
                                    (6)
                                     <a href="https://doi.org/10.1111/cpr.12832" title="DOI URL">https://doi.org/10.1111/cpr.12832</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cpr.12832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcpr.12832%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Proliferation%26atitle%3DAn%252Bapproach%252Busing%252BCaenorhabditis%252Belegans%252Bscreening%252Bnovel%252Btargets%252Bto%252Bsuppress%252Btumour%252Bcell%252Bproliferation%26aulast%3DMao%26aufirst%3DYu%25E2%2580%2590Qin%26date%3D2020%26date%3D2020%26volume%3D53%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramon Andrade  De Mello</span>, <span class="hlFld-ContribAuthor ">NathÃ¡lia MoisÃ©s  Neves</span>, <span class="hlFld-ContribAuthor ">Giovanna AraÃºjo  Amaral</span>, <span class="hlFld-ContribAuthor ">Estela Gudin  Lippo</span>, <span class="hlFld-ContribAuthor ">Pedro  Castelo-Branco</span>, <span class="hlFld-ContribAuthor ">Daniel Humberto  Pozza</span>, <span class="hlFld-ContribAuthor ">Carla Chizuru  Tajima</span>, <span class="hlFld-ContribAuthor ">Georgios  Antoniou</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2020,</strong> <em>9 </em>
                                    (6)
                                     , 1918. <a href="https://doi.org/10.3390/jcm9061918" title="DOI URL">https://doi.org/10.3390/jcm9061918</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm9061918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm9061918%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DThe%252BRole%252Bof%252BMET%252BInhibitor%252BTherapies%252Bin%252Bthe%252BTreatment%252Bof%252BAdvanced%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DDe%2BMello%26aufirst%3DRamon%2BAndrade%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D6%26spage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016âPresent). </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (11)
                                     , 2666. <a href="https://doi.org/10.3390/molecules25112666" title="DOI URL">https://doi.org/10.3390/molecules25112666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25112666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25112666%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DResearch%252BProgress%252Bof%252BSmall%252BMolecule%252BVEGFR%25252Fc-Met%252BInhibitors%252Bas%252BAnticancer%252BAgents%252B%2525282016%2525E2%252580%252593Present%252529%26aulast%3DZhang%26aufirst%3DQian%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D11%26spage%3D2666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Li</span>, <span class="hlFld-ContribAuthor ">Jiaojiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiantao  Shi</span>, <span class="hlFld-ContribAuthor ">Shi  Ding</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ye  Chen</span>, <span class="hlFld-ContribAuthor ">Ju  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (5)
                                     , 559-570. <a href="https://doi.org/10.2174/1871520620666200101143307" title="DOI URL">https://doi.org/10.2174/1871520620666200101143307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520620666200101143307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520620666200101143307%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252B4-phenoxypyridine%252BDerivatives%252BContaining%252BSemicarbazones%252BMoiety%252Bas%252BPotential%252Bc-Met%252BKinase%252BInhibitors%26aulast%3DLi%26aufirst%3DJun%26date%3D2020%26volume%3D20%26issue%3D5%26spage%3D559%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing  Huang</span>, <span class="hlFld-ContribAuthor ">Enliang  Li</span>, <span class="hlFld-ContribAuthor ">Hang  Shen</span>, <span class="hlFld-ContribAuthor ">Xun  Wang</span>, <span class="hlFld-ContribAuthor ">Tianyu  Tang</span>, <span class="hlFld-ContribAuthor ">Xiaozhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Xu</span>, <span class="hlFld-ContribAuthor ">Zengwei  Tang</span>, <span class="hlFld-ContribAuthor ">Chengxiang  Guo</span>, <span class="hlFld-ContribAuthor ">Xueli  Bai</span>, <span class="hlFld-ContribAuthor ">Tingbo  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcell.2020.00152" title="DOI URL">https://doi.org/10.3389/fcell.2020.00152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2020.00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2020.00152%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DTargeting%252Bthe%252BHGF%25252FMET%252BAxis%252Bin%252BCancer%252BTherapy%25253A%252BChallenges%252Bin%252BResistance%252Band%252BOpportunities%252Bfor%252BImprovement%26aulast%3DHuang%26aufirst%3DXing%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">Ruihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Zhang</span>, <span class="hlFld-ContribAuthor ">Peiyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Tuanli  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">SilverâCatalyzed Decarboxylative Allylation of Difluoroarylacetic Acids with Allyl Sulfones in Water. </span><span class="cited-content_cbyCitation_journal-name">Chemistry â An Asian Journal</span><span> <strong>2020,</strong> <em>15 </em>
                                    (7)
                                     , 1175-1179. <a href="https://doi.org/10.1002/asia.202000059" title="DOI URL">https://doi.org/10.1002/asia.202000059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.202000059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.202000059%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520An%2520Asian%2520Journal%26atitle%3DSilver%2525E2%252580%252590Catalyzed%252BDecarboxylative%252BAllylation%252Bof%252BDifluoroarylacetic%252BAcids%252Bwith%252BAllyl%252BSulfones%252Bin%252BWater%26aulast%3DLi%26aufirst%3DXiang%26date%3D2020%26volume%3D15%26issue%3D7%26spage%3D1175%26epage%3D1179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima Ezzahra  Bennani</span>, <span class="hlFld-ContribAuthor ">Latifa  Doudach</span>, <span class="hlFld-ContribAuthor ">Yahia  Cherrah</span>, <span class="hlFld-ContribAuthor ">Youssef  Ramli</span>, <span class="hlFld-ContribAuthor ">Khalid  Karrouchi</span>, <span class="hlFld-ContribAuthor ">M'hammed  Ansar</span>, <span class="hlFld-ContribAuthor ">My El Abbes  Faouzi</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>97 </em>, 103470. <a href="https://doi.org/10.1016/j.bioorg.2019.103470" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103470%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DOverview%252Bof%252Brecent%252Bdevelopments%252Bof%252Bpyrazole%252Bderivatives%252Bas%252Ban%252Banticancer%252Bagent%252Bin%252Bdifferent%252Bcell%252Bline%26aulast%3DBennani%26aufirst%3DFatima%2BEzzahra%26date%3D2020%26volume%3D97%26spage%3D103470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Chen</span>, <span class="hlFld-ContribAuthor ">Lin-Sheng  Zhuo</span>, <span class="hlFld-ContribAuthor ">Peng-Fei  Liu</span>, <span class="hlFld-ContribAuthor ">Wei-Rong  Fang</span>, <span class="hlFld-ContribAuthor ">Yun-Man  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112174. <a href="https://doi.org/10.1016/j.ejmech.2020.112174" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112174</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112174%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1%25252C6-naphthyridinone-based%252BMET%252Bkinase%252Binhibitor%252Bbearing%252Bquinoline%252Bmoiety%252Bas%252Bpromising%252Bantitumor%252Bdrug%252Bcandidate%26aulast%3DChen%26aufirst%3DTao%26date%3D2020%26volume%3D192%26spage%3D112174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tahereh  Damghani</span>, <span class="hlFld-ContribAuthor ">Tahereh  Sedghamiz</span>, <span class="hlFld-ContribAuthor ">Shahrzad  Sharifi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Pirhadi</span>. </span><span class="cited-content_cbyCitation_article-title">Critical c-Met-inhibitor interactions resolved from molecular dynamics simulations of different c-Met complexes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1203 </em>, 127456. <a href="https://doi.org/10.1016/j.molstruc.2019.127456" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.127456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.127456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.127456%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DCritical%252Bc-Met-inhibitor%252Binteractions%252Bresolved%252Bfrom%252Bmolecular%252Bdynamics%252Bsimulations%252Bof%252Bdifferent%252Bc-Met%252Bcomplexes%26aulast%3DDamghani%26aufirst%3DTahereh%26date%3D2020%26volume%3D1203%26spage%3D127456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emmanuel  Bresso</span>, <span class="hlFld-ContribAuthor ">Alessandro  Furlan</span>, <span class="hlFld-ContribAuthor ">Philippe  Noel</span>, <span class="hlFld-ContribAuthor ">Vincent  Leroux</span>, <span class="hlFld-ContribAuthor ">Flavio  Maina</span>, <span class="hlFld-ContribAuthor ">Rosanna  Dono</span>, <span class="hlFld-ContribAuthor ">Bernard  Maigret</span>. </span><span class="cited-content_cbyCitation_article-title">Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (4)
                                     , 938. <a href="https://doi.org/10.3390/molecules25040938" title="DOI URL">https://doi.org/10.3390/molecules25040938</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25040938%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DLarge-Scale%252BVirtual%252BScreening%252BAgainst%252Bthe%252BMET%252BKinase%252BDomain%252BIdentifies%252Ba%252BNew%252BPutative%252BInhibitor%252BType%26aulast%3DBresso%26aufirst%3DEmmanuel%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D4%26spage%3D938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sapana Sameer  Chaudhary</span>, <span class="hlFld-ContribAuthor ">Sameer  Choudhary</span>, <span class="hlFld-ContribAuthor ">Sakshi  Rawat</span>, <span class="hlFld-ContribAuthor ">Gouri  Ahir</span>, <span class="hlFld-ContribAuthor ">Anwar L.  Bilgrami</span>, <span class="hlFld-ContribAuthor ">Ghulam Md  Ashraf</span>. </span><span class="cited-content_cbyCitation_article-title">c-Met as a potential therapeutic target in triple negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 295-326. <a href="https://doi.org/10.1016/B978-0-12-818168-3.00011-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-818168-3.00011-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818168-3.00011-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818168-3.00011-5%26sid%3Dliteratum%253Aachs%26atitle%3Dc-Met%252Bas%252Ba%252Bpotential%252Btherapeutic%252Btarget%252Bin%252Btriple%252Bnegative%252Bbreast%252Bcancer%26aulast%3DChaudhary%26aufirst%3DSapana%2BSameer%26date%3D2020%26spage%3D295%26epage%3D326%26pub%3DElsevier%26atitle%3DCancer-Leading%252BProteases%26date%3D2020%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raeva  Malik</span>, <span class="hlFld-ContribAuthor ">Isa  Mambetsariev</span>, <span class="hlFld-ContribAuthor ">Jeremy  Fricke</span>, <span class="hlFld-ContribAuthor ">Neal  Chawla</span>, <span class="hlFld-ContribAuthor ">Arin  Nam</span>, <span class="hlFld-ContribAuthor ">Rebecca  Pharaon</span>, <span class="hlFld-ContribAuthor ">Ravi  Salgia</span>. </span><span class="cited-content_cbyCitation_article-title">MET receptor in oncology: From biomarker to therapeutic target. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 259-301. <a href="https://doi.org/10.1016/bs.acr.2020.04.006" title="DOI URL">https://doi.org/10.1016/bs.acr.2020.04.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.acr.2020.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.acr.2020.04.006%26sid%3Dliteratum%253Aachs%26atitle%3DMET%252Breceptor%252Bin%252Boncology%25253A%252BFrom%252Bbiomarker%252Bto%252Btherapeutic%252Btarget%26aulast%3DMalik%26aufirst%3DRaeva%26date%3D2020%26spage%3D259%26epage%3D301%26pub%3DElsevier%26atitle%3DReceptor%252BTyrosine%252BKinases%26date%3D2020%26volume%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Shu  Wang</span>, <span class="hlFld-ContribAuthor ">Lin-Sheng  Zhuo</span>, <span class="hlFld-ContribAuthor ">Fan-Peng  Yang</span>, <span class="hlFld-ContribAuthor ">Wen-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Guang-Fu  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111803. <a href="https://doi.org/10.1016/j.ejmech.2019.111803" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111803</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111803%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252BMET%252Binhibitors%252Bwith%252B1%25252C6-naphthyridinone%252Bscaffold%26aulast%3DWang%26aufirst%3DMing-Shu%26date%3D2020%26volume%3D185%26spage%3D111803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olivier  Bylicki</span>, <span class="hlFld-ContribAuthor ">Nicolas  Paleiron</span>, <span class="hlFld-ContribAuthor ">Jean-Baptiste  AssiÃ©</span>, <span class="hlFld-ContribAuthor ">Christos  ChouaÃ¯d</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Targeting the MET-Signaling Pathway in Non-SmallâCell Lung Cancer: Evidence to Date</p>. </span><span class="cited-content_cbyCitation_journal-name">OncoTargets and Therapy</span><span> <strong>2020,</strong> <em>Volume 13 </em>, 5691-5706. <a href="https://doi.org/10.2147/OTT.S219959" title="DOI URL">https://doi.org/10.2147/OTT.S219959</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/OTT.S219959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FOTT.S219959%26sid%3Dliteratum%253Aachs%26jtitle%3DOncoTargets%2520and%2520Therapy%26atitle%3D%25253Cp%25253ETargeting%252Bthe%252BMET-Signaling%252BPathway%252Bin%252BNon-Small%2525E2%252580%252593Cell%252BLung%252BCancer%25253A%252BEvidence%252Bto%252BDate%25253C%25252Fp%25253E%26aulast%3DBylicki%26aufirst%3DOlivier%26date%3D2020%26date%3D2020%26volume%3DVolume%252013%26spage%3D5691%26epage%3D5706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Korosh  Mashayekh</span>, <span class="hlFld-ContribAuthor ">Shahrzad  Sharifi</span>, <span class="hlFld-ContribAuthor ">Tahereh  Damghani</span>, <span class="hlFld-ContribAuthor ">Maryam  Elyasi</span>, <span class="hlFld-ContribAuthor ">Mohammad S.  Avestan</span>, <span class="hlFld-ContribAuthor ">Somayeh  Pirhadi</span>. </span><span class="cited-content_cbyCitation_article-title">Clustering and Sampling of the c-Met Conformational Space: A Computational Drug Discovery Study. </span><span class="cited-content_cbyCitation_journal-name">Combinatorial Chemistry & High Throughput Screening</span><span> <strong>2020,</strong> <em>22 </em>
                                    (9)
                                     , 635-648. <a href="https://doi.org/10.2174/1386207322666191024103902" title="DOI URL">https://doi.org/10.2174/1386207322666191024103902</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1386207322666191024103902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1386207322666191024103902%26sid%3Dliteratum%253Aachs%26jtitle%3DCombinatorial%2520Chemistry%2520%2526%2520High%2520Throughput%2520Screening%26atitle%3DClustering%252Band%252BSampling%252Bof%252Bthe%252Bc-Met%252BConformational%252BSpace%25253A%252BA%252BComputational%252BDrug%252BDiscovery%252BStudy%26aulast%3DMashayekh%26aufirst%3DKorosh%26date%3D2020%26volume%3D22%26issue%3D9%26spage%3D635%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingyuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yinhe  Wang</span>, <span class="hlFld-ContribAuthor ">Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Wanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yakun  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Yang</span>, <span class="hlFld-ContribAuthor ">Yunxia  Cao</span>, <span class="hlFld-ContribAuthor ">Siying  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway. </span><span class="cited-content_cbyCitation_journal-name">Cancer Biology & Therapy</span><span> <strong>2019,</strong> <em>20 </em>
                                    (12)
                                     , 1430-1442. <a href="https://doi.org/10.1080/15384047.2019.1647051" title="DOI URL">https://doi.org/10.1080/15384047.2019.1647051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15384047.2019.1647051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15384047.2019.1647051%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Biology%2520%2526%2520Therapy%26atitle%3DC7%252Bpeptide%252Binhibits%252Bhepatocellular%252Bcarcinoma%252Bmetastasis%252Bby%252Btargeting%252Bthe%252BHGF%25252Fc-Met%252Bsignaling%252Bpathway%26aulast%3DZhao%26aufirst%3DMingyuan%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D12%26spage%3D1430%26epage%3D1442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yin  Huaqi</span>, <span class="hlFld-ContribAuthor ">Qin  Caipeng</span>, <span class="hlFld-ContribAuthor ">Wang  Qiang</span>, <span class="hlFld-ContribAuthor ">Du  Yiqing</span>, <span class="hlFld-ContribAuthor ">Dai  Xiang</span>, <span class="hlFld-ContribAuthor ">Tang  Xu</span>, <span class="hlFld-ContribAuthor ">Zhang  Xiaowei</span>, <span class="hlFld-ContribAuthor ">Li  Qing</span>, <span class="hlFld-ContribAuthor ">Liu  Shijun</span>, <span class="hlFld-ContribAuthor ">Xu  Tao</span>. </span><span class="cited-content_cbyCitation_article-title">Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2019,</strong> <em>18 </em>
                                    (12)
                                     , 2433-2445. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0043" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0043%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DTranscription%252BFactor%252BSOX18%252BPromotes%252BClear%252BCell%252BRenal%252BCell%252BCarcinoma%252BProgression%252Band%252BAlleviates%252BCabozantinib-Mediated%252BInhibitory%252BEffects%26aulast%3DHuaqi%26aufirst%3DYin%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D12%26spage%3D2433%26epage%3D2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiyan  Sun</span>, <span class="hlFld-ContribAuthor ">Linsheng  Zhuo</span>, <span class="hlFld-ContribAuthor ">Huan  Dong</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Nengfang  She</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (24)
                                     , 4461. <a href="https://doi.org/10.3390/molecules24244461" title="DOI URL">https://doi.org/10.3390/molecules24244461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24244461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24244461%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDiscovery%252Bof%252B8-Amino-Substituted%252B2-Phenyl-2%25252C7-Naphthyridinone%252BDerivatives%252Bas%252BNew%252Bc-Kit%25252FVEGFR-2%252BKinase%252BInhibitors%26aulast%3DSun%26aufirst%3DHaiyan%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D24%26spage%3D4461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vegard Torp  Lien</span>, <span class="hlFld-ContribAuthor ">Margrethe Konstanse  Kristiansen</span>, <span class="hlFld-ContribAuthor ">Solveig  Pettersen</span>, <span class="hlFld-ContribAuthor ">Mads Haugland  Haugen</span>, <span class="hlFld-ContribAuthor ">Dag Erlend  Olberg</span>, <span class="hlFld-ContribAuthor ">Jo  Waaler</span>, <span class="hlFld-ContribAuthor ">Jo  Klaveness</span>. </span><span class="cited-content_cbyCitation_article-title">Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (63)
                                     , 37092-37100. <a href="https://doi.org/10.1039/C9RA08954C" title="DOI URL">https://doi.org/10.1039/C9RA08954C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA08954C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA08954C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DTowards%252Bdual%252Binhibitors%252Bof%252Bthe%252BMET%252Bkinase%252Band%252BWNT%252Bsignaling%252Bpathway%25253B%252Bdesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DLien%26aufirst%3DVegard%2BTorp%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D63%26spage%3D37092%26epage%3D37100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raju</span>, <span class="hlFld-ContribAuthor ">Almansour</span>, <span class="hlFld-ContribAuthor ">Natarajan</span>, <span class="hlFld-ContribAuthor ">Mohammad</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and In Vitro Mechanistic Investigation of Novel Hexacyclic Cage-Like Hybrid Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (21)
                                     , 3820. <a href="https://doi.org/10.3390/molecules24213820" title="DOI URL">https://doi.org/10.3390/molecules24213820</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24213820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24213820%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BIn%252BVitro%252BMechanistic%252BInvestigation%252Bof%252BNovel%252BHexacyclic%252BCage-Like%252BHybrid%252BHeterocycles%26aulast%3DRaju%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D21%26spage%3D3820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai Bing  Deng</span>, <span class="hlFld-ContribAuthor ">Chun Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing Quan  Dai</span>, <span class="hlFld-ContribAuthor ">Qian  Li</span>, <span class="hlFld-ContribAuthor ">Qian Gang  Zheng</span>, <span class="hlFld-ContribAuthor ">Hui Xin  Wan</span>, <span class="hlFld-ContribAuthor ">Hong Ping  Yu</span>, <span class="hlFld-ContribAuthor ">Feng  He</span>, <span class="hlFld-ContribAuthor ">Yao Chang  Xu</span>, <span class="hlFld-ContribAuthor ">Sylvia  Zhao</span>, <span class="hlFld-ContribAuthor ">Ji Yue Jeff  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Drug Metabolism and Pharmacokinetics</span><span> <strong>2019,</strong> <em>44 </em>
                                    (5)
                                     , 669-680. <a href="https://doi.org/10.1007/s13318-019-00557-9" title="DOI URL">https://doi.org/10.1007/s13318-019-00557-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13318-019-00557-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13318-019-00557-9%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Drug%2520Metabolism%2520and%2520Pharmacokinetics%26atitle%3DIn%252BVitro%252BMetabolism%252Bby%252BAldehyde%252BOxidase%252BLeads%252Bto%252BPoor%252BPharmacokinetic%252BProfile%252Bin%252BRats%252Bfor%252Bc-Met%252BInhibitor%252BMET401%26aulast%3DZhang%26aufirst%3DJiang%2BWei%26date%3D2019%26date%3D2019%26volume%3D44%26issue%3D5%26spage%3D669%26epage%3D680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Yu-Shun  Yang</span>, <span class="hlFld-ContribAuthor ">Zhong-Chang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress in the Development of Small Molecule c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (15)
                                     , 1276-1288. <a href="https://doi.org/10.2174/1568026619666190712205353" title="DOI URL">https://doi.org/10.2174/1568026619666190712205353</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190712205353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190712205353%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bin%252Bthe%252BDevelopment%252Bof%252BSmall%252BMolecule%252Bc-Met%252BInhibitors%26aulast%3DLv%26aufirst%3DPeng-Cheng%26date%3D2019%26volume%3D19%26issue%3D15%26spage%3D1276%26epage%3D1288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vegard Torp  Lien</span>, <span class="hlFld-ContribAuthor ">Solveig  Pettersen</span>, <span class="hlFld-ContribAuthor ">Mads Haugland  Haugen</span>, <span class="hlFld-ContribAuthor ">Dag Erlend  Olberg</span>, <span class="hlFld-ContribAuthor ">Gunhild M.  MÃ¦landsmo</span>, <span class="hlFld-ContribAuthor ">Jo  Klaveness</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 6âsubstituted quinolines derived from cabozantinib as câMet inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2019,</strong> <em>352 </em>
                                    (9)
                                     , 1900101. <a href="https://doi.org/10.1002/ardp.201900101" title="DOI URL">https://doi.org/10.1002/ardp.201900101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201900101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201900101%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B6%2525E2%252580%252590substituted%252Bquinolines%252Bderived%252Bfrom%252Bcabozantinib%252Bas%252Bc%2525E2%252580%252590Met%252Binhibitors%26aulast%3DLien%26aufirst%3DVegard%2BTorp%26date%3D2019%26date%3D2019%26volume%3D352%26issue%3D9%26spage%3D1900101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin-Sheng  Zhuo</span>, <span class="hlFld-ContribAuthor ">Hong-Chuang  Xu</span>, <span class="hlFld-ContribAuthor ">Ming-Shu  Wang</span>, <span class="hlFld-ContribAuthor ">Xing-E.  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhi-Hui  Ming</span>, <span class="hlFld-ContribAuthor ">Xiao-Lei  Zhu</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Guang-Fu  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 705-714. <a href="https://doi.org/10.1016/j.ejmech.2019.06.033" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.033%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2%25252C7-naphthyridinone-based%252BMET%252Bkinase%252Binhibitors%25253A%252BA%252Bpromising%252Bnovel%252Bscaffold%252Bfor%252Bantitumor%252Bdrug%252Bdevelopment%26aulast%3DZhuo%26aufirst%3DLin-Sheng%26date%3D2019%26volume%3D178%26spage%3D705%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Shen</span>, <span class="hlFld-ContribAuthor ">Feixiang  Wu</span>, <span class="hlFld-ContribAuthor ">Jiazhou  Ye</span>, <span class="hlFld-ContribAuthor ">Rong  Liang</span>, <span class="hlFld-ContribAuthor ">Ruping  Wang</span>, <span class="hlFld-ContribAuthor ">Ruoying  Yu</span>, <span class="hlFld-ContribAuthor ">Xue  Wu</span>, <span class="hlFld-ContribAuthor ">Yang W  Shao</span>, <span class="hlFld-ContribAuthor ">Jifeng  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Crizotinib-resistant
              MET
              mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (22)
                                     , 2585-2593. <a href="https://doi.org/10.2217/fon-2019-0140" title="DOI URL">https://doi.org/10.2217/fon-2019-0140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2019-0140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2019-0140%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DCrizotinib-resistant%252BMET%252Bmutations%252Bin%252Bgastric%252Bcancer%252Bpatients%252Bare%252Bsensitive%252Bto%252Btype%252BII%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DShen%26aufirst%3DBo%26date%3D2019%26volume%3D15%26issue%3D22%26spage%3D2585%26epage%3D2593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ran  Fang</span>, <span class="hlFld-ContribAuthor ">Bin  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Zhao</span>, <span class="hlFld-ContribAuthor ">Lingfeng  Yin</span>, <span class="hlFld-ContribAuthor ">Han  Wang</span>, <span class="hlFld-ContribAuthor ">Jingli  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">A New Synthesis of Cabozantinib. </span><span class="cited-content_cbyCitation_journal-name">Organic Preparations and Procedures International</span><span> <strong>2019,</strong> <em>51 </em>
                                    (4)
                                     , 381-387. <a href="https://doi.org/10.1080/00304948.2019.1615362" title="DOI URL">https://doi.org/10.1080/00304948.2019.1615362</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00304948.2019.1615362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00304948.2019.1615362%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Preparations%2520and%2520Procedures%2520International%26atitle%3DA%252BNew%252BSynthesis%252Bof%252BCabozantinib%26aulast%3DFang%26aufirst%3DRan%26date%3D2019%26date%3D2019%26volume%3D51%26issue%3D4%26spage%3D381%26epage%3D387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tahereh  Damghani</span>, <span class="hlFld-ContribAuthor ">Korosh  Mashayekh</span>, <span class="hlFld-ContribAuthor ">Somayeh  Pirhadi</span>, <span class="hlFld-ContribAuthor ">Omidreza  Firuzi</span>, <span class="hlFld-ContribAuthor ">Shahrzad  Sharifi</span>, <span class="hlFld-ContribAuthor ">Najmeh  Edraki</span>, <span class="hlFld-ContribAuthor ">Mehdi  Khoshneviszadeh</span>, <span class="hlFld-ContribAuthor ">Mohammad Sadegh  Avestan</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2019,</strong> <em>39 </em>
                                    (4)
                                     , 295-303. <a href="https://doi.org/10.1080/10799893.2019.1676258" title="DOI URL">https://doi.org/10.1080/10799893.2019.1676258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2019.1676258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2019.1676258%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DPrediction%252Bof%252Bcytotoxic%252Bactivity%252Bof%252Ba%252Bseries%252Bof%252B1H-pyrrolo%25255B2%25252C3-b%25255Dpyridine%252Bderivatives%252Bas%252Bpossible%252Binhibitors%252Bof%252Bc-Met%252Busing%252Bmolecular%252Bfingerprints%26aulast%3DDamghani%26aufirst%3DTahereh%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D4%26spage%3D295%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavithra K.  Balasubramanian</span>, <span class="hlFld-ContribAuthor ">Anand  Balupuri</span>, <span class="hlFld-ContribAuthor ">Swapnil P.  Bhujbal</span>, <span class="hlFld-ContribAuthor ">Seung Joo  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2019,</strong> <em>37 </em>
                                    (8)
                                     , 2165-2178. <a href="https://doi.org/10.1080/07391102.2018.1479309" title="DOI URL">https://doi.org/10.1080/07391102.2018.1479309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2018.1479309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2018.1479309%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3D3D-QSAR-aided%252Bdesign%252Bof%252Bpotent%252Bc-Met%252Binhibitors%252Busing%252Bmolecular%252Bdynamics%252Bsimulation%252Band%252Bbinding%252Bfree%252Benergy%252Bcalculation%26aulast%3DBalasubramanian%26aufirst%3DPavithra%2BK.%26date%3D2019%26date%3D2018%26volume%3D37%26issue%3D8%26spage%3D2165%26epage%3D2178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sakineh  Dadashpour</span>, <span class="hlFld-ContribAuthor ">Tuba TÃ¼ylÃ¼  KÃ¼Ã§Ã¼kkÄ±lÄ±nÃ§</span>, <span class="hlFld-ContribAuthor ">Beyza  AyazgÃ¶k</span>, <span class="hlFld-ContribAuthor ">Seyed Jalal  Hosseinimehr</span>, <span class="hlFld-ContribAuthor ">Ann M  Chippindale</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>, <span class="hlFld-ContribAuthor ">Hamid  Irannejad</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 1,2,4-triazolo-1,2,4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (10)
                                     , 1119-1136. <a href="https://doi.org/10.4155/fmc-2018-0412" title="DOI URL">https://doi.org/10.4155/fmc-2018-0412</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0412%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B1%25252C2%25252C4-triazolo-1%25252C2%25252C4-triazines%252Bwith%252Bthiomethylpyridine%252Bhinge%252Bbinders%252Bas%252Bpotent%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DDadashpour%26aufirst%3DSakineh%26date%3D2019%26volume%3D11%26issue%3D10%26spage%3D1119%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nele  Van Der Steen</span>, <span class="hlFld-ContribAuthor ">Ingrid  Garajova</span>, <span class="hlFld-ContribAuthor ">Christian  Rolfo</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavazzoni</span>, <span class="hlFld-ContribAuthor ">Elisa  Giovannetti</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 25-60. <a href="https://doi.org/10.1016/B978-0-12-813753-6.00002-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-813753-6.00002-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-813753-6.00002-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-813753-6.00002-0%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252Bthe%252BHepatocyte%252BGrowth%252BFactor%252BReceptor%252Bto%252BOvercome%252BResistance%252Bto%252BTargeted%252BTherapies%26aulast%3DVan%2BDer%2BSteen%26aufirst%3DNele%26date%3D2019%26spage%3D25%26epage%3D60%26pub%3DElsevier%26atitle%3DTargeting%252BCell%252BSurvival%252BPathways%252Bto%252BEnhance%252BResponse%252Bto%252BChemotherapy%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raju Suresh  Kumar</span>, <span class="hlFld-ContribAuthor ">Abdulrahman I.  Almansour</span>, <span class="hlFld-ContribAuthor ">Natarajan  Arumugam</span>, <span class="hlFld-ContribAuthor ">Faruq  Mohammad</span>, <span class="hlFld-ContribAuthor ">Waleed Shihan  Alshahrani</span>, <span class="hlFld-ContribAuthor ">Kotresha  D</span>, <span class="hlFld-ContribAuthor ">Mohammad  Altaf</span>, <span class="hlFld-ContribAuthor ">Mohammad  Azam</span>, <span class="hlFld-ContribAuthor ">J. Carlos  MenÃ©ndez</span>. </span><span class="cited-content_cbyCitation_article-title">Highly functionalized pyrrolidine analogues: stereoselective synthesis and caspase-dependent apoptotic activity. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (72)
                                     , 41226-41236. <a href="https://doi.org/10.1039/C8RA07985D" title="DOI URL">https://doi.org/10.1039/C8RA07985D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA07985D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA07985D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DHighly%252Bfunctionalized%252Bpyrrolidine%252Banalogues%25253A%252Bstereoselective%252Bsynthesis%252Band%252Bcaspase-dependent%252Bapoptotic%252Bactivity%26aulast%3DKumar%26aufirst%3DRaju%2BSuresh%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D72%26spage%3D41226%26epage%3D41236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Apicella</span>, <span class="hlFld-ContribAuthor ">Elisa  Giannoni</span>, <span class="hlFld-ContribAuthor ">Stephany  Fiore</span>, <span class="hlFld-ContribAuthor ">Karin Johanna  Ferrari</span>, <span class="hlFld-ContribAuthor ">Daniel  FernÃ¡ndez-PÃ©rez</span>, <span class="hlFld-ContribAuthor ">Claudio  Isella</span>, <span class="hlFld-ContribAuthor ">Carlotta  Granchi</span>, <span class="hlFld-ContribAuthor ">Filippo  Minutolo</span>, <span class="hlFld-ContribAuthor ">Antonino  Sottile</span>, <span class="hlFld-ContribAuthor ">Paolo Maria  Comoglio</span>, <span class="hlFld-ContribAuthor ">Enzo  Medico</span>, <span class="hlFld-ContribAuthor ">Filippo  Pietrantonio</span>, <span class="hlFld-ContribAuthor ">Marco  Volante</span>, <span class="hlFld-ContribAuthor ">Diego  Pasini</span>, <span class="hlFld-ContribAuthor ">Paola  Chiarugi</span>, <span class="hlFld-ContribAuthor ">Silvia  Giordano</span>, <span class="hlFld-ContribAuthor ">Simona  Corso</span>. </span><span class="cited-content_cbyCitation_article-title">Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. </span><span class="cited-content_cbyCitation_journal-name">Cell Metabolism</span><span> <strong>2018,</strong> <em>28 </em>
                                    (6)
                                     , 848-865.e6. <a href="https://doi.org/10.1016/j.cmet.2018.08.006" title="DOI URL">https://doi.org/10.1016/j.cmet.2018.08.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cmet.2018.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cmet.2018.08.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Metabolism%26atitle%3DIncreased%252BLactate%252BSecretion%252Bby%252BCancer%252BCells%252BSustains%252BNon-cell-autonomous%252BAdaptive%252BResistance%252Bto%252BMET%252Band%252BEGFR%252BTargeted%252BTherapies%26aulast%3DApicella%26aufirst%3DMaria%26date%3D2018%26volume%3D28%26issue%3D6%26spage%3D848%26epage%3D865.e6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhen Ting  Gao</span>, <span class="hlFld-ContribAuthor ">Zheng Tian  Yu</span>, <span class="hlFld-ContribAuthor ">Ji Yue (Jeff)  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolism of c-Met Kinase Inhibitors Containing Quinoline by Aldehyde Oxidase, Electron Donating, and Steric Hindrance Effect. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2018,</strong> <em>46 </em>
                                    (12)
                                     , 1847-1855. <a href="https://doi.org/10.1124/dmd.118.081919" title="DOI URL">https://doi.org/10.1124/dmd.118.081919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.118.081919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.118.081919%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DMetabolism%252Bof%252Bc-Met%252BKinase%252BInhibitors%252BContaining%252BQuinoline%252Bby%252BAldehyde%252BOxidase%25252C%252BElectron%252BDonating%25252C%252Band%252BSteric%252BHindrance%252BEffect%26aulast%3DZhang%26aufirst%3DJiang%2BWei%26date%3D2018%26date%3D2018%26volume%3D46%26issue%3D12%26spage%3D1847%26epage%3D1855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natarajan  Arumugam</span>, <span class="hlFld-ContribAuthor ">Abdulrahman I.  Almansour</span>, <span class="hlFld-ContribAuthor ">Raju Suresh  Kumar</span>, <span class="hlFld-ContribAuthor ">Dhaifallah M.  Al-thamili</span>, <span class="hlFld-ContribAuthor ">Govindasami  Periyasami</span>, <span class="hlFld-ContribAuthor ">V. S.  Periasamy</span>, <span class="hlFld-ContribAuthor ">Jegan  Athinarayanan</span>, <span class="hlFld-ContribAuthor ">Ali A.  Alshatwi</span>, <span class="hlFld-ContribAuthor ">S. M.  Mahalingam</span>, <span class="hlFld-ContribAuthor ">J. Carlos  MenÃ©ndez</span>. </span><span class="cited-content_cbyCitation_article-title">Regio and stereoselective synthesis of anticancer spirooxindolopyrrolidine embedded piperidone heterocyclic hybrids derived from one-pot cascade protocol. </span><span class="cited-content_cbyCitation_journal-name">Chemistry Central Journal</span><span> <strong>2018,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13065-018-0462-x" title="DOI URL">https://doi.org/10.1186/s13065-018-0462-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13065-018-0462-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13065-018-0462-x%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520Central%2520Journal%26atitle%3DRegio%252Band%252Bstereoselective%252Bsynthesis%252Bof%252Banticancer%252Bspirooxindolopyrrolidine%252Bembedded%252Bpiperidone%252Bheterocyclic%252Bhybrids%252Bderived%252Bfrom%252Bone-pot%252Bcascade%252Bprotocol%26aulast%3DArumugam%26aufirst%3DNatarajan%26date%3D2018%26date%3D2018%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aflah  Roohullah</span>, <span class="hlFld-ContribAuthor ">Adam  Cooper</span>, <span class="hlFld-ContribAuthor ">Anna J.  Lomax</span>, <span class="hlFld-ContribAuthor ">Jennifer  Aung</span>, <span class="hlFld-ContribAuthor ">Alan  Barge</span>, <span class="hlFld-ContribAuthor ">Lilian  Chow</span>, <span class="hlFld-ContribAuthor ">Mark  McHale</span>, <span class="hlFld-ContribAuthor ">Jayesh  Desai</span>, <span class="hlFld-ContribAuthor ">James R.  Whittle</span>, <span class="hlFld-ContribAuthor ">Ben  Tran</span>, <span class="hlFld-ContribAuthor ">Paul  de Souza</span>, <span class="hlFld-ContribAuthor ">Lisa G.  Horvath</span>. </span><span class="cited-content_cbyCitation_article-title">A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2018,</strong> <em>36 </em>
                                    (5)
                                     , 886-894. <a href="https://doi.org/10.1007/s10637-018-0588-7" title="DOI URL">https://doi.org/10.1007/s10637-018-0588-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-018-0588-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-018-0588-7%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DA%252Bphase%252BI%252Btrial%252Bto%252Bdetermine%252Bsafety%252Band%252Bpharmacokinetics%252Bof%252BASLAN002%25252C%252Ban%252Boral%252BMET%252Bsuperfamily%252Bkinase%252Binhibitor%25252C%252Bin%252Bpatients%252Bwith%252Badvanced%252Bor%252Bmetastatic%252Bsolid%252Bcancers%26aulast%3DRoohullah%26aufirst%3DAflah%26date%3D2018%26date%3D2018%26volume%3D36%26issue%3D5%26spage%3D886%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natarajan  Arumugam</span>, <span class="hlFld-ContribAuthor ">Abdulrahman I.  Almansour</span>, <span class="hlFld-ContribAuthor ">Raju Suresh  Kumar</span>, <span class="hlFld-ContribAuthor ">Vaiyapuri Subbarayan  Periasamy</span>, <span class="hlFld-ContribAuthor ">Jegan  Athinarayanan</span>, <span class="hlFld-ContribAuthor ">Ali A.  Alshatwi</span>, <span class="hlFld-ContribAuthor ">Periyasami  Govindasami</span>, <span class="hlFld-ContribAuthor ">Mohammad  Altaf</span>, <span class="hlFld-ContribAuthor ">J. Carlos  MenÃ©ndez</span>. </span><span class="cited-content_cbyCitation_article-title">Regio- and diastereoselective synthesis of anticancer spirooxindoles derived from tryptophan and histidine via three-component 1,3-dipolar cycloadditions in an ionic liquid. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2018,</strong> <em>74 </em>
                                    (38)
                                     , 5358-5366. <a href="https://doi.org/10.1016/j.tet.2018.04.032" title="DOI URL">https://doi.org/10.1016/j.tet.2018.04.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2018.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2018.04.032%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DRegio-%252Band%252Bdiastereoselective%252Bsynthesis%252Bof%252Banticancer%252Bspirooxindoles%252Bderived%252Bfrom%252Btryptophan%252Band%252Bhistidine%252Bvia%252Bthree-component%252B1%25252C3-dipolar%252Bcycloadditions%252Bin%252Ban%252Bionic%252Bliquid%26aulast%3DArumugam%26aufirst%3DNatarajan%26date%3D2018%26volume%3D74%26issue%3D38%26spage%3D5358%26epage%3D5366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Libo  Yan</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Qiao</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Bingren  Xiang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2018,</strong> <em>36 </em>
                                    (8)
                                     , 2015-2031. <a href="https://doi.org/10.1080/07391102.2017.1340852" title="DOI URL">https://doi.org/10.1080/07391102.2017.1340852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2017.1340852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2017.1340852%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DInsight%252Binto%252Bthe%252Bkey%252Bfeatures%252Bfor%252Bligand%252Bbinding%252Bin%252BY1230%252Bmutated%252Bc-Met%252Bkinase%252Bdomain%252Bby%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DYan%26aufirst%3DLibo%26date%3D2018%26date%3D2017%26volume%3D36%26issue%3D8%26spage%3D2015%26epage%3D2031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natarajan  Arumugam</span>, <span class="hlFld-ContribAuthor ">Abdulrahman  Almansour</span>, <span class="hlFld-ContribAuthor ">Raju  Suresh Kumar</span>, <span class="hlFld-ContribAuthor ">Periyasami  Govindasami</span>, <span class="hlFld-ContribAuthor ">Dhaifallah  Al-thamili</span>, <span class="hlFld-ContribAuthor ">Rajapandian  Krishnamoorthy</span>, <span class="hlFld-ContribAuthor ">Vaiyapuri  Periasamy</span>, <span class="hlFld-ContribAuthor ">Ali  Alshatwi</span>, <span class="hlFld-ContribAuthor ">S.  Mahalingam</span>, <span class="hlFld-ContribAuthor ">Shankar  Thangamani</span>, <span class="hlFld-ContribAuthor ">J.  MenÃ©ndez</span>. </span><span class="cited-content_cbyCitation_article-title">Multicomponent Domino Synthesis, Anticancer Activity and Molecular Modeling Simulation of Complex Dispirooxindolopyrrolidines. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (5)
                                     , 1094. <a href="https://doi.org/10.3390/molecules23051094" title="DOI URL">https://doi.org/10.3390/molecules23051094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23051094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23051094%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMulticomponent%252BDomino%252BSynthesis%25252C%252BAnticancer%252BActivity%252Band%252BMolecular%252BModeling%252BSimulation%252Bof%252BComplex%252BDispirooxindolopyrrolidines%26aulast%3DArumugam%26aufirst%3DNatarajan%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D5%26spage%3D1094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Jingyun  Zhao</span>, <span class="hlFld-ContribAuthor ">Beichen  Zhang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>150 </em>, 809-816. <a href="https://doi.org/10.1016/j.ejmech.2018.03.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%25255B1%25252C2%25252C4%25255Dtriazolo%25255B3%25252C4-b%25255D%25255B1%25252C3%25252C4%25255Dthiadiazole%252Bderivatives%252Bas%252Bnovel%25252C%252Bpotent%252Band%252Bselective%252Bc-Met%252Bkinase%252Binhibitors%25253A%252BSynthesis%25252C%252BSAR%252Bstudy%25252C%252Band%252Bbiological%252Bactivity%26aulast%3DZhang%26aufirst%3DLi%26date%3D2018%26volume%3D150%26spage%3D809%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Yong  Xi</span>, <span class="hlFld-ContribAuthor ">Yanyan  Shen</span>, <span class="hlFld-ContribAuthor ">Xinying  Yang</span>, <span class="hlFld-ContribAuthor ">Yi  Su</span>, <span class="hlFld-ContribAuthor ">Yiming  Sun</span>, <span class="hlFld-ContribAuthor ">Yinglei  Gao</span>, <span class="hlFld-ContribAuthor ">Yuchi  Ma</span>, <span class="hlFld-ContribAuthor ">Bing  Xiong</span>, <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (4)
                                     , 751-762. <a href="https://doi.org/10.1158/1535-7163.MCT-17-0368" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-0368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-0368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-0368%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DPreclinical%252BEvaluation%252Bof%252BSCC244%252B%252528Glumetinib%252529%25252C%252Ba%252BNovel%25252C%252BPotent%25252C%252Band%252BHighly%252BSelective%252BInhibitor%252Bof%252Bc-Met%252Bin%252BMET-dependent%252BCancer%252BModels%26aulast%3DAi%26aufirst%3DJing%26date%3D2018%26date%3D2017%26volume%3D17%26issue%3D4%26spage%3D751%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Todd  Bell</span>, <span class="hlFld-ContribAuthor ">Virginia  Espina</span>, <span class="hlFld-ContribAuthor ">Lindsay  Lundberg</span>, <span class="hlFld-ContribAuthor ">Chelsea  Pinkham</span>, <span class="hlFld-ContribAuthor ">Ashwini  Brahms</span>, <span class="hlFld-ContribAuthor ">Brian  Carey</span>, <span class="hlFld-ContribAuthor ">Shih-Chao  Lin</span>, <span class="hlFld-ContribAuthor ">Bibha  Dahal</span>, <span class="hlFld-ContribAuthor ">Caitlin  Woodson</span>, <span class="hlFld-ContribAuthor ">Cynthia  de la Fuente</span>, <span class="hlFld-ContribAuthor ">Lance  Liotta</span>, <span class="hlFld-ContribAuthor ">Charles  Bailey</span>, <span class="hlFld-ContribAuthor ">Kylene  Kehn-Hall</span>. </span><span class="cited-content_cbyCitation_article-title">Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2018,</strong> <em>10 </em>
                                    (4)
                                     , 191. <a href="https://doi.org/10.3390/v10040191" title="DOI URL">https://doi.org/10.3390/v10040191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v10040191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv10040191%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DCombination%252BKinase%252BInhibitor%252BTreatment%252BSuppresses%252BRift%252BValley%252BFever%252BVirus%252BReplication%26aulast%3DBell%26aufirst%3DTodd%26date%3D2018%26date%3D2018%26volume%3D10%26issue%3D4%26spage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nariyoshi  Shinomiya</span>, <span class="hlFld-ContribAuthor ">Qian  Xie</span>, <span class="hlFld-ContribAuthor ">George F.  Vande Woude</span>. </span><span class="cited-content_cbyCitation_article-title">Met Activation and Carcinogenesis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 129-154. <a href="https://doi.org/10.1007/978-981-10-7296-3_7" title="DOI URL">https://doi.org/10.1007/978-981-10-7296-3_7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-10-7296-3_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-10-7296-3_7%26sid%3Dliteratum%253Aachs%26atitle%3DMet%252BActivation%252Band%252BCarcinogenesis%26aulast%3DShinomiya%26aufirst%3DNariyoshi%26date%3D2018%26date%3D2017%26spage%3D129%26epage%3D154%26pub%3DSpringer%2520Singapore%26atitle%3DRegulation%252Bof%252BSignal%252BTransduction%252Bin%252BHuman%252BCell%252BResearch%26aulast%3DShinomiya%26aufirst%3DNariyoshi%26date%3D2018%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Palak K.  Parikh</span>, <span class="hlFld-ContribAuthor ">Manjunath D.  Ghate</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the discovery of small molecule c-Met Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1103-1138. <a href="https://doi.org/10.1016/j.ejmech.2017.08.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bdiscovery%252Bof%252Bsmall%252Bmolecule%252Bc-Met%252BKinase%252Binhibitors%26aulast%3DParikh%26aufirst%3DPalak%2BK.%26date%3D2018%26volume%3D143%26spage%3D1103%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Qiufeng  Liu</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Shihe  Hu</span>, <span class="hlFld-ContribAuthor ">Tiantian  Chen</span>, <span class="hlFld-ContribAuthor ">Huifang  Li</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Yechun  Xu</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 491-502. <a href="https://doi.org/10.1016/j.ejmech.2017.11.073" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.073%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252Boptimization%252Band%252Bbiological%252Bevaluation%252Bfor%252Bnovel%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DYuan%26aufirst%3DHaoliang%26date%3D2018%26volume%3D143%26spage%3D491%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nichola  Cruickshanks</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Fang  Yuan</span>, <span class="hlFld-ContribAuthor ">Mary  Pahuski</span>, <span class="hlFld-ContribAuthor ">Myron  Gibert</span>, <span class="hlFld-ContribAuthor ">Roger  Abounader</span>. </span><span class="cited-content_cbyCitation_article-title">Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2017,</strong> <em>9 </em>
                                    (12)
                                     , 87. <a href="https://doi.org/10.3390/cancers9070087" title="DOI URL">https://doi.org/10.3390/cancers9070087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers9070087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers9070087%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DRole%252Band%252BTherapeutic%252BTargeting%252Bof%252Bthe%252BHGF%25252FMET%252BPathway%252Bin%252BGlioblastoma%26aulast%3DCruickshanks%26aufirst%3DNichola%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D12%26spage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Audelaure  Junca</span>, <span class="hlFld-ContribAuthor ">Claire  Villalva</span>, <span class="hlFld-ContribAuthor ">GaÃ«lle  Tachon</span>, <span class="hlFld-ContribAuthor ">Pierre  Rivet</span>, <span class="hlFld-ContribAuthor ">Ulrich  Cortes</span>, <span class="hlFld-ContribAuthor ">Karline  Guilloteau</span>, <span class="hlFld-ContribAuthor ">AnaÃ¯s  Balbous</span>, <span class="hlFld-ContribAuthor ">Julie  Godet</span>, <span class="hlFld-ContribAuthor ">Michel  Wager</span>, <span class="hlFld-ContribAuthor ">Lucie  Karayan-Tapon</span>. </span><span class="cited-content_cbyCitation_article-title">Crizotinib targets in glioblastoma stem cells. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2017,</strong> <em>6 </em>
                                    (11)
                                     , 2625-2634. <a href="https://doi.org/10.1002/cam4.1167" title="DOI URL">https://doi.org/10.1002/cam4.1167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.1167%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DCrizotinib%252Btargets%252Bin%252Bglioblastoma%252Bstem%252Bcells%26aulast%3DJunca%26aufirst%3DAudelaure%26date%3D2017%26date%3D2017%26volume%3D6%26issue%3D11%26spage%3D2625%26epage%3D2634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Pilotto</span>, <span class="hlFld-ContribAuthor ">L.  Carbognin</span>, <span class="hlFld-ContribAuthor ">N.  Karachaliou</span>, <span class="hlFld-ContribAuthor ">P.C.  Ma</span>, <span class="hlFld-ContribAuthor ">R.  Rosell</span>, <span class="hlFld-ContribAuthor ">G.  Tortora</span>, <span class="hlFld-ContribAuthor ">E.  Bria</span>. </span><span class="cited-content_cbyCitation_article-title">Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2017,</strong> <em>60 </em>, 1-11. <a href="https://doi.org/10.1016/j.ctrv.2017.08.002" title="DOI URL">https://doi.org/10.1016/j.ctrv.2017.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2017.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DTracking%252BMET%252Bde-addiction%252Bin%252Blung%252Bcancer%25253A%252BA%252Broad%252Btowards%252Bthe%252Boncogenic%252Btarget%26aulast%3DPilotto%26aufirst%3DS.%26date%3D2017%26volume%3D60%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julia  Rotow</span>, <span class="hlFld-ContribAuthor ">Trever G.  Bivona</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding and targeting resistance mechanisms in NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Cancer</span><span> <strong>2017,</strong> <em>17 </em>
                                    (11)
                                     , 637-658. <a href="https://doi.org/10.1038/nrc.2017.84" title="DOI URL">https://doi.org/10.1038/nrc.2017.84</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrc.2017.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrc.2017.84%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Cancer%26atitle%3DUnderstanding%252Band%252Btargeting%252Bresistance%252Bmechanisms%252Bin%252BNSCLC%26aulast%3DRotow%26aufirst%3DJulia%26date%3D2017%26date%3D2017%26volume%3D17%26issue%3D11%26spage%3D637%26epage%3D658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lars D.  Engstrom</span>, <span class="hlFld-ContribAuthor ">Ruth  Aranda</span>, <span class="hlFld-ContribAuthor ">Matthew  Lee</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Tovar</span>, <span class="hlFld-ContribAuthor ">Curt J.  Essenburg</span>, <span class="hlFld-ContribAuthor ">Zachary  Madaj</span>, <span class="hlFld-ContribAuthor ">Harrah  Chiang</span>, <span class="hlFld-ContribAuthor ">David  Briere</span>, <span class="hlFld-ContribAuthor ">Jill  Hallin</span>, <span class="hlFld-ContribAuthor ">Pedro P.  Lopez-Casas</span>, <span class="hlFld-ContribAuthor ">Natalia  BaÃ±os</span>, <span class="hlFld-ContribAuthor ">Camino  Menendez</span>, <span class="hlFld-ContribAuthor ">Manuel  Hidalgo</span>, <span class="hlFld-ContribAuthor ">Vanessa  Tassell</span>, <span class="hlFld-ContribAuthor ">Richard  Chao</span>, <span class="hlFld-ContribAuthor ">Darya I.  Chudova</span>, <span class="hlFld-ContribAuthor ">Richard B.  Lanman</span>, <span class="hlFld-ContribAuthor ">Peter  Olson</span>, <span class="hlFld-ContribAuthor ">Lyudmilla  Bazhenova</span>, <span class="hlFld-ContribAuthor ">Sandip Pravin  Patel</span>, <span class="hlFld-ContribAuthor ">Carrie  Graveel</span>, <span class="hlFld-ContribAuthor ">Mizuki  Nishino</span>, <span class="hlFld-ContribAuthor ">Geoffrey I.  Shapiro</span>, <span class="hlFld-ContribAuthor ">Nir  Peled</span>, <span class="hlFld-ContribAuthor ">Mark M.  Awad</span>, <span class="hlFld-ContribAuthor ">Pasi A.  JÃ¤nne</span>, <span class="hlFld-ContribAuthor ">James G.  Christensen</span>. </span><span class="cited-content_cbyCitation_article-title">Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring
              MET
              Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2017,</strong> <em>23 </em>
                                    (21)
                                     , 6661-6672. <a href="https://doi.org/10.1158/1078-0432.CCR-17-1192" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-1192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-1192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-1192%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DGlesatinib%252BExhibits%252BAntitumor%252BActivity%252Bin%252BLung%252BCancer%252BModels%252Band%252BPatients%252BHarboring%252BMET%252BExon%252B14%252BMutations%252Band%252BOvercomes%252BMutation-mediated%252BResistance%252Bto%252BType%252BI%252BMET%252BInhibitors%252Bin%252BNonclinical%252BModels%26aulast%3DEngstrom%26aufirst%3DLars%2BD.%26date%3D2017%26date%3D2017%26volume%3D23%26issue%3D21%26spage%3D6661%26epage%3D6672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abeer H.  Elmaidomy</span>, <span class="hlFld-ContribAuthor ">Mohamed M.  Mohyeldin</span>, <span class="hlFld-ContribAuthor ">Mostafa M.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Hossam M.  Hassan</span>, <span class="hlFld-ContribAuthor ">Elham  Amin</span>, <span class="hlFld-ContribAuthor ">Mostafa E.  Rateb</span>, <span class="hlFld-ContribAuthor ">Mona H.  Hetta</span>, <span class="hlFld-ContribAuthor ">Khalid A.  El Sayed</span>. </span><span class="cited-content_cbyCitation_article-title">Acylated Iridoids and Rhamnopyranoses from
              Premna odorata
              (Lamiaceae) as Novel Mesenchymal-Epithelial Transition Factor Receptor Inhibitors for the Control of Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Phytotherapy Research</span><span> <strong>2017,</strong> <em>31 </em>
                                    (10)
                                     , 1546-1556. <a href="https://doi.org/10.1002/ptr.5882" title="DOI URL">https://doi.org/10.1002/ptr.5882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ptr.5882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fptr.5882%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytotherapy%2520Research%26atitle%3DAcylated%252BIridoids%252Band%252BRhamnopyranoses%252Bfrom%252BPremna%252Bodorata%252B%252528Lamiaceae%252529%252Bas%252BNovel%252BMesenchymal-Epithelial%252BTransition%252BFactor%252BReceptor%252BInhibitors%252Bfor%252Bthe%252BControl%252Bof%252BBreast%252BCancer%26aulast%3DElmaidomy%26aufirst%3DAbeer%2BH.%26date%3D2017%26date%3D2017%26volume%3D31%26issue%3D10%26spage%3D1546%26epage%3D1556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Beichen  Zhang</span>, <span class="hlFld-ContribAuthor ">Jingyun  Zhao</span>, <span class="hlFld-ContribAuthor ">Yanle  Zhi</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1 H -pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 942-951. <a href="https://doi.org/10.1016/j.ejmech.2017.06.057" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.06.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.06.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.06.057%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluation%252Bof%252B4%25252C5%25252C6%25252C7-tetrahydro-1%252BH%252B-pyrazolo%25255B4%25252C3-c%25255Dpyridine%252Bderivatives%252Bas%252Bnovel%252Bc-Met%252Binhibitors%26aulast%3DZhang%26aufirst%3DLi%26date%3D2017%26volume%3D138%26spage%3D942%26epage%3D951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Li</span>, <span class="hlFld-ContribAuthor ">Jin-ji  Yang</span>, <span class="hlFld-ContribAuthor ">Xu-chao  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhou  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Su</span>, <span class="hlFld-ContribAuthor ">Lan-ying  Gou</span>, <span class="hlFld-ContribAuthor ">Yu  Bai</span>, <span class="hlFld-ContribAuthor ">Qing  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhenfan  Yang</span>, <span class="hlFld-ContribAuthor ">Han  Han-Zhang</span>, <span class="hlFld-ContribAuthor ">Wen-Zhao  Zhong</span>, <span class="hlFld-ContribAuthor ">Shannon  Chuai</span>, <span class="hlFld-ContribAuthor ">Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi  Xie</span>, <span class="hlFld-ContribAuthor ">Hongfei  Gao</span>, <span class="hlFld-ContribAuthor ">Huajun  Chen</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Zheng  Wang</span>, <span class="hlFld-ContribAuthor ">Xue-ning  Yang</span>, <span class="hlFld-ContribAuthor ">Bin-chao  Wang</span>, <span class="hlFld-ContribAuthor ">Bin  Gan</span>, <span class="hlFld-ContribAuthor ">Zhi-hong  Chen</span>, <span class="hlFld-ContribAuthor ">Ben-yuan  Jiang</span>, <span class="hlFld-ContribAuthor ">Si-pei  Wu</span>, <span class="hlFld-ContribAuthor ">Si-yang  Liu</span>, <span class="hlFld-ContribAuthor ">Chong-rui  Xu</span>, <span class="hlFld-ContribAuthor ">Yi-long  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired
              MET
              Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in NonâSmall Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2017,</strong> <em>23 </em>
                                    (16)
                                     , 4929-4937. <a href="https://doi.org/10.1158/1078-0432.CCR-16-3273" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-16-3273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-16-3273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-16-3273%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DAcquired%252BMET%252BY1248H%252Band%252BD1246N%252BMutations%252BMediate%252BResistance%252Bto%252BMET%252BInhibitors%252Bin%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%26aulast%3DLi%26aufirst%3DAnna%26date%3D2017%26date%3D2017%26volume%3D23%26issue%3D16%26spage%3D4929%26epage%3D4937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ju  Liu</span>, <span class="hlFld-ContribAuthor ">Di  Yang</span>, <span class="hlFld-ContribAuthor ">Xiuxiu  Yang</span>, <span class="hlFld-ContribAuthor ">Minhua  Nie</span>, <span class="hlFld-ContribAuthor ">Guodong  Wu</span>, <span class="hlFld-ContribAuthor ">Zhunchao  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (16)
                                     , 4475-4486. <a href="https://doi.org/10.1016/j.bmc.2017.06.037" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.06.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.06.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B4-phenoxyquinoline%252Bderivatives%252Bcontaining%252B3-oxo-3%25252C4-dihydroquinoxaline%252Bmoiety%252Bas%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DLiu%26aufirst%3DJu%26date%3D2017%26volume%3D25%26issue%3D16%26spage%3D4475%26epage%3D4486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiu-Qiong  Fu</span>, <span class="hlFld-ContribAuthor ">Ting  Li</span>, <span class="hlFld-ContribAuthor ">Tao  Su</span>, <span class="hlFld-ContribAuthor ">Hui  Guo</span>, <span class="hlFld-ContribAuthor ">Pei-Li  Zhu</span>, <span class="hlFld-ContribAuthor ">Anfernee Kai-Wing  Tse</span>, <span class="hlFld-ContribAuthor ">Shi-Ming  Liu</span>, <span class="hlFld-ContribAuthor ">Zhi-Ling  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Computational and experimental prediction of molecules involved in the anti-melanoma action of berberine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Ethnopharmacology</span><span> <strong>2017,</strong> <em>208 </em>, 225-235. <a href="https://doi.org/10.1016/j.jep.2017.07.023" title="DOI URL">https://doi.org/10.1016/j.jep.2017.07.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jep.2017.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jep.2017.07.023%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Ethnopharmacology%26atitle%3DComputational%252Band%252Bexperimental%252Bprediction%252Bof%252Bmolecules%252Binvolved%252Bin%252Bthe%252Banti-melanoma%252Baction%252Bof%252Bberberine%26aulast%3DLiu%26aufirst%3DBin%26date%3D2017%26volume%3D208%26spage%3D225%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Jing  Li</span>, <span class="hlFld-ContribAuthor ">Guan-Zhao  Wu</span>, <span class="hlFld-ContribAuthor ">Quentin  Kaas</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>, <span class="hlFld-ContribAuthor ">Ri-Lei  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Development of efficient docking strategies and structure-activity relationship study of the c-Met type II inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2017,</strong> <em>75 </em>, 241-249. <a href="https://doi.org/10.1016/j.jmgm.2017.04.004" title="DOI URL">https://doi.org/10.1016/j.jmgm.2017.04.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2017.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2017.04.004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDevelopment%252Bof%252Befficient%252Bdocking%252Bstrategies%252Band%252Bstructure-activity%252Brelationship%252Bstudy%252Bof%252Bthe%252Bc-Met%252Btype%252BII%252Binhibitors%26aulast%3DLi%26aufirst%3DMing-Jing%26date%3D2017%26volume%3D75%26spage%3D241%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiangfeng  Li</span>, <span class="hlFld-ContribAuthor ">Xin  Xu</span>, <span class="hlFld-ContribAuthor ">Shuai  Meng</span>, <span class="hlFld-ContribAuthor ">Zhen  Liang</span>, <span class="hlFld-ContribAuthor ">Xiao  Wang</span>, <span class="hlFld-ContribAuthor ">Mingjie  Xu</span>, <span class="hlFld-ContribAuthor ">Song  Wang</span>, <span class="hlFld-ContribAuthor ">Shiqi  Li</span>, <span class="hlFld-ContribAuthor ">Yi  Zhu</span>, <span class="hlFld-ContribAuthor ">Bo  Xie</span>, <span class="hlFld-ContribAuthor ">Yiwei  Lin</span>, <span class="hlFld-ContribAuthor ">Xiangyi  Zheng</span>, <span class="hlFld-ContribAuthor ">Ben  Liu</span>, <span class="hlFld-ContribAuthor ">Liping  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelialâmesenchymal transition progression in bladder cancer. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2017,</strong> <em>8 </em>
                                    (8)
                                     , e3010-e3010. <a href="https://doi.org/10.1038/cddis.2017.331" title="DOI URL">https://doi.org/10.1038/cddis.2017.331</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/cddis.2017.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fcddis.2017.331%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DMET%25252FSMAD3%25252FSNAIL%252Bcircuit%252Bmediated%252Bby%252BmiR-323a-3p%252Bis%252Binvolved%252Bin%252Bregulating%252Bepithelial%2525E2%252580%252593mesenchymal%252Btransition%252Bprogression%252Bin%252Bbladder%252Bcancer%26aulast%3DLi%26aufirst%3DJiangfeng%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D8%26spage%3De3010%26epage%3De3010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>, <span class="hlFld-ContribAuthor ">Rangxiao  Zhuang</span>, <span class="hlFld-ContribAuthor ">Ruoyu  He</span>, <span class="hlFld-ContribAuthor ">Jianjun  Xi</span>, <span class="hlFld-ContribAuthor ">Xuwang  Pan</span>, <span class="hlFld-ContribAuthor ">Yidan  Shao</span>, <span class="hlFld-ContribAuthor ">Jinming  Pan</span>, <span class="hlFld-ContribAuthor ">Jingjing  Sun</span>, <span class="hlFld-ContribAuthor ">Zhaobin  Cai</span>, <span class="hlFld-ContribAuthor ">Shourong  Liu</span>, <span class="hlFld-ContribAuthor ">Weiwei  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (12)
                                     , 3195-3205. <a href="https://doi.org/10.1016/j.bmc.2017.04.003" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.04.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.04.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Ba%252Bseries%252Bof%252Bpyridine%252Band%252Bpyrimidine%252Bderivatives%252Bas%252Btype%252BII%252Bc-Met%252Binhibitors%26aulast%3DZhao%26aufirst%3DYanmei%26date%3D2017%26volume%3D25%26issue%3D12%26spage%3D3195%26epage%3D3205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qidong  Tang</span>, <span class="hlFld-ContribAuthor ">Linxiao  Wang</span>, <span class="hlFld-ContribAuthor ">Yongli  Duan</span>, <span class="hlFld-ContribAuthor ">Wenhui  Wang</span>, <span class="hlFld-ContribAuthor ">Shunmin  Huang</span>, <span class="hlFld-ContribAuthor ">Jia  Zhi</span>, <span class="hlFld-ContribAuthor ">Shuang  Jia</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>, <span class="hlFld-ContribAuthor ">Ping  Wang</span>, <span class="hlFld-ContribAuthor ">Rong  Luo</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>133 </em>, 97-106. <a href="https://doi.org/10.1016/j.ejmech.2017.03.045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.03.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.03.045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B7-azaindole%252Bderivatives%252Bbearing%252Bdihydropyridazine%252Bmoiety%252Bas%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DTang%26aufirst%3DQidong%26date%3D2017%26volume%3D133%26spage%3D97%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaya  Baba</span>, <span class="hlFld-ContribAuthor ">Laura S.  Schmidt</span>, <span class="hlFld-ContribAuthor ">W. Marston  Linehan</span>. </span><span class="cited-content_cbyCitation_article-title">Hereditary Renal Cell Carcinoma. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 19-82. <a href="https://doi.org/10.1007/978-4-431-55531-5_2" title="DOI URL">https://doi.org/10.1007/978-4-431-55531-5_2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-4-431-55531-5_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-4-431-55531-5_2%26sid%3Dliteratum%253Aachs%26atitle%3DHereditary%252BRenal%252BCell%252BCarcinoma%26aulast%3DBaba%26aufirst%3DMasaya%26date%3D2017%26date%3D2017%26spage%3D19%26epage%3D82%26pub%3DSpringer%2520Japan%26atitle%3DRenal%252BCell%252BCarcinoma%26aulast%3DOya%26aufirst%3DMototsugu%26date%3D2017%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Boezio</span>, <span class="hlFld-ContribAuthor ">E.A.  Peterson</span>, <span class="hlFld-ContribAuthor ">J.-C.  Harmange</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of AMG 337: Using Structure Guided Scaffold Hybridization to Optimize Physicochemical Properties and Target Coverage of a MET Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 138-160. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12462-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12462-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12462-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12462-X%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Bof%252BAMG%252B337%25253A%252BUsing%252BStructure%252BGuided%252BScaffold%252BHybridization%252Bto%252BOptimize%252BPhysicochemical%252BProperties%252Band%252BTarget%252BCoverage%252Bof%252Ba%252BMET%252BKinase%252BInhibitor%26aulast%3DBoezio%26aufirst%3DA.A.%26date%3D2017%26spage%3D138%26epage%3D160%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sai-Hong Ignatius  Ou</span>, <span class="hlFld-ContribAuthor ">Lauren  Young</span>, <span class="hlFld-ContribAuthor ">Alexa B.  Schrock</span>, <span class="hlFld-ContribAuthor ">Adrienne  Johnson</span>, <span class="hlFld-ContribAuthor ">Samuel J.  Klempner</span>, <span class="hlFld-ContribAuthor ">Viola W.  Zhu</span>, <span class="hlFld-ContribAuthor ">Vincent A.  Miller</span>, <span class="hlFld-ContribAuthor ">Siraj M.  Ali</span>. </span><span class="cited-content_cbyCitation_article-title">Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (1)
                                     , 137-140. <a href="https://doi.org/10.1016/j.jtho.2016.09.119" title="DOI URL">https://doi.org/10.1016/j.jtho.2016.09.119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2016.09.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2016.09.119%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DEmergence%252Bof%252BPreexisting%252BMET%252BY1230C%252BMutation%252Bas%252Ba%252BResistance%252BMechanism%252Bto%252BCrizotinib%252Bin%252BNSCLC%252Bwith%252BMET%252BExon%252B14%252BSkipping%26aulast%3DOu%26aufirst%3DSai-Hong%2BIgnatius%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3D137%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander  Drilon</span>, <span class="hlFld-ContribAuthor ">Federico  Cappuzzo</span>, <span class="hlFld-ContribAuthor ">Sai-Hong Ignatius  Ou</span>, <span class="hlFld-ContribAuthor ">D. Ross  Camidge</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (1)
                                     , 15-26. <a href="https://doi.org/10.1016/j.jtho.2016.10.014" title="DOI URL">https://doi.org/10.1016/j.jtho.2016.10.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2016.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2016.10.014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DTargeting%252BMET%252Bin%252BLung%252BCancer%25253A%252BWill%252BExpectations%252BFinally%252BBe%252BMET%25253F%26aulast%3DDrilon%26aufirst%3DAlexander%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3D15%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy A.  Yap</span>, <span class="hlFld-ContribAuthor ">Sanjay  Popat</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (1)
                                     , 12-14. <a href="https://doi.org/10.1016/j.jtho.2016.10.019" title="DOI URL">https://doi.org/10.1016/j.jtho.2016.10.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2016.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2016.10.019%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DTargeting%252BMET%252BExon%252B14%252BSkipping%252BAlterations%25253A%252BHas%252BLung%252BCancer%252BMET%252BIts%252BMatch%25253F%26aulast%3DYap%26aufirst%3DTimothy%2BA.%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3D12%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magda  Bahcall</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>, <span class="hlFld-ContribAuthor ">Cloud P.  Paweletz</span>, <span class="hlFld-ContribAuthor ">Jyoti D.  Patel</span>, <span class="hlFld-ContribAuthor ">Ryan S.  Alden</span>, <span class="hlFld-ContribAuthor ">Yanan  Kuang</span>, <span class="hlFld-ContribAuthor ">Adrian G.  Sacher</span>, <span class="hlFld-ContribAuthor ">Nam Doo  Kim</span>, <span class="hlFld-ContribAuthor ">Christine A.  Lydon</span>, <span class="hlFld-ContribAuthor ">Mark M.  Awad</span>, <span class="hlFld-ContribAuthor ">Michael T.  Jaklitsch</span>, <span class="hlFld-ContribAuthor ">Lynette M.  Sholl</span>, <span class="hlFld-ContribAuthor ">Pasi A.  JÃ¤nne</span>, <span class="hlFld-ContribAuthor ">Geoffrey R.  Oxnard</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired
              MET
              D1228V
              Mutation and Resistance to MET Inhibition in Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2016,</strong> <em>6 </em>
                                    (12)
                                     , 1334-1341. <a href="https://doi.org/10.1158/2159-8290.CD-16-0686" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-16-0686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-16-0686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-16-0686%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DAcquired%252BMET%252BD1228V%252BMutation%252Band%252BResistance%252Bto%252BMET%252BInhibition%252Bin%252BLung%252BCancer%26aulast%3DBahcall%26aufirst%3DMagda%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D12%26spage%3D1334%26epage%3D1341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ju  Liu</span>, <span class="hlFld-ContribAuthor ">Minhua  Nie</span>, <span class="hlFld-ContribAuthor ">Yanjing  Wang</span>, <span class="hlFld-ContribAuthor ">Jinxing  Hu</span>, <span class="hlFld-ContribAuthor ">Feng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanlin  Gao</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>123 </em>, 431-446. <a href="https://doi.org/10.1016/j.ejmech.2016.07.059" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.07.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.07.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.07.059%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bstructure-activity%252Brelationships%252Bof%252Bnovel%252B4-phenoxyquinoline%252Bderivatives%252Bcontaining%252B1%25252C2%25252C4-triazolone%252Bmoiety%252Bas%252Bc-Met%252Bkinase%252Binhibitors%26aulast%3DLiu%26aufirst%3DJu%26date%3D2016%26volume%3D123%26spage%3D431%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J  Cui</span>, <span class="hlFld-ContribAuthor ">T  Xia</span>, <span class="hlFld-ContribAuthor ">D  Xie</span>, <span class="hlFld-ContribAuthor ">Y  Gao</span>, <span class="hlFld-ContribAuthor ">Z  Jia</span>, <span class="hlFld-ContribAuthor ">D  Wei</span>, <span class="hlFld-ContribAuthor ">L  Wang</span>, <span class="hlFld-ContribAuthor ">S  Huang</span>, <span class="hlFld-ContribAuthor ">M  Quan</span>, <span class="hlFld-ContribAuthor ">K  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2016,</strong> <em>35 </em>
                                    (36)
                                     , 4708-4718. <a href="https://doi.org/10.1038/onc.2016.14" title="DOI URL">https://doi.org/10.1038/onc.2016.14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/onc.2016.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fonc.2016.14%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DHGF%25252FMet%252Band%252BFOXM1%252Bform%252Ba%252Bpositive%252Bfeedback%252Bloop%252Band%252Brender%252Bpancreatic%252Bcancer%252Bcells%252Bresistance%252Bto%252BMet%252Binhibition%252Band%252Baggressive%252Bphenotypes%26aulast%3DCui%26aufirst%3DJ%26date%3D2016%26date%3D2016%26volume%3D35%26issue%3D36%26spage%3D4708%26epage%3D4718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan E.  Henry</span>, <span class="hlFld-ContribAuthor ">Evan R.  Barry</span>, <span class="hlFld-ContribAuthor ">Lillian  Castriotta</span>, <span class="hlFld-ContribAuthor ">Brendon  Ladd</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Markovets</span>, <span class="hlFld-ContribAuthor ">Garry  Beran</span>, <span class="hlFld-ContribAuthor ">Yongxin  Ren</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Ammar  Adam</span>, <span class="hlFld-ContribAuthor ">Michael  Zinda</span>, <span class="hlFld-ContribAuthor ">Corinne  Reimer</span>, <span class="hlFld-ContribAuthor ">Weiguo  Qing</span>, <span class="hlFld-ContribAuthor ">Weiguo  Su</span>, <span class="hlFld-ContribAuthor ">Edwin  Clark</span>, <span class="hlFld-ContribAuthor ">Celina M.  D'Cruz</span>, <span class="hlFld-ContribAuthor ">Alwin G.  Schuller</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (36)
                                     , 57651-57670. <a href="https://doi.org/10.18632/oncotarget.10859" title="DOI URL">https://doi.org/10.18632/oncotarget.10859</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.10859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.10859%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DAcquired%252Bsavolitinib%252Bresistance%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252Barises%252Bvia%252Bmultiple%252Bmechanisms%252Bthat%252Bconverge%252Bon%252BMET-independent%252BmTOR%252Band%252BMYC%252Bactivation%26aulast%3DHenry%26aufirst%3DRyan%2BE.%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D36%26spage%3D57651%26epage%3D57670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Zhao</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Leduo  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Hao</span>, <span class="hlFld-ContribAuthor ">Chen  Shi</span>, <span class="hlFld-ContribAuthor ">Guangxin  Xia</span>, <span class="hlFld-ContribAuthor ">Jianxin  Yu</span>, <span class="hlFld-ContribAuthor ">Yanjun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymalâepithelial transition factor (c-Met) protein kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (18)
                                     , 4281-4290. <a href="https://doi.org/10.1016/j.bmc.2016.07.019" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.07.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.07.019%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Boptimization%252Bof%252Ba%252Bseries%252Bof%252Bimidazo%25255B4%25252C5-b%25255Dpyrazine%252Bderivatives%252Bas%252Bhighly%252Bpotent%252Band%252Bexquisitely%252Bselective%252Binhibitors%252Bof%252Bthe%252Bmesenchymal%2525E2%252580%252593epithelial%252Btransition%252Bfactor%252B%252528c-Met%252529%252Bprotein%252Bkinase%26aulast%3DZhao%26aufirst%3DFei%26date%3D2016%26volume%3D24%26issue%3D18%26spage%3D4281%26epage%3D4290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Cui</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Chunhua  Ma</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Yingxia  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (18)
                                     , 4483-4486. <a href="https://doi.org/10.1016/j.bmcl.2016.07.077" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.07.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.07.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.07.077%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bc-Met%252Bkinase%252Binhibitors%252Bbearing%252B2-oxo-1%25252C2-dihydroquinoline%252Bscaffold%26aulast%3DCui%26aufirst%3DHong%26date%3D2016%26volume%3D26%26issue%3D18%26spage%3D4483%26epage%3D4486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Garima  Verma</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">The therapeutic voyage of pyrazole and its analogs: A review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>120 </em>, 170-201. <a href="https://doi.org/10.1016/j.ejmech.2016.04.077" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.077%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Btherapeutic%252Bvoyage%252Bof%252Bpyrazole%252Band%252Bits%252Banalogs%25253A%252BA%252Breview%26aulast%3DKhan%26aufirst%3DMohemmed%2BFaraz%26date%3D2016%26volume%3D120%26spage%3D170%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm401427c&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm401427c%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-11&amp;citedByCount=132&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="âtrueâ" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0018.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Examples of Receptor Tyrosine Kinase Drugs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of MET and HGF/SF.<a onclick="showRef(event, 'cit4b'); return false;" href="javascript:void(0);" class="ref cit4b">(4b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. HGF/MET signaling.<a onclick="showRef(event, 'cit22b'); return false;" href="javascript:void(0);" class="ref cit22b">(22b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. apo-MET crystal structures: (A) PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W">1R1W</a> and (B) PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G15">2G15</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Class Ia of Selective MET Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of <b>2</b> bound to the kinase domain of unphosphorylated MET. The backbone trace of the activation loop is highlighted in cyan and hydrogen bonds are indicated as dashed lines (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WKM">2WKM</a>).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of <b>2</b> and <b>3</b> bound to MET (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WKM">2WKM</a>, cyan colore, and PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WGJ">2WGJ</a>, gray colore).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 3. Discovery of Highly Selective MET Inhibitors<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal structure of unphosphorylated MET kinase domain with <b>11</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZZE">3ZZE</a>).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 4. Class Ib of the Exquisitely Selective MET Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cocrystal structure of unphosphorylated MET kinase domain with <b>16</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZXZ">3ZXZ</a>).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Hybrid design leading to the discovery of <b>22</b>.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 5. Class II of Nonselective MET Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Interaction surface of <b>28</b> with MET having DFG out conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8">3LQ8</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Interaction surface of an analogue of <b>31</b> with MET having DFG-in conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3U6I">3U6I</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 6. Other MET Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=cht6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/medium/jm-2013-01427c_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Cocrystal structure of activated MET with an analogue of <b>34</b> having 4-piperidine ring on pyrazole (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7O">3R7O</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm401427c/production/images/large/jm-2013-01427c_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401427c&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 177 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">â</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0liR-F5YKGIacA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">â</span> <span class="NLM_lpage">1134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lhiYlfxmHycxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">â</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lhiYlfxmHycxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Trusolino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">MET signalling: principles and functions in development, organ regeneration and cancer</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrm3012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21102609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGrurfI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=834-848&author=L.+Trusolinoauthor=A.+Bertottiauthor=P.+M.+Comoglio&title=MET+signalling%3A+principles+and+functions+in+development%2C+organ+regeneration+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">MET signalling: principles and functions in development, organ regeneration and cancer</span></div><div class="casAuthors">Trusolino, Livio; Bertotti, Andrea; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">834-848</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The MET tyrosine kinase receptor (also known as the HGF receptor) promotes tissue remodelling, which underlies developmental morphogenesis, wound repair, organ homeostasis and cancer metastasis, by integrating growth, survival and migration cues in response to environmental stimuli or cell-autonomous perturbations.  The versatility of MET-mediated biol. responses is sustained by qual. and quant. signal modulation.  Qual. mechanisms include the engagement of dedicated signal transducers and the subcellular compartmentalization of MET signalling pathways, whereas quant. regulation involves MET partnering with adaptor amplifiers or being degraded through the shedding of its extracellular domain or through intracellular ubiquitylation.  Controlled activation of MET signalling can be exploited in regenerative medicine, whereas MET inhibition might slow down tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzaWXvEKEpVrVg90H21EOLACvtfcHk0lhiYlfxmHycxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGrurfI&md5=c97f7b6ff2522bc0d20d0371d07c5ea2</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrm3012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3012%26sid%3Dliteratum%253Aachs%26aulast%3DTrusolino%26aufirst%3DL.%26aulast%3DBertotti%26aufirst%3DA.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DMET%2520signalling%253A%2520principles%2520and%2520functions%2520in%2520development%252C%2520organ%2520regeneration%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D834%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span> </span><span class="NLM_article-title">Targeting MET in cancer: rationale and progress</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">â</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc3205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22270953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSmu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=89-103&author=E.+Gherardiauthor=W.+Birchmeierauthor=C.+Birchmeierauthor=G.+Vande+Woude&title=Targeting+MET+in+cancer%3A+rationale+and+progress"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MET in cancer: rationale and progress</span></div><div class="casAuthors">Gherardi, Ermanno; Birchmeier, Walter; Birchmeier, Carmen; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-103</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of cancer.  Genetic and biochem. data have demonstrated that the growth and motility factor hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, the tyrosine kinase MET, have a causal role in all of these processes, thus providing a strong rationale for targeting these mols. in cancer.  Parallel progress in understanding the structure and function of HGF/SF, MET and assocd. signalling components has led to the successful development of blocking antibodies and a large no. of small-mol. MET kinase inhibitors.  In this Review, we discuss these advances, as well as results from recent clin. studies that demonstrate that inhibiting MET signalling in several types of solid human tumors has major therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6JxJEFNd5E7Vg90H21EOLACvtfcHk0lhhQuwiUV14bA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSmu7s%253D&md5=ea16195614f1dd385ed48fd29bad9a8d</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrc3205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3205%26sid%3Dliteratum%253Aachs%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DTargeting%2520MET%2520in%2520cancer%253A%2520rationale%2520and%2520progress%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D89%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKinnon, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramnath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Expression and mutational analysis of <i>MET</i> in human solid cancers</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1025</span><span class="NLM_x">â</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fgcc.20604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18709663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1025-1037&author=P.+C.+Maauthor=M.+S.+Tretiakovaauthor=A.+C.+MacKinnonauthor=N.+Ramnathauthor=C.+Johnsonauthor=S.+Dietrichauthor=T.+Seiwertauthor=J.+G.+Christensenauthor=R.+Jagadeeswaranauthor=T.+Krauszauthor=E.+E.+Vokesauthor=A.+N.+Husainauthor=R.+Salgia&title=Expression+and+mutational+analysis+of+MET+in+human+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and mutational analysis of MET in human solid cancers</span></div><div class="casAuthors">Ma, Patrick C.; Tretiakova, Maria S.; MacKinnon, Alexander C.; Ramnath, Nithya; Johnson, Candace; Dietrich, Sascha; Seiwert, Tanguy; Christensen, James G.; Jagadeeswaran, Ramasamy; Krausz, Thomas; Vokes, Everett E.; Husain, Aliya N.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1025-1037</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) regulate a variety of cellular functions, many of which can be dysregulated in human cancers.  Activated MET signaling can lead to cell motility and scattering, angiogenesis, proliferation, branching morphogenesis, invasion, and eventual metastasis.  We performed systematic anal. of the expression of the MET receptor and its ligand HGF in tumor tissue microarrays (TMA) from human solid cancers.  Std. immunohistochem. (IHC) and a computerized automated scoring system were used.  DNA sequencing for MET mutations in both nonkinase and kinase domains was also performed.  MET was differentially overexpressed in human solid cancers.  The ligand HGF was widely expressed in both tumors, primarily intratumoral, and nonmalignant tissues.  The MET/HGF likely is functional and may be activated in autocrine fashion in vivo.  MET and stem cell factor (SCF) were found to be pos. stained in the bronchioalevolar junctions of lung tumors.  A no. of novel mutations of MET were identified, particularly in the extracellular semaphorin domain and the juxtamembrane domain.  MET-HGF pathway can be assayed in TMAs and is often overexpressed in a wide variety of human solid cancers.  MET can be activated through overexpression, mutation, or autocrine signaling in malignant cells.  Mutations in the nonkinase regions of MET might play an important role in tumorigenesis and tumor progression.  MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnenTNgIcAbVg90H21EOLACvtfcHk0lhhQuwiUV14bA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE&md5=cf53884177f20939300673fb034ac91f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fgcc.20604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.20604%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DMacKinnon%26aufirst%3DA.%2BC.%26aulast%3DRamnath%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DDietrich%26aufirst%3DS.%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DExpression%2520and%2520mutational%2520analysis%2520of%2520MET%2520in%2520human%2520solid%2520cancers%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2008%26volume%3D47%26spage%3D1025%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Maulik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikhande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kijima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of the hepatocyte growth factor receptor, MET, in oncogenesis and potential for therapeutic inhibition</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">â</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2FS1359-6101%2801%2900029-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=11750879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=41-59&author=G.+Maulikauthor=A.+Shrikhandeauthor=T.+Kijimaauthor=P.+C.+Maauthor=P.+T.+Morrisonauthor=R.+Salgia&title=Role+of+the+hepatocyte+growth+factor+receptor%2C+MET%2C+in+oncogenesis+and+potential+for+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition</span></div><div class="casAuthors">Maulik, Gautam; Shrikhande, Amol; Kijima, Takashi; Ma, Patrick C.; Morrison, Paul T.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-59</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review is given.  Receptor tyrosine kinases have become important therapeutic targets for anti-neoplastic molecularly targeted therapies.  C-Met is a receptor tyrosine kinase shown to be over-expressed and mutated in a variety of malignancies.  Stimulation of c-Met via its ligand hepatocyte growth factor also known as scatter factor (HGF/SF), leads to a plethora of biol. and biochem. effects in the cell.  There has been considerable knowledge gained on the role of c-Met-HGF/SF axis in normal and malignant cells.  This review summarizes the structure of c-Met and HGF/SF and their family members.  Since there are known mutations of c-Met in solid tumors, particularly in papillary renal cell carcinoma, we have summarized the various mutations and over-expression of c-Met known thus far.  Stimulation of c-Met can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis.  The biol. functions altered by c-Met are quite unique and described in detail.  Along with biol. functions, various signal transduction pathways, including the cytoskeleton are altered with the activation of c-Met-HGF/SF loop.  We have recently shown the phosphorylation of focal adhesion proteins, such as paxillin and p125FAK in response to c-Met stimulation in lung cancer cells, and this is detailed here.  Finally, c-Met when mutated or over-expressed in malignant cells serves as an important therapeutic target and the most recent data in terms of inhibition of c-Met and downstream signal transduction pathways is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom2mu2QMKr_7Vg90H21EOLACvtfcHk0liVqgdJC3p3aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1ahuro%253D&md5=aead14efa103c522ef374b0a16e51b35</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1359-6101%2801%2900029-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6101%252801%252900029-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaulik%26aufirst%3DG.%26aulast%3DShrikhande%26aufirst%3DA.%26aulast%3DKijima%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DMorrison%26aufirst%3DP.%2BT.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%252C%2520MET%252C%2520in%2520oncogenesis%2520and%2520potential%2520for%2520therapeutic%2520inhibition%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2002%26volume%3D13%26spage%3D41%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wilson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridlyand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penuel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">â</span> <span class="NLM_lpage">509</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=505-509&author=T.+R.+Wilsonauthor=J.+Fridlyandauthor=Y.+Yanauthor=E.+Penuelauthor=L.+Burtonauthor=E.+Chanauthor=J.+Pengauthor=E.+Linauthor=Y.+Wangauthor=J.+Sosmanauthor=A.+Ribasauthor=J.+Liauthor=J.+Moffatauthor=D.+P.+Sutherlinauthor=H.+Koeppenauthor=M.+Merchantauthor=R.+Neveauthor=J.+Settleman&title=Widespread+potential+for+growth-factor-driven+resistance+to+anticancer+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DFridlyand%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DNeve%26aufirst%3DR.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DWidespread%2520potential%2520for%2520growth-factor-driven%2520resistance%2520to%2520anticancer%2520kinase%2520inhibitors%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D505%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">MET amplication leads to gefitinib resistance in lung cancer by activating ERBB signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">â</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+amplication+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplication%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toschi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=77-88&author=A.+B.+Turkeauthor=K.+Zejnullahuauthor=Y.+L.+Wuauthor=Y.+Songauthor=D.+Dias-Santagataauthor=E.+Lifshitsauthor=L.+Toschiauthor=A.+Rogersauthor=T.+Mokauthor=L.+Sequistauthor=N.+I.+Lindemanauthor=C.+Murphyauthor=S.+Akhavanfardauthor=B.+Y.+Yeapauthor=Y.+Xiaoauthor=M.+Capellettiauthor=A.+J.+Iafrateauthor=C.+Leeauthor=J.+G.+Christensenauthor=J.+A.+Engelmanauthor=P.+A.+J%C3%A4nne&title=Preexistence+and+clonal+selection+of+MET+amplification+in+EGFR+mutant+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DRogers%26aufirst%3DA.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DSequist%26aufirst%3DL.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DMurphy%26aufirst%3DC.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPreexistence%2520and%2520clonal%2520selection%2520of%2520MET%2520amplification%2520in%2520EGFR%2520mutant%2520NSCLC%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26spage%3D77%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Straussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barzily-Rokni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mongare, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span> </span><span class="NLM_article-title">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnature11183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22763439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=500-504&author=R.+Straussmanauthor=T.+Morikawaauthor=K.+Sheeauthor=M.+Barzily-Rokniauthor=Z.+R.+Qianauthor=J.+Duauthor=A.+Davisauthor=M.+M.+Mongareauthor=J.+Gouldauthor=D.+T.+Frederickauthor=Z.+A.+Cooperauthor=P.+B.+Chapmanauthor=D.+B.+Solitauthor=A.+Ribasauthor=R.+S.+Loauthor=K.+T.+Flahertyauthor=S.+Oginoauthor=J.+A.+Wargoauthor=T.+R.+Golub&title=Tumour+micro-environment+elicits+innate+resistance+to+RAF+inhibitors+through+HGF+secretion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span></div><div class="casAuthors">Straussman, Ravid; Morikawa, Teppei; Shee, Kevin; Barzily-Rokni, Michal; Qian, Zhi Rong; Du, Jinyan; Davis, Ashli; Mongare, Margaret M.; Gould, Joshua; Frederick, Dennie T.; Cooper, Zachary A.; Chapman, Paul B.; Solit, David B.; Ribas, Antoni; Lo, Roger S.; Flaherty, Keith T.; Ogino, Shuji; Wargo, Jennifer A.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">500-504</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drug resistance presents a challenge to the treatment of cancer patients.  Many studies have focused on cell-autonomous mechanisms of drug resistance.  By contrast, the authors proposed that the tumor micro-environment confers innate resistance to therapy.  Here the authors developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs.  The authors found that stroma-mediated resistance is common, particularly to targeted agents.  The authors characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance.  Proteomic anal. showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signaling pathways, and immediate resistance to RAF inhibition.  Immunohistochem. expts. confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment.  Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma.  A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines.  More generally, this study indicates that the systematic dissection of interactions between tumors and their micro-environment can uncover important mechanisms underlying drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwanlhJUTP4LVg90H21EOLACvtfcHk0lhcfqX-vfVYlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J&md5=0616b5feed3c5dc2a53ee2ee382a6c33</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature11183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11183%26sid%3Dliteratum%253Aachs%26aulast%3DStraussman%26aufirst%3DR.%26aulast%3DMorikawa%26aufirst%3DT.%26aulast%3DShee%26aufirst%3DK.%26aulast%3DBarzily-Rokni%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DZ.%2BR.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DMongare%26aufirst%3DM.%2BM.%26aulast%3DGould%26aufirst%3DJ.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DTumour%2520micro-environment%2520elicits%2520innate%2520resistance%2520to%2520RAF%2520inhibitors%2520through%2520HGF%2520secretion%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D500%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Cooper, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, D. G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tainsky, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croce, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Molecular cloning of a new transforming gene from a chemically transformed human cell line</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=1984&pages=29-33&author=C.+S.+Cooperauthor=M.+Parkauthor=D.+G+Blairauthor=M.+A.+Tainskyauthor=K.+Huebnerauthor=C.+M.+Croceauthor=G.+F.+Vande+Woude&title=Molecular+cloning+of+a+new+transforming+gene+from+a+chemically+transformed+human+cell+line"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DC.%2BS.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DD.%2BG%26aulast%3DTainsky%26aufirst%3DM.%2BA.%26aulast%3DHuebner%26aufirst%3DK.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DMolecular%2520cloning%2520of%2520a%2520new%2520transforming%2520gene%2520from%2520a%2520chemically%2520transformed%2520human%2520cell%2520line%26jtitle%3DNature%26date%3D1984%26volume%3D311%26spage%3D29%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Dean, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Beau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robins, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">The human MET oncogene is related to the tyrosine kinase oncogenes</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">â</span> <span class="NLM_lpage">388</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=1985&pages=385-388&author=M.+Deanauthor=M.+Parkauthor=M.+M.+Le+Beauauthor=T.+S.+Robinsauthor=M.+O.+Diazauthor=J.+D.+Rowleyauthor=D.+G.+Blairauthor=G.+F.+Vande+Woude&title=The+human+MET+oncogene+is+related+to+the+tyrosine+kinase+oncogenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DRobins%26aufirst%3DT.%2BS.%26aulast%3DDiaz%26aufirst%3DM.%2BO.%26aulast%3DRowley%26aufirst%3DJ.%2BD.%26aulast%3DBlair%26aufirst%3DD.%2BG.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DThe%2520human%2520MET%2520oncogene%2520is%2520related%2520to%2520the%2520tyrosine%2520kinase%2520oncogenes%26jtitle%3DNature%26date%3D1985%26volume%3D318%26spage%3D385%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Park, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaul, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonda, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">6379</span><span class="NLM_x">â</span> <span class="NLM_lpage">6383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1987&pages=6379-6383&author=M.+Parkauthor=M.+Deanauthor=K.+Kaulauthor=M.+J.+Braunauthor=M.+A.+Gondaauthor=G.+F.+Vande+Woude&title=Sequence+of+MET+protooncogene+cDNA+has+features+characteristic+of+the+tyrosine+kinase+family+of+growth-factor+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DM.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DKaul%26aufirst%3DK.%26aulast%3DBraun%26aufirst%3DM.%2BJ.%26aulast%3DGonda%26aufirst%3DM.%2BA.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DSequence%2520of%2520MET%2520protooncogene%2520cDNA%2520has%2520features%2520characteristic%2520of%2520the%2520tyrosine%2520kinase%2520family%2520of%2520growth-factor%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1987%26volume%3D84%26spage%3D6379%26epage%3D6383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponzetto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Tyrosine kinase receptor indistinguishable from the MET protein</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">â</span> <span class="NLM_lpage">156</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1989&pages=155-156&author=S.+Giordanoauthor=C.+Ponzettoauthor=M.+F.+Di+Renzoauthor=C.+S.+Cooperauthor=P.+M.+Comoglio&title=Tyrosine+kinase+receptor+indistinguishable+from+the+MET+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DPonzetto%26aufirst%3DC.%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26aulast%3DCooper%26aufirst%3DC.%2BS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DTyrosine%2520kinase%2520receptor%2520indistinguishable%2520from%2520the%2520MET%2520protein%26jtitle%3DNature%26date%3D1989%26volume%3D339%26spage%3D155%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youles, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miguel, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blundell, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iamele, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gough, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandyopadhyay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, P. J. G.</span><span> </span><span class="NLM_article-title">Functional map and domain structure of MET, the product of the MET protooncogene and receptor for hepatocyte growth factor/scatter factor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12039</span><span class="NLM_x">â</span> <span class="NLM_lpage">12044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12039-12044&author=E.+Gherardiauthor=M.+E.+Youlesauthor=R.+N.+Miguelauthor=T.+L.+Blundellauthor=L.+Iameleauthor=J.+Goughauthor=A.+Bandyopadhyayauthor=G.+Hartmannauthor=P.+J.+G.+Butler&title=Functional+map+and+domain+structure+of+MET%2C+the+product+of+the+MET+protooncogene+and+receptor+for+hepatocyte+growth+factor%2Fscatter+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DYoules%26aufirst%3DM.%2BE.%26aulast%3DMiguel%26aufirst%3DR.%2BN.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DIamele%26aufirst%3DL.%26aulast%3DGough%26aufirst%3DJ.%26aulast%3DBandyopadhyay%26aufirst%3DA.%26aulast%3DHartmann%26aufirst%3DG.%26aulast%3DButler%26aufirst%3DP.%2BJ.%2BG.%26atitle%3DFunctional%2520map%2520and%2520domain%2520structure%2520of%2520MET%252C%2520the%2520product%2520of%2520the%2520MET%2520protooncogene%2520and%2520receptor%2520for%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D12039%26epage%3D12044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ponzetto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maina, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dalla Zonca, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panayotou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">â</span> <span class="NLM_lpage">271</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1994&pages=261-271&author=C.+Ponzettoauthor=A.+Bardelliauthor=Z.+Zhenauthor=F.+Mainaauthor=P.+dalla+Zoncaauthor=S.+Giordanoauthor=A.+Grazianiauthor=G.+Panayotouauthor=P.+M.+Comoglio&title=A+multifunctional+docking+site+mediates+signaling+and+transformation+by+the+hepatocyte+growth+factor%2Fscatter+factor+receptor+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPonzetto%26aufirst%3DC.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DZhen%26aufirst%3DZ.%26aulast%3DMaina%26aufirst%3DF.%26aulast%3Ddalla%2BZonca%26aufirst%3DP.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DGraziani%26aufirst%3DA.%26aulast%3DPanayotou%26aufirst%3DG.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DA%2520multifunctional%2520docking%2520site%2520mediates%2520signaling%2520and%2520transformation%2520by%2520the%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520receptor%2520family%26jtitle%3DCell%26date%3D1994%26volume%3D77%26spage%3D261%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Bottaro, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faletto, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kmiecik, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aaronson, S. A.</span><span> </span><span class="NLM_article-title">Identification of the hepatocyte growth factor receptor as the MET proto-oncogene product</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">251</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">â</span> <span class="NLM_lpage">804</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1991&pages=802-804&author=D.+P.+Bottaroauthor=J.+S.+Rubinauthor=D.+L.+Falettoauthor=A.+M.+Chanauthor=T.+E.+Kmiecikauthor=G.+F.+Vande+Woudeauthor=S.+A.+Aaronson&title=Identification+of+the+hepatocyte+growth+factor+receptor+as+the+MET+proto-oncogene+product"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBottaro%26aufirst%3DD.%2BP.%26aulast%3DRubin%26aufirst%3DJ.%2BS.%26aulast%3DFaletto%26aufirst%3DD.%2BL.%26aulast%3DChan%26aufirst%3DA.%2BM.%26aulast%3DKmiecik%26aufirst%3DT.%2BE.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DAaronson%26aufirst%3DS.%2BA.%26atitle%3DIdentification%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520as%2520the%2520MET%2520proto-oncogene%2520product%26jtitle%3DScience%26date%3D1991%26volume%3D251%26spage%3D802%26epage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Shimomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagaya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, N.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">6370</span><span class="NLM_x">â</span> <span class="NLM_lpage">6376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=6370-6376&author=T.+Shimomuraauthor=K.+Dendaauthor=A.+Kitamuraauthor=T.+Kawaguchiauthor=M.+Kitoauthor=J.+Kondoauthor=S.+Kagayaauthor=L.+Qinauthor=H.+Takataauthor=K.+Miyazawaauthor=N.+Kitamura&title=Hepatocyte+growth+factor+activator+inhibitor%2C+a+novel+Kunitz-type+serine+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimomura%26aufirst%3DT.%26aulast%3DDenda%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DA.%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DKito%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DJ.%26aulast%3DKagaya%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DTakata%26aufirst%3DH.%26aulast%3DMiyazawa%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DN.%26atitle%3DHepatocyte%2520growth%2520factor%2520activator%2520inhibitor%252C%2520a%2520novel%2520Kunitz-type%2520serine%2520protease%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D6370%26epage%3D6376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kawaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, N.</span><span> </span><span class="NLM_article-title">Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">27558</span><span class="NLM_x">â</span> <span class="NLM_lpage">27564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=27558-27564&author=T.+Kawaguchiauthor=L.+Qinauthor=T.+Shimomuraauthor=J.+Kondoauthor=K.+Matsumotoauthor=K.+Dendaauthor=N.+Kitamura&title=Purification+and+cloning+of+hepatocyte+growth+factor+activator+inhibitor+type+2%2C+a+Kunitz-type+serine+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DShimomura%26aufirst%3DT.%26aulast%3DKondo%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DDenda%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DN.%26atitle%3DPurification%2520and%2520cloning%2520of%2520hepatocyte%2520growth%2520factor%2520activator%2520inhibitor%2520type%25202%252C%2520a%2520Kunitz-type%2520serine%2520protease%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D27558%26epage%3D27564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Holmes, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillozzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deakin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carafoli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherardi, E.</span><span> </span><span class="NLM_article-title">Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">â</span> <span class="NLM_lpage">408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2007&pages=395-408&author=O.+Holmesauthor=S.+Pillozziauthor=J.+A.+Deakinauthor=F.+Carafoliauthor=L.+Kempauthor=P.+J.+Butlerauthor=M.+Lyonauthor=E.+Gherardi&title=Insights+into+the+structure%2Ffunction+of+hepatocyte+growth+factor%2Fscatter+factor+from+studies+with+individual+domains"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DO.%26aulast%3DPillozzi%26aufirst%3DS.%26aulast%3DDeakin%26aufirst%3DJ.%2BA.%26aulast%3DCarafoli%26aufirst%3DF.%26aulast%3DKemp%26aufirst%3DL.%26aulast%3DButler%26aufirst%3DP.%2BJ.%26aulast%3DLyon%26aufirst%3DM.%26aulast%3DGherardi%26aufirst%3DE.%26atitle%3DInsights%2520into%2520the%2520structure%252Ffunction%2520of%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520from%2520studies%2520with%2520individual%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D367%26spage%3D395%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnesano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span> </span><span class="NLM_article-title">A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of MET</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">21267</span><span class="NLM_x">â</span> <span class="NLM_lpage">21277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=21267-21277&author=C.+Basilicoauthor=A.+Arnesanoauthor=M.+Galluzzoauthor=P.+M.+Comoglioauthor=P.+Michieli&title=A+high+affinity+hepatocyte+growth+factor-binding+site+in+the+immunoglobulin-like+region+of+MET"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DArnesano%26aufirst%3DA.%26aulast%3DGalluzzo%26aufirst%3DM.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DMichieli%26aufirst%3DP.%26atitle%3DA%2520high%2520affinity%2520hepatocyte%2520growth%2520factor-binding%2520site%2520in%2520the%2520immunoglobulin-like%2520region%2520of%2520MET%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D21267%26epage%3D21277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Birchmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">MET, metastasis, motility and more</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">â</span> <span class="NLM_lpage">925</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrm1261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=14685170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFeju7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=915-925&author=C.+Birchmeierauthor=W.+Birchmeierauthor=E.+Gherardiauthor=G.+F.+Vande+Woude&title=MET%2C+metastasis%2C+motility+and+more"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Met, metastasis, motility and more</span></div><div class="casAuthors">Birchmeier, Carmen; Birhcmeier, Walter; Gherardi, Ermanno; Vande Woude, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-925</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatocyte growth factor. scatter factor and its receptor, the tyrosine kinase Met, arose late in evolution and are unique to vertebrates.  In spite of this, Met uses mols. such as Gab1 - homologues of which are present in Caenorhabditis elegans and Drosophila melanogaster - for downstream signalling. Pivotal roles for Met in development and cancer have been established: Met controls cell migration and growth in embryogenesis; it also controls growth, invasion and metastasis in cancer cells; and activating Met mutations predispose to human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG_-6XRpZ-sLVg90H21EOLACvtfcHk0lgvV0EE4E-hxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFeju7s%253D&md5=ff5a02c73415784480c628fe65299a81</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1038%2Fnrm1261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1261%26sid%3Dliteratum%253Aachs%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DBirchmeier%26aufirst%3DW.%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DMET%252C%2520metastasis%252C%2520motility%2520and%2520more%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D915%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">Novel therapeutic inhibitors of the c-Met signaling pathway in cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2207</span><span class="NLM_x">â</span> <span class="NLM_lpage">2214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-08-1306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19318488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVWltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=2207-2214&author=J.+P.+Ederauthor=G.+F.+Vande+Woudeauthor=S.+A.+Boernerauthor=P.+M.+LoRusso&title=Novel+therapeutic+inhibitors+of+the+c-Met+signaling+pathway+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer</span></div><div class="casAuthors">Eder, Joseph Paul; Vande Woude, George F.; Boerner, Scott A.; Lo Russo, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2207-2214</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  A wide variety of human malignancies exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the breast, liver, lung, ovary, kidney, and thyroid.  Notably, activating mutations in c-Met have been pos. identified in patients with a particular hereditary form of papillary renal cancer, directly implicating c-Met in human tumorigenesis.  Aberrant signaling of the c-Met signaling pathway due to dysregulation of the c-Met receptor or overexpression of its ligand, hepatocyte growth factor (HGF), has been assocd. with an aggressive phenotype.  Extensive evidence that c-Met signaling is involved in the progression and spread of several cancers and an enhanced understanding of its role in disease have generated considerable interest in c-Met and HGF as major targets in cancer drug development.  This has led to the development of a variety of c-Met pathway antagonists with potential clin. applications.  The three main approaches of pathway-selective anticancer drug development have included antagonism of ligand/receptor interaction, inhibition of the tyrosine kinase catalytic activity, and blockade of the receptor/effector interaction.  Several c-Met antagonists are now under clin. investigation.  Preliminary clin. results of several of these agents, including both monoclonal antibodies and small-mol. tyrosine kinase inhibitors, have been encouraging.  Several multitargeted therapies have also been under investigation in the clinic and have demonstrated promise, particularly with regard to tyrosine kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QBC0vQz8BrVg90H21EOLACvtfcHk0lgvV0EE4E-hxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVWltrY%253D&md5=48b4fc788b2b2cab1ce523047e33721d</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1306%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DNovel%2520therapeutic%2520inhibitors%2520of%2520the%2520c-Met%2520signaling%2520pathway%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D2207%26epage%3D2214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Weidner, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cesare, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span> </span><span class="NLM_article-title">Interaction between Gab1 and the MET receptor tyrosine kinase is responsible for epithelial morphogenesis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=1996&pages=173-176&author=K.+M.+Weidnerauthor=S.+Di+Cesareauthor=M.+Sachsauthor=V.+Brinkmannauthor=J.+Behrensauthor=W.+Birchmeier&title=Interaction+between+Gab1+and+the+MET+receptor+tyrosine+kinase+is+responsible+for+epithelial+morphogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeidner%26aufirst%3DK.%2BM.%26aulast%3DDi%2BCesare%26aufirst%3DS.%26aulast%3DSachs%26aufirst%3DM.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DBehrens%26aufirst%3DJ.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DInteraction%2520between%2520Gab1%2520and%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520is%2520responsible%2520for%2520epithelial%2520morphogenesis%26jtitle%3DNature%26date%3D1996%26volume%3D384%26spage%3D173%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Mosesson, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarden, Y.</span><span> </span><span class="NLM_article-title">Derailed endocytosis: an emerging feature of cancer. <i>Nat. Rev</i></span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">â</span> <span class="NLM_lpage">850</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=835-850&author=Y.+Mosessonauthor=G.+B.+Millsauthor=Y.+Yarden&title=Derailed+endocytosis%3A+an+emerging+feature+of+cancer.+Nat.+Rev"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMosesson%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DDerailed%2520endocytosis%253A%2520an%2520emerging%2520feature%2520of%2520cancer.%2520Nat.%2520Rev%26jtitle%3DCancer%26date%3D2008%26volume%3D8%26spage%3D835%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Joffre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ©nard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calleja, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kermorgant, S.</span><span> </span><span class="NLM_article-title">A direct role for MET endocytosis in tumorigenesis</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">â</span> <span class="NLM_lpage">837</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fncb2257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21642981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlCnsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=827-837&author=C.+Joffreauthor=R.+Barrowauthor=L.+M%C3%A9nardauthor=V.+Callejaauthor=I.+R.+Hartauthor=S.+Kermorgant&title=A+direct+role+for+MET+endocytosis+in+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A direct role for Met endocytosis in tumorigenesis</span></div><div class="casAuthors">Joffre, Carine; Barrow, Rachel; Menard, Ludovic; Calleja, Veronique; Hart, Ian R.; Kermorgant, Stephanie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">827-837</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Compartmentalization of signals generated by receptor tyrosine kinase (RTK) endocytosis has emerged as a major determinant of various cell functions.  Here, using tumor-assocd. Met-activating mutations, we demonstrate a direct link between endocytosis and tumorigenicity.  Met mutants exhibit increased endocytosis/recycling activity and decreased levels of degrdn., leading to accumulation on endosomes, activation of the GTPase Rac1, loss of actin stress fibers and increased levels of cell migration.  Blocking endocytosis inhibited mutants' anchorage-independent growth, in vivo tumorigenesis and metastasis while maintaining their activation.  One mutant resistant to inhibition by a Met-specific tyrosine kinase inhibitor was sensitive to endocytosis inhibition.  Thus, oncogenicity of Met mutants results not only from activation but also from their altered endocytic trafficking, indicating that endosomal signalling may be a crucial mechanism regulating RTK-dependent tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmd_oor_T__LVg90H21EOLACvtfcHk0lhf2wbvKJGvoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlCnsLY%253D&md5=db50f30287d6c1024265275baf80e695</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fncb2257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb2257%26sid%3Dliteratum%253Aachs%26aulast%3DJoffre%26aufirst%3DC.%26aulast%3DBarrow%26aufirst%3DR.%26aulast%3DM%25C3%25A9nard%26aufirst%3DL.%26aulast%3DCalleja%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DI.%2BR.%26aulast%3DKermorgant%26aufirst%3DS.%26atitle%3DA%2520direct%2520role%2520for%2520MET%2520endocytosis%2520in%2520tumorigenesis%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2011%26volume%3D13%26spage%3D827%26epage%3D837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Hammond, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UrbÃ©, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clague, M. J.</span><span> </span><span class="NLM_article-title">Down-regulation of MET, the receptor for hepatocyte growth factor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2761</span><span class="NLM_x">â</span> <span class="NLM_lpage">2770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=2761-2770&author=D.+E.+Hammondauthor=S.+Urb%C3%A9author=G.+F.+Vande+Woudeauthor=M.+J.+Clague&title=Down-regulation+of+MET%2C+the+receptor+for+hepatocyte+growth+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHammond%26aufirst%3DD.%2BE.%26aulast%3DUrb%25C3%25A9%26aufirst%3DS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DClague%26aufirst%3DM.%2BJ.%26atitle%3DDown-regulation%2520of%2520MET%252C%2520the%2520receptor%2520for%2520hepatocyte%2520growth%2520factor%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D2761%26epage%3D2770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Foveau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vingtdeux, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fafeur, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulasne, D.</span><span> </span><span class="NLM_article-title">Down-regulation of the MET receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2495</span><span class="NLM_x">â</span> <span class="NLM_lpage">2507</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1091%2Fmbc.E08-09-0969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19297528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotVyqur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=2495-2507&author=B.+Foveauauthor=F.+Ancotauthor=C.+Leroyauthor=A.+Petrelliauthor=K.+Reissauthor=V.+Vingtdeuxauthor=S.+Giordanoauthor=V.+Fafeurauthor=D.+Tulasne&title=Down-regulation+of+the+MET+receptor+tyrosine+kinase+by+presenilin-dependent+regulated+intramembrane+proteolysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis</span></div><div class="casAuthors">Foveau, Benedicte; Ancot, Frederic; Leroy, Catherine; Petrelli, Annalisa; Reiss, Karina; Vingtdeux, Valerie; Giordano, Silvia; Fafeur, Veronique; Tulasne, David</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2495-2507</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Hepatocyte growth factor/scatter factor (HGF/SF) acts through the membrane-anchored Met receptor tyrosine kinase to induce invasive growth.  Deregulation of this signaling is assocd. with tumorigenesis and involves, in most cases, overexpression of the receptor.  We demonstrate that Met is processed in epithelial cells by presenilin-dependent regulated intramembrane proteolysis (PS-RIP) independently of ligand stimulation.  The proteolytic process involves sequential cleavage by metalloproteases and the Î³-secretase complex, leading to generation of labile fragments.  In normal epithelial cells, although expression of cleavable Met by PS-RIP is down-regulated, uncleavable Met displayed membrane accumulation and induced ligand-independent motility and morphogenesis.  Inversely, in transformed cells, the Met inhibitory antibody DN30 is able to promote Met PS-RIP, resulting in down-regulation of the receptor and inhibition of the Met-dependent invasive growth.  This demonstrates the original involvement of a proteolytic process in degrdn. of the Met receptor implicated in neg. regulation of invasive growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryEBvF43sQbLVg90H21EOLACvtfcHk0lhf2wbvKJGvoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotVyqur0%253D&md5=68e1b3d30567e1a746b3947cb8670905</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1091%2Fmbc.E08-09-0969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.E08-09-0969%26sid%3Dliteratum%253Aachs%26aulast%3DFoveau%26aufirst%3DB.%26aulast%3DAncot%26aufirst%3DF.%26aulast%3DLeroy%26aufirst%3DC.%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DReiss%26aufirst%3DK.%26aulast%3DVingtdeux%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DFafeur%26aufirst%3DV.%26aulast%3DTulasne%26aufirst%3DD.%26atitle%3DDown-regulation%2520of%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520by%2520presenilin-dependent%2520regulated%2520intramembrane%2520proteolysis%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2009%26volume%3D20%26spage%3D2495%26epage%3D2507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavassa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sottile, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naldini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Targeting the tumor and its microenvironment by a dual-function decoy MET receptor</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">â</span> <span class="NLM_lpage">73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=61-73&author=P.+Michieliauthor=M.+Mazzoneauthor=C.+Basilicoauthor=S.+Cavassaauthor=A.+Sottileauthor=L.+Naldiniauthor=P.+M.+Comoglio&title=Targeting+the+tumor+and+its+microenvironment+by+a+dual-function+decoy+MET+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DMazzone%26aufirst%3DM.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DCavassa%26aufirst%3DS.%26aulast%3DSottile%26aufirst%3DA.%26aulast%3DNaldini%26aufirst%3DL.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DTargeting%2520the%2520tumor%2520and%2520its%2520microenvironment%2520by%2520a%2520dual-function%2520decoy%2520MET%2520receptor%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D61%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narsimhan, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medico, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaglia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Expression of the MET/HGF receptor in normal and neoplastic human tissues</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1997</span><span class="NLM_x">â</span> <span class="NLM_lpage">2003</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=1719465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK38XhvFSluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1991&pages=1997-2003&author=M.+F.+Di+Renzoauthor=R.+P.+Narsimhanauthor=M.+Oliveroauthor=S.+Brettiauthor=S.+Giordanoauthor=E.+Medicoauthor=P.+Gagliaauthor=P.+Zaraauthor=P.+M.+Comoglio&title=Expression+of+the+MET%2FHGF+receptor+in+normal+and+neoplastic+human+tissues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the Met/HGF receptor in normal and neoplastic human tissues</span></div><div class="casAuthors">Di Renzo, M. F.; Narsimhan, R. P.; Olivero, M.; Bretti, S.; Giordano, S.; Medico, E.; Gaglia, P.; Zara, P.; Comoglio, P. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1997-2003</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The MET oncogene encodes a transmembrane tyrosine kinase receptor.  Recently, hepatocyte growth factor (HGF), a potent growth factor for hepatocytes involved in liver regeneration, has been proposed as a ligand.  In this paper, the physiol. role of the human Met/HGF receptor is investigated by studying its specific distribution in normal and neoplastic tissues.  Northern blot anal. has shown that the MET gene is selectively expressed in several epithelial tissues.  High levels of MET mRNA have been found in liver, gastrointestinal tract, thyroid and kidney.  Western blot anal. has shown that the levels of the Met protein generally correspond to those of the mRNA.  However, in the thyroid, where there is a high level of MET mRNA, the protein was barely detectable, suggesting translational or posttranslational regulation.  The protein was also detected in the brain.  Normal or increased levels of MET mRNA and Met protein were consistently found in fresh samples of carcinomas as well as in epithelial tumor cell lines.  In thyroid carcinomas of a specific histiotype the amt. of Met protein, almost undetectable in the normal counterpart, was found to be increased more than 100-fold.  The tissue distribution of the Met/HGF receptor indicates that this mol. is involved in growth control of epithelial cells other than hepatocytes and suggests that its increased expression may confer a growth advantage to neoplastic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobwF4weEnvMLVg90H21EOLACvtfcHk0li0Pnxlqb3nGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvFSluw%253D%253D&md5=d58184b28f486759cc74906ecd9bf3b9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26aulast%3DNarsimhan%26aufirst%3DR.%2BP.%26aulast%3DOlivero%26aufirst%3DM.%26aulast%3DBretti%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DMedico%26aufirst%3DE.%26aulast%3DGaglia%26aufirst%3DP.%26aulast%3DZara%26aufirst%3DP.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DExpression%2520of%2520the%2520MET%252FHGF%2520receptor%2520in%2520normal%2520and%2520neoplastic%2520human%2520tissues%26jtitle%3DOncogene%26date%3D1991%26volume%3D6%26spage%3D1997%26epage%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Tajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higuchi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span> </span><span class="NLM_article-title">Tissue distribution of hepatocyte growth factor receptor and its exclusive down-regulation in a regenerating organ after injury</span> <span class="citation_source-journal">J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">â</span> <span class="NLM_lpage">406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=1316892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK38XhvFWqtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1992&pages=401-406&author=H.+Tajimaauthor=O.+Higuchiauthor=K.+Mizunoauthor=T.+Nakamura&title=Tissue+distribution+of+hepatocyte+growth+factor+receptor+and+its+exclusive+down-regulation+in+a+regenerating+organ+after+injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue distribution of hepatocyte growth factor receptor and its exclusive down-regulation in a regenerating organ after injury</span></div><div class="casAuthors">Tajima, Hisao; Higuchi, Osamu; Mizuno, Kensaku; Nakamura, Toshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry </span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">401-6</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    </div><div class="casAbstract">Using 125I-labeled hepatocyte growth factor (HGF) as a ligand, the authors examd. the tissue distribution of the HGF receptor in adult rats.  Specific binding of 125I-HGF was detected in the plasma membranes of liver, spleen, kidney, lung, adrenal gland, pituitary, and thyroid.  Scatchard anal. of HGF binding in liver, spleen, kidney, lung, and adrenal gland revealed the presence of a single class of high affinity receptor with a dissocn. const. (Kd) of 20-30 pM.  The max. no. of binding sites (Bmax) was 400-3,000 sites per ng of plasma membrane protein, the highest no. being in the liver.  Such a wide distribution of a high affinity HGF receptor indicates that HGF may be a multifunctional growth factor, targeting to a variety of organs, and not restricted to liver.  After 70% partial hepatectomy, specific binding of 125I-HGF to membranes of the residual liver rapidly decreased, but there was no change in the kidney, lung, and spleen.  After unilateral nephrectomy rapid down-regulation of the HGF receptor was evident in the remaining kidney, but not in other organs including the liver.  These findings suggest the presence of control mechanisms governing HGF receptor function only in a regenerating organ after injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8WmbEALbtQLVg90H21EOLACvtfcHk0li0Pnxlqb3nGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvFWqtbc%253D&md5=3e1fcf9c606aa4a589bb1a6209df70b9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTajima%26aufirst%3DH.%26aulast%3DHiguchi%26aufirst%3DO.%26aulast%3DMizuno%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DTissue%2520distribution%2520of%2520hepatocyte%2520growth%2520factor%2520receptor%2520and%2520its%2520exclusive%2520down-regulation%2520in%2520a%2520regenerating%2520organ%2520after%2520injury%26jtitle%3DJ.%2520Biochem.%26date%3D1992%26volume%3D111%26spage%3D401%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span> </span><span class="NLM_article-title">Invasive growth: from development to metastasis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">â</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=857-862&author=P.+M.+Comoglioauthor=L.+Trusolino&title=Invasive+growth%3A+from+development+to+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DTrusolino%26aufirst%3DL.%26atitle%3DInvasive%2520growth%253A%2520from%2520development%2520to%2520metastasis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D857%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Schmidt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bladt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goedecke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zschiesche, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, C.</span><span> </span><span class="NLM_article-title">Scatter factor/hepatocyte growth factor is essential for liver development</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">â</span> <span class="NLM_lpage">702</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=699-702&author=C.+Schmidtauthor=F.+Bladtauthor=S.+Goedeckeauthor=V.+Brinkmannauthor=W.+Zschiescheauthor=M.+Sharpeauthor=E.+Gherardiauthor=C.+Birchmeier&title=Scatter+factor%2Fhepatocyte+growth+factor+is+essential+for+liver+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DBladt%26aufirst%3DF.%26aulast%3DGoedecke%26aufirst%3DS.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DZschiesche%26aufirst%3DW.%26aulast%3DSharpe%26aufirst%3DM.%26aulast%3DGherardi%26aufirst%3DE.%26aulast%3DBirchmeier%26aufirst%3DC.%26atitle%3DScatter%2520factor%252Fhepatocyte%2520growth%2520factor%2520is%2520essential%2520for%2520liver%2520development%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D699%26epage%3D702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Uehara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minowa, O..</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuno, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, N.</span><span> </span><span class="NLM_article-title">Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">702</span><span class="NLM_x">â</span> <span class="NLM_lpage">705</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=702-705&author=Y.+Ueharaauthor=O..+Minowaauthor=C.+Moriauthor=K.+Shiotaauthor=J.+Kunoauthor=T.+Nodaauthor=N.+Kitamura&title=Placental+defect+and+embryonic+lethality+in+mice+lacking+hepatocyte+growth+factor%2Fscatter+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUehara%26aufirst%3DY.%26aulast%3DMinowa%26aufirst%3DO..%26aulast%3DMori%26aufirst%3DC.%26aulast%3DShiota%26aufirst%3DK.%26aulast%3DKuno%26aufirst%3DJ.%26aulast%3DNoda%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DN.%26atitle%3DPlacental%2520defect%2520and%2520embryonic%2520lethality%2520in%2520mice%2520lacking%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D702%26epage%3D705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Bladt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riethmacher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isenmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguzzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, C.</span><span> </span><span class="NLM_article-title">Essential role for the MET receptor in the migration of myogenic precursor cells into the limb bud</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">768</span><span class="NLM_x">â</span> <span class="NLM_lpage">771</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=1995&pages=768-771&author=F.+Bladtauthor=D.+Riethmacherauthor=S.+Isenmannauthor=A.+Aguzziauthor=C.+Birchmeier&title=Essential+role+for+the+MET+receptor+in+the+migration+of+myogenic+precursor+cells+into+the+limb+bud"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBladt%26aufirst%3DF.%26aulast%3DRiethmacher%26aufirst%3DD.%26aulast%3DIsenmann%26aufirst%3DS.%26aulast%3DAguzzi%26aufirst%3DA.%26aulast%3DBirchmeier%26aufirst%3DC.%26atitle%3DEssential%2520role%2520for%2520the%2520MET%2520receptor%2520in%2520the%2520migration%2520of%2520myogenic%2520precursor%2520cells%2520into%2520the%2520limb%2520bud%26jtitle%3DNature%26date%3D1995%26volume%3D373%26spage%3D768%26epage%3D771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Maina, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponzetto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, R.</span><span> </span><span class="NLM_article-title">MET receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3341</span><span class="NLM_x">â</span> <span class="NLM_lpage">3350</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=3341-3350&author=F.+Mainaauthor=M.+C.+Hiltonauthor=C.+Ponzettoauthor=A.+M.+Daviesauthor=R.+Klein&title=MET+receptor+signaling+is+required+for+sensory+nerve+development+and+HGF+promotes+axonal+growth+and+survival+of+sensory+neurons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaina%26aufirst%3DF.%26aulast%3DHilton%26aufirst%3DM.%2BC.%26aulast%3DPonzetto%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DKlein%26aufirst%3DR.%26atitle%3DMET%2520receptor%2520signaling%2520is%2520required%2520for%2520sensory%2520nerve%2520development%2520and%2520HGF%2520promotes%2520axonal%2520growth%2520and%2520survival%2520of%2520sensory%2520neurons%26jtitle%3DGenes%2520Dev.%26date%3D1997%26volume%3D11%26spage%3D3341%26epage%3D3350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Sachs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brohmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zechner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">HÃ¼lsken, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeper, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birchmeier, W.</span><span> </span><span class="NLM_article-title">Essential role of Gab1 for signaling by the MET receptor in vivo</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">1375</span><span class="NLM_x">â</span> <span class="NLM_lpage">1384</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2000&pages=1375-1384&author=M.+Sachsauthor=H.+Brohmannauthor=D.+Zechnerauthor=T.+M%C3%BCllerauthor=J.+H%C3%BClskenauthor=I.+Waltherauthor=U.+Schaeperauthor=C.+Birchmeierauthor=W.+Birchmeier&title=Essential+role+of+Gab1+for+signaling+by+the+MET+receptor+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSachs%26aufirst%3DM.%26aulast%3DBrohmann%26aufirst%3DH.%26aulast%3DZechner%26aufirst%3DD.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%26aulast%3DH%25C3%25BClsken%26aufirst%3DJ.%26aulast%3DWalther%26aufirst%3DI.%26aulast%3DSchaeper%26aufirst%3DU.%26aulast%3DBirchmeier%26aufirst%3DC.%26aulast%3DBirchmeier%26aufirst%3DW.%26atitle%3DEssential%2520role%2520of%2520Gab1%2520for%2520signaling%2520by%2520the%2520MET%2520receptor%2520in%2520vivo%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2000%26volume%3D150%26spage%3D1375%26epage%3D1384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Huh, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Factor, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SÃ¡nchez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conner, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorgeirsson, S. S.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor/MET signaling pathway is required for efficient liver regeneration and repair</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">4477</span><span class="NLM_x">â</span> <span class="NLM_lpage">4482</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=4477-4482&author=C.+G.+Huhauthor=V.+M.+Factorauthor=A.+S%C3%A1nchezauthor=K.+Uchidaauthor=E.+A.+Connerauthor=S.+S.+Thorgeirsson&title=Hepatocyte+growth+factor%2FMET+signaling+pathway+is+required+for+efficient+liver+regeneration+and+repair"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuh%26aufirst%3DC.%2BG.%26aulast%3DFactor%26aufirst%3DV.%2BM.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DA.%26aulast%3DUchida%26aufirst%3DK.%26aulast%3DConner%26aufirst%3DE.%2BA.%26aulast%3DThorgeirsson%26aufirst%3DS.%2BS.%26atitle%3DHepatocyte%2520growth%2520factor%252FMET%2520signaling%2520pathway%2520is%2520required%2520for%2520efficient%2520liver%2520regeneration%2520and%2520repair%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D4477%26epage%3D4482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Michalopoulos, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeFrances, M. C.</span><span> </span><span class="NLM_article-title">Liver regeneration</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">â</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1126%2Fscience.276.5309.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=9082986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK2sXitlyqt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=60-66&author=G.+K.+Michalopoulosauthor=M.+C.+DeFrances&title=Liver+regeneration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Liver regeneration</span></div><div class="casAuthors">Michalopoulos, George K.; DeFrances, Marie C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5309</span>),
    <span class="NLM_cas:pages">60-66</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 98 refs.  Liver regeneration after the loss of hepatic tissue is a fundamental parameter of liver response to injury.  Recognized as a phenomenon from mythol. times, it is now defined as an orchestrated response induced by specific external stimuli and involving sequential changes in gene expression, growth factor prodn., and morphol. structure.  Many growth factors and cytokines, most notably hepatocyte growth factor, epidermal growth factor, transforming growth factor-Î±, interleukin-6, tumor necrosis factor-Î±, insulin, and norepinephrine, appear to play important roles in this process.  This review attempts to integrate the findings of the last three decades and looks toward clues as to the nature of the causes that trigger this fascinating organ and cellular response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryWZQ48IfGpbVg90H21EOLACvtfcHk0lg7kMinhF5v3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitlyqt78%253D&md5=3961787026f78ecfbd3032e6c6f8fc90</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.276.5309.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.276.5309.60%26sid%3Dliteratum%253Aachs%26aulast%3DMichalopoulos%26aufirst%3DG.%2BK.%26aulast%3DDeFrances%26aufirst%3DM.%2BC.%26atitle%3DLiver%2520regeneration%26jtitle%3DScience%26date%3D1997%26volume%3D276%26spage%3D60%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Liu, Y.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action</span> <span class="citation_source-journal">Am. J. Physiol.: Renal Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">F7</span><span class="NLM_x">â</span> <span class="NLM_lpage">F16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2004&pages=F7-F16&author=Y.+Liu&title=Hepatocyte+growth+factor+in+kidney+fibrosis%3A+therapeutic+potential+and+mechanisms+of+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DHepatocyte%2520growth%2520factor%2520in%2520kidney%2520fibrosis%253A%2520therapeutic%2520potential%2520and%2520mechanisms%2520of%2520action%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Renal%2520Physiol.%26date%3D2004%26volume%3D287%26spage%3DF7%26epage%3DF16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Chmielowiec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, W. G.</span><span> </span><span class="NLM_article-title">MET is essential for wound healing in the skin</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">162</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2007&pages=151-162&author=J.+Chmielowiecauthor=F.+Rugeauthor=P.+Priceauthor=K.+G.+Hardingauthor=W.+G.+Jiang&title=MET+is+essential+for+wound+healing+in+the+skin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChmielowiec%26aufirst%3DJ.%26aulast%3DRuge%26aufirst%3DF.%26aulast%3DPrice%26aufirst%3DP.%26aulast%3DHarding%26aufirst%3DK.%2BG.%26aulast%3DJiang%26aufirst%3DW.%2BG.%26atitle%3DMET%2520is%2520essential%2520for%2520wound%2520healing%2520in%2520the%2520skin%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2007%26volume%3D177%26spage%3D151%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">â</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0liIWeeICRZZnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Cepero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sierra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1396</span><span class="NLM_x">â</span> <span class="NLM_lpage">1409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.2174%2F138161210791033905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20166985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFynsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1396-1409&author=V.+Ceperoauthor=J.+R.+Sierraauthor=S.+Giordano&title=Tyrosine+kinases+as+molecular+targets+to+inhibit+cancer+progression+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis</span></div><div class="casAuthors">Cepero, V.; Sierra, J. R.; Giordano, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1396-1409</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  During the last decades, the improvement of our knowledge of the mechanisms responsible for cancer development has led to the introduction of new promising strategies of treatment, based on "mol. targeted" drugs.  These drugs are designed to act on specific mols., identified as major players in the maintenance of the malignant status.  The development of inhibitors, mainly monoclonal antibodies and small-mols., directed against activated oncogenes has been the most widely used approach for this kind of treatment.  Among the oncogenes implicated in human cancers, tyrosine kinases play a crit. role.  This observation, together with the discovery that cancer cells can be dependent for their survival from the continuous expression of activated oncogenes (a concept defined as "oncogene addiction"), has made protein kinases ideal targets for targeted therapy in cancer.  As the field of targeted therapies is now rapidly growing and a comprehensive survey would be too wide, this review will thus mainly focus on strategies aimed at inhibiting tyrosine kinases and their signal transduction pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovwa2l5kFkH7Vg90H21EOLACvtfcHk0liIWeeICRZZnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFynsrg%253D&md5=1e5b7e673a31ae4d85bdc91b6ac63117</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F138161210791033905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161210791033905%26sid%3Dliteratum%253Aachs%26aulast%3DCepero%26aufirst%3DV.%26aulast%3DSierra%26aufirst%3DJ.%2BR.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DTyrosine%2520kinases%2520as%2520molecular%2520targets%2520to%2520inhibit%2520cancer%2520progression%2520and%2520metastasis%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2010%26volume%3D16%26spage%3D1396%26epage%3D1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span> </span><span class="NLM_article-title">Drug development of MET inhibitors: targeting oncogene addiction and expedience</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">504</span><span class="NLM_x">â</span> <span class="NLM_lpage">516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=504-516&author=P.+M.+Comoglioauthor=S.+Giordanoauthor=L.+Trusolino&title=Drug+development+of+MET+inhibitors%3A+targeting+oncogene+addiction+and+expedience"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DTrusolino%26aufirst%3DL.%26atitle%3DDrug%2520development%2520of%2520MET%2520inhibitors%253A%2520targeting%2520oncogene%2520addiction%2520and%2520expedience%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D504%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Boccaccio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Invasive growth: a MET-driven genetic programme for cancer and stem cells</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">â</span> <span class="NLM_lpage">645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc1912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=16862193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFGlu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=637-645&author=C.+Boccaccioauthor=P.+M.+Comoglio&title=Invasive+growth%3A+a+MET-driven+genetic+programme+for+cancer+and+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Invasive growth: a MET-driven genetic programme for cancer and stem cells</span></div><div class="casAuthors">Boccaccio, Carla; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metastasis follows the inappropriate activation of a genetic program termed invasive growth, which is a physiol. process that occurs during embryonic development and post-natal organ regeneration.  Burgeoning evidence indicates that invasive growth is also executed by stem and progenitor cells, and is usurped by cancer stem cells.  The MET proto-oncogene, which is expressed in both stem and cancer cells, is a key regulator of invasive growth.  Recent findings indicate that the MET tyrosine-kinase receptor is a sensor of adverse microenvironmental conditions (such as hypoxia) and drives cell invasion and metastasis through the transcriptional activation of a set of genes that control blood coagulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNb2dfp5v27Vg90H21EOLACvtfcHk0liIWeeICRZZnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFGlu70%253D&md5=79319c46d57d395726d389e6cd03068f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrc1912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1912%26sid%3Dliteratum%253Aachs%26aulast%3DBoccaccio%26aufirst%3DC.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DInvasive%2520growth%253A%2520a%2520MET-driven%2520genetic%2520programme%2520for%2520cancer%2520and%2520stem%2520cells%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D637%26epage%3D645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span>Hepatocyte Growth Factor/Scatter Factor (HGF/SF), MET and Cancer References. <a href="http://www.vai.org/MET/Index.aspx" class="extLink">http://www.vai.org/MET/Index.aspx</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Hepatocyte+Growth+Factor%2FScatter+Factor+%28HGF%2FSF%29%2C+MET+and+Cancer+References.+http%3A%2F%2Fwww.vai.org%2FMET%2FIndex.aspx."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Migliore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">Molecular cancer therapy: Can our expectation be MET?</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=641-651&author=C.+Miglioreauthor=S.+Giordano&title=Molecular+cancer+therapy%3A+Can+our+expectation+be+MET%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMigliore%26aufirst%3DC.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DMolecular%2520cancer%2520therapy%253A%2520Can%2520our%2520expectation%2520be%2520MET%253F%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeesh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nallasura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lader, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarbaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Functional expression and mutations of MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">â</span> <span class="NLM_lpage">1488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1479-1488&author=P.+C.+Maauthor=R.+Jagadeeswaranauthor=S.+Jagadeeshauthor=M.+S.+Tretiakovaauthor=V.+Nallasuraauthor=E.+A.+Foxauthor=M.+Hansenauthor=E.+Schaeferauthor=K.+Naokiauthor=A.+Laderauthor=W.+Richardsauthor=D.+Sugarbakerauthor=A.+N.+Husainauthor=J.+G.+Christensenauthor=R.+Salgia&title=Functional+expression+and+mutations+of+MET+and+its+therapeutic+inhibition+with+SU11274+and+small+interfering+RNA+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DJagadeesh%26aufirst%3DS.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DNallasura%26aufirst%3DV.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DSchaefer%26aufirst%3DE.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DLader%26aufirst%3DA.%26aulast%3DRichards%26aufirst%3DW.%26aulast%3DSugarbaker%26aufirst%3DD.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DFunctional%2520expression%2520and%2520mutations%2520of%2520MET%2520and%2520its%2520therapeutic%2520inhibition%2520with%2520SU11274%2520and%2520small%2520interfering%2520RNA%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D1479%26epage%3D1488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">van Leenders, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sookhlall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teubel, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ridder, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reneman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacchetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vissers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Weerden, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenster, G.</span><span> </span><span class="NLM_article-title">Activation of MET induces a stem-like phenotype in human prostate cancer</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e26753</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e26753&author=G.+J.+van+Leendersauthor=R.+Sookhlallauthor=W.+J.+Teubelauthor=C.+M.+de+Ridderauthor=S.+Renemanauthor=A.+Sacchettiauthor=K.+J.+Vissersauthor=W.+van+Weerdenauthor=G.+Jenster&title=Activation+of+MET+induces+a+stem-like+phenotype+in+human+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BLeenders%26aufirst%3DG.%2BJ.%26aulast%3DSookhlall%26aufirst%3DR.%26aulast%3DTeubel%26aufirst%3DW.%2BJ.%26aulast%3Dde%2BRidder%26aufirst%3DC.%2BM.%26aulast%3DReneman%26aufirst%3DS.%26aulast%3DSacchetti%26aufirst%3DA.%26aulast%3DVissers%26aufirst%3DK.%2BJ.%26aulast%3Dvan%2BWeerden%26aufirst%3DW.%26aulast%3DJenster%26aufirst%3DG.%26atitle%3DActivation%2520of%2520MET%2520induces%2520a%2520stem-like%2520phenotype%2520in%2520human%2520prostate%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De26753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Pennacchietti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">â</span> <span class="NLM_lpage">361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=347-361&author=S.+Pennacchiettiauthor=P.+Michieliauthor=M.+Galluzzoauthor=M.+Mazzoneauthor=S.+Giordanoauthor=P.+M.+Comoglio&title=Hypoxia+promotes+invasive+growth+by+transcriptional+activation+of+the+MET+protooncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPennacchietti%26aufirst%3DS.%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DGalluzzo%26aufirst%3DM.%26aulast%3DMazzone%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DHypoxia%2520promotes%2520invasive%2520growth%2520by%2520transcriptional%2520activation%2520of%2520the%2520MET%2520protooncogene%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D3%26spage%3D347%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Casaletto, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClatchey, A. I.</span><span> </span><span class="NLM_article-title">Spatial regulation of receptor tyrosine kinases in development and cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">â</span> <span class="NLM_lpage">400</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc3277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22622641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xntlyks7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=387-400&author=J.+B.+Casalettoauthor=A.+I.+McClatchey&title=Spatial+regulation+of+receptor+tyrosine+kinases+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Spatial regulation of receptor tyrosine kinases in development and cancer</span></div><div class="casAuthors">Casaletto, Jessica B.; McClatchey, Andrea I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-400</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  During development and tissue homeostasis, patterns of cellular organization, proliferation and movement are highly choreographed.  Receptor tyrosine kinases (RTKs) have a crucial role in establishing these patterns.  Individual cells and tissues exhibit tight spatial control of the RTKs that they express, enabling tissue morphogenesis and function, while preventing unwarranted cell division and migration that can contribute to tumorigenesis.  Indeed, RTKs are deregulated in most human cancers and are a major focus of targeted therapeutics.  A growing appreciation of the essential role of spatial RTK regulation during development prompts the realization that spatial deregulation of RTKs is likely to contribute broadly to cancer development and may affect the sensitivity and resistance of cancer to pharmacol. RTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0roP5DmwDDrVg90H21EOLACvtfcHk0ljp3iCD0xcRaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xntlyks7Y%253D&md5=87d62276b4319a41ec37befe62dde0a1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrc3277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3277%26sid%3Dliteratum%253Aachs%26aulast%3DCasaletto%26aufirst%3DJ.%2BB.%26aulast%3DMcClatchey%26aufirst%3DA.%2BI.%26atitle%3DSpatial%2520regulation%2520of%2520receptor%2520tyrosine%2520kinases%2520in%2520development%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D387%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">PatanÃ¨, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coltella, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sponza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliverom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigna, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naldini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferracini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span> </span><span class="NLM_article-title">MET overexpression turns human primary osteoblasts into osteosarcomas</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">4750</span><span class="NLM_x">â</span> <span class="NLM_lpage">4757</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4750-4757&author=S.+Patan%C3%A8author=S.+Avnetauthor=N.+Coltellaauthor=B.+Costaauthor=S.+Sponzaauthor=M.+Oliveromauthor=E.+Vignaauthor=L.+Naldiniauthor=N.+Baldiniauthor=R.+Ferraciniauthor=S.+Corsoauthor=S.+Giordanoauthor=P.+M.+Comoglioauthor=M.+F.+Di+Renzo&title=MET+overexpression+turns+human+primary+osteoblasts+into+osteosarcomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatan%25C3%25A8%26aufirst%3DS.%26aulast%3DAvnet%26aufirst%3DS.%26aulast%3DColtella%26aufirst%3DN.%26aulast%3DCosta%26aufirst%3DB.%26aulast%3DSponza%26aufirst%3DS.%26aulast%3DOliverom%26aufirst%3DM.%26aulast%3DVigna%26aufirst%3DE.%26aulast%3DNaldini%26aufirst%3DL.%26aulast%3DBaldini%26aufirst%3DN.%26aulast%3DFerracini%26aufirst%3DR.%26aulast%3DCorso%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26atitle%3DMET%2520overexpression%2520turns%2520human%2520primary%2520osteoblasts%2520into%2520osteosarcomas%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4750%26epage%3D4757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Houldsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordon-Cardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelsen, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaganti, R. S.</span><span> </span><span class="NLM_article-title">Gene amplification in gastric and esophageal adenocarcinomas</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">6417</span><span class="NLM_x">â</span> <span class="NLM_lpage">6422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1990&pages=6417-6422&author=J.+Houldsworthauthor=C.+Cordon-Cardoauthor=M.+Ladanyiauthor=D.+P.+Kelsenauthor=R.+S.+Chaganti&title=Gene+amplification+in+gastric+and+esophageal+adenocarcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHouldsworth%26aufirst%3DJ.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DKelsen%26aufirst%3DD.%2BP.%26aulast%3DChaganti%26aufirst%3DR.%2BS.%26atitle%3DGene%2520amplification%2520in%2520gastric%2520and%2520esophageal%2520adenocarcinomas%26jtitle%3DCancer%2520Res.%26date%3D1990%26volume%3D50%26spage%3D6417%26epage%3D6422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Umeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiota, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, H.</span><span> </span><span class="NLM_article-title">Clinical significance of MET oncogene alterations in human colorectal cancer</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=314-321&author=K.+Umekiauthor=G.+Shiotaauthor=H.+Kawasaki&title=Clinical+significance+of+MET+oncogene+alterations+in+human+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUmeki%26aufirst%3DK.%26aulast%3DShiota%26aufirst%3DG.%26aulast%3DKawasaki%26aufirst%3DH.%26atitle%3DClinical%2520significance%2520of%2520MET%2520oncogene%2520alterations%2520in%2520human%2520colorectal%2520cancer%26jtitle%3DOncology%26date%3D1999%26volume%3D56%26spage%3D314%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Beau-Faller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegeli, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuville, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legrain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mennecier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wihlm, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quoix, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaub, M. P.</span><span> </span><span class="NLM_article-title">MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naÃ¯ve cohort</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">â</span> <span class="NLM_lpage">339</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1097%2FJTO.0b013e318168d9d4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18379349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BD1c3it1Gjsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=331-339&author=M.+Beau-Fallerauthor=A.+M.+Ruppertauthor=A.+C.+Voegeliauthor=A.+Neuvilleauthor=N.+Meyerauthor=E.+Guerinauthor=M.+Legrainauthor=B.+Mennecierauthor=J.+M.+Wihlmauthor=G.+Massardauthor=E.+Quoixauthor=P.+Oudetauthor=M.+P.+Gaub&title=MET+gene+copy+number+in+non-small+cell+lung+cancer%3A+molecular+analysis+in+a+targeted+tyrosine+kinase+inhibitor+na%C3%AFve+cohort"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort</span></div><div class="casAuthors">Beau-Faller Michele; Ruppert Anne-Marie; Voegeli Anne-Claire; Neuville Agnes; Meyer Nicolas; Guerin Eric; Legrain Michele; Mennecier Bertrand; Wihlm Jean-Marie; Massard Gilbert; Quoix Elisabeth; Oudet Pierre; Gaub Marie P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Recent clinical success of epidermal growth factor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) have raised hopes that targeting other deregulated growth factor signaling, such as the hepatocyte growth factor/MET pathway, will lead to new therapeutic options for NSCLC.  Furthermore, NSCLC present secondary EGFR-TKIs resistance related to exons 20 and 19 EGFR mutations or more recently to MET amplification.  The aim of this study was to determine MET copy number related to EGFR copy number and K-Ras mutations in a targeted TKI naive NSCLC cohort.  METHODS:  We investigated 106 frozen tumors from surgically resected NSCLC patients.  Genes copy number of MET and EGFR were assessed by quantitative relative real-time polymerase chain reaction and K-Ras mutations by sequencing.  RESULTS:  MET is amplified in 22 cases (21%) and deleted in nine cases (8.5%).  EGFR is amplified in 31 cases (29%).  K-Ras is mutated in 11 cases (10.5%).  As observed for EGFR amplification, MET amplification is never associated with K-Ras mutation.  MET amplification could be associated with EGFR amplification.  MET amplification is not related to clinical and pathologic features.  MET amplification and EGFR amplification showed a trend toward poor prognosis in adenocarcinomas.  CONCLUSION:  In EGFR-TKIs naive NSCLC patients, MET amplification is a frequent event, which could be associated with EGFR amplification, but not with K-Ras mutation.  MET amplification may identify a subset of NSCLC for new targeted therapy.  It will also be important to evaluate MET copy number to properly interpret future clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQu7DmD4BD9JQxyojvcjibhfW6udTcc2eaX010qMNNNAbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3it1Gjsw%253D%253D&md5=1457e4a0a360a8344356cee8a538ad55</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e318168d9d4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e318168d9d4%26sid%3Dliteratum%253Aachs%26aulast%3DBeau-Faller%26aufirst%3DM.%26aulast%3DRuppert%26aufirst%3DA.%2BM.%26aulast%3DVoegeli%26aufirst%3DA.%2BC.%26aulast%3DNeuville%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DGuerin%26aufirst%3DE.%26aulast%3DLegrain%26aufirst%3DM.%26aulast%3DMennecier%26aufirst%3DB.%26aulast%3DWihlm%26aufirst%3DJ.%2BM.%26aulast%3DMassard%26aufirst%3DG.%26aulast%3DQuoix%26aufirst%3DE.%26aulast%3DOudet%26aufirst%3DP.%26aulast%3DGaub%26aufirst%3DM.%2BP.%26atitle%3DMET%2520gene%2520copy%2520number%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520molecular%2520analysis%2520in%2520a%2520targeted%2520tyrosine%2520kinase%2520inhibitor%2520na%25C3%25AFve%2520cohort%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2008%26volume%3D3%26spage%3D331%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Tong, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, H. K.</span><span> </span><span class="NLM_article-title">Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization</span> <span class="citation_source-journal">J. Neurosurg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">â</span> <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=14758948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Glt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2004&pages=187-193&author=C.+Y.+Tongauthor=A.+B.+Huiauthor=X.+L.+Yinauthor=J.+C.+Pangauthor=X.+L.+Zhuauthor=W.+S.+Poonauthor=H.+K.+Ng&title=Detection+of+oncogene+amplifications+in+medulloblastomas+by+comparative+genomic+hybridization+and+array-based+comparative+genomic+hybridization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization</span></div><div class="casAuthors">Tong, Carol Y. K.; Hui, Angela B. Y.; Yin, Xiao-Lu; Pang, Jesse C. S.; Zhu, Xian-Lun; Poon, Wai-Sang; Ng, Ho-Keung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurosurgery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">2, Suppl.</span>),
    <span class="NLM_cas:pages">187-193</span>CODEN:
                <span class="NLM_cas:coden">JONSAC</span>;
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    
            (<span class="NLM_cas:orgname">American Association of Neurological Surgeons</span>)
        </div><div class="casAbstract">Object: Few studies have been conducted to investigate the genomic survey of oncogene amplification in medulloblastoma.  Low frequency of N-myc, C-myc, and epidermal grow factor receptor (EGFR) gene amplification (< 10%) has been reported in medulloblastoma.  Previous comparative genomic hybridization (CGH) study of primary medulloblastomas has revealed chromosomal amplification on 2p21, 3p, 5p15.3, 7q, 8q24, 11q22.3, and 17q.  The aim of this study was to detect common oncogenes involved in medulloblastoma tumorigenesis.  Methods: The authors studied a series of 14 samples by performing CGH and array-based CGH.  The CGH anal. detected nonrandom losses on 8p, 17p, 16q, 8q, and 1p, whereas gains were found on 17q, 12q, 7q, and 1p.  Array-based CGH was conducted to investigate amplification of 58 oncogenes throughout the genome of these samples.  Gene amplifications identified for the first time included PGY1 at 7q21.1, MDM2 at 12q14.3-q15, and ERBB2 at 17q21.2.  The highest frequencies of oncogene gain were detected in D17S1670 (61.5%), PIK3CA (46.2%), PGY1 (38.5%), MET (38.5%), ERBB2 (38.5%), and CSE1L (38.5%).  The gain in gene copy nos. was confirmed in 34 addnl. archival medulloblastoma cases by using fluorescence in situ hybridization anal.  Conclusions: This is the first genome-wide survey of multiple oncogene amplifications involved in the development of medulloblastoma.  Gains of several candidate oncogenes such as D17S1670, ERBB2, PIK3CA, PGY1, MET, and CSE1L were frequently detected.  These genes may be used as mol. markers and therapeutic targets of medulloblastomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMsX-htjJnZbVg90H21EOLACvtfcHk0lg7zR4AcLOgdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Glt78%253D&md5=2fcd8ee56c687a8f4ae5771a3ade51c1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DC.%2BY.%26aulast%3DHui%26aufirst%3DA.%2BB.%26aulast%3DYin%26aufirst%3DX.%2BL.%26aulast%3DPang%26aufirst%3DJ.%2BC.%26aulast%3DZhu%26aufirst%3DX.%2BL.%26aulast%3DPoon%26aufirst%3DW.%2BS.%26aulast%3DNg%26aufirst%3DH.%2BK.%26atitle%3DDetection%2520of%2520oncogene%2520amplifications%2520in%2520medulloblastomas%2520by%2520comparative%2520genomic%2520hybridization%2520and%2520array-based%2520comparative%2520genomic%2520hybridization%26jtitle%3DJ.%2520Neurosurg.%26date%3D2004%26volume%3D100%26spage%3D187%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Beroukhim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nghiemphu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsueh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linhart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kau, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prensner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiasi, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demichelis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lander, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellinghoff, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span> </span><span class="NLM_article-title">Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">20007</span><span class="NLM_x">â</span> <span class="NLM_lpage">20012</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=20007-20012&author=R.+Beroukhimauthor=G.+Getzauthor=L.+Nghiemphuauthor=J.+Barretinaauthor=T.+Hsuehauthor=D.+Linhartauthor=I.+Vivancoauthor=J.+C.+Leeauthor=J.+H.+Huangauthor=S.+Alexanderauthor=J.+Duauthor=T.+Kauauthor=R.+K.+Thomasauthor=K.+Shahauthor=H.+Sotoauthor=S.+Pernerauthor=J.+Prensnerauthor=R.+M.+Debiasiauthor=F.+Demichelisauthor=C.+Hattonauthor=M.+A.+Rubinauthor=L.+A.+Garrawayauthor=S.+F.+Nelsonauthor=L.+Liauauthor=P.+S.+Mischelauthor=T.+F.+Cloughesyauthor=M.+Meyersonauthor=T.+A.+Golubauthor=E.+S.+Landerauthor=I.+K.+Mellinghoffauthor=W.+R.+Sellers&title=Assessing+the+significance+of+chromosomal+aberrations+in+cancer%3A+methodology+and+application+to+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DNghiemphu%26aufirst%3DL.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DHsueh%26aufirst%3DT.%26aulast%3DLinhart%26aufirst%3DD.%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DJ.%2BH.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DKau%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DSoto%26aufirst%3DH.%26aulast%3DPerner%26aufirst%3DS.%26aulast%3DPrensner%26aufirst%3DJ.%26aulast%3DDebiasi%26aufirst%3DR.%2BM.%26aulast%3DDemichelis%26aufirst%3DF.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DLiau%26aufirst%3DL.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BA.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DAssessing%2520the%2520significance%2520of%2520chromosomal%2520aberrations%2520in%2520cancer%253A%2520methodology%2520and%2520application%2520to%2520glioma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D20007%26epage%3D20012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Lennerz, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackerman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauwers, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4803</span><span class="NLM_x">â</span> <span class="NLM_lpage">4810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2011.35.4928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22042947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslygs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4803-4810&author=J.+K.+Lennerzauthor=E.+L.+Kwakauthor=A.+Ackermanauthor=M.+Michaelauthor=S.+B.+Foxauthor=K.+Bergethonauthor=G.+Y.+Lauwersauthor=J.+G.+Christensenauthor=K.+D.+Wilnerauthor=D.+A.+Haberauthor=R.+Salgiaauthor=Y.+J.+Bangauthor=J.+W.+Clarkauthor=B.+J.+Solomonauthor=A.+J.+Iafrate&title=MET+amplification+identifies+a+small+and+aggressive+subgroup+of+esophagogastric+adenocarcinoma+with+evidence+of+responsiveness+to+crizotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib</span></div><div class="casAuthors">Lennerz, Jochen K.; Kwak, Eunice L.; Ackerman, Allison; Michael, Michael; Fox, Stephen B.; Bergethon, Kristin; Lauwers, Gregory Y.; Christensen, James G.; Wilner, Keith D.; Haber, Daniel A.; Salgia, Ravi; Bang, Yung-Jue; Clark, Jeffrey W.; Solomon, Benjamin J.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4803-4810</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a mol. marker for targeted therapy.  We examd. a GEC cohort with follow-up and reported the clin. response of four addnl. patients with MET-amplified tumors to the small mol. inhibitor crizotinib as part of an expanded phase 1 cohort study.  Patients and Methods: From 2007 to 2009, patients with GEC were genetically screened as a consecutive series of 489 tumors (stages 0, I, and II, 39%; III, 25%; IV, 36%; n = 222 esophageal, including n = 21 squamous carcinomas).  MET, EGFR, and HER2 amplification status was assessed by using fluorescence in situ hybridization.  Results: Ten (2%) of 489 patients screened harbored MET amplification; 23 (4.7%) harbored EGFR amplification; 45 (8.9%) harbored HER2 amplification; and 411 (84%) were wild type for all three genes (ie, neg.).  MET-amplified tumors were typically high-grade adenocarcinomas that presented at advanced stages (5%; n = 4 of 80).  EGFR-amplified tumors showed the highest fraction of squamous cell carcinoma (17%; n = 4 of 23).  HER2, MET, and EGFR amplification were, with one exception (MET and EGFR pos.), mutually exclusive events.  Survival anal. in patients with stages III and IV disease showed substantially shorter median survival in MET/EGFR-amplified groups, with a rank order for all groups by median survival (from most to least aggressive): MET (7.1 mo; P < .001) less than EGFR (11.2 mo; P = .16) less than HER2 (16.9 mo; P = .89) when compared with the neg. group (16.2 mo).  Two of four patients with MET-amplified tumors treated with crizotinib experienced tumor shrinkage (-30% and -16%) and experienced progression after 3.7 and 3.5 mo.  Conclusion MET amplification defines a small and aggressive subset of GEC with indications of transient sensitivity to the targeted MET inhibitor crizotinib (PF-02341066).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvuLInpDQR7Vg90H21EOLACvtfcHk0lhnGri3Phvq6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslygs7w%253D&md5=c98cb00019310228b39247e23c18d5c4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.4928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.4928%26sid%3Dliteratum%253Aachs%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DAckerman%26aufirst%3DA.%26aulast%3DMichael%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DS.%2BB.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DLauwers%26aufirst%3DG.%2BY.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DMET%2520amplification%2520identifies%2520a%2520small%2520and%2520aggressive%2520subgroup%2520of%2520esophagogastric%2520adenocarcinoma%2520with%2520evidence%2520of%2520responsiveness%2520to%2520crizotinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D4803%26epage%3D4810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Zeng, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiser, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forslund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimbel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culliford, A. T.,  4th</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAlessio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barany, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paty, P. B.</span><span> </span><span class="NLM_article-title">MET gene amplification is associated with advanced stage colorectal cancer and liver metastases</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">258</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2Fj.canlet.2008.02.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18395971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtlWhsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=2008&pages=258-269&author=Z.+S.+Zengauthor=M.+R.+Weiserauthor=E.+Kuntzauthor=C.+T.+Chenauthor=S.+A.+Khanauthor=A.+Forslundauthor=G.+M.+Nashauthor=M.+Gimbelauthor=Y.+Yamaguchiauthor=A.+T.+Cullifordauthor=M.+D%E2%80%99Alessioauthor=F.+Baranyauthor=P.+B.+Paty&title=MET+gene+amplification+is+associated+with+advanced+stage+colorectal+cancer+and+liver+metastases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases</span></div><div class="casAuthors">Zeng, Zhao-Shi; Weiser, Martin R.; Kuntz, Eleanor; Chen, Chin-Tung; Khan, Sajid A.; Forslund, Ann; Nash, Garrett M.; Gimbel, Mark; Yamaguchi, Yuka; Culliford, Alfred T.; D'Alessio, Matthew; Barany, Francis; Paty, Philip B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">258-269</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The c-Met proto-oncogene encodes a receptor tyrosine kinase (TK) that promotes invasive tumor growth and metastasis.  Recent studies show that the presence of c-Met gene amplification is predictive for selective c-Met TK inhibitors in gastric cancer and lung cancer.  In this study, the authors utilized a highly quant. PCR/ligase detection reaction technique to quantify c-Met gene copy no. in primary colorectal cancer (CRC) (N = 247), liver metastases (N = 147), and paired normal tissues.  The authors identified no differences in c-Met gene copy no. between normal colonic mucosa and liver tissue.  However, mean c-Met gene copy no. was significantly elevated in CRC compared with normal mucosa (P < 0.001), and in liver metastases compared with normal liver (P < 0.001).  Furthermore, a significant increase in c-Met was seen in liver metastases compared with primary CRC (P < 0.0001).  C-Met gene amplification was obsd. in 2% (3/177) of localized cancers, 9% (6/70) of cancers with distant metastases (P < 0.02), and 18% (25/147) of liver metastases (P < 0.01).  Among patients treated by liver resection, there was a trend toward poorer 3-yr survival in assocn. with c-Met gene amplification (P = 0.07).  Slight increases in c-Met copy no. can be detected in localized CRCs, but gene amplification is largely restricted to Stage IV primary cancers and liver metastases.  C-Met gene amplification is linked to metastatic progression, and is a viable target for a significant subset of advanced CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw_J0gO8jQzbVg90H21EOLACvtfcHk0lhnGri3Phvq6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtlWhsbw%253D&md5=82b091ddcc6225d0068b3b3f59e906fc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.02.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.02.049%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DZ.%2BS.%26aulast%3DWeiser%26aufirst%3DM.%2BR.%26aulast%3DKuntz%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DKhan%26aufirst%3DS.%2BA.%26aulast%3DForslund%26aufirst%3DA.%26aulast%3DNash%26aufirst%3DG.%2BM.%26aulast%3DGimbel%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DCulliford%26aufirst%3DA.%2BT.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DM.%26aulast%3DBarany%26aufirst%3DF.%26aulast%3DPaty%26aufirst%3DP.%2BB.%26atitle%3DMET%2520gene%2520amplification%2520is%2520associated%2520with%2520advanced%2520stage%2520colorectal%2520cancer%2520and%2520liver%2520metastases%26jtitle%3DCancer%2520Lett.%26date%3D2008%26volume%3D265%26spage%3D258%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Smolen, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohapatra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barmettler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archibald, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sgroi, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">2316</span><span class="NLM_x">â</span> <span class="NLM_lpage">2321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=2316-2321&author=G.+A.+Smolenauthor=R.+Sordellaauthor=B.+Muirauthor=G.+Mohapatraauthor=A.+Barmettlerauthor=H.+Archibaldauthor=W.+J.+Kimauthor=R.+A.+Okimotoauthor=D.+W.+Bellauthor=D.+C.+Sgroiauthor=J.+G.+Christensenauthor=J.+Settlemanauthor=D.+A.+Haber&title=Amplification+of+MET+may+identify+a+subset+of+cancers+with+extreme+sensitivity+to+the+selective+tyrosine+kinase+inhibitor+PHA-665752"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DG.%2BA.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DMuir%26aufirst%3DB.%26aulast%3DMohapatra%26aufirst%3DG.%26aulast%3DBarmettler%26aufirst%3DA.%26aulast%3DArchibald%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DW.%2BJ.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSgroi%26aufirst%3DD.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DAmplification%2520of%2520MET%2520may%2520identify%2520a%2520subset%2520of%2520cancers%2520with%2520extreme%2520sensitivity%2520to%2520the%2520selective%2520tyrosine%2520kinase%2520inhibitor%2520PHA-665752%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D2316%26epage%3D2321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKinnon, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramnath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Expression and mutational analysis of MET in human solid cancers</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1025</span><span class="NLM_x">â</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fgcc.20604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18709663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1025-1037&author=P.+C.+Maauthor=M.+S.+Tretiakovaauthor=A.+C.+MacKinnonauthor=N.+Ramnathauthor=C.+Johnsonauthor=S.+Dietrichauthor=T.+Seiwertauthor=J.+G.+Christensenauthor=R.+Jagadeeswaranauthor=T.+Krauszauthor=E.+E.+Vokesauthor=A.+N.+Husainauthor=R.+Salgia&title=Expression+and+mutational+analysis+of+MET+in+human+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and mutational analysis of MET in human solid cancers</span></div><div class="casAuthors">Ma, Patrick C.; Tretiakova, Maria S.; MacKinnon, Alexander C.; Ramnath, Nithya; Johnson, Candace; Dietrich, Sascha; Seiwert, Tanguy; Christensen, James G.; Jagadeeswaran, Ramasamy; Krausz, Thomas; Vokes, Everett E.; Husain, Aliya N.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1025-1037</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) regulate a variety of cellular functions, many of which can be dysregulated in human cancers.  Activated MET signaling can lead to cell motility and scattering, angiogenesis, proliferation, branching morphogenesis, invasion, and eventual metastasis.  We performed systematic anal. of the expression of the MET receptor and its ligand HGF in tumor tissue microarrays (TMA) from human solid cancers.  Std. immunohistochem. (IHC) and a computerized automated scoring system were used.  DNA sequencing for MET mutations in both nonkinase and kinase domains was also performed.  MET was differentially overexpressed in human solid cancers.  The ligand HGF was widely expressed in both tumors, primarily intratumoral, and nonmalignant tissues.  The MET/HGF likely is functional and may be activated in autocrine fashion in vivo.  MET and stem cell factor (SCF) were found to be pos. stained in the bronchioalevolar junctions of lung tumors.  A no. of novel mutations of MET were identified, particularly in the extracellular semaphorin domain and the juxtamembrane domain.  MET-HGF pathway can be assayed in TMAs and is often overexpressed in a wide variety of human solid cancers.  MET can be activated through overexpression, mutation, or autocrine signaling in malignant cells.  Mutations in the nonkinase regions of MET might play an important role in tumorigenesis and tumor progression.  MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnenTNgIcAbVg90H21EOLACvtfcHk0ljwRohI78jT6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE&md5=cf53884177f20939300673fb034ac91f</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2Fgcc.20604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.20604%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DMacKinnon%26aufirst%3DA.%2BC.%26aulast%3DRamnath%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DDietrich%26aufirst%3DS.%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DExpression%2520and%2520mutational%2520analysis%2520of%2520MET%2520in%2520human%2520solid%2520cancers%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2008%26volume%3D47%26spage%3D1025%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Ghiso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">Targeting MET: why, where and how?</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">â</span> <span class="NLM_lpage">518</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2Fj.coph.2013.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23797036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSmurnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=511-518&author=E.+Ghisoauthor=S.+Giordano&title=Targeting+MET%3A+why%2C+where+and+how%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MET: why, where and how?</span></div><div class="casAuthors">Ghiso, Elena; Giordano, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-518</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite the initial skepticism, targeted therapies represent a new perspective in the treatment of cancer.  Tyrosine kinases, and in particular receptor tyrosine kinases (RTKs), are considered ideal targets for this type of therapy.  MET, the tyrosine kinase receptor for the Hepatocyte Growth Factor (HGF), has recently become a very interesting and studied target in oncol.  In this review we discuss firstly 'why' the MET/HGF pathway can be considered a target in human tumors; secondly 'where' MET/HGF inhibition can be useful in cancer treatment and finally 'how' MET and HGF can be inhibited using either monoclonal antibodies or tyrosine kinase inhibitors.  We also highlight some questions in the anti-MET/HGF targeted therapy field that are still waiting for an answer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq33qI6WAqWJ7Vg90H21EOLACvtfcHk0ljwRohI78jT6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSmurnL&md5=507f17d762550af451af791c1527d50d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2013.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2013.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DGhiso%26aufirst%3DE.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DTargeting%2520MET%253A%2520why%252C%2520where%2520and%2520how%253F%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2013%26volume%3D13%26spage%3D511%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Schmidt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duh, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choyke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubensky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">AllikMETs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chidambaram, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergerheim, U. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltis, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamarron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernues, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lips, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geil, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orcutt, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stackhouse, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slife, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brauch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niehans, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storkel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerman, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linehan, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zbar, B.</span><span> </span><span class="NLM_article-title">Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">â</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fng0597-68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=9140397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK2sXivFKhsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=68-73&author=L.+Schmidtauthor=F.+M.+Duhauthor=F.+Chenauthor=T.+Kishidaauthor=G.+Glennauthor=P.+Choykeauthor=S.+W.+Schererauthor=Z.+Zhuangauthor=I.+Lubenskyauthor=M.+Deanauthor=R.+AllikMETsauthor=A.+Chidambaramauthor=U.+R.+Bergerheimauthor=J.+T.+Feltisauthor=C.+Casadevallauthor=A.+Zamarronauthor=M.+Bernuesauthor=S.+Richardauthor=C.+J.+Lipsauthor=M.+M.+Waltherauthor=L.+C.+Tsuiauthor=L.+Geilauthor=M.+L.+Orcuttauthor=T.+Stackhouseauthor=J.+Lipanauthor=L.+Slifeauthor=H.+Brauchauthor=J.+Deckerauthor=G.+Niehansauthor=M.+D.+Hughsonauthor=H.+Mochauthor=S.+Storkelauthor=M.+I.+Lermanauthor=W.+M.+Linehanauthor=B.+Zbar&title=Germline+and+somatic+mutations+in+the+tyrosine+kinase+domain+of+the+MET+proto-oncogene+in+papillary+renal+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas</span></div><div class="casAuthors">Schmidt, Laura; Duh, Fuh-Mei; Chen, Fan; Kishida, Takeshi; Glenn, Gladys; Choyke, Peter; Scherer, Stephen W.; Zhuang, Zhenping; Lubensky, Irina; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumors.  The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance.  HPRC is histol. and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8).  Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome.  Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of both copies of the VHL gene by mutation, and/or by hypermethylation.  We found that the HPRC gene was located at chromosome 7q31.1-34 in a 27-centimorgan (cM) interval between D7S496 and D7S1837.  We identified missense mutations located in the tyrosine kinase domain of the MET gene in the germline of affected members of HPRC families and in a subset of sporadic papillary renal carcinomas.  Three mutations in the MET gene are located in codons that are homologous to those in c-kit and RET, proto-oncogenes that are targets of naturally-occurring mutations.  The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm-x_dqJPR-7Vg90H21EOLACvtfcHk0lhDGh8wz3bG9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFKhsbw%253D&md5=7209dbbaa538b418defad117830df3c9</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fng0597-68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0597-68%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DL.%26aulast%3DDuh%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DKishida%26aufirst%3DT.%26aulast%3DGlenn%26aufirst%3DG.%26aulast%3DChoyke%26aufirst%3DP.%26aulast%3DScherer%26aufirst%3DS.%2BW.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DLubensky%26aufirst%3DI.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DAllikMETs%26aufirst%3DR.%26aulast%3DChidambaram%26aufirst%3DA.%26aulast%3DBergerheim%26aufirst%3DU.%2BR.%26aulast%3DFeltis%26aufirst%3DJ.%2BT.%26aulast%3DCasadevall%26aufirst%3DC.%26aulast%3DZamarron%26aufirst%3DA.%26aulast%3DBernues%26aufirst%3DM.%26aulast%3DRichard%26aufirst%3DS.%26aulast%3DLips%26aufirst%3DC.%2BJ.%26aulast%3DWalther%26aufirst%3DM.%2BM.%26aulast%3DTsui%26aufirst%3DL.%2BC.%26aulast%3DGeil%26aufirst%3DL.%26aulast%3DOrcutt%26aufirst%3DM.%2BL.%26aulast%3DStackhouse%26aufirst%3DT.%26aulast%3DLipan%26aufirst%3DJ.%26aulast%3DSlife%26aufirst%3DL.%26aulast%3DBrauch%26aufirst%3DH.%26aulast%3DDecker%26aufirst%3DJ.%26aulast%3DNiehans%26aufirst%3DG.%26aulast%3DHughson%26aufirst%3DM.%2BD.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DStorkel%26aufirst%3DS.%26aulast%3DLerman%26aufirst%3DM.%2BI.%26aulast%3DLinehan%26aufirst%3DW.%2BM.%26aulast%3DZbar%26aufirst%3DB.%26atitle%3DGermline%2520and%2520somatic%2520mutations%2520in%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520MET%2520proto-oncogene%2520in%2520papillary%2520renal%2520carcinomas%26jtitle%3DNat.%2520Genet.%26date%3D1997%26volume%3D16%26spage%3D68%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artigiani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gual, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Different point mutations in the MET oncogene elicit distinct biological properties</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">â</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=399-406&author=S.+Giordanoauthor=A.+Maffeauthor=T.+A.+Williamsauthor=S.+Artigianiauthor=P.+Gualauthor=A.+Bardelliauthor=C.+Basilicoauthor=P.+Michieliauthor=P.+M.+Comoglio&title=Different+point+mutations+in+the+MET+oncogene+elicit+distinct+biological+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DMaffe%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DT.%2BA.%26aulast%3DArtigiani%26aufirst%3DS.%26aulast%3DGual%26aufirst%3DP.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DDifferent%2520point%2520mutations%2520in%2520the%2520MET%2520oncogene%2520elicit%2520distinct%2520biological%2520properties%26jtitle%3DFASEB%2520J.%26date%3D2000%26volume%3D14%26spage%3D399%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Graveel, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">A mouse model of activating MET mutations</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">518</span><span class="NLM_x">â</span> <span class="NLM_lpage">520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=518-520&author=C.+R.+Graveelauthor=C.+A.+Londonauthor=G.+F.+Vande+Woude&title=A+mouse+model+of+activating+MET+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGraveel%26aufirst%3DC.%2BR.%26aulast%3DLondon%26aufirst%3DC.%2BA.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DA%2520mouse%2520model%2520of%2520activating%2520MET%2520mutations%26jtitle%3DCell%2520Cycle%26date%3D2005%26volume%3D4%26spage%3D518%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Ghadjar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank-Liss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simcock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegyi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aebersold, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, Y.</span><span> </span><span class="NLM_article-title">MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers</span> <span class="citation_source-journal">Clin. Exp. Metastasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">â</span> <span class="NLM_lpage">815</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1007%2Fs10585-009-9280-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19639388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWls7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=809-815&author=P.+Ghadjarauthor=W.+Blank-Lissauthor=M.+Simcockauthor=I.+Hegyiauthor=K.+T.+Beerauthor=H.+Mochauthor=D.+M.+Aebersoldauthor=Y.+Zimmer&title=MET+Y1253D-activating+point+mutation+and+development+of+distant+metastasis+in+advanced+head+and+neck+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers</span></div><div class="casAuthors">Ghadjar, Pirus; Blank-Liss, Wieslawa; Simcock, Mathew; Hegyi, Ivan; Beer, Karl T.; Moch, Holger; Aebersold, Daniel M.; Zimmer, Yitzhak</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Metastasis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">809-815</span>CODEN:
                <span class="NLM_cas:coden">CEXMD2</span>;
        ISSN:<span class="NLM_cas:issn">0262-0898</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We investigated if the MET-activating point mutation Y1253D influences clin. outcomes in patients with advanced squamous cell carcinoma of the head and neck (HNSCC).  The study population consisted of 152 HNSCC patients treated by hyperfractionated radiotherapy alone or concomitant with chemotherapy between Sept. 1994 and July 2000.  Tumors were screened for the presence of the MET-activating point mutation Y1253D.  Seventy-eight patients (51%) received radiotherapy alone, 74 patients (49%) underwent radiotherapy concomitant with chemotherapy.  Median patient age was 54 years and median follow-up was 5.5 years.  Distant metastasis-free survival, local relapse-free survival and overall survival were compared with MET Y1253D status.  During follow-up, 29 (19%) patients developed distant metastasis.  MET Y1253D was detected in tumors of 21 out of 152 patients (14%).  Distant metastasis-free survival (P = 0.008) was assocd. with MET Y1253D.  In a multivariate Cox regression model, adjusted for T-category, only presence of MET Y1253D was assocd. with decreased distant metastasis-free survival: hazard ratio = 2.5 (95% confidence interval: 1.1, 5.8).  The obsd. assocn. between MET Y1253D-activating point mutation and decreased distant metastasis-free survival in advanced HNSCC suggests that MET may be a potential target for specific treatment interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmUFtMYBRo1bVg90H21EOLACvtfcHk0lhDGh8wz3bG9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWls7%252FI&md5=cf6c9006cb2ce536bf9869dd23ed93bf</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs10585-009-9280-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10585-009-9280-9%26sid%3Dliteratum%253Aachs%26aulast%3DGhadjar%26aufirst%3DP.%26aulast%3DBlank-Liss%26aufirst%3DW.%26aulast%3DSimcock%26aufirst%3DM.%26aulast%3DHegyi%26aufirst%3DI.%26aulast%3DBeer%26aufirst%3DK.%2BT.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DAebersold%26aufirst%3DD.%2BM.%26aulast%3DZimmer%26aufirst%3DY.%26atitle%3DMET%2520Y1253D-activating%2520point%2520mutation%2520and%2520development%2520of%2520distant%2520metastasis%2520in%2520advanced%2520head%2520and%2520neck%2520cancers%26jtitle%3DClin.%2520Exp.%2520Metastasis%26date%3D2009%26volume%3D26%26spage%3D809%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennacchietti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MaffÃ¨, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamagnone, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Mutant MET-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5221</span><span class="NLM_x">â</span> <span class="NLM_lpage">5231</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=5221-5231&author=P.+Michieliauthor=C.+Basilicoauthor=S.+Pennacchiettiauthor=A.+Maff%C3%A8author=L.+Tamagnoneauthor=S.+Giordanoauthor=A.+Bardelliauthor=P.+M.+Comoglio&title=Mutant+MET-mediated+transformation+is+ligand-dependent+and+can+be+inhibited+by+HGF+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DPennacchietti%26aufirst%3DS.%26aulast%3DMaff%25C3%25A8%26aufirst%3DA.%26aulast%3DTamagnone%26aufirst%3DL.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DMutant%2520MET-mediated%2520transformation%2520is%2520ligand-dependent%2520and%2520can%2520be%2520inhibited%2520by%2520HGF%2520antagonists%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D5221%26epage%3D5231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Gumustekin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kargi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulut, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozukizil, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulukus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oztop, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atabey, N.</span><span> </span><span class="NLM_article-title">HGF/MET overexpressions, but not MET mutation, correlates with progression of non-small cell lung cancer</span> <span class="citation_source-journal">Pathol. Oncol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1007%2Fs12253-011-9430-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21779788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVeqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=209-218&author=M.+Gumustekinauthor=A.+Kargiauthor=G.+Bulutauthor=A.+Gozukizilauthor=C.+Ulukusauthor=I.+Oztopauthor=N.+Atabey&title=HGF%2FMET+overexpressions%2C+but+not+MET+mutation%2C+correlates+with+progression+of+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">HGF/c-Met Overexpressions, but not Met Mutation, Correlates with Progression of Non-small Cell Lung Cancer</span></div><div class="casAuthors">Gumustekin, Mukaddes; Kargi, Aydanur; Bulut, Gulay; Gozukizil, Aysim; Ulukus, Cagnur; Oztop, Ilhan; Atabey, Nese</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-218</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hepatocyte Growth Factor (HGF) and its receptor c-Met are suggested to play an important role in progression of solid organ tumors by mediating cell motility, invasion and metastasis.  Overexpression of HGF and c-Met have been shown in non-small-cell lung cancer (NSCLC).  However, their role in tumor progression is not clearly defined.  The aim of this study is to det. the role of HGF/c-Met pathway and its assocn. with invasion related markers and clinicopathol. parameters in NSCLC.  Immunohistochem. anal. was performed on 63 paraffin-embedded NSCLC tumor sections.  The expressions of invasion related markers such as Matrix Metalloproteinases (MMPs) 2 and 9, Tissue Inhibitor Metalloproteinase (TIMP) 1 and 3 and RhoA were also examd.  Co-expression of HGF/c-Met was significantly assocd. with lymph node invasion and TIMP-3 and RhoA overexpressions.  There were pos. correlation between TIMP-3 overexpression and advanced stage and neg. correlation between RhoA overexpression and survival.  DNA sequencing for Met mutations in both nonkinase and tyrosine kinase (TK) domain was established.  A single nucleotide polymorphism (SNP) in sema domain and two SNPs in TK domain of c-Met were found.  There was no statistically significant correlation between the presence of c-Met alterations and clinicopathol. parameters except shorter survival time in cases with two SNPs in TK domain.  These results suggest that HGF/c-Met might exert their effects in tumor progression in assocn. with RhoA and probably with TIMP-3.  The blockade of the HGF/c-Met pathway with RhoA and/or TIMP-3 inhibitors may be an effective therapeutic target for NSCLC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-j4l7V3eLFbVg90H21EOLACvtfcHk0li-7EezZH4Z7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVeqtbk%253D&md5=ca0c25c427bd55104df0e63060f8886f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs12253-011-9430-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-011-9430-7%26sid%3Dliteratum%253Aachs%26aulast%3DGumustekin%26aufirst%3DM.%26aulast%3DKargi%26aufirst%3DA.%26aulast%3DBulut%26aufirst%3DG.%26aulast%3DGozukizil%26aufirst%3DA.%26aulast%3DUlukus%26aufirst%3DC.%26aulast%3DOztop%26aufirst%3DI.%26aulast%3DAtabey%26aufirst%3DN.%26atitle%3DHGF%252FMET%2520overexpressions%252C%2520but%2520not%2520MET%2520mutation%252C%2520correlates%2520with%2520progression%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2012%26volume%3D18%26spage%3D209%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Peschard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.</span><span> </span><span class="NLM_article-title">From Tpr-MET to MET tumorigenesis and tubes</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1276</span><span class="NLM_x">â</span> <span class="NLM_lpage">1285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=1276-1285&author=P.+Peschardauthor=M.+Park&title=From+Tpr-MET+to+MET+tumorigenesis+and+tubes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeschard%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DM.%26atitle%3DFrom%2520Tpr-MET%2520to%2520MET%2520tumorigenesis%2520and%2520tubes%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D1276%26epage%3D1285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Otsuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaRochelle, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottaro, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anver, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlino, G.</span><span> </span><span class="NLM_article-title">MET autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">5157</span><span class="NLM_x">â</span> <span class="NLM_lpage">5167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=5157-5167&author=T.+Otsukaauthor=H.+Takayamaauthor=R.+Sharpauthor=G.+Celliauthor=W.+J.+LaRochelleauthor=D.+P.+Bottaroauthor=N.+Ellmoreauthor=W.+Vieiraauthor=J.+W.+Owensauthor=M.+Anverauthor=G.+Merlino&title=MET+autocrine+activation+induces+development+of+malignant+melanoma+and+acquisition+of+the+metastatic+phenotype"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOtsuka%26aufirst%3DT.%26aulast%3DTakayama%26aufirst%3DH.%26aulast%3DSharp%26aufirst%3DR.%26aulast%3DCelli%26aufirst%3DG.%26aulast%3DLaRochelle%26aufirst%3DW.%2BJ.%26aulast%3DBottaro%26aufirst%3DD.%2BP.%26aulast%3DEllmore%26aufirst%3DN.%26aulast%3DVieira%26aufirst%3DW.%26aulast%3DOwens%26aufirst%3DJ.%2BW.%26aulast%3DAnver%26aufirst%3DM.%26aulast%3DMerlino%26aufirst%3DG.%26atitle%3DMET%2520autocrine%2520activation%2520induces%2520development%2520of%2520malignant%2520melanoma%2520and%2520acquisition%2520of%2520the%2520metastatic%2520phenotype%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D5157%26epage%3D5167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Xie, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worschech, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Giorgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefene, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essenburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeKoning, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâRourke, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marincola, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">570</span><span class="NLM_x">â</span> <span class="NLM_lpage">575</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=570-575&author=Q.+Xieauthor=R.+Bradleyauthor=L.+Kangauthor=J.+Koemanauthor=M.+L.+Asciertoauthor=A.+Worschechauthor=V.+De+Giorgiauthor=E.+Wangauthor=L.+Kefeneauthor=Y.+Suauthor=C.+Essenburgauthor=D.+W.+Kaufmanauthor=T.+DeKoningauthor=M.+A.+Enterauthor=T.+J.+O%E2%80%99Rourkeauthor=F.+M.+Marincolaauthor=G.+F.+Vande+Woude&title=Hepatocyte+growth+factor+%28HGF%29+autocrine+activation+predicts+sensitivity+to+MET+inhibition+in+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DBradley%26aufirst%3DR.%26aulast%3DKang%26aufirst%3DL.%26aulast%3DKoeman%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DM.%2BL.%26aulast%3DWorschech%26aufirst%3DA.%26aulast%3DDe%2BGiorgi%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DKefene%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DEssenburg%26aufirst%3DC.%26aulast%3DKaufman%26aufirst%3DD.%2BW.%26aulast%3DDeKoning%26aufirst%3DT.%26aulast%3DEnter%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DT.%2BJ.%26aulast%3DMarincola%26aufirst%3DF.%2BM.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DHepatocyte%2520growth%2520factor%2520%2528HGF%2529%2520autocrine%2520activation%2520predicts%2520sensitivity%2520to%2520MET%2520inhibition%2520in%2520glioblastoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D570%26epage%3D575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Kentsis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tholouli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valk, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delwel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutok, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licht, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">â</span> <span class="NLM_lpage">1122</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnm.2819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22683780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Ciu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1118-1122&author=A.+Kentsisauthor=C.+Reedauthor=K.+L.+Riceauthor=T.+Sandaauthor=S.+J.+Rodigauthor=E.+Tholouliauthor=A.+Christieauthor=P.+J.+Valkauthor=R.+Delwelauthor=V.+Ngoauthor=J.+L.+Kutokauthor=S.+E.+Dahlbergauthor=L.+A.+Moreauauthor=R.+J.+Byersauthor=J.+G.+Christensenauthor=G.+Vande+Woudeauthor=J.+D.+Lichtauthor=A.+L.+Kungauthor=L.+M.+Staudtauthor=A.+T.+Look&title=Autocrine+activation+of+the+MET+receptor+tyrosine+kinase+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia</span></div><div class="casAuthors">Kentsis, Alex; Reed, Casie; Rice, Kim L.; Sanda, Takaomi; Rodig, Scott J.; Tholouli, Eleni; Christie, Amanda; Valk, Peter J. M.; Delwel, Ruud; Ngo, Vu; Kutok, Jeffery L.; Dahlberg, Suzanne E.; Moreau, Lisa A.; Byers, Richard J.; Christensen, James G.; Woude, George Vande; Licht, Jonathan D.; Kung, Andrew L.; Staudt, Louis M.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1118-1122</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the treatment of acute myeloid leukemia (AML) has improved substantially in the past 3 decades, more than half of all patients develop disease that is refractory to intensive chemotherapy.  Functional genomics approaches offer a means to discover specific mols. mediating the aberrant growth and survival of cancer cells.  Thus, using a loss-of-function RNA interference genomic screen, we identified the aberrant expression of hepatocyte growth factor (HGF) as a crucial element in AML pathogenesis.  We found HGF expression leading to autocrine activation of its receptor tyrosine kinase, MET, in nearly half of the AML cell lines and clin. samples we studied.  Genetic depletion of HGF or MET potently inhibited the growth and survival of HGF-expressing AML cells.  However, leukemic cells treated with the specific MET kinase inhibitor crizotinib developed resistance resulting from compensatory upregulation of HGF expression, leading to the restoration of MET signaling.  In cases of AML where MET is coactivated with other tyrosine kinases, such as fibroblast growth factor receptor 1 (FGFR1), concomitant inhibition of FGFR1 and MET blocked this compensatory HGF upregulation, resulting in sustained logarithmic cell killing both in vitro and in xenograft models in vivo.  These results show a widespread dependence of AML cells on autocrine activation of MET, as well as the key role of compensatory upregulation of HGF expression in maintaining leukemogenic signaling by this receptor.  We anticipate that these findings will lead to the design of addnl. strategies to block adaptive cellular responses that drive compensatory ligand expression as an essential component of the targeted inhibition of oncogenic receptors in human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5q5ejcRZRTLVg90H21EOLACvtfcHk0lh99JM0I7PYVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Ciu7g%253D&md5=c0817d9a114964db126b8e7ab684bd66</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnm.2819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2819%26sid%3Dliteratum%253Aachs%26aulast%3DKentsis%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DC.%26aulast%3DRice%26aufirst%3DK.%2BL.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DTholouli%26aufirst%3DE.%26aulast%3DChristie%26aufirst%3DA.%26aulast%3DValk%26aufirst%3DP.%2BJ.%26aulast%3DDelwel%26aufirst%3DR.%26aulast%3DNgo%26aufirst%3DV.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DMoreau%26aufirst%3DL.%2BA.%26aulast%3DByers%26aufirst%3DR.%2BJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DAutocrine%2520activation%2520of%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D1118%26epage%3D1122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Tokunou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iba, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saitoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirohashi, S.</span><span> </span><span class="NLM_article-title">MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">1451</span><span class="NLM_x">â</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1016%2FS0002-9440%2810%2964096-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=11290563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtVWhtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=1451-1463&author=M.+Tokunouauthor=T.+Nikiauthor=K.+Eguchiauthor=S.+Ibaauthor=H.+Tsudaauthor=T.+Yamadaauthor=Y.+Matsunoauthor=H.+Kondoauthor=Y.+Saitohauthor=H.+Imamuraauthor=S.+Hirohashi&title=MET+expression+in+myofibroblasts%3A+role+in+autocrine+activation+and+prognostic+significance+in+lung+adenocarcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">c-MET expression in myofibroblasts: Role in autocrine activation and prognostic significance in lung adenocarcinoma</span></div><div class="casAuthors">Tokunou, Masahide; Niki, Toshiro; Eguchi, Keisuke; Iba, Sanae; Tsuda, Hitoshi; Yamada, Tesshi; Matsuno, Yoshihiro; Kondo, Haruhiko; Saitoh, Yukihito; Imamura, Hiroji; Hirohashi, Setsuo</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1451-1463</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Hepatocyte growth factor (HGF) plays important roles in tumor development and progression.  It is currently thought that the main action of HGF is of a paracrine nature: HGF produced by mesenchymal cells acts on epithelial cells that express its receptor c-MET.  In this investigation, we explored the significance of c-MET expression in myofibroblasts, both in culture and in patients with lung adenocarcinoma.  We first showed that human myofibroblasts derived from primary lung cancer expressed c-MET mRNA and protein by reverse transcription-polymerase chain reaction and Western blot anal.  Proliferation of myofibroblasts was stimulated in a dose-dependent manner by exogenously added recombinant human HGF whereas it was inhibited in a dose-dependent manner by neutralizing antibody to HGF.  The addn. of HGF in the culture medium stimulated tyrosine phosphorylation of c-MET.  The c-MET protein was immunohistochem. detected in myofibroblasts in the invasive area of lung adenocarcinoma.  Finally, the prognostic significance of c-MET expression in stromal myofibroblasts was explored in patients with small-sized lung adenocarcinomas.  C-MET-pos. myofibroblasts were obsd. in 69 of 131 cases (53%).  A significant relationship between myofibroblast c-MET expression and shortened patient survival was obsd. in a whole cohort of patients including all pathol. stages (two-sided P = 0.0089 by log-rank test) and in patients with stage IA disease (two-sided P = 0.0019 by log-rank test).  These data suggest that the HGF/c-MET system constitutes an autocrine activation loop in cancer-stromal myofibroblasts.  This autocrine system may play a role in invasion and metastasis of lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYzb_qAZjt0bVg90H21EOLACvtfcHk0lixXOTNrhGngA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtVWhtrY%253D&md5=5c9ef86275b6dab96dc5b60b7786b8e9</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2964096-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252964096-5%26sid%3Dliteratum%253Aachs%26aulast%3DTokunou%26aufirst%3DM.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DEguchi%26aufirst%3DK.%26aulast%3DIba%26aufirst%3DS.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DMatsuno%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DH.%26aulast%3DSaitoh%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DH.%26aulast%3DHirohashi%26aufirst%3DS.%26atitle%3DMET%2520expression%2520in%2520myofibroblasts%253A%2520role%2520in%2520autocrine%2520activation%2520and%2520prognostic%2520significance%2520in%2520lung%2520adenocarcinoma%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2001%26volume%3D158%26spage%3D1451%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Vaupel, P.</span><span> </span><span class="NLM_article-title">The role of hypoxia-induced factors in tumor progression</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=10-17&author=P.+Vaupel&title=The+role+of+hypoxia-induced+factors+in+tumor+progression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVaupel%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520hypoxia-induced%2520factors%2520in%2520tumor%2520progression%26jtitle%3DOncologist%26date%3D2004%26volume%3D9%26spage%3D10%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Hayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minekawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmichi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, Y.</span><span> </span><span class="NLM_article-title">Up-regulation of MET protooncogene product expression through hypoxia-inducible factor-1 alpha is involved in trophoblast invasion under low-oxygen tension</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">4682</span><span class="NLM_x">â</span> <span class="NLM_lpage">4689</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2005&pages=4682-4689&author=M.+Hayashiauthor=M.+Sakataauthor=T.+Takedaauthor=M.+Taharaauthor=T.+Yamamotoauthor=Y.+Okamotoauthor=R.+Minekawaauthor=A.+Isobeauthor=M.+Ohmichiauthor=K.+Tasakaauthor=Y.+Murata&title=Up-regulation+of+MET+protooncogene+product+expression+through+hypoxia-inducible+factor-1+alpha+is+involved+in+trophoblast+invasion+under+low-oxygen+tension"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DSakata%26aufirst%3DM.%26aulast%3DTakeda%26aufirst%3DT.%26aulast%3DTahara%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DMinekawa%26aufirst%3DR.%26aulast%3DIsobe%26aufirst%3DA.%26aulast%3DOhmichi%26aufirst%3DM.%26aulast%3DTasaka%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DY.%26atitle%3DUp-regulation%2520of%2520MET%2520protooncogene%2520product%2520expression%2520through%2520hypoxia-inducible%2520factor-1%2520alpha%2520is%2520involved%2520in%2520trophoblast%2520invasion%2520under%2520low-oxygen%2520tension%26jtitle%3DEndocrinology%26date%3D2005%26volume%3D146%26spage%3D4682%26epage%3D4689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Bhardwaj, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortez, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komaki, R. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, J. W.</span><span> </span><span class="NLM_article-title">Modulation of MET signaling and cellular sensitivity to radiation: potential implications for therapy</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">1768</span><span class="NLM_x">â</span> <span class="NLM_lpage">1775</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2013&pages=1768-1775&author=V.+Bhardwajauthor=T.+Casconeauthor=M.+A.+Cortezauthor=A.+Aminiauthor=J.+Evansauthor=R.+U.+Komakiauthor=J.+V.+Heymachauthor=J.+W.+Welsh&title=Modulation+of+MET+signaling+and+cellular+sensitivity+to+radiation%3A+potential+implications+for+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhardwaj%26aufirst%3DV.%26aulast%3DCascone%26aufirst%3DT.%26aulast%3DCortez%26aufirst%3DM.%2BA.%26aulast%3DAmini%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DJ.%26aulast%3DKomaki%26aufirst%3DR.%2BU.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DWelsh%26aufirst%3DJ.%2BW.%26atitle%3DModulation%2520of%2520MET%2520signaling%2520and%2520cellular%2520sensitivity%2520to%2520radiation%253A%2520potential%2520implications%2520for%2520therapy%26jtitle%3DCancer%26date%3D2013%26volume%3D119%26spage%3D1768%26epage%3D1775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">De Bacco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luraghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medico, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girolami, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriele, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccaccio, C.</span><span> </span><span class="NLM_article-title">Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">â</span> <span class="NLM_lpage">661</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1093%2Fjnci%2Fdjr093" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=645-661&author=F.+De+Baccoauthor=P.+Luraghiauthor=E.+Medicoauthor=G.+Reatoauthor=F.+Girolamiauthor=T.+Pereraauthor=P.+Gabrieleauthor=P.+M.+Comoglioauthor=C.+Boccaccio&title=Induction+of+MET+by+ionizing+radiation+and+its+role+in+radioresistance+and+invasive+growth+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr093%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBacco%26aufirst%3DF.%26aulast%3DLuraghi%26aufirst%3DP.%26aulast%3DMedico%26aufirst%3DE.%26aulast%3DReato%26aufirst%3DG.%26aulast%3DGirolami%26aufirst%3DF.%26aulast%3DPerera%26aufirst%3DT.%26aulast%3DGabriele%26aufirst%3DP.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DBoccaccio%26aufirst%3DC.%26atitle%3DInduction%2520of%2520MET%2520by%2520ionizing%2520radiation%2520and%2520its%2520role%2520in%2520radioresistance%2520and%2520invasive%2520growth%2520of%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2011%26volume%3D20%26spage%3D645%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Aebersold, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laissue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greiner, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djonov, V.</span><span> </span><span class="NLM_article-title">Involvement of the hepatocyte growth factor/scatter factor receptor MET and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">â</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2F1097-0215%2820010220%2996%3A1%3C41%3A%3AAID-IJC5%3E3.0.CO%3B2-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=11241329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht1WjsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2001&pages=41-54&author=D.+M.+Aebersoldauthor=A.+Kollarauthor=K.+T.+Beerauthor=J.+Laissueauthor=R.+H.+Greinerauthor=V.+Djonov&title=Involvement+of+the+hepatocyte+growth+factor%2Fscatter+factor+receptor+MET+and+of+Bcl-xL+in+the+resistance+of+oropharyngeal+cancer+to+ionizing+radiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-XL in the resistance of oropharyngeal cancer to ionizing radiation</span></div><div class="casAuthors">Aebersold, Daniel M.; Kollar, Attila; Beer, Karl T.; Laissue, Jean; Greiner, Richard H.; Djonov, Valentin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-54</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The activation of cytoplasmic signal transduction pathways by a no. of growth factors and their tyrosine-kinase receptors, including hepatocyte growth factor/scatter factor (HGF/SF) and its receptor c-met, exerts an inhibitory influence on apoptosis induced by ionizing radiation in vitro.  The clin. relevance of the aforementioned ligand-receptor pair, of Bcl-XL, which is targeted by HGF/SF/c-met signaling, and of Bcl-2, was assessed by evaluating their predictive and prognostic impact in a cohort of 97 patients with radically irradiated squamous cell cancers of the oropharynx.  Immunohistochem. expression of c-met and Bcl-XL was correlated with decreased rates of complete remission of the primary tumor in both the univariate (c-met: P = 0.01; Bcl-XL: P = 0.001) and multivariate analyses.  Expression of c-met was, moreover, a significant and independent predictor of impaired local failure-free survival (P = 0.003), disease-free survival (P = 0.003) and overall survival (p = 0.001).  Bcl-2 expression was, on the other hand, assocd. with a favorable outcome, in terms of both local failure-free survival (P = 0.01) and overall survival (P = 0.001).  In accordance with in vitro data, c-met and Bcl-XL appear to be involved in the resistance of oropharyngeal cancers to ionizing radiation, and may therefore represent attractive targets for radiosensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrucBJiW4Yw_bVg90H21EOLACvtfcHk0lixXOTNrhGngA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht1WjsbY%253D&md5=528bea78ffb195ffe8e3537ab76a07c4</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1002%2F1097-0215%2820010220%2996%3A1%3C41%3A%3AAID-IJC5%3E3.0.CO%3B2-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0215%252820010220%252996%253A1%253C41%253A%253AAID-IJC5%253E3.0.CO%253B2-F%26sid%3Dliteratum%253Aachs%26aulast%3DAebersold%26aufirst%3DD.%2BM.%26aulast%3DKollar%26aufirst%3DA.%26aulast%3DBeer%26aufirst%3DK.%2BT.%26aulast%3DLaissue%26aufirst%3DJ.%26aulast%3DGreiner%26aufirst%3DR.%2BH.%26aulast%3DDjonov%26aufirst%3DV.%26atitle%3DInvolvement%2520of%2520the%2520hepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520receptor%2520MET%2520and%2520of%2520Bcl-xL%2520in%2520the%2520resistance%2520of%2520oropharyngeal%2520cancer%2520to%2520ionizing%2520radiation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2001%26volume%3D96%26spage%3D41%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Kim, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Go, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeon, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span> </span><span class="NLM_article-title">Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy</span> <span class="citation_source-journal">Head Neck</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1458</span><span class="NLM_x">â</span> <span class="NLM_lpage">1466</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fhed.21611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21928418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BC3MfksFOksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=1458-1466&author=Y.+J.+Kimauthor=H.+Goauthor=H.+G.+Wuauthor=Y.+K.+Jeonauthor=S.+W.+Parkauthor=S.+H.+Lee&title=Immunohistochemical+study+identifying+prognostic+biomolecular+markers+in+nasopharyngeal+carcinoma+treated+by+radiotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy</span></div><div class="casAuthors">Kim Yeon-Joo; Go Heounjeong; Wu Hong-Gyun; Jeon Yoon Kyung; Park Suk Won; Lee Seung Hee</div><div class="citationInfo"><span class="NLM_cas:title">Head & neck</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1458-66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We evaluated the predictive significance of 14 reported markers using immunohistochemical study in nasopharyngeal carcinoma.  METHODS:  Immunohistochemical stainings were done in 38 patients for Met, cyclooxygenase-2 (COX-2), nm23-H1, epidermal growth factor receptor (EGFR), p63, early growth response factor 1 (Egr1), chromosome segregation 1-like (CSE1L), cathepsin-D (aspartyl protease), C-erbB2, p53, signal transducers and activators of transcription (STAT3/STAT5), CD138 (Syndecan-1), and LIN28 with the usual methods.  RESULTS:  The median follow-up time was 30 months (11-83 months).  High Met and CD138 expression were statistically significant negative prognostic factors on survival.  The expression of Egr1 had a positive prognostic effect on survival.  The combined score of these 3 markers, Met plus CD138 minus Egr1, was a strong prognostic factor.  The median survival curve was distinctly separated in accord with this combined score.  No prognostic value was revealed in COX-2, nm23-H1, EGFR, p63, CSE1L, cathepsin-D, C-erbB2, p53, STAT3, STAT5, and LIN28.  CONCLUSIONS:  The combined score of these markers could be used to stratify biomolecular risk groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXR1WENWHNhS-bLEOO4dYpfW6udTcc2eboxkH_qFK8Brntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfksFOksg%253D%253D&md5=d1e322d2a85e22d9ec65cb5827515c40</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fhed.21611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhed.21611%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DGo%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DH.%2BG.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DPark%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DS.%2BH.%26atitle%3DImmunohistochemical%2520study%2520identifying%2520prognostic%2520biomolecular%2520markers%2520in%2520nasopharyngeal%2520carcinoma%2520treated%2520by%2520radiotherapy%26jtitle%3DHead%2520Neck%26date%3D2011%26volume%3D33%26spage%3D1458%26epage%3D1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Skibinski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skibinska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor (HGF) protects MET-expressing Burkittâs lymphoma cell lines from apoptotic death induced by DNA damaging agents</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">â</span> <span class="NLM_lpage">1569</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=1562-1569&author=G.+Skibinskiauthor=A.+Skibinskaauthor=K.+James&title=Hepatocyte+growth+factor+%28HGF%29+protects+MET-expressing+Burkitt%E2%80%99s+lymphoma+cell+lines+from+apoptotic+death+induced+by+DNA+damaging+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkibinski%26aufirst%3DG.%26aulast%3DSkibinska%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DK.%26atitle%3DHepatocyte%2520growth%2520factor%2520%2528HGF%2529%2520protects%2520MET-expressing%2520Burkitt%25E2%2580%2599s%2520lymphoma%2520cell%2520lines%2520from%2520apoptotic%2520death%2520induced%2520by%2520DNA%2520damaging%2520agents%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D1562%26epage%3D1569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Bowers, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abounader, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laterra, J.</span><span> </span><span class="NLM_article-title">Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">4277</span><span class="NLM_x">â</span> <span class="NLM_lpage">4283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=4277-4283&author=D.+C.+Bowersauthor=S.+Fanauthor=K.+A.+Walterauthor=R.+Abounaderauthor=J.+A.+Williamsauthor=E.+M.+Rosenauthor=J.+Laterra&title=Scatter+factor%2Fhepatocyte+growth+factor+protects+against+cytotoxic+death+in+human+glioblastoma+via+phosphatidylinositol+3-kinase-+and+AKT-dependent+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DD.%2BC.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DK.%2BA.%26aulast%3DAbounader%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26aulast%3DRosen%26aufirst%3DE.%2BM.%26aulast%3DLaterra%26aufirst%3DJ.%26atitle%3DScatter%2520factor%252Fhepatocyte%2520growth%2520factor%2520protects%2520against%2520cytotoxic%2520death%2520in%2520human%2520glioblastoma%2520via%2520phosphatidylinositol%25203-kinase-%2520and%2520AKT-dependent%2520pathways%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D4277%26epage%3D4283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Mitamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuragi, N.</span><span> </span><span class="NLM_article-title">Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET</span> <span class="citation_source-journal">Oncogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e40</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e40&author=T.+Mitamuraauthor=H.+Watariauthor=L.+Wangauthor=H.+Kannoauthor=M.+K.+Hassanauthor=M.+Miyazakiauthor=Y.+Katohauthor=T.+Kimuraauthor=M.+Taninoauthor=H.+Nishiharaauthor=S.+Tanakaauthor=N.+Sakuragi&title=Downregulation+of+miRNA-31+induces+taxane+resistance+in+ovarian+cancer+cells+through+increase+of+receptor+tyrosine+kinase+MET"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitamura%26aufirst%3DT.%26aulast%3DWatari%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKanno%26aufirst%3DH.%26aulast%3DHassan%26aufirst%3DM.%2BK.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DKatoh%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DTanino%26aufirst%3DM.%26aulast%3DNishihara%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DSakuragi%26aufirst%3DN.%26atitle%3DDownregulation%2520of%2520miRNA-31%2520induces%2520taxane%2520resistance%2520in%2520ovarian%2520cancer%2520cells%2520through%2520increase%2520of%2520receptor%2520tyrosine%2520kinase%2520MET%26jtitle%3DOncogenesis%26date%3D2013%26volume%3D2%26spage%3De40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Tang, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yam, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A. S.</span><span> </span><span class="NLM_article-title">MET overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">â</span> <span class="NLM_lpage">138</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=128-138&author=M.+K.+Tangauthor=H.+Y.+Zhouauthor=J.+W.+Yamauthor=A.+S.+Wong&title=MET+overexpression+contributes+to+the+acquired+apoptotic+resistance+of+nonadherent+ovarian+cancer+cells+through+a+cross+talk+mediated+by+phosphatidylinositol+3-kinase+and+extracellular+signal-regulated+kinase+1%2F2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DM.%2BK.%26aulast%3DZhou%26aufirst%3DH.%2BY.%26aulast%3DYam%26aufirst%3DJ.%2BW.%26aulast%3DWong%26aufirst%3DA.%2BS.%26atitle%3DMET%2520overexpression%2520contributes%2520to%2520the%2520acquired%2520apoptotic%2520resistance%2520of%2520nonadherent%2520ovarian%2520cancer%2520cells%2520through%2520a%2520cross%2520talk%2520mediated%2520by%2520phosphatidylinositol%25203-kinase%2520and%2520extracellular%2520signal-regulated%2520kinase%25201%252F2%26jtitle%3DNeoplasia%26date%3D2010%26volume%3D12%26spage%3D128%26epage%3D138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Avan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quint, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frampton, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maftouh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelliccioni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuurhuis, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannetti, E.</span><span> </span><span class="NLM_article-title">Enhancement of the antiproliferative activity of gemcitabine by modulation of MET pathway in pancreatic cancer</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">â</span> <span class="NLM_lpage">950</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.2174%2F138161213804547312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22973962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktF2ltb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=940-950&author=A.+Avanauthor=K.+Quintauthor=F.+Nicoliniauthor=N.+Funelauthor=A.+E.+Framptonauthor=M.+Maftouhauthor=S.+Pelliccioniauthor=G.+J.+Schuurhuisauthor=G.+J.+Petersauthor=E.+Giovannetti&title=Enhancement+of+the+antiproliferative+activity+of+gemcitabine+by+modulation+of+MET+pathway+in+pancreatic+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer</span></div><div class="casAuthors">Avan, Amir; Quint, Karl; Nicolini, Francesco; Funel, Niccola; Frampton, Adam E.; Maftouh, Mina; Pelliccioni, Serena; Schuurhuis, Gerrit J.; Peters, Godefridus J.; Giovannetti, Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">940-950</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Pancreatic-ductal-adenocarcinoma (PDAC) is amongst the most lethal malignancies, mainly because of its metastatic spread and multifactorial chemoresistance.  Since c-Met is a marker of pancreatic-cancer-stem-cells (CSC), playing a key role in metastasis and chemoresistance, this study evaluated the therapeutic potential of the novel c-Met/ALK inhibitor crizotinib against PDAC cells, including the Capan-1-gemcitabine-resistant cells (Capan-1-R).  Crizotinib inhibited PDAC cell-growth with IC50 of 1.5 Î¼M in Capan-1-R, and synergistically enhanced the antiproliferative and proapoptotic activity of gemcitabine, as detected by sulforhodamine-B-assay, flow cytometry and combination-index method.  Capan-1-R had higher expression of the CSC markers CD44+/CD133+/CD326+, but their combined expression was significantly reduced by crizotinib, as detected by quant.-RT-PCR and FACS-anal.  Similarly, Capan-1-R cells had significantly higher protein-expression of c-Met (â2-fold), and increased migratory activity, which was reduced by crizotinib (e.g., >50% redn. of cell-migration in Capan-1-R after 8-h exposure, compared to untreated-cells), in assocn. with reduced vimentin expression.  Capan-1-R had also significantly higher mRNA expression of the gemcitabine catabolism-enzyme CDA, potentially explaining the higher CDA activity and statistically significant lower levels of gemcitabine-nucleotides in Capan-1-R compared to Capan-1, as detected by Liq.-chromatog.-mass-spectrometry.  Conversely, crizotinib significantly reduced CDA expression in both Capan-1 and Capan-1-R cells.  In aggregate, these data show the ability of crizotinib to specifically target CSC-like-subpopulations, interfere with cell-proliferation, induce apoptosis, reduce migration and synergistically interact with gemcitabine, supporting further studies on this novel therapeutic approach for PDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRVbq6jTSM_bVg90H21EOLACvtfcHk0lgfS_GZztZ_HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktF2ltb0%253D&md5=2e50057edbbc26d230903ad580c3bc28</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.2174%2F138161213804547312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161213804547312%26sid%3Dliteratum%253Aachs%26aulast%3DAvan%26aufirst%3DA.%26aulast%3DQuint%26aufirst%3DK.%26aulast%3DNicolini%26aufirst%3DF.%26aulast%3DFunel%26aufirst%3DN.%26aulast%3DFrampton%26aufirst%3DA.%2BE.%26aulast%3DMaftouh%26aufirst%3DM.%26aulast%3DPelliccioni%26aufirst%3DS.%26aulast%3DSchuurhuis%26aufirst%3DG.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DGiovannetti%26aufirst%3DE.%26atitle%3DEnhancement%2520of%2520the%2520antiproliferative%2520activity%2520of%2520gemcitabine%2520by%2520modulation%2520of%2520MET%2520pathway%2520in%2520pancreatic%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D940%26epage%3D950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to targeted cancer therapies</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">999</span><span class="NLM_x">â</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.2217%2Ffon.12.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22894672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WlsLzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=999-1014&author=M.+R.+Lacknerauthor=T.+R.+Wilsonauthor=J.+Settleman&title=Mechanisms+of+acquired+resistance+to+targeted+cancer+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to targeted cancer therapies</span></div><div class="casAuthors">Lackner, Mark R.; Wilson, Timothy R.; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">999-1014</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Drugs that target genomically defined vulnerabilities in human tumors have now been clin. validated as effective cancer therapies.  However, the relatively rapid acquisition of resistance to such treatments that is obsd. in virtually all cases significantly limits their utility and remains a substantial challenge to the clin. management of advanced cancers.  As mol. mechanisms of resistance have begun to be elucidated, new strategies to overcome or prevent the development of resistance have begun to emerge.  In some cases, specific mutational mechanisms contribute directly to acquired drug resistance, and in other cases it appears that nonmutational and possibly epigenetic mechanisms play a significant role.  This article discusses the various genetic and nongenetic mechanisms of acquired drug resistance that have been reported in the context of rationally targeted' drug therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooztN62IERZrVg90H21EOLACvtfcHk0lgfS_GZztZ_HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WlsLzK&md5=8a0a8ccb076874d753bfed5ace2ba169</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2217%2Ffon.12.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.12.86%26sid%3Dliteratum%253Aachs%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520targeted%2520cancer%2520therapies%26jtitle%3DFuture%2520Oncol.%26date%3D2012%26volume%3D8%26spage%3D999%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Crespan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucca, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maga, G.</span><span> </span><span class="NLM_article-title">Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2836</span><span class="NLM_x">â</span> <span class="NLM_lpage">2847</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.2174%2F092986711796150513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21651495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2rtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2836-2847&author=E.+Crespanauthor=E.+Zuccaauthor=G.+Maga&title=Overcoming+the+drug+resistance+problem+with+second-generation+tyrosine+kinase+inhibitors%3A+from+enzymology+to+structural+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models</span></div><div class="casAuthors">Crespan, E.; Zucca, E.; Maga, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2836-2847</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation is one of the major pathways used by eukaryotic cells to propagate signals to the final effectors, regulating multiple aspects of the living cell, such as metab., growth, differentiation, adhesion, motility, genome stability and death.  In this context, tyrosine kinases (TKs) play a central role in signal transduction and their overexpression or disregulated activity has been implicated in tumor onset and malignancy progression.  To date, eight TKs inhibitors have been approved by FDA for the treatment of specific tumors.  In spite of their efficacy, insurgence of resistance is a common feature after prolonged administration.  The selective pressure by these drugs, in fact, induces clonal expansion of subsets of cancer cells harboring TKs mutations, leading to decreased inhibition potency.  Alternatively, resistance to TK inhibitors can be acquired through the activation of others, often unrelated, TKs.  For this reason, while stringent target selectivity of TKs inhibitors has been always considered a desirable feature in order to limit toxicity, mols. targeting different TKs have been recently shown to be promising anti-cancer agents as well.  Understanding the mol. mechanisms that confer resistance to TK inhibitors, through a combination of enzymic, structural and cellular studies, is essential in the development of second generation inhibitors active also towards drug resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTAw7AY9OLMbVg90H21EOLACvtfcHk0lgfS_GZztZ_HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2rtbw%253D&md5=2646df643c23872eda9cbd111268b3ad</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2174%2F092986711796150513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796150513%26sid%3Dliteratum%253Aachs%26aulast%3DCrespan%26aufirst%3DE.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DMaga%26aufirst%3DG.%26atitle%3DOvercoming%2520the%2520drug%2520resistance%2520problem%2520with%2520second-generation%2520tyrosine%2520kinase%2520inhibitors%253A%2520from%2520enzymology%2520to%2520structural%2520models%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2836%26epage%3D2847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Trusolino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertotti, A.</span><span> </span><span class="NLM_article-title">Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">â</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=876-880&author=L.+Trusolinoauthor=A.+Bertotti&title=Compensatory+pathways+in+oncogenic+kinase+signaling+and+resistance+to+targeted+therapies%3A+six+degrees+of+separation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrusolino%26aufirst%3DL.%26aulast%3DBertotti%26aufirst%3DA.%26atitle%3DCompensatory%2520pathways%2520in%2520oncogenic%2520kinase%2520signaling%2520and%2520resistance%2520to%2520targeted%2520therapies%253A%2520six%2520degrees%2520of%2520separation%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D876%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit86b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Logue, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, D. K.</span><span> </span><span class="NLM_article-title">Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=641-650&author=J.+S.+Logueauthor=D.+K.+Morrison&title=Complexity+in+the+signaling+network%3A+insights+from+the+use+of+targeted+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLogue%26aufirst%3DJ.%2BS.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DComplexity%2520in%2520the%2520signaling%2520network%253A%2520insights%2520from%2520the%2520use%2520of%2520targeted%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D641%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltman, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digumarthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosper, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernovsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanuti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Genotyping and histological evolution of lung cancers acquiring resistance to EGFR inhibitors</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">75ra26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87a&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1126%2Fscitranslmed.3002003" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=75ra26&author=L.+V.+Sequistauthor=A.+W.+Waltmanauthor=D.+Dias-Santagataauthor=S.+Digumarthyauthor=A.+B.+Turkeauthor=P.+Fidiasauthor=K.+Bergethonauthor=A.+T.+Shawauthor=S.+Gettingerauthor=A.+K.+Cosperauthor=S.+Akhavanfardauthor=R.+S.+Heistauthor=J.+Temelauthor=J.+G.+Christensenauthor=J.+C.+Wainauthor=T.+J.+Lynchauthor=K.+Vernovskyauthor=E.+J.+Markauthor=M.+Lanutiauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=Genotyping+and+histological+evolution+of+lung+cancers+acquiring+resistance+to+EGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87a&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002003%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DWaltman%26aufirst%3DA.%2BW.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DCosper%26aufirst%3DA.%2BK.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DTemel%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DVernovsky%26aufirst%3DK.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DLanuti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DGenotyping%2520and%2520histological%2520evolution%2520of%2520lung%2520cancers%2520acquiring%2520resistance%2520to%2520EGFR%2520inhibitors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D75ra26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit87b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">â</span> <span class="NLM_lpage">2247</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87b&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87b&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87b&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87bR"><div class="casContent"><span class="casTitleNuber">87b</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lhwbbmF-2lW8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit87b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toschi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JÃ¤nne, P. A.</span><span> </span><span class="NLM_article-title">Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=77-88&author=A.+B.+Turkeauthor=K.+Zejnullahuauthor=Y.+L.+Wuauthor=Y.+Songauthor=D.+Dias-Santagataauthor=E.+Lifshitsauthor=L.+Toschiauthor=A.+Rogersauthor=T.+Mokauthor=L.+Sequistauthor=N.+I.+Lindemanauthor=C.+Murphyauthor=S.+Akhavanfardauthor=B.+Y.+Yeapauthor=Y.+Xiaoauthor=M.+Capellettiauthor=A.+J.+Iafrateauthor=C.+Leeauthor=J.+G.+Christensenauthor=J.+A.+Engelmanauthor=P.+A.+J%C3%A4nne&title=Preexistence+and+clonal+selection+of+MET+amplification+in+EGFR+mutant+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DRogers%26aufirst%3DA.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DSequist%26aufirst%3DL.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DMurphy%26aufirst%3DC.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPreexistence%2520and%2520clonal%2520selection%2520of%2520MET%2520amplification%2520in%2520EGFR%2520mutant%2520NSCLC%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26spage%3D77%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Yano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuramam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanibuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sone, S.</span><span> </span><span class="NLM_article-title">Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9479</span><span class="NLM_x">â</span> <span class="NLM_lpage">9487</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9479-9487&author=S.+Yanoauthor=W.+Wangauthor=Q.+Liauthor=K.+Matsumotoauthor=H.+Sakuramamauthor=T.+Nakamuraauthor=H.+Oginoauthor=S.+Kakiuchiauthor=M.+Hanibuchiauthor=Y.+Nishiokaauthor=H.+Ueharaauthor=T.+Mitsudomiauthor=Y.+Yatabeauthor=T.+Nakamuraauthor=S.+Sone&title=Hepatocyte+growth+factor+induces+gefitinib+resistance+of+lung+adenocarcinoma+with+epidermal+growth+factor+receptor-activating+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYano%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DSakuramam%26aufirst%3DH.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DOgino%26aufirst%3DH.%26aulast%3DKakiuchi%26aufirst%3DS.%26aulast%3DHanibuchi%26aufirst%3DM.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DHepatocyte%2520growth%2520factor%2520induces%2520gefitinib%2520resistance%2520of%2520lung%2520adenocarcinoma%2520with%2520epidermal%2520growth%2520factor%2520receptor-activating%2520mutations%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9479%26epage%3D9487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valtorta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siravegna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartore-Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassingena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zecchin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apicella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliardi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galimi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauricella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronesem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, L. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velculescu, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Nicolantonio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siena, S.</span><span> </span><span class="NLM_article-title">Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">â</span> <span class="NLM_lpage">673</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=658-673&author=A.+Bardelliauthor=S.+Corsoauthor=A.+Bertottiauthor=S.+Hoborauthor=E.+Valtortaauthor=G.+Siravegnaauthor=A.+Sartore-Bianchiauthor=E.+Scalaauthor=A.+Cassingenaauthor=D.+Zecchinauthor=M.+Apicellaauthor=G.+Migliardiauthor=F.+Galimiauthor=C.+Lauricellaauthor=C.+Zanonauthor=T.+Pereraauthor=S.+Veronesemauthor=G.+Cortiauthor=A.+Amatuauthor=M.+Gambacortaauthor=L.+A.+Diazauthor=M.+Sausenauthor=V.+E.+Velculescuauthor=P.+Comoglioauthor=L.+Trusolinoauthor=F.+Di+Nicolantonioauthor=S.+Giordanoauthor=S.+Siena&title=Amplification+of+the+MET+receptor+drives+resistance+to+anti-EGFR+therapies+in+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DCorso%26aufirst%3DS.%26aulast%3DBertotti%26aufirst%3DA.%26aulast%3DHobor%26aufirst%3DS.%26aulast%3DValtorta%26aufirst%3DE.%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DScala%26aufirst%3DE.%26aulast%3DCassingena%26aufirst%3DA.%26aulast%3DZecchin%26aufirst%3DD.%26aulast%3DApicella%26aufirst%3DM.%26aulast%3DMigliardi%26aufirst%3DG.%26aulast%3DGalimi%26aufirst%3DF.%26aulast%3DLauricella%26aufirst%3DC.%26aulast%3DZanon%26aufirst%3DC.%26aulast%3DPerera%26aufirst%3DT.%26aulast%3DVeronesem%26aufirst%3DS.%26aulast%3DCorti%26aufirst%3DG.%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DSausen%26aufirst%3DM.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DComoglio%26aufirst%3DP.%26aulast%3DTrusolino%26aufirst%3DL.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DAmplification%2520of%2520the%2520MET%2520receptor%2520drives%2520resistance%2520to%2520anti-EGFR%2520therapies%2520in%2520colorectal%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D658%26epage%3D673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Mohammadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliseenkova, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span> </span><span class="NLM_article-title">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5896</span><span class="NLM_x">â</span> <span class="NLM_lpage">5904</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1093%2Femboj%2F17.20.5896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=9774334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Cmurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=5896-5904&author=M.+Mohammadiauthor=S.+Froumauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=R.+L.+Panekauthor=G.+H.+Luauthor=A.+V.+Eliseenkovaauthor=D.+Greenauthor=J.+Schlessingerauthor=S.+R.+Hubbard&title=Crystal+structure+of+an+angiogenesis+inhibitor+bound+to+the+FGF+receptor+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span></div><div class="casAuthors">Mohammadi, Moosa; Froum, Scott; Hamby, James M.; Schroeder, Mel C.; Panek, Robert L.; Lu, Gina H.; Eliseenkova, Anna V.; Green, David; Schlessinger, Joseph; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5896-5904</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is an essential physiol. process in development, yet also plays a major role in the progression of human diseases such as diabetic retinopathy, atherosclerosis and cancer.  The effects of the most potent angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin and fibroblast growth factor (FGF) are mediated through cell surface receptors that possess intrinsic protein tyrosine kinase activity.  In this report, the authors describe a synthetic compd. of the pyrido[2,3-d]pyrimidine class, designated PD 173074, that selectively inhibits the tyrosine kinase activities of the FGF and VEGF receptors.  The authors show that systemic administration of PD 173074 in mice can effectively block angiogenesis induced by either FGF or VEGF with no apparent toxicity.  To elucidate the determinants of selectivity, the authors have detd. the crystal structure of PD 173074 in complex with the tyrosine kinase domain of FGF receptor 1 at 2.5 Ã resoln.  A high degree of surface complementarity between PD 173074 and the hydrophobic, ATP-binding pocket of FGF receptor 1 underlies the potency and selectivity of this inhibitor.  PD 173074 is thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the treatment of cancer and other diseases whose progression is dependent upon new blood vessel formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4zdEklzyMx7Vg90H21EOLACvtfcHk0lghnm0iY0bHlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Cmurs%253D&md5=a76b085ddc9d352878a2c6bc9d1cd6ff</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.20.5896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.20.5896%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DFroum%26aufirst%3DS.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520an%2520angiogenesis%2520inhibitor%2520bound%2520to%2520the%2520FGF%2520receptor%2520tyrosine%2520kinase%2520domain%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26spage%3D5896%26epage%3D5904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Paulson, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linklater, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghuis, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">App, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oostendorp, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettinga, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnik, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graveel, C. R.</span><span> </span><span class="NLM_article-title">MET and ERBB2 are coexpressed in ERBB2+ breast cancers and contribute to innate resistance</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1112</span><span class="NLM_x">â</span> <span class="NLM_lpage">1121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1541-7786.MCR-13-0042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23825050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCgu77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1112-1121&author=A.+K.+Paulsonauthor=E.+S.+Linklaterauthor=B.+D.+Berghuisauthor=C.+A.+Appauthor=L.+D.+Oostendorpauthor=J.+E.+Paulsonauthor=J.+E.+Pettingaauthor=M.+K.+Melnikauthor=G.+F.+Vande+Woudeauthor=C.+R.+Graveel&title=MET+and+ERBB2+are+coexpressed+in+ERBB2%2B+breast+cancers+and+contribute+to+innate+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance</span></div><div class="casAuthors">Paulson, Amanda K.; Linklater, Erik S.; Berghuis, Bree D.; App, Colleen A.; Oostendorp, Leon D.; Paulson, Jayne E.; Pettinga, Jane E.; Melnik, Marianne K.; Vande Woude, George F.; Graveel, Carrie R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1112-1121</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Breast cancer displays significant intratumoral heterogeneity, which has been shown to have a substantial impact on both innate and acquired resistance to tyrosine kinase inhibitors.  The heterogeneous expression of multiple receptor tyrosine kinases (RTK) in cancers supports tumor signaling robustness and plays a significant role in resistance to targeted inhibition.  Recent studies have revealed interactions between the MET receptor and the ERBB receptor family in the therapeutic resistance of several cancers.  In this study, the relationship between MET expression/activity and the expression/activity of the ERBB receptor family in human breast cancer was interrogated.  Importantly, a significant percentage of ERBB2+ tumors coexpressing MET and ERBB2 were obsd. and displayed significant heterogeneity with subpopulations of cells that are MET-/ERBB2+, MET+/ERBB2-, and MET+/ERBB2+.  In a MET+/ERBB2+ breast cancer cell line, MET depletion resulted in increased ERBB2 activation, and conversely, ERBB2 depletion resulted in increased MET activation.  Neither EGFR nor ERBB3 compensated for MET or ERBB2 knockdown.  The loss of either MET or ERBB2 led to a decrease in PI3K/AKT signaling and increased dependency on MAPK.  These data show that a subset of ERBB2+ breast cancers express MET and contain MET+/ERBB2+ subpopulations.  Moreover, anal. of RTK activation during ERBB2 knockdown indicated that MET signaling is a compensatory pathway of resistance.  Implications: ERBB2+ breast cancers with MET+/ERBB2+ subpopulations may have an innate resistance to ERBB2 inhibition and may benefit from combined MET and ERBB2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Y7xfx01AHLVg90H21EOLACvtfcHk0li8pYyVJ39Otg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCgu77K&md5=bbf01aa7c2d26426bc47f52a1c956e9d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-13-0042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-13-0042%26sid%3Dliteratum%253Aachs%26aulast%3DPaulson%26aufirst%3DA.%2BK.%26aulast%3DLinklater%26aufirst%3DE.%2BS.%26aulast%3DBerghuis%26aufirst%3DB.%2BD.%26aulast%3DApp%26aufirst%3DC.%2BA.%26aulast%3DOostendorp%26aufirst%3DL.%2BD.%26aulast%3DPaulson%26aufirst%3DJ.%2BE.%26aulast%3DPettinga%26aufirst%3DJ.%2BE.%26aulast%3DMelnik%26aufirst%3DM.%2BK.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26aulast%3DGraveel%26aufirst%3DC.%2BR.%26atitle%3DMET%2520and%2520ERBB2%2520are%2520coexpressed%2520in%2520ERBB2%252B%2520breast%2520cancers%2520and%2520contribute%2520to%2520innate%2520resistance%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2013%26volume%3D11%26spage%3D1112%26epage%3D1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Harbinski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craig, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanghavi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buness, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatenay-Rivauday, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myer, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graus-Porta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiedt, R.</span><span> </span><span class="NLM_article-title">Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">â</span> <span class="NLM_lpage">959</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=948-959&author=F.+Harbinskiauthor=V.+J.+Craigauthor=S.+Sanghaviauthor=D.+Jefferyauthor=L.+Liuauthor=K.+A.+Sheppardauthor=S.+Wagnerauthor=C.+Stammauthor=A.+Bunessauthor=C.+Chatenay-Rivaudayauthor=Y.+Yaoauthor=F.+Heauthor=C.+X.+Luauthor=V.+Guagnanoauthor=T.+Metzauthor=P.+M.+Finanauthor=F.+Hofmannauthor=W.+R.+Sellersauthor=J.+A.+Porterauthor=V.+E.+Myerauthor=D.+Graus-Portaauthor=C.+J.+Wilsonauthor=A.+Bucklerauthor=R.+Tiedt&title=Rescue+screens+with+secreted+proteins+reveal+compensatory+potential+of+receptor+tyrosine+kinases+in+driving+cancer+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarbinski%26aufirst%3DF.%26aulast%3DCraig%26aufirst%3DV.%2BJ.%26aulast%3DSanghavi%26aufirst%3DS.%26aulast%3DJeffery%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSheppard%26aufirst%3DK.%2BA.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBuness%26aufirst%3DA.%26aulast%3DChatenay-Rivauday%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DC.%2BX.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DMetz%26aufirst%3DT.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DGraus-Porta%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DBuckler%26aufirst%3DA.%26aulast%3DTiedt%26aufirst%3DR.%26atitle%3DRescue%2520screens%2520with%2520secreted%2520proteins%2520reveal%2520compensatory%2520potential%2520of%2520receptor%2520tyrosine%2520kinases%2520in%2520driving%2520cancer%2520growth%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D948%26epage%3D959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Timofeevski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Enzymatic characterization of MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5339</span><span class="NLM_x">â</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900438w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5339-5349&author=S.+L.+Timofeevskiauthor=M.+A.+McTigueauthor=K.+Ryanauthor=J.+Cuiauthor=H.+Y.+Zouauthor=J.+X.+Zhuauthor=F.+Chauauthor=G.+Altonauthor=S.+Karlicekauthor=J.+G.+Christensenauthor=B.+W.+Murray&title=Enzymatic+characterization+of+MET+receptor+tyrosine+kinase+oncogenic+mutants+and+kinetic+studies+with+aminopyridine+and+triazolopyrazine+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=10.1021%2Fbi900438w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900438w%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeevski%26aufirst%3DS.%2BL.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DJ.%2BX.%26aulast%3DChau%26aufirst%3DF.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DEnzymatic%2520characterization%2520of%2520MET%2520receptor%2520tyrosine%2520kinase%2520oncogenic%2520mutants%2520and%2520kinetic%2520studies%2520with%2520aminopyridine%2520and%2520triazolopyrazine%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D5339%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit94b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chiara, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugliese, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Mutations in the MET oncogene unveil a âdual switchâ mechanism controlling tyrosine kinase activity</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">29352</span><span class="NLM_x">â</span> <span class="NLM_lpage">29358</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=29352-29358&author=F.+Chiaraauthor=P.+Michieliauthor=L.+Puglieseauthor=P.+M.+Comoglio&title=Mutations+in+the+MET+oncogene+unveil+a+%E2%80%9Cdual+switch%E2%80%9D+mechanism+controlling+tyrosine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChiara%26aufirst%3DF.%26aulast%3DMichieli%26aufirst%3DP.%26aulast%3DPugliese%26aufirst%3DL.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DMutations%2520in%2520the%2520MET%2520oncogene%2520unveil%2520a%2520%25E2%2580%259Cdual%2520switch%25E2%2580%259D%2520mechanism%2520controlling%2520tyrosine%2520kinase%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D29352%26epage%3D29358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Schiering, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor MET and its complex with the microbial alkaloid K-252a</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12654</span><span class="NLM_x">â</span> <span class="NLM_lpage">12659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=R.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+MET+and+its+complex+with+the+microbial+alkaloid+K-252a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520MET%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupka, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizizad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span> </span><span class="NLM_article-title">Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">â</span> <span class="NLM_lpage">3568</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=3563-3568&author=W.+Wangauthor=A.+Marimuthuauthor=J.+Tsaiauthor=A.+Kumarauthor=H.+I.+Krupkaauthor=C.+Zhangauthor=B.+Powellauthor=Y.+Suzukiauthor=H.+Nguyenauthor=M.+Tabrizizadauthor=C.+Luuauthor=B.+L.+West&title=Structural+characterization+of+autoinhibited+c-Met+kinase+produced+by+coexpression+in+bacteria+with+phosphatase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DKrupka%26aufirst%3DH.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DB.%2BL.%26atitle%3DStructural%2520characterization%2520of%2520autoinhibited%2520c-Met%2520kinase%2520produced%2520by%2520coexpression%2520in%2520bacteria%2520with%2520phosphatase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D3563%26epage%3D3568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, W. A.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">746</span><span class="NLM_x">â</span> <span class="NLM_lpage">754</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2F372746a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=7997262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1994&pages=746-754&author=S.+R.+Hubbardauthor=L.+Weiauthor=L.+Ellisauthor=W.+A.+Hendrickson&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+human+insulin+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the human insulin receptor</span></div><div class="casAuthors">Hubbard, Stevan R.; Wei, Lei; Ellis, Leland; Hendrickson, Wayne A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6508</span>),
    <span class="NLM_cas:pages">746-54</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The x-ray crystal structure of the tyrosine kinase domain of the human insulin receptor has been detd. by multiwavelength anomalous diffraction phasing and refined to 2.1 Ã resoln.  The structure reveals the determinants of substrate preference for tyrosine rather than serine or threonine and a novel autoinhibition mechanism whereby one of the tyrosines that is autophosphorylated in response to insulin, Tyr 1162, is bound in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp222kk0byoTrVg90H21EOLACvtfcHk0ljngiwyW69N3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisl2qu7o%253D&md5=ad60bacc76a642b2957c55ff82274cab</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2F372746a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F372746a0%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DHendrickson%26aufirst%3DW.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520human%2520insulin%2520receptor%26jtitle%3DNature%26date%3D1994%26volume%3D372%26spage%3D746%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Mroczkowski, B.; McTigue, M. A.; Sarup, J.; Murray, B. W.; Hickey, M.; Parge, H.; Zhu, J.</span><span> </span><span class="NLM_article-title">Catalytic Domains of the Human Hepatocyte Growth Factor Receptor Kinase and Material and Methods for Identification Thereof</span>.  EP1243596 A1,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=B.+Mroczkowski&author=M.+A.+McTigue&author=J.+Sarup&author=B.+W.+Murray&author=M.+Hickey&author=H.+Parge&author=J.+Zhu&title=Catalytic+Domains+of+the+Human+Hepatocyte+Growth+Factor+Receptor+Kinase+and+Material+and+Methods+for+Identification+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMroczkowski%26aufirst%3DB.%26atitle%3DCatalytic%2520Domains%2520of%2520the%2520Human%2520Hepatocyte%2520Growth%2520Factor%2520Receptor%2520Kinase%2520and%2520Material%2520and%2520Methods%2520for%2520Identification%2520Thereof%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-DubÃ©, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">â</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">â</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=S.+Sistlaauthor=T.+L.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-RÎ² tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0lhFOq880Gw6yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DS.%26aulast%3DLuu%26aufirst%3DT.%2BL.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Cui, J.; Zhang, R.; Shen, H.; Chu, J. Y.; Zhang, F.-J.; Koenig, M.; Do, S. H.; Li, X.; Wei, C. C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Preparation of 4-Aryl Substituted Indolinones as Protein Kinase Signal Transduction Modulators for Inhibiting Abnormal Cell Proliferation</span>. PCT Int. Appl. WO0255517,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=R.+Zhang&author=H.+Shen&author=J.+Y.+Chu&author=F.-J.+Zhang&author=M.+Koenig&author=S.+H.+Do&author=X.+Li&author=C.+C.+Wei&author=P.+C.+Tang&title=Preparation+of+4-Aryl+Substituted+Indolinones+as+Protein+Kinase+Signal+Transduction+Modulators+for+Inhibiting+Abnormal+Cell+Proliferation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DPreparation%2520of%25204-Aryl%2520Substituted%2520Indolinones%2520as%2520Protein%2520Kinase%2520Signal%2520Transduction%2520Modulators%2520for%2520Inhibiting%2520Abnormal%2520Cell%2520Proliferation%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Cui, J.; Ramphal, Y.; Liang, C.; Sun, L.; Wei, C. C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">5-Aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone Derivatives As Kinase Inhibitors</span>. PCT Int. Appl. WO2002096361 A2,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+Cui&author=Y.+Ramphal&author=C.+Liang&author=L.+Sun&author=C.+C.+Wei&author=P.+C.+Tang&title=5-Aralkylsulfonyl-3-%28pyrrol-2-ylmethylidene%29-2-indolinone+Derivatives+As+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3D5-Aralkylsulfonyl-3-%2528pyrrol-2-ylmethylidene%2529-2-indolinone%2520Derivatives%2520As%2520Kinase%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiewlich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlett, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the MET [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">â</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=14617781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovFCqtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=1085-1092&author=X.+Wangauthor=P.+Leauthor=C.+Liangauthor=J.+Chanauthor=D.+Kiewlichauthor=T.+Millerauthor=D.+Harrisauthor=L.+Sunauthor=A.+Riceauthor=S.+Vasileauthor=R.+A.+Blakeauthor=A.+R.+Howlettauthor=N.+Patelauthor=G.+McMahonauthor=K.+E.+Lipson&title=Potent+and+selective+inhibitors+of+the+MET+%5Bhepatocyte+growth+factor%2Fscatter+factor+%28HGF%2FSF%29+receptor%5D+tyrosine+kinase+block+HGF%2FSF-induced+tumor+cell+growth+and+invasion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion</span></div><div class="casAuthors">Wang, Xueyan; Le, Phuong; Liang, Congxin; Chan, Julie; Kiewlich, David; Miller, Todd; Harris, Dave; Sun, Li; Rice, Audie; Vasile, Stefan; Blake, Robert A.; Howlett, Anthony R.; Patel, Neela; McMahon, Gerald; Lipson, Kenneth E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The hepatocyte growth factor/scatter factor (HGF/SF) receptor, Met, mediates various cellular responses on activation with its ligand, including proliferation, survival, motility, invasion, and tubular morphogenesis.  Met expression is frequently up-regulated in sarcomas and carcinomas.  Exptl. evidence suggests that Met activation correlates with poor clin. outcome and the likelihood of metastasis.  Therefore, inhibitors of Met tyrosine kinase may be useful for the treatment of a wide variety of cancers that have spread from the primary site.  We have discovered potent and selective pyrrole-indolinone Met kinase inhibitors and characterized them for their ability to inhibit HGF/SF-induced cellular responses in vitro.  These compds. inhibit HGF/SF-induced receptor phosphorylation in a dose-dependent manner.  They also inhibit the HGF/SF-induced motility and invasion of epithelial and carcinoma cells.  Therefore, these compds. represent a class of prototype small mols. that selectively inhibit the Met kinase and could lead to identification of compds. with potential therapeutic utility in treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVAQRRxT_J1rVg90H21EOLACvtfcHk0lhFOq880Gw6yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovFCqtL8%253D&md5=3b3141600b15ed4f9c97d86fb7ade81d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DKiewlich%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DRice%26aufirst%3DA.%26aulast%3DVasile%26aufirst%3DS.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DHowlett%26aufirst%3DA.%2BR.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520MET%2520%255Bhepatocyte%2520growth%2520factor%252Fscatter%2520factor%2520%2528HGF%252FSF%2529%2520receptor%255D%2520tyrosine%2520kinase%2520block%2520HGF%252FSF-induced%2520tumor%2520cell%2520growth%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D1085%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuruganti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruslim, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramphal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D. B.</span><span> </span><span class="NLM_article-title">A selective small molecule inhibitor of MET kinase inhibits MET-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7345</span><span class="NLM_x">â</span> <span class="NLM_lpage">7355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7345-7355&author=J.+G.+Christensenauthor=R.+Schreckauthor=J.+Burrowsauthor=P.+Kurugantiauthor=E.+Chanauthor=P.+Leauthor=J.+Chenauthor=X.+Wangauthor=L.+Ruslimauthor=R.+Blakeauthor=K.+E.+Lipsonauthor=J.+Ramphalauthor=S.+Doauthor=J.+J.+Cuiauthor=J.+M.+Cherringtonauthor=D.+B.+Mendel&title=A+selective+small+molecule+inhibitor+of+MET+kinase+inhibits+MET-dependent+phenotypes+in+vitro+and+exhibits+cytoreductive+antimutor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DKuruganti%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRuslim%26aufirst%3DL.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DRamphal%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DMendel%26aufirst%3DD.%2BB.%26atitle%3DA%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520MET%2520kinase%2520inhibits%2520MET-dependent%2520phenotypes%2520in%2520vitro%2520and%2520exhibits%2520cytoreductive%2520antimutor%2520activity%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7345%26epage%3D7355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and MET, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">â</span> <span class="NLM_lpage">3322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+MET%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, â¼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-Î³, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lhfagYnLX18iQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520MET%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6804</span><span class="NLM_x">â</span> <span class="NLM_lpage">6820</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=6804-6820&author=D.+Zhangauthor=X.+Zhangauthor=J.+Aiauthor=Y.+Zhaiauthor=Z.+Liangauthor=Y.+Wangauthor=Y.+Chenauthor=C.+Liauthor=F.+Zhaoauthor=H.+Jiangauthor=M.+Gengauthor=C.+Luoauthor=H.+Liu&title=Synthesis+and+biological+evaluation+of+2-amino-5-aryl-3-benzylthiopyridine+scaffold+based+potent+c-Met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-amino-5-aryl-3-benzylthiopyridine%2520scaffold%2520based%2520potent%2520c-Met%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D6804%26epage%3D6820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span> </span><span class="NLM_article-title">Aminopyridyl/pyrazinyl spiro[indoline-3,4â²-piperidine]-2-ones as highly selective and efficacious MET/ALK inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">806</span><span class="NLM_x">â</span> <span class="NLM_lpage">810</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml400203d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=806-810&author=J.+Liauthor=N.+Wuauthor=Y.+Tianauthor=J.+Zhangauthor=S.+Wu&title=Aminopyridyl%2Fpyrazinyl+spiro%5Bindoline-3%2C4%E2%80%B2-piperidine%5D-2-ones+as+highly+selective+and+efficacious+MET%2FALK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fml400203d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400203d%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DS.%26atitle%3DAminopyridyl%252Fpyrazinyl%2520spiro%255Bindoline-3%252C4%25E2%2580%25B2-piperidine%255D-2-ones%2520as%2520highly%2520selective%2520and%2520efficacious%2520MET%252FALK%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D806%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Steinig, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.-H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadalbajoo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares-Greco, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertella, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bittner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turton, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokhale, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landfair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span> </span><span class="NLM_article-title">Novel 6-aminofuro[3,2-<i>c</i>]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4381</span><span class="NLM_x">â</span> <span class="NLM_lpage">4387</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4381-4387&author=A.+G.+Steinigauthor=A.-H+Liauthor=J.+Wangauthor=X.+Chenauthor=H.+Dongauthor=C.+Ferraroauthor=M.+Jinauthor=M.+Kadalbajooauthor=A.+Kleinbergauthor=K.+M.+Stolzauthor=P.+A.+Tavares-Grecoauthor=T.+Wangauthor=M.+R.+Albertellaauthor=Y.+Pengauthor=L.+Crewauthor=J.+Kahlerauthor=J.+Kanauthor=R.+Schulzauthor=A.+Cookeauthor=M.+Bittnerauthor=R.+W.+Turtonauthor=M.+Franklinauthor=P.+Gokhaleauthor=D.+Landfairauthor=C.+Mantisauthor=J.+Workmanauthor=R.+Wildauthor=J.+Pachterauthor=D.+Epsteinauthor=M.+J.+Mulvihill&title=Novel+6-aminofuro%5B3%2C2-c%5Dpyridines+as+potent%2C+orally+efficacious+inhibitors+of+cMET+and+RON+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSteinig%26aufirst%3DA.%2BG.%26aulast%3DLi%26aufirst%3DA.-H%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DFerraro%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DM.%26aulast%3DKadalbajoo%26aufirst%3DM.%26aulast%3DKleinberg%26aufirst%3DA.%26aulast%3DStolz%26aufirst%3DK.%2BM.%26aulast%3DTavares-Greco%26aufirst%3DP.%2BA.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlbertella%26aufirst%3DM.%2BR.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DCrew%26aufirst%3DL.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DKan%26aufirst%3DJ.%26aulast%3DSchulz%26aufirst%3DR.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DBittner%26aufirst%3DM.%26aulast%3DTurton%26aufirst%3DR.%2BW.%26aulast%3DFranklin%26aufirst%3DM.%26aulast%3DGokhale%26aufirst%3DP.%26aulast%3DLandfair%26aufirst%3DD.%26aulast%3DMantis%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DJ.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DPachter%26aufirst%3DJ.%26aulast%3DEpstein%26aufirst%3DD.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26atitle%3DNovel%25206-aminofuro%255B3%252C2-c%255Dpyridines%2520as%2520potent%252C%2520orally%2520efficacious%2520inhibitors%2520of%2520cMET%2520and%2520RON%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4381%26epage%3D4387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Nishii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyano, H.</span><span> </span><span class="NLM_article-title">Discovery of 6-benzyloxyquinolines as MET selective kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1405</span><span class="NLM_x">â</span> <span class="NLM_lpage">1409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1405-1409&author=H.+Nishiiauthor=T.+Chibaauthor=K.+Morikamiauthor=T.+A.+Fukamiauthor=H.+Sakamotoauthor=K.+Koauthor=H.+Koyano&title=Discovery+of+6-benzyloxyquinolines+as+MET+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishii%26aufirst%3DH.%26aulast%3DChiba%26aufirst%3DT.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DKo%26aufirst%3DK.%26aulast%3DKoyano%26aufirst%3DH.%26atitle%3DDiscovery%2520of%25206-benzyloxyquinolines%2520as%2520MET%2520selective%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1405%26epage%3D1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Stanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4920</span><span class="NLM_x">â</span> <span class="NLM_lpage">4931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F0008-5472.CAN-10-3879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21613408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4920-4931&author=C.+M.+Lovlyauthor=J.+M.+Heuckmannauthor=E.+de+Stanchinaauthor=H.+Chenauthor=R.+K.+Thomasauthor=C.+Liangauthor=W.+Pao&title=Insights+into+ALK-driven+cancers+revealed+through+development+of+novel+ALK+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Lovly, Christine M.; Heuckmann, Johannes M.; de Stanchina, Elisa; Chen, Heidi; Thomas, Roman K.; Liang, Chris; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4920-4931</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings.  In this study, we report the identification and biol. characterization of X-376 and X-396, two potent and highly specific ALK small mol. tyrosine kinase inhibitors (TKIs).  In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clin. trials.  Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles.  Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein.  Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations assocd. with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant.  Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin.  Our findings offer preclin. proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.  Cancer Res; 71(14); 4920-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCEJra8njI7Vg90H21EOLACvtfcHk0liK3auoJValtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D&md5=000cbd1295c9d9fa6a43027f08c31247</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-3879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-3879%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DInsights%2520into%2520ALK-driven%2520cancers%2520revealed%2520through%2520development%2520of%2520novel%2520ALK%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4920%26epage%3D4931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Novel 5-(benzyloxy)pyridin-2(1<i>H</i>)-one derivatives as potent MET inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2408</span><span class="NLM_x">â</span> <span class="NLM_lpage">2413</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2408-2413&author=D.+Zhangauthor=J.+Aiauthor=Z.+Liangauthor=W.+Zhuauthor=X.+Pengauthor=X.+Chenauthor=Y.+Jiauthor=H.+Jiangauthor=C.+Luoauthor=M.+Gengauthor=H.+Liu&title=Novel+5-%28benzyloxy%29pyridin-2%281H%29-one+derivatives+as+potent+MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DNovel%25205-%2528benzyloxy%2529pyridin-2%25281H%2529-one%2520derivatives%2520as%2520potent%2520MET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2408%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Hann, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">KeserÃ¼, G. M.</span><span> </span><span class="NLM_article-title">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">â</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrd3701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22543468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=355-365&author=M.+M.+Hannauthor=G.+M.+Keser%C3%BC&title=Finding+the+sweet+spot%3A+the+role+of+nature+and+nurture+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span></div><div class="casAuthors">Hann, Michael M.; Keserue, Gyoergy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Given its position at the heart of small-mol. drug discovery, medicinal chem. has an important role in tackling the well-known productivity challenges in pharmaceutical research and development.  In recent years, extensive analyses of successful and failed discovery compds. and drug candidates have improved our understanding of the role of physicochem. properties in drug attrition.  Based on the clarified challenges in finding the 'sweet spot' in medicinal chem. programs, we suggest that this goal can be achieved through a combination of first identifying chem. starting points with appropriate 'nature' and then rigorously 'nurturing' them during lead optimization.  Here, we discuss scientific, strategic, organizational and cultural considerations for medicinal chem. practices, with the aim of promoting more effective use of what is already known, as well as a wider appreciation of the risks of pursuing suboptimal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrURciGjB2A3LVg90H21EOLACvtfcHk0liK3auoJValtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D&md5=90170e3f4e69e52bfa38667df380516a</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fnrd3701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3701%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26atitle%3DFinding%2520the%2520sweet%2520spot%253A%2520the%2520role%2520of%2520nature%2520and%2520nurture%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D355%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Tarcsay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">NyÃ­ri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span> </span><span class="NLM_article-title">Impact of lipophilic efficiency on compound quality</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">â</span> <span class="NLM_lpage">1260</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201388p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1252-1260&author=A.+Tarcsayauthor=K.+Ny%C3%ADriauthor=G.+M.+Keseru&title=Impact+of+lipophilic+efficiency+on+compound+quality"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Lipophilic Efficiency on Compound Quality</span></div><div class="casAuthors">Tarcsay, Akos; Nyiri, Kinga; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lipophilic efficiency indexes such as LLE and LELP were suggested to support balanced optimization of potency and ADMET profile.  Here we investigated the performance of LLE and LELP on multiple data sets representing different stages of drug discovery including fragment and HTS hits and leads, development candidates, phase II compds., and launched drugs.  Analyzing their impact on ADME and safety properties and binding thermodn., we found that both LLE and LELP help identifying better quality compds.  LLE is sensible for the development stages but does not prefer fragment-type hits, while LELP has an advantage for this class of compds. and discriminates preferred starting points effectively.  Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE in risk assessment at least on the present data set.  On the basis of the results reported here, monitoring lipophilic efficiency metrics could contribute significantly to compd. quality and might improve the output of medicinal chem. programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB8xs6-5DL7Vg90H21EOLACvtfcHk0linQ7__Fhc6tA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D&md5=2536abef781f52806013016971c78bcb</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm201388p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201388p%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DNy%25C3%25ADri%26aufirst%3DK.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DImpact%2520of%2520lipophilic%2520efficiency%2520on%2520compound%2520quality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1252%26epage%3D1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Wager, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekaran, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalobos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Will, Y.</span><span> </span><span class="NLM_article-title">Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">â</span> <span class="NLM_lpage">434</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn100007x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVaqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=420-434&author=T.+T.+Wagerauthor=R.+Y.+Chandrasekaranauthor=X.+Houauthor=M.+D.+Troutmanauthor=P.+R.+Verhoestauthor=A.+Villalobosauthor=Y.+Will&title=Defining+desirable+central+nervous+system+drug+space+through+the+alignment+of+molecular+properties%2C+in+vitro+ADME%2C+and+safety+attributes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes</span></div><div class="casAuthors">Wager, Travis T.; Chandrasekaran, Ramalakshmi Y.; Hou, Xinjun; Troutman, Matthew D.; Verhoest, Patrick R.; Villalobos, Anabella; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">420-434</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of our effort to increase survival of drug candidates and to move our medicinal chem. design to higher probability space for success in the Neuroscience therapeutic area, we embarked on a detailed study of the property space for a collection of central nervous system (CNS) mols.  We carried out a thorough anal. of properties for 119 marketed CNS drugs and a set of 108 Pfizer CNS candidates.  In particular, we focused on understanding the relationships between physicochem. properties, in vitro ADME (absorption, distribution, metab., and elimination) attributes, primary pharmacol. binding efficiencies, and in vitro safety data for these two sets of compds.  This scholarship provides guidance for the design of CNS mols. in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEMBo2f34BrVg90H21EOLACvtfcHk0linQ7__Fhc6tA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVaqtbk%253D&md5=85716be86290fd85e93c6b8d5621683c</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fcn100007x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100007x%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DChandrasekaran%26aufirst%3DR.%2BY.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DDefining%2520desirable%2520central%2520nervous%2520system%2520drug%2520space%2520through%2520the%2520alignment%2520of%2520molecular%2520properties%252C%2520in%2520vitro%2520ADME%252C%2520and%2520safety%2520attributes%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D420%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-DubÃ©, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8091</span><span class="NLM_x">â</span> <span class="NLM_lpage">8109</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300967g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8091-8109&author=J.+J.+Cuiauthor=M.+McTigueauthor=M.+Nambuauthor=M.+Tran-Dub%C3%A9author=M.+Pairishauthor=H.+Shenauthor=L.+Jiaauthor=H.+Chengauthor=J.+Hoffmanauthor=P.+Leauthor=M.+Jalaieauthor=G.+H.+Goetzauthor=K.+Ryanauthor=N.+Grodskyauthor=Y.+L.+Dengauthor=M.+Parkerauthor=S.+Timofeevskiauthor=B.+W.+Murrayauthor=S.+Yamazakiauthor=S.+Aguirreauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Discovery+of+a+novel+class+of+exquisitely+selective+mesenchymal-epithelial+transition+factor+%28MET%29+protein+kinase+inhibitors+and+identification+of+the+clinical+candidate+2-%284-%281-%28quinolin-6-ylmethyl%29-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-b%5Dpyrazin-6-yl%29-1H-pyrazol-1-yl%29ethanol+%28PF-04217903%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%2BH.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520exquisitely%2520selective%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528MET%2529%2520protein%2520kinase%2520inhibitors%2520and%2520identification%2520of%2520the%2520clinical%2520candidate%25202-%25284-%25281-%2528quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2520%2528PF-04217903%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8091%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Koenig, M.; Cui, J.; Wei, C. C.; Do, S. H.; Zhang, F.-J.; Vojkovsky, T.; Ramphal, J.; Yang, G.; Mattson, M.; Nelson, C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Indolinone Hydrazides as MET Inhibitors</span>. PCT Int. Appl. WO2005005378,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Koenig&author=J.+Cui&author=C.+C.+Wei&author=S.+H.+Do&author=F.-J.+Zhang&author=T.+Vojkovsky&author=J.+Ramphal&author=G.+Yang&author=M.+Mattson&author=C.+Nelson&author=P.+C.+Tang&title=Indolinone+Hydrazides+as+MET+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoenig%26aufirst%3DM.%26atitle%3DIndolinone%2520Hydrazides%2520as%2520MET%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Vojkovsky, T.; Koenig, M.; Zhang, F.-J.; Cui, J.</span><span> </span><span class="NLM_article-title">Tetracyclic Compounds as MET Inhibitors</span>. PCT Int. Appl. WO2005004808,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Vojkovsky&author=M.+Koenig&author=F.-J.+Zhang&author=J.+Cui&title=Tetracyclic+Compounds+as+MET+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVojkovsky%26aufirst%3DT.%26atitle%3DTetracyclic%2520Compounds%2520as%2520MET%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Zhang, F.-J.; Vojkovsky, T.; Huang, P.; Liang, C.; Do, S. H.; Koenig, M.; Cui, J.</span><span> </span><span class="NLM_article-title">Preparation of Triazolotriazines as MET Modulators for Treating Cancer</span>. PCT Int. Appl. WO2005010005,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=F.-J.+Zhang&author=T.+Vojkovsky&author=P.+Huang&author=C.+Liang&author=S.+H.+Do&author=M.+Koenig&author=J.+Cui&title=Preparation+of+Triazolotriazines+as+MET+Modulators+for+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.-J.%26atitle%3DPreparation%2520of%2520Triazolotriazines%2520as%2520MET%2520Modulators%2520for%2520Treating%2520Cancer%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Cui, J.; Botrous, I.</span><span> </span><span class="NLM_article-title">Arylmethyl Triazolo and Imidazopyrazines as MET Inhibitors</span>. PCT Int. Appl. WO2005004607,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+Cui&author=I.+Botrous&title=Arylmethyl+Triazolo+and+Imidazopyrazines+as+MET+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DArylmethyl%2520Triazolo%2520and%2520Imidazopyrazines%2520as%2520MET%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-DubÃ©, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Lessons from (<i>S</i>)-6-(1-(6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6651</span><span class="NLM_x">â</span> <span class="NLM_lpage">6665</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400926x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6651-6665&author=J.+J.+Cuiauthor=H.+Shenauthor=M.+Tran-Dub%C3%A9author=M.+Nambuauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=S.+Yamazakiauthor=S.+Aguirreauthor=M.+Parkerauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Lessons+from+%28S%29-6-%281-%286-%281-methyl-1H-pyrazol-4-yl%29-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-b%5Dpyridazin-3-yl%29ethyl%29quinoline+%28PF-04254644%29%2C+an+inhibitor+of+receptor+tyrosine+kinase+c-Met+with+high+protein+kinase+selectivity+but+broad+phosphodiesterase+family+inhibition+leading+to+myocardial+degeneration+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fjm400926x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400926x%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DLessons%2520from%2520%2528S%2529-6-%25281-%25286-%25281-methyl-1H-pyrazol-4-yl%2529-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-b%255Dpyridazin-3-yl%2529ethyl%2529quinoline%2520%2528PF-04254644%2529%252C%2520an%2520inhibitor%2520of%2520receptor%2520tyrosine%2520kinase%2520c-Met%2520with%2520high%2520protein%2520kinase%2520selectivity%2520but%2520broad%2520phosphodiesterase%2520family%2520inhibition%2520leading%2520to%2520myocardial%2520degeneration%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6651%26epage%3D6665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Aguirre, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collette, W.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobrowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasi, E. R.</span><span> </span><span class="NLM_article-title">Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">â</span> <span class="NLM_lpage">428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1177%2F0192623310364027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20231546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1Ontbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=416-428&author=S.+A.+Aguirreauthor=J.+R.+Heyenauthor=W.+Colletteauthor=W.+Bobrowskiauthor=E.+R.+Blasi&title=Cardiovascular+effects+in+rats+following+exposure+to+a+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Aguirre, Shirley A.; Heyen, Jonathan R.; Collette, Walter, III; Bobrowski, Walter; Blasi, Eileen R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">416-428</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase receptor (RTK) signaling pathway, mesenchymal-epithelial transition factor (c-Met)/hepatocyte growth factor receptor (HGFR), has been implicated in oncogenesis and is a target of interest in cancer therapy.  PF-04254644 is a potent and selective inhibitor of c-Met/HGFR.  Wide ligand binding profiling of PF-04254644 revealed a potentially significant interaction with phosphodiesterase (PDE) 3, and follow-up PDE enzyme activity assays confirmed PF-04254644 as a potent inhibitor of PDE3 as well as other PDEs (1, 2, 5, 10, and 11).  Clin. observations, lab., and echocardiog. parameters were recorded in Sprague-Dawley (SD) rats that received PF-04254644 oral dosing for up to seven consecutive days.  Toxicol. evaluations revealed myocardial degeneration as an adverse event at all tested doses.  Echocardiog. evaluations revealed an increase in heart rate (HR) and contractility after the first dose with PF-04254644 and myocardial fibrosis correlated with decreased cardiac function after repeat dosing.  A study in telemetry-instrumented rats substantiated that PF-04254644 induced a sustained increased HR and decreased contractility after six days of treatment.  Data suggest that the decreased cardiac function and cardiotoxicity are likely due to inhibition of multiple PDEs by PF-04254644.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_6wrzHn8abVg90H21EOLACvtfcHk0lhcYGcaQN6YUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1Ontbc%253D&md5=59dc667b0b8436e87cb5b4ae1ec56778</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1177%2F0192623310364027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623310364027%26sid%3Dliteratum%253Aachs%26aulast%3DAguirre%26aufirst%3DS.%2BA.%26aulast%3DHeyen%26aufirst%3DJ.%2BR.%26aulast%3DCollette%26aufirst%3DW.%26aulast%3DBobrowski%26aufirst%3DW.%26aulast%3DBlasi%26aufirst%3DE.%2BR.%26atitle%3DCardiovascular%2520effects%2520in%2520rats%2520following%2520exposure%2520to%2520a%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DToxicol.%2520Pathol.%26date%3D2010%26volume%3D38%26spage%3D416%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirakawa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition</span> <span class="citation_source-journal">J. Appl. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1008</span><span class="NLM_x">â</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fjat.2801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22936366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yks7bM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=1008-1020&author=W.+Huauthor=B.+Hirakawaauthor=B.+Jessenauthor=M.+Leeauthor=S.+A.+Aguirre&title=Tyrosine+kinase+inhibitor-induced+myocardial+degeneration+in+rats+through+off-target+phosphodiesterase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition</span></div><div class="casAuthors">Hu, Wenyue; Hirakawa, Brad; Jessen, Bart; Lee, Michelle; Aguirre, Shirley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1008-1020</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">PF-04254644 is a selective kinase inhibitor of mesenchymal epithelial transition factor/hepatocyte growth factor receptor with known off-target inhibitory activity against the phosphodiesterase (PDE) family.  Rats given repeated oral doses of PF-04254644 developed a mild to moderate myocardial degeneration accompanied by sustained increase in heart rate and contractility.  Investigative studies were conducted to delineate the mechanisms of toxicity.  Microarray anal. of Sprague-Dawley rat hearts in a 6 day repeat dose study with PF-04254644 or milrinone, a selective PDE3 inhibitor, revealed similar perturbation of the cyclic adenosine monophosphate (c-AMP) pathway.  PDE inhibition and activation of c-AMP were further substantiated using PDE3B immunofluorescence staining and through a c-AMP response element reporter gene assay.  The intracellular calcium and oxidative stress signaling pathways were more perturbed by treatment with PF-04254644 than milrinone.  The rat cardiomyocytes calcium assay found a dose-dependent increase in intracellular calcium with PF-04254644 treatment.  These data suggest that cardiotoxicity of PF-04254644 was probably due to activation of c-AMP signaling, and possibly subsequent disruption of intracellular calcium and oxidative stress signaling pathways.  The greater response with PF-04254644 as compared with milrinone in gene expression and micro- and ultrastructural changes is probably due to the broader panel of PDEs inhibition.  Copyright Â© 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3XR4RRu0a4rVg90H21EOLACvtfcHk0lhcYGcaQN6YUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yks7bM&md5=5565a0333f18d96b4a9524f5decc6425</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fjat.2801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.2801%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHirakawa%26aufirst%3DB.%26aulast%3DJessen%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DAguirre%26aufirst%3DS.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitor-induced%2520myocardial%2520degeneration%2520in%2520rats%2520through%2520off-target%2520phosphodiesterase%2520inhibition%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2012%26volume%3D32%26spage%3D1008%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Perera, T.; Lavrijssen, T.; Janssens, B.; Geerts, T.; King, P.; Mevellec, L.; Cummings, M. D.; Lu, T.; Johnson, D.; Page, M.</span><span> </span><span class="NLM_article-title">JNJ-38877605: A Selective MET Kinase Inhibitor Inducing Regression of MET-Driven Tumor Models</span>. Presented at the 99th AACR Annual Meeting; San Diego, CA, Apr 12â16,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>No. 4837.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+Perera&author=T.+Lavrijssen&author=B.+Janssens&author=T.+Geerts&author=P.+King&author=L.+Mevellec&author=M.+D.+Cummings&author=T.+Lu&author=D.+Johnson&author=M.+Page&title=JNJ-38877605%3A+A+Selective+MET+Kinase+Inhibitor+Inducing+Regression+of+MET-Driven+Tumor+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%26atitle%3DJNJ-38877605%253A%2520A%2520Selective%2520MET%2520Kinase%2520Inhibitor%2520Inducing%2520Regression%2520of%2520MET-Driven%2520Tumor%2520Models%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bounaud, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huser, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felce, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froning, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterman, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubol, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessert, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwinn, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leon, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emtage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burley, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, S. H.</span><span> </span><span class="NLM_article-title">SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3181</span><span class="NLM_x">â</span> <span class="NLM_lpage">3190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1535-7163.MCT-09-0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19934279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3181-3190&author=S.+G.+Buchananauthor=J.+Hendleauthor=P.+S.+Leeauthor=C.+R.+Smithauthor=P.+Y.+Bounaudauthor=K.+A.+Jessenauthor=C.+M.+Tangauthor=N.+H.+Huserauthor=J.+D.+Felceauthor=K.+J.+Froningauthor=M.+C.+Petermanauthor=B.+E.+Aubolauthor=S.+F.+Gessertauthor=J.+M.+Sauderauthor=K.+D.+Schwinnauthor=M.+Russellauthor=I.+A.+Rooneyauthor=J.+Adamsauthor=B.+C.+Leonauthor=T.+H.+Doauthor=J.+M.+Blaneyauthor=P.+A.+Sprengelerauthor=D.+A.+Thompsonauthor=L.+Smythauthor=L.+A.+Pelletierauthor=S.+Atwellauthor=K.+Holmeauthor=S.+R.+Wassermanauthor=S.+Emtageauthor=S.+K.+Burleyauthor=S.+H.+Reich&title=SGX523+is+an+exquisitely+selective%2C+ATP-competitive+inhibitor+of+the+MET+receptor+tyrosine+kinase+with+antitumor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</span></div><div class="casAuthors">Buchanan, Sean G.; Hendle, Jorg; Lee, Patrick S.; Smith, Christopher R.; Bounaud, Pierre-Yves; Jessen, Katti A.; Tang, Crystal M.; Huser, Nanni H.; Felce, Jeremy D.; Froning, Karen J.; Peterman, Marshall C.; Aubol, Brandon E.; Gessert, Steve F.; Sauder, J. Michael; Schwinn, Kenneth D.; Russell, Marijane; Rooney, Isabelle A.; Adams, Jason; Leon, Barbara C.; Do, Tuan H.; Blaney, Jeff M.; Sprengeler, Paul A.; Thompson, Devon A.; Smyth, Lydia; Pelletier, Laura A.; Atwell, Shane; Holme, Kevin; Wasserman, Stephen R.; Emtage, Spencer; Burley, Stephen K.; Reich, Siegfried H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3181-3190</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics.  Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers.  In other cancers, such as glioblastoma, autocrine activation of MET has been demonstrated.  Several classes of ATP-competitive inhibitor have been described, which inhibit MET but also other kinases.  Here, we describe SGX523, a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET.  SGX523 potently inhibited MET with an IC50 of 4 nmol/L and is >1000-fold selective vs. the >200-fold selectivity of other protein kinases tested in biochem. assays.  Crystallog. study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the selectivity.  SGX523 inhibited MET-mediated signaling, cell proliferation, and cell migration at nanomolar concns. but had no effect on signaling dependent on other protein kinases, including the closely related RON, even at micromolar concns.  SGX523 inhibition of MET in vivo was assocd. with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers, confirming the dependence of these tumors on MET catalytic activity.  Our results show that SGX523 is the most selective inhibitor of MET catalytic activity described to date and is thus a useful tool to investigate the role of MET kinase in cancer without the confounding effects of promiscuous protein kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplt9w6z--VQ7Vg90H21EOLACvtfcHk0lht1qwU6702qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbzI&md5=7410ae811f0bf2d3298691ed34d35878</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0477%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DHendle%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DBounaud%26aufirst%3DP.%2BY.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DTang%26aufirst%3DC.%2BM.%26aulast%3DHuser%26aufirst%3DN.%2BH.%26aulast%3DFelce%26aufirst%3DJ.%2BD.%26aulast%3DFroning%26aufirst%3DK.%2BJ.%26aulast%3DPeterman%26aufirst%3DM.%2BC.%26aulast%3DAubol%26aufirst%3DB.%2BE.%26aulast%3DGessert%26aufirst%3DS.%2BF.%26aulast%3DSauder%26aufirst%3DJ.%2BM.%26aulast%3DSchwinn%26aufirst%3DK.%2BD.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DRooney%26aufirst%3DI.%2BA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DLeon%26aufirst%3DB.%2BC.%26aulast%3DDo%26aufirst%3DT.%2BH.%26aulast%3DBlaney%26aufirst%3DJ.%2BM.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DSmyth%26aufirst%3DL.%26aulast%3DPelletier%26aufirst%3DL.%2BA.%26aulast%3DAtwell%26aufirst%3DS.%26aulast%3DHolme%26aufirst%3DK.%26aulast%3DWasserman%26aufirst%3DS.%2BR.%26aulast%3DEmtage%26aufirst%3DS.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DReich%26aufirst%3DS.%2BH.%26atitle%3DSGX523%2520is%2520an%2520exquisitely%2520selective%252C%2520ATP-competitive%2520inhibitor%2520of%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3181%26epage%3D3190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Tiedt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenkolbe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleton, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepfer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buck, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddy, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haasen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span> </span><span class="NLM_article-title">A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">5255</span><span class="NLM_x">â</span> <span class="NLM_lpage">5264</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=5255-5264&author=R.+Tiedtauthor=E.+Degenkolbeauthor=P.+Furetauthor=B.+A.+Appletonauthor=S.+Wagnerauthor=J.+Schoepferauthor=E.+Buckauthor=D.+A.+Ruddyauthor=J.+E.+Monahanauthor=M.+D.+Jonesauthor=J.+Blankauthor=D.+Haasenauthor=P.+Drueckesauthor=M.+Wartmannauthor=C.+McCarthyauthor=W.+R.+Sellersauthor=F.+Hofmann&title=A+drug+resistance+screen+using+a+selective+MET+inhibitor+reveals+a+spectrum+of+mutations+that+partially+overlap+with+activating+mutations+found+in+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DDegenkolbe%26aufirst%3DE.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DRuddy%26aufirst%3DD.%2BA.%26aulast%3DMonahan%26aufirst%3DJ.%2BE.%26aulast%3DJones%26aufirst%3DM.%2BD.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DHaasen%26aufirst%3DD.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26atitle%3DA%2520drug%2520resistance%2520screen%2520using%2520a%2520selective%2520MET%2520inhibitor%2520reveals%2520a%2520spectrum%2520of%2520mutations%2520that%2520partially%2520overlap%2520with%2520activating%2520mutations%2520found%2520in%2520cancer%2520patients%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D5255%26epage%3D5264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marando, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblish, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behshad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span> </span><span class="NLM_article-title">A novel kinase inhibitor, INCB28060, blocks MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7127</span><span class="NLM_x">â</span> <span class="NLM_lpage">7138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-11-1157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21918175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7127-7138&author=X.+Liuauthor=Q.+Wangauthor=G.+Yangauthor=C.+Marandoauthor=H.+K.+Koblishauthor=L.+M.+Hallauthor=J.+S.+Fridmanauthor=E.+Behshadauthor=R.+Wynnauthor=Y.+Liauthor=J.+Boerauthor=S.+Diamondauthor=C.+Heauthor=M.+Xuauthor=J.+Zhuoauthor=W.+Yaoauthor=R.+C.+Newtonauthor=P.+A.+Scherle&title=A+novel+kinase+inhibitor%2C+INCB28060%2C+blocks+MET-dependent+signaling%2C+neoplastic+activities%2C+and+cross-talk+with+EGFR+and+HER-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3</span></div><div class="casAuthors">Liu, Xiangdong; Wang, Qian; Yang, Gengjie; Marando, Cindy; Koblish, Holly K.; Hall, Leslie M.; Fridman, Jordan S.; Behshad, Elham; Wynn, Richard; Li, Yu; Boer, Jason; Diamond, Sharon; He, Chunhong; Xu, Meizhong; Zhuo, Jincong; Yao, Wenqing; Newton, Robert C.; Scherle, Peggy A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7127-7138</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The c-MET receptor tyrosine kinase plays important roles in the formation, progression, and dissemination of human cancer and presents an attractive therapeutic target.  This study describes the preclin. characterization of INCB28060, a novel inhibitor of c-MET kinase.  Exptl. Design: Studies were conducted using a series of in vitro and in vivo biochem. and biol. expts.  RESULTS: INCB28060 exhibits picomolar enzymic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases.  This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines.  As a result, INCB28060 potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro.  Oral dosing of INCB28060 results in time- and dose-dependent inhibition of c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models, and the inhibitor is well tolerated at doses that achieve complete tumor inhibition.  In a further exploration of potential interactions between c-MET and other signaling pathways, we found that activated c-MET pos. regulates the activity of epidermal growth factor receptors (EGFR) and HER-3, as well as expression of their ligands.  These effects are reversed with INCB28060 treatment.  Finally, we confirmed that circulating hepatocyte growth factor levels are significantly elevated in patients with various cancers.  CONCLUSIONS: Activated c-MET has pleiotropic effects on multiple cancer-promoting signaling pathways and may play a crit. role in driving tumor cell growth and survival.  INCB28060 is a potent and selective c-MET kinase inhibitor that may have therapeutic potential in cancer treatment.  Clin Cancer Res; 17(22); 7127-38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqqT6dM1mGprVg90H21EOLACvtfcHk0lhGcfJxm-HKnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7nK&md5=c272514704702cb5cbcc9e405bea3c53</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1157%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMarando%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DHall%26aufirst%3DL.%2BM.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBehshad%26aufirst%3DE.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZhuo%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520kinase%2520inhibitor%252C%2520INCB28060%252C%2520blocks%2520MET-dependent%2520signaling%252C%2520neoplastic%2520activities%252C%2520and%2520cross-talk%2520with%2520EGFR%2520and%2520HER-3%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7127%26epage%3D7138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridrich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimanovich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S.</span><span> </span><span class="NLM_article-title">Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the MET kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2879</span><span class="NLM_x">â</span> <span class="NLM_lpage">2882</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800043g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2879-2882&author=B.+K.+Albrechtauthor=J.+C.+Harmangeauthor=D.+Bauerauthor=L.+Berryauthor=C.+Bodeauthor=A.+A.+Boezioauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=C.+Fridrichauthor=S.+Hiraiauthor=D.+Hoffmanauthor=J.+F.+Larrowauthor=P.+Kaplan-Lefkoauthor=J.+Linauthor=J.+Lohmanauthor=A.+M.+Longauthor=J.+Moriguchiauthor=A.+O%E2%80%99Connorauthor=M.+H.+Potashmanauthor=M.+Reeseauthor=K.+Rexauthor=A.+Siegmundauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+Bellon&title=Discovery+and+optimization+of+triazolopyridazines+as+potent+and+selective+inhibitors+of+the+MET+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm800043g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800043g%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMoriguchi%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DA.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DReese%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520triazolopyridazines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520MET%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2879%26epage%3D2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santostefano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimanovich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span> </span><span class="NLM_article-title">Discovery and optimization of potent and selective triazolopyridazine series of MET inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6307</span><span class="NLM_x">â</span> <span class="NLM_lpage">6312</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6307-6312&author=A.+A.+Boezioauthor=L.+Berryauthor=B.+K.+Albrechtauthor=D.+Bauerauthor=S.+F.+Bellonauthor=C.+Bodeauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=M.+Fangauthor=S.+Hiraiauthor=P.+Kaplan-Lefkoauthor=J.+F.+Larrowauthor=M.+H.+Linauthor=J.+Lohmanauthor=M.+H.+Potashmanauthor=Y.+Quauthor=K.+Rexauthor=M.+Santostefanoauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+potent+and+selective+triazolopyridazine+series+of+MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DFang%26aufirst%3DM.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSantostefano%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520potent%2520and%2520selective%2520triazolopyridazine%2520series%2520of%2520MET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6307%26epage%3D6312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Bode, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span> </span><span class="NLM_article-title">Discovery and optimization of a potent and selective triazolopyridinone series of MET inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4089</span><span class="NLM_x">â</span> <span class="NLM_lpage">4093</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4089-4093&author=C.+M.+Bodeauthor=A.+A.+Boezioauthor=B.+K.+Albrechtauthor=S.+F.+Bellonauthor=L.+Berryauthor=M.+A.+Broomeauthor=D.+Choquetteauthor=I.+Dussaultauthor=R.+T.+Lewisauthor=M.+H.+Linauthor=K.+Rexauthor=D.+A.+Whittingtonauthor=Y.+Yangauthor=J.+C.+Harmange&title=Discovery+and+optimization+of+a+potent+and+selective+triazolopyridinone+series+of+MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520potent%2520and%2520selective%2520triazolopyridinone%2520series%2520of%2520MET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4089%26epage%3D4093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Bladt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friese-Hamim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knuehl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fittschen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GrÃ¤dler, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyring, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaehrling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pehl, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stieber, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaukat, A.</span><span> </span><span class="NLM_article-title">EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective MET inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2941</span><span class="NLM_x">â</span> <span class="NLM_lpage">2951</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-12-3247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23553846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12ju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2941-2951&author=F.+Bladtauthor=B.+Fadenauthor=M.+Friese-Hamimauthor=C.+Knuehlauthor=C.+Wilmauthor=C.+Fittschenauthor=U.+Gr%C3%A4dlerauthor=M.+Meyringauthor=D.+Dorschauthor=F.+Jaehrlingauthor=U.+Pehlauthor=F.+Stieberauthor=O.+Schadtauthor=A.+Blaukat&title=EMD+1214063+and+EMD+1204831+constitute+a+new+class+of+potent+and+highly+selective+MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors</span></div><div class="casAuthors">Bladt, Friedhelm; Faden, Bettina; Friese-Hamim, Manja; Knuehl, Christine; Wilm, Claudia; Fittschen, Claus; Graedler, Ulrich; Meyring, Michael; Dorsch, Dieter; Jaehrling, Frank; Pehl, Ulrich; Stieber, Frank; Schadt, Oliver; Blaukat, Andree</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2941-2951</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The mesenchymal-epithelial transition factor (c-Met) receptor, also known as hepatocyte growth factor receptor (HGFR), controls morphogenesis, a process that is physiol. required for embryonic development and tissue repair.  Aberrant c-Met activation is assocd. with a variety of human malignancies including cancers of the lung, kidney, stomach, liver, and brain.  In this study, we investigated the properties of two novel compds. developed to selectively inhibit the c-Met receptor in antitumor therapeutic interventions.  Exptl. Design: The pharmacol. properties, c-Met inhibitory activity, and antitumor effects of EMD 1214063 and EMD 1204831 were investigated in vitro and in vivo, using human cancer cell lines and mouse xenograft models.  Results: EMD 1214063 and EMD 1204831 selectively suppressed the c-Met receptor tyrosine kinase activity.  Their inhibitory activity was potent [inhibitory 50% concn. (IC50), 3 nmol/L and 9 nmol/L, resp.] and highly selective, when compared with their effect on a panel of 242 human kinases.  Both EMD 1214063 and EMD 1204831 inhibited c-Met phosphorylation and downstream signaling in a dose-dependent fashion, but differed in the duration of their inhibitory activity.  In murine xenograft models, both compds. induced regression of human tumors, regardless of whether c-Met activation was HGF dependent or independent.  Both drugs were well tolerated and induced no substantial wt. loss after more than 3 wk of treatment.  Conclusions: Our results indicate selective c-Met inhibition by EMD 1214063 and EMD 1204831 and strongly support clin. testing of these compds. in the context of molecularly targeted anticancer strategies.  Clin Cancer Res; 19(11); 2941-51. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP2ZWzE5rC6LVg90H21EOLACvtfcHk0lha8xfY7ckx8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12ju78%253D&md5=a1d24bf9fdaea35808c7468a6e7d197f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3247%26sid%3Dliteratum%253Aachs%26aulast%3DBladt%26aufirst%3DF.%26aulast%3DFaden%26aufirst%3DB.%26aulast%3DFriese-Hamim%26aufirst%3DM.%26aulast%3DKnuehl%26aufirst%3DC.%26aulast%3DWilm%26aufirst%3DC.%26aulast%3DFittschen%26aufirst%3DC.%26aulast%3DGr%25C3%25A4dler%26aufirst%3DU.%26aulast%3DMeyring%26aufirst%3DM.%26aulast%3DDorsch%26aufirst%3DD.%26aulast%3DJaehrling%26aufirst%3DF.%26aulast%3DPehl%26aufirst%3DU.%26aulast%3DStieber%26aufirst%3DF.%26aulast%3DSchadt%26aufirst%3DO.%26aulast%3DBlaukat%26aufirst%3DA.%26atitle%3DEMD%25201214063%2520and%2520EMD%25201204831%2520constitute%2520a%2520new%2520class%2520of%2520potent%2520and%2520highly%2520selective%2520MET%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2941%26epage%3D2951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fclinicaltrials.gov."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, P.</span><span> </span><span class="NLM_article-title">Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1575</span><span class="NLM_x">â</span> <span class="NLM_lpage">1587</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1575-1587&author=D.+Dalvieauthor=H.+Sunauthor=C.+Xiangauthor=Q.+Huauthor=Y.+Jiangauthor=P.+Kang&title=Effect+of+structural+variation+on+aldehyde+oxidase-catalyzed+oxidation+of+zoniporide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXiang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DP.%26atitle%3DEffect%2520of%2520structural%2520variation%2520on%2520aldehyde%2520oxidase-catalyzed%2520oxidation%2520of%2520zoniporide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1575%26epage%3D1587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R. K.</span><span> </span><span class="NLM_article-title">Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">369</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=363-369&author=J.+R.+Infanteauthor=T.+Ruggauthor=M.+Gordonauthor=I.+Rooneyauthor=L.+Rosenauthor=K.+Zehauthor=R.+Liuauthor=H.+A.+Burrisauthor=R.+K.+Ramanathan&title=Unexpected+renal+toxicity+associated+with+SGX523%2C+a+small+molecule+inhibitor+of+MET"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DRugg%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DRooney%26aufirst%3DI.%26aulast%3DRosen%26aufirst%3DL.%26aulast%3DZeh%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26atitle%3DUnexpected%2520renal%2520toxicity%2520associated%2520with%2520SGX523%252C%2520a%2520small%2520molecule%2520inhibitor%2520of%2520MET%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D363%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maduskuie, T. P.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falahatpisheh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span> </span><span class="NLM_article-title">Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1277</span><span class="NLM_x">â</span> <span class="NLM_lpage">1285</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1124%2Fdmd.110.032375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20421447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWktrjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1277-1285&author=S.+Diamondauthor=J.+Boerauthor=T.+P.+Maduskuieauthor=N.+Falahatpishehauthor=Y.+Liauthor=S.+Yeleswaram&title=Species-specific+metabolism+of+SGX523+by+aldehyde+oxidase+and+the+toxicological+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications</span></div><div class="casAuthors">Diamond, Sharon; Boer, Jason; Maduskuie, Thomas P., Jr.; Falahatpisheh, Nikoo; Li, Yu; Yeleswaram, Swamy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1277-1285</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">An investigation was conducted to follow up on the apparent species-dependent toxicity reported for 6-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio]quinoline (SGX523), a mesenchymal-epithelial transition factor (c-MET) inhibitor that entered clin. development for the treatment of solid tumors.  Patients treated with SGX523 exhibited compromised renal function presumably resulting from crystal deposits in renal tubules.  Our independent metabolite profiling of SGX523 indicates that a major NADPH-independent, late-eluting metabolite [6-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)quinolin-2(1H)-one (M11)] was generated by monkey and human liver S-9, and to a lesser extent by rat S-9, whereas M11 was absent in dog S-9 incubations.  We confirmed the identity of M11 as 2-quinolinone-SGX523.  Expts. with various molybdenum hydroxylase inhibitors showed that aldehyde oxidase (AO), and not xanthine oxidase, metabolized SGX523 to M11 in monkey and human liver cytosol.  In addn., the oxygen incorporated into M11 was derived from water rather than atm. oxygen, corroborating M11 formation via AO.  After oral dosing in monkeys, metabolite profiling of plasma and urine showed that SGX523 was indeed metabolized to M11 and its N-demethyl analog (M8).  In urine, M11 levels were â¼70-fold greater than that of SGX523, and the soly. of M11 in urine was only 3% of that of SGX523.  In summary, SGX523 is metabolized by AO in a species-specific manner to a markedly less-sol. metabolite, M11.  We propose that M11 is likely involved in the obsd. obstructive nephropathy reported in clin. studies.  Moreover, this study illustrates the need to conduct thorough metabolic evaluations early in drug development to select the most relevant nonclin. species for toxicol. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryx8buDjc41LVg90H21EOLACvtfcHk0lha8xfY7ckx8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWktrjM&md5=27450436ad7a69d72d4cc8ae9860ccd9</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032375%26sid%3Dliteratum%253Aachs%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DMaduskuie%26aufirst%3DT.%2BP.%26aulast%3DFalahatpisheh%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYeleswaram%26aufirst%3DS.%26atitle%3DSpecies-specific%2520metabolism%2520of%2520SGX523%2520by%2520aldehyde%2520oxidase%2520and%2520the%2520toxicological%2520implications%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1277%26epage%3D1285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Fujiwara, Y.; Miwa, A.; Nakamura, K.; Nishitoba, T.; Osawa, T.; Senga, T.</span><span> </span><span class="NLM_article-title">Quinoline Derivative and Quinazoline Derivative Inhibiting Self-Phosphorylation of Hepatocytus Proliferator Receptor, and Medicinal Composition Containing the Same</span>. PCT Int. Appl. WO2003000660,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=Y.+Fujiwara&author=A.+Miwa&author=K.+Nakamura&author=T.+Nishitoba&author=T.+Osawa&author=T.+Senga&title=Quinoline+Derivative+and+Quinazoline+Derivative+Inhibiting+Self-Phosphorylation+of+Hepatocytus+Proliferator+Receptor%2C+and+Medicinal+Composition+Containing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DY.%26atitle%3DQuinoline%2520Derivative%2520and%2520Quinazoline%2520Derivative%2520Inhibiting%2520Self-Phosphorylation%2520of%2520Hepatocytus%2520Proliferator%2520Receptor%252C%2520and%2520Medicinal%2520Composition%2520Containing%2520the%2520Same%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Elisei, R.; Schlumberger, M. J.; MÃ¼ller, S. P.; SchÃ¶ffski, P.; Brose, M. S.; Shah, M. H.; Licitra, L.; Jarzab, B.; Medvedev, V.; Kreissl, M. C.; Niederle, B.; Cohen, E. E.; Wirth, L. J.; Ali, H.; Hessel, C.; Yaron, Y.; Ball, D.; Nelkin, B.; Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span> [Online early access]. DOI: <span class="refDoi">Â DOI: 10.1200/JCO.2012.48.4659</span> . Published Online: Sep 3,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=24002501" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Elisei&author=M.+J.+Schlumberger&author=S.+P.+M%C3%BCller&author=P.+Sch%C3%B6ffski&author=M.+S.+Brose&author=M.+H.+Shah&author=L.+Licitra&author=B.+Jarzab&author=V.+Medvedev&author=M.+C.+Kreissl&author=B.+Niederle&author=E.+E.+Cohen&author=L.+J.+Wirth&author=H.+Ali&author=C.+Hessel&author=Y.+Yaron&author=D.+Ball&author=B.+Nelkin&author=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26doi%3D10.1200%2FJCO.2012.48.4659%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2298</span><span class="NLM_x">â</span> <span class="NLM_lpage">2308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0licNijzfVUmBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">â</span> <span class="NLM_lpage">8016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tohyama, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funasaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirotori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obaishi, H.</span><span> </span><span class="NLM_article-title">E7050: a dual MET and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">â</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1111%2Fj.1349-7006.2009.01343.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19832844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVOisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2010&pages=210-215&author=T.+Nakagawaauthor=O.+Tohyamaauthor=A.+Yamaguchiauthor=T.+Matsushimaauthor=K.+Takahashiauthor=S.+Funasakaauthor=S.+Shirotoriauthor=M.+Asadaauthor=H.+Obaishi&title=E7050%3A+a+dual+MET+and+VEGFR-2+tyrosine+kinase+inhibitor+promotes+tumor+regression+and+prolongs+survival+in+mouse+xenograft+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models</span></div><div class="casAuthors">Nakagawa, Takayuki; Tohyama, Osamu; Yamaguchi, Atsumi; Matsushima, Tomohiro; Takahashi, Keiko; Funasaka, Setsuo; Shirotori, Shuji; Asada, Makoto; Obaishi, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">C-Met is the cellular receptor for hepatocyte growth factor (HGF) and is known to be dysregulated in various types of human cancers.  Activation of the HGF/c-Met pathway causes tumor progression, invasion, and metastasis.  Vascular endothelial growth factor (VEGF) is also known as a key mol. in tumor progression through the induction of tumor angiogenesis.  Because of their key roles in tumor progression, these pathways provide attractive targets for therapeutic intervention.  We have generated a novel, orally active, small mol. compd., E7050, which inhibits both c-Met and vascular endothelial growth factor receptor (VEGFR)-2.  In vitro studies indicate that E7050 potently inhibits phosphorylation of both c-Met and VEGFR-2.  E7050 also potently represses the growth of both c-met amplified tumor cells and endothelial cells stimulated with either HGF or VEGF.  In vivo studies using E7050 showed inhibition of the phosphorylation of c-Met and VEGFR-2 in tumors, and strong inhibition of tumor growth and tumor angiogenesis in xenograft models.  Treatment of some tumor lines contg. c-met amplifications with high doses of E7050 (50-200 mg/kg) induced tumor regression and disappearance.  In a peritoneal dissemination model, E7050 showed an antitumor effect against peritoneal tumors as well as a significant prolongation of lifespan in treated mice.  Our results indicate that E7050 is a potent inhibitor of c-Met and VEGFR-2 and has therapeutic potential for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd7smhBTumtLVg90H21EOLACvtfcHk0ljxyYoropiC4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVOisA%253D%253D&md5=e8ce73fa1262f767cea173f0561d8e35</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2009.01343.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2009.01343.x%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DTohyama%26aufirst%3DO.%26aulast%3DYamaguchi%26aufirst%3DA.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DFunasaka%26aufirst%3DS.%26aulast%3DShirotori%26aufirst%3DS.%26aulast%3DAsada%26aufirst%3DM.%26aulast%3DObaishi%26aufirst%3DH.%26atitle%3DE7050%253A%2520a%2520dual%2520MET%2520and%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitor%2520promotes%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DCancer%2520Sci.%26date%3D2010%26volume%3D101%26spage%3D210%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Bonfils, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroun, C. R.</span><span> </span><span class="NLM_article-title">The combination of MGCD265, a MET/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">8 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">1790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1790&issue=8+Suppl.&author=C.+Bonfilsauthor=N.+Beaulieuauthor=M.+Fournelauthor=H.+Ste-Croixauthor=J.+M.+Bestermanauthor=C.+R.+Maroun&title=The+combination+of+MGCD265%2C+a+MET%2FVEGFR+inhibitor+in+clinical+development%2C+and+erlotinib+potently+inhibits+tumor+growth+by+altering+multiple+pathways+including+glycolysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26atitle%3DThe%2520combination%2520of%2520MGCD265%252C%2520a%2520MET%252FVEGFR%2520inhibitor%2520in%2520clinical%2520development%252C%2520and%2520erlotinib%2520potently%2520inhibits%2520tumor%2520growth%2520by%2520altering%2520multiple%2520pathways%2520including%2520glycolysis%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3D8%2520Suppl%26spage%3D1790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fellows, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAngelo, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span> </span><span class="NLM_article-title">Structure-based design of novel class II MET inhibitors: 1. Identification of pyrazolone-based derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1858</span><span class="NLM_x">â</span> <span class="NLM_lpage">1867</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201330u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1858-1867&author=M.+H.+Normanauthor=L.+Liuauthor=M.+Leeauthor=N.+Xiauthor=I.+Fellowsauthor=N.+D.+D%E2%80%99Angeloauthor=C.+Dominguezauthor=K.+Rexauthor=S.+F.+Bellonauthor=T.+S.+Kimauthor=I.+Dussault&title=Structure-based+design+of+novel+class+II+MET+inhibitors%3A+1.+Identification+of+pyrazolone-based+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm201330u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201330u%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DFellows%26aufirst%3DI.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DKim%26aufirst%3DT.%2BS.%26aulast%3DDussault%26aufirst%3DI.%26atitle%3DStructure-based%2520design%2520of%2520novel%2520class%2520II%2520MET%2520inhibitors%253A%25201.%2520Identification%2520of%2520pyrazolone-based%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1858%26epage%3D1867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimanovich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. S.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally bioavailable MET inhibitor: 1-(2-hydroxy-2-methylpropyl)-<i>N</i>-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazole-4-carboxamide (AMG 458)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3688</span><span class="NLM_x">â</span> <span class="NLM_lpage">3691</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800401t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3688-3691&author=L.+Liuauthor=A.+Siegmundauthor=N.+Xiauthor=P.+Kaplan-Lefkoauthor=K.+Rexauthor=A.+Chenauthor=J.+Linauthor=J.+Moriguchiauthor=L.+Berryauthor=L.+Huangauthor=Y.+Tefferaauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+F.+Bellonauthor=M.+Leeauthor=R.+Shimanovichauthor=A.+Bakauthor=C.+Dominguezauthor=M.+H.+Normanauthor=J.+C.+Harmangeauthor=I.+Dussaultauthor=T.+S.+Kim&title=Discovery+of+a+potent%2C+selective%2C+and+orally+bioavailable+MET+inhibitor%3A+1-%282-hydroxy-2-methylpropyl%29-N-%285-%287-methoxyquinolin-4-yloxy%29pyridin-2-yl%29-5-methyl-3-oxo-2-phenyl-2%2C3-dihydro-1H-pyrazole-4-carboxamide+%28AMG+458%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142a&amp;dbid=16384&amp;doi=10.1021%2Fjm800401t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800401t%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoriguchi%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DBak%26aufirst%3DA.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DT.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520MET%2520inhibitor%253A%25201-%25282-hydroxy-2-methylpropyl%2529-N-%25285-%25287-methoxyquinolin-4-yloxy%2529pyridin-2-yl%2529-5-methyl-3-oxo-2-phenyl-2%252C3-dihydro-1H-pyrazole-4-carboxamide%2520%2528AMG%2520458%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3688%26epage%3D3691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit142b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAngelo, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span> </span><span class="NLM_article-title">Structure-based design of novel class II MET inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1868</span><span class="NLM_x">â</span> <span class="NLM_lpage">1897</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201331s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1868-1897&author=L.+Liuauthor=M.+H.+Normanauthor=M.+Leeauthor=N.+Xiauthor=A.+Siegmundauthor=A.+A.+Boezioauthor=S.+Bookerauthor=D.+Choquetteauthor=N.+D.+D%E2%80%99Angeloauthor=J.+Germainauthor=K.+Yangauthor=Y.+Yangauthor=Y.+Zhangauthor=S.+F.+Bellonauthor=D.+A.+Whittingtonauthor=J.+C.+Harmangeauthor=C.+Dominguezauthor=T.+S.+Kimauthor=I.+Dussault&title=Structure-based+design+of+novel+class+II+MET+inhibitors%3A+2.+SAR+and+kinase+selectivity+profiles+of+the+pyrazolone+series"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142b&amp;dbid=16384&amp;doi=10.1021%2Fjm201331s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201331s%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DXi%26aufirst%3DN.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DBooker%26aufirst%3DS.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DD%25E2%2580%2599Angelo%26aufirst%3DN.%2BD.%26aulast%3DGermain%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DHarmange%26aufirst%3DJ.%2BC.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DT.%2BS.%26aulast%3DDussault%26aufirst%3DI.%26atitle%3DStructure-based%2520design%2520of%2520novel%2520class%2520II%2520MET%2520inhibitors%253A%25202.%2520SAR%2520and%2520kinase%2520selectivity%2520profiles%2520of%2520the%2520pyrazolone%2520series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1868%26epage%3D1897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the MET kinase superfamily</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">â</span> <span class="NLM_lpage">1254</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801586s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1251-1254&author=G.+M.+Schroederauthor=Y.+Anauthor=Z.+W.+Caiauthor=X.+T.+Chenauthor=C.+Clarkauthor=L.+A.+Corneliusauthor=J.+Daiauthor=J.+Gullo-Brownauthor=A.+Guptaauthor=B.+Henleyauthor=J.+T.+Huntauthor=R.+Jeyaseelanauthor=A.+Kamathauthor=K.+Kimauthor=J.+Lippyauthor=L.+J.+Lombardoauthor=V.+Manneauthor=S.+Oppenheimerauthor=J.+S.+Sackauthor=R.+J.+Schmidtauthor=G.+Shenauthor=K.+Stefanskiauthor=J.+S.+Tokarskiauthor=G.+L.+Trainorauthor=B.+S.+Wautletauthor=D.+Weiauthor=D.+K.+Williamsauthor=Y.+Zhangauthor=Y.+Zhangauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+N-%284-%282-amino-3-chloropyridin-4-yloxy%29-3-fluorophenyl%29-4-ethoxy-1-%284-fluorophenyl%29-2-oxo-1%2C2-dihydropyridine-3-carboxamide+%28BMS-777607%29%2C+a+selective+and+orally+efficacious+inhibitor+of+the+MET+kinase+superfamily"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm801586s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801586s%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25284-%25282-amino-3-chloropyridin-4-yloxy%2529-3-fluorophenyl%2529-4-ethoxy-1-%25284-fluorophenyl%2529-2-oxo-1%252C2-dihydropyridine-3-carboxamide%2520%2528BMS-777607%2529%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520the%2520MET%2520kinase%2520superfamily%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1251%26epage%3D1254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Hurley, L. H.; Mahadevan, D.; Han, H.; Bearss, D. J.; Vankayalapati, H.; Bashyam, S.; Munoz, R. M.; Warner, S. L.; Della Croce, K.; Von Hoff, D. D.; Grand, C. L.; Welsh, J.</span><span> </span><span class="NLM_article-title">Preparation of Fused Pyrimidines as Therapeutic Protein Kinase Inhibitors</span>. US2008/0051414,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=L.+H.+Hurley&author=D.+Mahadevan&author=H.+Han&author=D.+J.+Bearss&author=H.+Vankayalapati&author=S.+Bashyam&author=R.+M.+Munoz&author=S.+L.+Warner&author=K.+Della+Croce&author=D.+D.+Von+Hoff&author=C.+L.+Grand&author=J.+Welsh&title=Preparation+of+Fused+Pyrimidines+as+Therapeutic+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHurley%26aufirst%3DL.%2BH.%26atitle%3DPreparation%2520of%2520Fused%2520Pyrimidines%2520as%2520Therapeutic%2520Protein%2520Kinase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Baxter, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuffey, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauser, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuchtern, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inloes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, S. M.</span><span> </span><span class="NLM_article-title">Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">â</span> <span class="NLM_lpage">812</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1007%2Fs00280-010-1380-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20563581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVemsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=809-812&author=P.+A.+Baxterauthor=P.+A.+Thompsonauthor=L.+M.+McGuffeyauthor=B.+W.+Gibsonauthor=R.+C.+Dauserauthor=J.+G.+Nuchternauthor=C.+Shiauthor=R.+Inloesauthor=G.+Choyauthor=S.+Redkarauthor=S.+M.+Blaney&title=Plasma+and+cerebrospinal+fluid+pharmacokinetics+of+MP470+in+non-human+primates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates</span></div><div class="casAuthors">Baxter, P. A.; Thompson, P. A.; McGuffey, L. M.; Gibson, B. W.; Dauser, R. C.; Nuchtern, J. G.; Shi, C.; Inloes, R.; Choy, G.; Redkar, S.; Blaney, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">809-812</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: MP470 is a multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRÎ±, Flt3, c-Met and c-Ret that is being evaluated as an anticancer agent.  The plasma and cerebrospinal fluid (CSF) pharmacokinetics of MP470 were studied in a non-human primate model that is highly predictive of CSF penetration in humans.  Methods: Oral MP470, 300 mg, was administered to four non-human primates.  Serial samples of blood were collected from four animals and CSF samples from three animals for pharmacokinetic studies.  Plasma and CSF concns. were measured using an LC-MS/MS assay.  Both model-independent and model-dependent methods were used to analyze the pharmacokinetic data.  Results: Following a one-time oral dose of 300 mg, the MP470 plasma area under the curve (AUC) was 1,690 Â± 821 nM h (mean Â± SD).  The half-life of MP470 in the plasma was 11.0 Â± 3.4 h.  There was no measurable MP470 in the CSF.  Conclusions: Although CSF penetration is minimal, MP470 has demonstrated potent activity against cancer cell lines in vitro and in vivo, and further clin. investigation is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD1mRQVSgLB7Vg90H21EOLACvtfcHk0lhvY83T1pAj5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVemsro%253D&md5=ac917f160193bbf661629032ee7889a7</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs00280-010-1380-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-010-1380-3%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DP.%2BA.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DMcGuffey%26aufirst%3DL.%2BM.%26aulast%3DGibson%26aufirst%3DB.%2BW.%26aulast%3DDauser%26aufirst%3DR.%2BC.%26aulast%3DNuchtern%26aufirst%3DJ.%2BG.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DInloes%26aufirst%3DR.%26aulast%3DChoy%26aufirst%3DG.%26aulast%3DRedkar%26aufirst%3DS.%26aulast%3DBlaney%26aufirst%3DS.%2BM.%26atitle%3DPlasma%2520and%2520cerebrospinal%2520fluid%2520pharmacokinetics%2520of%2520MP470%2520in%2520non-human%2520primates%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D67%26spage%3D809%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Pan, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariv, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span> </span><span class="NLM_article-title">MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated MET receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1524</span><span class="NLM_x">â</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1524-1533&author=B.+S.+Panauthor=G.+K.+Chanauthor=M.+Chenardauthor=A.+Chiauthor=L.+J.+Davisauthor=S.+V.+Deshmukhauthor=J.+B.+Gibbsauthor=S.+Gilauthor=G.+Hangauthor=H.+Hatchauthor=J.+P.+Jewellauthor=I.+Karivauthor=J.+D.+Katzauthor=K.+Kuniiauthor=W.+Luauthor=B.+A.+Lutterbachauthor=C.+P.+Paweletzauthor=X.+Quauthor=J.+F.+Reillyauthor=A.+A.+Szewczakauthor=Q.+Zengauthor=N.+E.+Kohlauthor=C.+J.+Dinsmore&title=MK-2461%2C+a+novel+multitargeted+kinase+inhibitor%2C+preferentially+inhibits+the+activated+MET+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DB.%2BS.%26aulast%3DChan%26aufirst%3DG.%2BK.%26aulast%3DChenard%26aufirst%3DM.%26aulast%3DChi%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DL.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DGibbs%26aufirst%3DJ.%2BB.%26aulast%3DGil%26aufirst%3DS.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26atitle%3DMK-2461%252C%2520a%2520novel%2520multitargeted%2520kinase%2520inhibitor%252C%2520preferentially%2520inhibits%2520the%2520activated%2520MET%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1524%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leggett, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. J.</span><span> </span><span class="NLM_article-title">ARQ 197, a novel and selective inhibitor of the human MET receptor tyrosine kinase with antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">â</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.+R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+novel+and+selective+inhibitor+of+the+human+MET+receptor+tyrosine+kinase+with+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0lgaH4MHF111tw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BR.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520the%2520human%2520MET%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh-hara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span> </span><span class="NLM_article-title">Cytotoxic activity of tivantinib (ARQ 197) is not due solely to MET inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">3087</span><span class="NLM_x">â</span> <span class="NLM_lpage">3096</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=3087-3096&author=R.+Katayamaauthor=A.+Aoyamaauthor=T.+Yamoriauthor=J.+Qiauthor=T.+Oh-haraauthor=Y.+Songauthor=J.+A.+Engelmanauthor=N.+Fujita&title=Cytotoxic+activity+of+tivantinib+%28ARQ+197%29+is+not+due+solely+to+MET+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DAoyama%26aufirst%3DA.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DOh-hara%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DFujita%26aufirst%3DN.%26atitle%3DCytotoxic%2520activity%2520of%2520tivantinib%2520%2528ARQ%2520197%2529%2520is%2520not%2520due%2520solely%2520to%2520MET%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D3087%26epage%3D3096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Basilico, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennacchietti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigna, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiriaco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arena, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdembri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michieli, P.</span><span> </span><span class="NLM_article-title">Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2381</span><span class="NLM_x">â</span> <span class="NLM_lpage">2392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-12-3459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23532890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWrurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2381-2392&author=C.+Basilicoauthor=S.+Pennacchiettiauthor=E.+Vignaauthor=C.+Chiriacoauthor=S.+Arenaauthor=A.+Bardelliauthor=D.+Valdembriauthor=G.+Seriniauthor=P.+Michieli&title=Tivantinib+%28ARQ197%29+displays+cytotoxic+activity+that+is+independent+of+its+ability+to+bind+MET"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET</span></div><div class="casAuthors">Basilico, Cristina; Pennacchietti, Selma; Vigna, Elisa; Chiriaco, Cristina; Arena, Sabrina; Bardelli, Alberto; Valdembri, Donatella; Serini, Guido; Michieli, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2381-2392</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: MET, the high-affinity receptor for hepatocyte growth factor, is frequently deregulated in human cancer.  Tivantinib (ARQ197; Arqule), a staurosporine deriv. that binds to the dephosphorylated MET kinase in vitro, is being tested clin. as a highly selective MET inhibitor.  However, the mechanism of action of tivantinib is still unclear.  The activity of tivantinib was analyzed in multiple cellular models, including: cells displaying c-MET gene amplification, strictly addicted' to MET signaling; cells with normal c-MET gene copy no., not dependent on MET for growth; cells not expressing MET; somatic knockout cells in which the ATP-binding cleft of MET, where tivantinib binds, was deleted by homologous recombination; and a cell system poisoned' by MET kinase hyperactivation, where cells die unless cultured in the presence of a specific MET inhibitor.  Tivantinib displayed cytotoxic activity independently of c-MET gene copy no. and regardless of the presence or absence of MET.  In both wild-type and isogenic knockout cells, tivantinib perturbed microtubule dynamics, induced G2/M arrest, and promoted apoptosis.  Tivantinib did not rescue survival of cells poisoned' by MET kinase hyperactivation, but further incremented cell death.  In all cell models analyzed, tivantinib did not inhibit HGF-dependent or -independent MET tyrosine autophosphorylation.  We conclude that tivantinib displays cytotoxic activity via mol. mechanisms that are independent from its ability to bind MET.  This notion has a relevant impact on the interpretation of clin. results, on the design of future clin. trials, and on the selection of patients receiving tivantinib treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0izNZX9sR77Vg90H21EOLACvtfcHk0lgaH4MHF111tw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWrurY%253D&md5=42642dc65760984e663edcae9f819a9a</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3459%26sid%3Dliteratum%253Aachs%26aulast%3DBasilico%26aufirst%3DC.%26aulast%3DPennacchietti%26aufirst%3DS.%26aulast%3DVigna%26aufirst%3DE.%26aulast%3DChiriaco%26aufirst%3DC.%26aulast%3DArena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DValdembri%26aufirst%3DD.%26aulast%3DSerini%26aufirst%3DG.%26aulast%3DMichieli%26aufirst%3DP.%26atitle%3DTivantinib%2520%2528ARQ197%2529%2520displays%2520cytotoxic%2520activity%2520that%2520is%2520independent%2520of%2520its%2520ability%2520to%2520bind%2520MET%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2381%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Peters, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">MET: a promising anticancer therapeutic target</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150a&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrclinonc.2012.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150a&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOrtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=314-326&author=S.+Petersauthor=A.+A.+Adjei&title=MET%3A+a+promising+anticancer+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150aR"><div class="casContent"><span class="casTitleNuber">150a</span><div class="casTitle"><span class="NLM_cas:atitle">MET: a promising anticancer therapeutic target</span></div><div class="casAuthors">Peters, Solange; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">314-326</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Targeting the MET pathway is an increasingly attractive anticancer strategy.  In this Review, this pathway is viewed from the clin. perspective, assessing the available agents in terms of efficacy and toxicity and looking forward to biomarker-driven application in the clinic.  The MET pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination.  Abnormalities in MET signalling have been reported to correlate with poor clin. outcomes and drug resistance in patients with cancer.  Thus, MET has emerged as an attractive target for cancer therapy.  Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clin. trials.  In general, initial results from these studies indicate only a modest benefit in unselected populations.  In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1VV_hiW_CLVg90H21EOLACvtfcHk0ljgOzggLbx-BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOrtL0%253D&md5=db84521545ee290e245a5b541b103ff1</span></div><a href="/servlet/linkout?suffix=cit150a&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.71%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DMET%253A%2520a%2520promising%2520anticancer%2520therapeutic%2520target%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D314%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit150b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Robinson, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A. B.</span><span> </span><span class="NLM_article-title">The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">122</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=115-122&author=K.+W.+Robinsonauthor=A.+B.+Sandler&title=The+role+of+MET+receptor+tyrosine+kinase+in+non-small+cell+lung+cancer+and+clinical+development+of+targeted+anti-MET+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DK.%2BW.%26aulast%3DSandler%26aufirst%3DA.%2BB.%26atitle%3DThe%2520role%2520of%2520MET%2520receptor%2520tyrosine%2520kinase%2520in%2520non-small%2520cell%2520lung%2520cancer%2520and%2520clinical%2520development%2520of%2520targeted%2520anti-MET%2520agents%26jtitle%3DOncologist%26date%3D2013%26volume%3D18%26spage%3D115%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeesh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nallasura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lader, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarbaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Functional expression and mutations of MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">â</span> <span class="NLM_lpage">1488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1479-1488&author=P.+C.+Maauthor=R.+Jagadeeswaranauthor=S.+Jagadeeshauthor=M.+S.+Tretiakovaauthor=V.+Nallasuraauthor=E.+A.+Foxauthor=M.+Hansenauthor=E.+Schaeferauthor=K.+Naokiauthor=A.+Laderauthor=W.+Richardsauthor=D.+Sugarbakerauthor=A.+N.+Husainauthor=J.+G.+Christensenauthor=R.+Salgia&title=Functional+expression+and+mutations+of+MET+and+its+therapeutic+inhibition+with+SU11274+and+small+interfering+RNA+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DJagadeesh%26aufirst%3DS.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DNallasura%26aufirst%3DV.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DSchaefer%26aufirst%3DE.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DLader%26aufirst%3DA.%26aulast%3DRichards%26aufirst%3DW.%26aulast%3DSugarbaker%26aufirst%3DD.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DFunctional%2520expression%2520and%2520mutations%2520of%2520MET%2520and%2520its%2520therapeutic%2520inhibition%2520with%2520SU11274%2520and%2520small%2520interfering%2520RNA%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D1479%26epage%3D1488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skokan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajapathy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felicioni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Grammastro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciarrotta, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttitta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Incarbone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toschi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finocchiaro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Destro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terracciano, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roncalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alloisio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span> </span><span class="NLM_article-title">Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1667</span><span class="NLM_x">â</span> <span class="NLM_lpage">1674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2008.19.1635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=19255323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BD1M3ktlKruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=1667-1674&author=F.+Cappuzzoauthor=A.+Marchettiauthor=M.+Skokanauthor=E.+Rossiauthor=S.+Gajapathyauthor=L.+Felicioniauthor=M.+Del+Grammastroauthor=M.+G.+Sciarrottaauthor=F.+Buttittaauthor=M.+Incarboneauthor=L.+Toschiauthor=G.+Finocchiaroauthor=A.+Destroauthor=L.+Terraccianoauthor=M.+Roncalliauthor=M.+Alloisioauthor=A.+Santoroauthor=M.+Varella-Garcia&title=Increased+MET+gene+copy+number+negatively+affects+survival+of+surgically+resected+non-small-cell+lung+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients</span></div><div class="casAuthors">Cappuzzo Federico; Marchetti Antonio; Skokan Margaret; Rossi Elisa; Gajapathy Sujatha; Felicioni Lara; Del Grammastro Maela; Sciarrotta Maria Grazia; Buttitta Fiamma; Incarbone Matteo; Toschi Luca; Finocchiaro Giovanna; Destro Annarita; Terracciano Luigi; Roncalli Massimo; Alloisio Marco; Santoro Armando; Varella-Garcia Marileila</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1667-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To investigate the prognostic role of genomic gain for MET and epidermal growth factor receptor (EGFR) genes in surgically resected non-small-cell lung cancer (NSCLC).  PATIENTS AND METHODS:  This retrospective study included 447 NSCLC patients with available tumor tissue from primary lung tumor and survival data.  EGFR and MET status was evaluated by fluorescent in situ hybridization (FISH) in tissue microarray sections.  RESULTS:  EGFR FISH results were obtained in 376 cases.  EGFR gene amplification and high polysomy (EGFR FISH+) were observed in 10.4% and 32.4% of cases, respectively.  EGFR FISH-positive patients had a nonsignificant shorter survival than EGFR FISH-negative patients (P = .4).  Activating EGFR mutations were detected in 9.7% of 144 stage I-II disease with no impact on survival.  MET FISH analysis was performed in 435 cases.  High MET gene copy number (mean > or = 5 copies/cell) was observed in 48 cases (MET+, 11.1%), including 18 cases with true gene amplification (4.1%).  MET+ status was associated with advanced stage (P = .01), with grade 3 (P = .016) and with EGFR FISH+ result (P < .0001).  No patient with activating EGFR mutation resulted MET+.  In the whole population, MET-positive patients had shorter survival than MET-negative patients (P = .005).  Multivariable model confirmed that MET-negative patients had a significant reduction in the risk of death than MET-positive patients (hazard ratio, 0.66; P = .04).  CONCLUSION:  MET increased gene copy number is an independent negative prognostic factor in surgically resected NSCLC.  EGFR gene gain does not impact survival after resection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnc5G-Os6-WzdblLE_E9PWfW6udTcc2eYtlnpw74jmhrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3ktlKruw%253D%253D&md5=41bfbb70eb8a9e4ffd2964caf68e2511</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.1635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.1635%26sid%3Dliteratum%253Aachs%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMarchetti%26aufirst%3DA.%26aulast%3DSkokan%26aufirst%3DM.%26aulast%3DRossi%26aufirst%3DE.%26aulast%3DGajapathy%26aufirst%3DS.%26aulast%3DFelicioni%26aufirst%3DL.%26aulast%3DDel%2BGrammastro%26aufirst%3DM.%26aulast%3DSciarrotta%26aufirst%3DM.%2BG.%26aulast%3DButtitta%26aufirst%3DF.%26aulast%3DIncarbone%26aufirst%3DM.%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DFinocchiaro%26aufirst%3DG.%26aulast%3DDestro%26aufirst%3DA.%26aulast%3DTerracciano%26aufirst%3DL.%26aulast%3DRoncalli%26aufirst%3DM.%26aulast%3DAlloisio%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26atitle%3DIncreased%2520MET%2520gene%2520copy%2520number%2520negatively%2520affects%2520survival%2520of%2520surgically%2520resected%2520non-small-cell%2520lung%2520cancer%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D1667%26epage%3D1674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Sadiq, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">MET as a possible target for non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">â</span> <span class="NLM_lpage">1096</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2012.43.9422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23401458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2mtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1089-1096&author=A.+A.+Sadiqauthor=R.+Salgia&title=MET+as+a+possible+target+for+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">MET as a possible target for non-small-cell lung cancer</span></div><div class="casAuthors">Sadiq, Ahad A.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1089-1096</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Lung cancer is a heterogeneous group of disorders that is now being subdivided into mol. subtypes with dedicated targeted therapies.  The MET receptor tyrosine kinase has been identified as aberrantly overexpressed, potentially having activating mutations, and amplified in certain subsets of lung cancers.  The ligand hepatocyte growth factor (HGF) can also be overexpressed in lung cancer or expressed in stroma, and both the MET receptor and the HGF ligand can be targets for therapeutics, esp. in lung cancer.  Activation of MET leads to a plethora of biochem. and biol. changes both in normal and cancerous cells.  Preclinically, it has been shown that silencing or inactivating MET leads to decreased viability of cancer cells.  There are a no. of compds. against MET/HGF in clin. trials that have been shown to be active in lung cancers.  This review will summarize the biol. of MET as well as its therapeutic inhibition in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT3C3GIW14j7Vg90H21EOLACvtfcHk0lgZA_I86fnkLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2mtbc%253D&md5=38e65a5dc6c8819995f38e596d230a27</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.9422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.9422%26sid%3Dliteratum%253Aachs%26aulast%3DSadiq%26aufirst%3DA.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DMET%2520as%2520a%2520possible%2520target%2520for%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1089%26epage%3D1096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Tanizaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takezawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1624</span><span class="NLM_x">â</span> <span class="NLM_lpage">1631</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1097%2FJTO.0b013e31822591e9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21716144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BC3MfjsFymtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1624-1631&author=J.+Tanizakiauthor=I.+Okamotoauthor=K.+Okamotoauthor=K.+Takezawaauthor=K.+Kuwataauthor=H.+Yamaguchiauthor=K.+Nakagawa&title=MET+tyrosine+kinase+inhibitor+crizotinib+%28PF-02341066%29+shows+differential+antitumor+effects+in+non-small+cell+lung+cancer+according+to+MET+alterations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations</span></div><div class="casAuthors">Tanizaki Junko; Okamoto Isamu; Okamoto Kunio; Takezawa Ken; Kuwata Kiyoko; Yamaguchi Haruka; Nakagawa Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1624-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Tyrosine kinase inhibitors (TKIs) targeted to MET are undergoing clinical trials in patients with solid tumors, but the precise mechanism of the antitumor activity of these drugs remains unclear.  We examined the antitumor action of the MET-TKI crizotinib (PF-02341066) in lung cancer cells that are positive or negative for MET amplification or mutation.  METHODS:  The antitumor action of crizotinib was evaluated on the basis of signal transduction, cell proliferation, apoptosis, and progression of tumor xenografts.  RESULTS:  Inhibition of MET signaling by crizotinib or by RNA interference-mediated MET depletion resulted in the induction of apoptosis accompanied by inhibition of AKT and extracellular signal-regulated kinase phosphorylation in lung cancer cells with MET amplification but not in cells with a MET mutation or in those without amplification or mutation of MET.  These results suggest that MET signaling is essential for the survival of cells with MET amplification but not for that of cells without this genetic change, including those with a MET mutation.  Crizotinib up-regulated the expression of BIM, a proapoptotic member of the Bcl-2 family, and down-regulated that of survivin, a member of the inhibitor of apoptosis protein family, in cells with MET amplification.  Forced depletion of BIM and expression of survivin each inhibited crizotinib-induced apoptosis, suggesting that both up-regulation of BIM and down-regulation of survivin contribute to the proapoptotic effect of crizotinib.  CONCLUSIONS:  Crizotinib shows a marked antitumor action in MET amplification-positive lung cancer cells but not in cells without MET amplification, including those with a MET mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8hMQlXKWgvS86Js-BCLiifW6udTcc2eaUSa51eY3CJ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfjsFymtA%253D%253D&md5=69a87a8667cd239d19735f3fcb3feddc</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31822591e9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31822591e9%26sid%3Dliteratum%253Aachs%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DKuwata%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DMET%2520tyrosine%2520kinase%2520inhibitor%2520crizotinib%2520%2528PF-02341066%2529%2520shows%2520differential%2520antitumor%2520effects%2520in%2520non-small%2520cell%2520lung%2520cancer%2520according%2520to%2520MET%2520alterations%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D1624%26epage%3D1631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">â</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1097%2FJTO.0b013e31821528d3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21623265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=942-946&author=S.-H.+I.+Ouauthor=E.+L.+Kwakauthor=C.+Siwak-Tappauthor=J.+Dyauthor=K.+Bergethonauthor=J.+W.+Clarkauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=R.+G.+Makiauthor=Y.-J.+Bangauthor=D.-W.+Kimauthor=J.+Christensenauthor=W.+Tanauthor=K.+D.+Wilnerauthor=R.+Salgiaauthor=A.+J.+Iafrate&title=Activity+of+crizotinib+%28PF02341066%29%2C+a+dual+mesenchymal-epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor%2C+in+a+non-small+cell+lung+cancer+patient+with+de+novo+MET+amplification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Kwak Eunice L; Siwak-Tapp Christina; Dy Joni; Bergethon Kristin; Clark Jeffrey W; Camidge D Ross; Solomon Benjamin J; Maki Robert G; Bang Yung-Jue; Kim Dong-Wan; Christensen James; Tan Weiwei; Wilner Keith D; Salgia Ravi; Iafrate A John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is a dual MET and ALK inhibitor.  Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC).  Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1REpDHXMT37jnyZkbE8yXfW6udTcc2eaUSa51eY3CJ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D&md5=920657051f20d097e6cd1d83b0aa7e10</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31821528d3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31821528d3%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DDy%26aufirst%3DJ.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DActivity%2520of%2520crizotinib%2520%2528PF02341066%2529%252C%2520a%2520dual%2520mesenchymal-epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%252C%2520in%2520a%2520non-small%2520cell%2520lung%2520cancer%2520patient%2520with%2520de%2520novo%2520MET%2520amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Spigel, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramlau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldschmidt, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement-Duchene, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlesi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlov, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertheim, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A. C.</span><span> </span><span class="NLM_article-title">Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">7505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=7505&author=D.+R.+Spigelauthor=T.+J.+Ervinauthor=R.+Ramlauauthor=D.+B.+Danielauthor=J.+H.+Goldschmidtauthor=G.+R.+Blumenscheinauthor=M.+J.+Krzakowskiauthor=G.+Robinetauthor=C.+Clement-Ducheneauthor=F.+Barlesiauthor=R.+Govindanauthor=T.+Patelauthor=S.+V.+Orlovauthor=M.+S.+Wertheimauthor=J.+Zhaauthor=A.+Panditaauthor=W.+Yuauthor=R.+L.+Yauchauthor=P.+H.+Patelauthor=A.+C.+Peterson&title=Final+efficacy+results+from+OAM4558g%2C+a+randomized+phase+II+study+evaluating+MetMAb+or+placebo+in+combination+with+erlotinib+in+advanced+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DErvin%26aufirst%3DT.%2BJ.%26aulast%3DRamlau%26aufirst%3DR.%26aulast%3DDaniel%26aufirst%3DD.%2BB.%26aulast%3DGoldschmidt%26aufirst%3DJ.%2BH.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DKrzakowski%26aufirst%3DM.%2BJ.%26aulast%3DRobinet%26aufirst%3DG.%26aulast%3DClement-Duchene%26aufirst%3DC.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DT.%26aulast%3DOrlov%26aufirst%3DS.%2BV.%26aulast%3DWertheim%26aufirst%3DM.%2BS.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DPandita%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DPatel%26aufirst%3DP.%2BH.%26aulast%3DPeterson%26aufirst%3DA.%2BC.%26atitle%3DFinal%2520efficacy%2520results%2520from%2520OAM4558g%252C%2520a%2520randomized%2520phase%2520II%2520study%2520evaluating%2520MetMAb%2520or%2520placebo%2520in%2520combination%2520with%2520erlotinib%2520in%2520advanced%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D7505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Ou, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argiris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usari, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, F.</span><span> </span><span class="NLM_article-title">Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2610</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2610&author=S.+I.+Ouauthor=R.+Govindanauthor=K.+D.+Eatonauthor=G.+A.+Ottersonauthor=M.+Gutierrezauthor=A.+C.+Mitaauthor=A.+Argirisauthor=N.+Bregaauthor=T.+Usariauthor=W.+Tanauthor=S.+N.+Hoauthor=F.+Robert&title=Phase+I%2FII+dose-finding+study+of+crizotinib+%28CRIZ%29+in+combination+with+erlotinib+%28E%29+in+patients+%28pts%29+with+advanced+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DEaton%26aufirst%3DK.%2BD.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DArgiris%26aufirst%3DA.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DHo%26aufirst%3DS.%2BN.%26aulast%3DRobert%26aufirst%3DF.%26atitle%3DPhase%2520I%252FII%2520dose-finding%2520study%2520of%2520crizotinib%2520%2528CRIZ%2529%2520in%2520combination%2520with%2520erlotinib%2520%2528E%2529%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D2610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Ferlay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, D. M.</span><span> </span><span class="NLM_article-title">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">2893</span><span class="NLM_x">â</span> <span class="NLM_lpage">2917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1002%2Fijc.25516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21351269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWhs7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=2893-2917&author=J.+Ferlayauthor=H.+R.+Shinauthor=F.+Brayauthor=D.+Formanauthor=C.+Mathersauthor=D.+M.+Parkin&title=Estimates+of+worldwide+burden+of+cancer+in+2008%3A+GLOBOCAN+2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</span></div><div class="casAuthors">Ferlay, Jacques; Shin, Hai-Rim; Bray, Freddie; Forman, David; Mathers, Colin; Parkin, Donald Maxwell</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2893-2917</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Ests. of the worldwide incidence and mortality from 27 cancers in 2008 have been prepd. for 182 countries as part of the GLOBOCAN series published by the International Agency for Research on Cancer.  In this article, we present the results for 20 world regions, summarizing the global patterns for the eight most common cancers.  Overall, an estd. 12.7 million new cancer cases and 7.6 million cancer deaths occur in 2008, with 56% of new cancer cases and 63% of the cancer deaths occurring in the less developed regions of the world.  The most commonly diagnosed cancers worldwide are lung (1.61 million, 12.7% of the total), breast (1.38 million, 10.9%) and colorectal cancers (1.23 million, 9.7%).  The most common causes of cancer death are lung cancer (1.38 million, 18.2% of the total), stomach cancer (738,000 deaths, 9.7%) and liver cancer (696,000 deaths, 9.2%).  Cancer is neither rare anywhere in the world, nor mainly confined to high-resource countries.  Striking differences in the patterns of cancer from region to region are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNEfa8G4I-C7Vg90H21EOLACvtfcHk0lgF8UK7D191CQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWhs7fO&md5=986c00d4fc94238145c1d56b8dfc4840</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fijc.25516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25516%26sid%3Dliteratum%253Aachs%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DH.%2BR.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DForman%26aufirst%3DD.%26aulast%3DMathers%26aufirst%3DC.%26aulast%3DParkin%26aufirst%3DD.%2BM.%26atitle%3DEstimates%2520of%2520worldwide%2520burden%2520of%2520cancer%2520in%25202008%253A%2520GLOBOCAN%25202008%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D127%26spage%3D2893%26epage%3D2917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Goyal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzumdar, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span> </span><span class="NLM_article-title">Targeting the HGF/c-MET pathway in hepatocellular carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2310</span><span class="NLM_x">â</span> <span class="NLM_lpage">2318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-12-2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23388504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWrtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2310-2318&author=L.+Goyalauthor=M.+D.+Muzumdarauthor=A.+X.+Zhu&title=Targeting+the+HGF%2Fc-MET+pathway+in+hepatocellular+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma</span></div><div class="casAuthors">Goyal, Lipika; Muzumdar, Mandar D.; Zhu, Andrew X.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2310-2318</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and mortality worldwide.  Despite improvements in local therapies, including surgical resection, liver transplantation, and transarterial embolization, the prognosis remains poor for the majority of patients who develop recurrence or present with advanced disease.  Systemic therapy with the tyrosine kinase inhibitor sorafenib represents a milestone in advanced HCC but provides a limited survival benefit.  Ongoing efforts to study hepatocarcinogenesis have identified an important role for c-MET signaling in the promotion of tumor growth, angiogenesis, and metastasis.  In this review, we summarize the preclin. data from human tissue, cell lines, and animal models that implicate c-MET in the pathogenesis of HCC.  We also evaluate potential biomarkers that may est. prognosis or predict response to c-MET inhibitors for more rational clin. trial design.  Finally, we discuss the latest clin. trials of c-MET inhibitors in advanced HCC.  Clin Cancer Res; 19(9); 2310-8. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq72oTEvzdBqbVg90H21EOLACvtfcHk0lgF8UK7D191CQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWrtb8%253D&md5=1b73508518b06dfa8dc4297e0cf0f22d</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2791%26sid%3Dliteratum%253Aachs%26aulast%3DGoyal%26aufirst%3DL.%26aulast%3DMuzumdar%26aufirst%3DM.%2BD.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26atitle%3DTargeting%2520the%2520HGF%252Fc-MET%2520pathway%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2310%26epage%3D2318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Park, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Na, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zbar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span> </span><span class="NLM_article-title">Somatic mutations in the kinase domain of the MET/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=307-310&author=W.+S.+Parkauthor=S.+M.+Dongauthor=S.+Y.+Kimauthor=E.+Y.+Naauthor=M.+S.+Shinauthor=J.+H.+Piauthor=B.+J+Kimauthor=J.+H.+Baeauthor=Y.+K.+Hongauthor=K.+S.+Leeauthor=S.+H.+Leeauthor=N.+J.+Yooauthor=J.+J.+Jangauthor=S.+Packauthor=Z.+Zhuangauthor=L.+Schmidtauthor=B.+Zbarauthor=J.+Y.+Lee&title=Somatic+mutations+in+the+kinase+domain+of+the+MET%2Fhepatocyte+growth+factor+receptor+gene+in+childhood+hepatocellular+carcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DW.%2BS.%26aulast%3DDong%26aufirst%3DS.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DNa%26aufirst%3DE.%2BY.%26aulast%3DShin%26aufirst%3DM.%2BS.%26aulast%3DPi%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DB.%2BJ%26aulast%3DBae%26aufirst%3DJ.%2BH.%26aulast%3DHong%26aufirst%3DY.%2BK.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DYoo%26aufirst%3DN.%2BJ.%26aulast%3DJang%26aufirst%3DJ.%2BJ.%26aulast%3DPack%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DSchmidt%26aufirst%3DL.%26aulast%3DZbar%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26atitle%3DSomatic%2520mutations%2520in%2520the%2520kinase%2520domain%2520of%2520the%2520MET%252Fhepatocyte%2520growth%2520factor%2520receptor%2520gene%2520in%2520childhood%2520hepatocellular%2520carcinomas%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D307%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Sennino, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, D. M.</span><span> </span><span class="NLM_article-title">Controlling escape from angiogenesis inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">â</span> <span class="NLM_lpage">709</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1038%2Fnrc3366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23001349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlyltbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=699-709&author=B.+Senninoauthor=D.+M.+McDonald&title=Controlling+escape+from+angiogenesis+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling escape from angiogenesis inhibitors</span></div><div class="casAuthors">Sennino, Barbara; McDonald, Donald M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">699-709</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Selective inhibition of vascular endothelial growth factor (VEGF) increases the efficacy of chemotherapy and has beneficial effects on multiple advanced cancers, but response is often limited and the disease eventually progresses.  Changes in the tumor microenvironment - hypoxia among them - that result from vascular pruning, suppressed angiogenesis and other consequences of VEGF inhibition can promote escape and tumor progression.  New therapeutic approaches that target pathways that are involved in the escape mechanisms add the benefits of blocking tumor progression to those of slowing tumor growth by inhibiting angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB0CTfbTo7k7Vg90H21EOLACvtfcHk0li43JVpgu4g4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlyltbvL&md5=a08b3fba4193491e932863b8c7e8aacc</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fnrc3366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3366%26sid%3Dliteratum%253Aachs%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DMcDonald%26aufirst%3DD.%2BM.%26atitle%3DControlling%2520escape%2520from%2520angiogenesis%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D699%26epage%3D709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Rimassa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borbath, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvagni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Laethem, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Vlierberghe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolligs, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barahona, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasbarrini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lencioni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbadessa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span> </span><span class="NLM_article-title">Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4006</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=4006&author=L.+Rimassaauthor=C.+Portaauthor=I.+Borbathauthor=B.+Danieleauthor=S.+Salvagniauthor=J.+L.+Van+Laethemauthor=H.+Van+Vlierbergheauthor=J.+Trojanauthor=F.+Kolligsauthor=A.+Weissauthor=N.+Barahonaauthor=A.+Gasbarriniauthor=M.+Lencioniauthor=A.+Pandeauthor=M.+Lamarauthor=Y.+Chenauthor=G.+Abbadessaauthor=B.+Schwartzauthor=A.+Santoro&title=Tivantinib+%28ARQ+197%29+versus+placebo+in+patients+%28Pts%29+with+hepatocellular+carcinoma+%28HCC%29+who+failed+one+systemic+therapy%3A+results+of+a+randomized+controlled+phase+II+trial+%28RCT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRimassa%26aufirst%3DL.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBorbath%26aufirst%3DI.%26aulast%3DDaniele%26aufirst%3DB.%26aulast%3DSalvagni%26aufirst%3DS.%26aulast%3DVan%2BLaethem%26aufirst%3DJ.%2BL.%26aulast%3DVan%2BVlierberghe%26aufirst%3DH.%26aulast%3DTrojan%26aufirst%3DJ.%26aulast%3DKolligs%26aufirst%3DF.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DBarahona%26aufirst%3DN.%26aulast%3DGasbarrini%26aufirst%3DA.%26aulast%3DLencioni%26aufirst%3DM.%26aulast%3DPande%26aufirst%3DA.%26aulast%3DLamar%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DAbbadessa%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSantoro%26aufirst%3DA.%26atitle%3DTivantinib%2520%2528ARQ%2520197%2529%2520versus%2520placebo%2520in%2520patients%2520%2528Pts%2529%2520with%2520hepatocellular%2520carcinoma%2520%2528HCC%2529%2520who%2520failed%2520one%2520systemic%2520therapy%253A%2520results%2520of%2520a%2520randomized%2520controlled%2520phase%2520II%2520trial%2520%2528RCT%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D4006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Verslype, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohn, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramies, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span> </span><span class="NLM_article-title">Activity of cabozantinib (XL 184) in hepatocellular carcinoma patients (pts): results from a phase II randomized discontinuation trial (RDT)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=4007&author=C.+Verslypeauthor=A.+L.+Cohnauthor=R.+K.+Kelleyauthor=T.-S.+Yangauthor=W.-C.+Suauthor=D.+A.+Ramiesauthor=Y.+Leeauthor=X.+Shenauthor=E.+Van+Cutsem&title=Activity+of+cabozantinib+%28XL+184%29+in+hepatocellular+carcinoma+patients+%28pts%29%3A+results+from+a+phase+II+randomized+discontinuation+trial+%28RDT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerslype%26aufirst%3DC.%26aulast%3DCohn%26aufirst%3DA.%2BL.%26aulast%3DKelley%26aufirst%3DR.%2BK.%26aulast%3DYang%26aufirst%3DT.-S.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DRamies%26aufirst%3DD.%2BA.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26atitle%3DActivity%2520of%2520cabozantinib%2520%2528XL%2520184%2529%2520in%2520hepatocellular%2520carcinoma%2520patients%2520%2528pts%2529%253A%2520results%2520from%2520a%2520phase%2520II%2520randomized%2520discontinuation%2520trial%2520%2528RDT%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D4007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">SchÃ¶ffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonasch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagawa, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma</span> <span class="citation_source-journal">BJU Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">â</span> <span class="NLM_lpage">686</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21156020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GgtbfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=679-686&author=P.+Sch%C3%B6ffskiauthor=J.+A.+Garciaauthor=W.+M.+Stadlerauthor=T.+Gilauthor=E.+Jonaschauthor=S.+T.+Tagawaauthor=M.+Smittauthor=X.+Yangauthor=K.+S.+Olinerauthor=A.+Andersonauthor=M.+Zhuauthor=F.+Kabbinavar&title=A+phase+II+study+of+the+efficacy+and+safety+of+AMG+102+in+patients+with+metastatic+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma</span></div><div class="casAuthors">Schoffski, Patrick; Garcia, Jorge A.; Stadler, Walter M.; Gil, Thierry; Jonasch, Eric; Tagawa, Scott T.; Smitt, Melanie; Yang, Xinqun; Oliner, Kelly S.; Anderson, Abraham; Zhu, Min; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-686</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy and safety of single-agent AMG 102, an investigational, fully human monoclonal antibody to hepatocyte growth factor/scatter factor (HGF/SF), in renal cell carcinoma (RCC).  Patients and Methods: This open-label phase II study included patients â¥18 years old with histol. confirmed, advanced or metastatic RCC (mRCC) and Eastern Cooperative Oncol. Group performance status 0 to 2.  AMG 102 was administered i.v. at 10 or 20 mg/kg once every 2 wk.  A two-stage design was used at each dose level and the primary endpoint was objective best confirmed response (by Response Evaluation Criteria in Solid Tumors) at any time.  Results: Sixty-one patients with mRCC enrolled and received AMG 102 (40 at 10 mg/kg; 21 at 20 mg/kg).  Overall, 70.5% were men, median age was 59 years (range, 39 to 84 years), and 92% had received previous anti-vascular endothelial growth factor therapy.  RCC histologies were: clear cell (75.4%), papillary (11.5%), chromophobe (4.9%) and unclassified (8.2%).  One confirmed partial response occurred at 10 mg/kg, maintained for over 2.5 years; 26 patients (43%) had stable disease, 10 (16%) for â¥32 wk.  The median profression-free survival was 3.7 mo at 10 mg/kg and 2.0 mo at 20 mg/kg.  The commonest adverse events were edema (45.9%), fatigue (37.7%) and nausea (27.9%).  Grade 3 or 4 adverse events occurred in 33% of patients, the most common being edema (9.8%).  Baseline levels of plasma HGF/SF and sol. c-Met as well as archival-tumor c-Met did not correlate with measures of efficacy.  Conclusion: Single-agent AMG 102 was tolerable, but it is unclear if AMG 102 was growth inhibitory in this population of patients with mRCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp923Wc40CHhLVg90H21EOLACvtfcHk0ljKl1htGzxg2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GgtbfM&md5=368f1a948f5cd1a64b57c9b3368d9477</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DGarcia%26aufirst%3DJ.%2BA.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DGil%26aufirst%3DT.%26aulast%3DJonasch%26aufirst%3DE.%26aulast%3DTagawa%26aufirst%3DS.%2BT.%26aulast%3DSmitt%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DOliner%26aufirst%3DK.%2BS.%26aulast%3DAnderson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520AMG%2520102%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DBJU%2520Int.%26date%3D2011%26volume%3D108%26spage%3D679%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Diamond, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanteti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ching, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lira, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenmakers, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">e254</span><span class="NLM_x">â</span> <span class="NLM_lpage">258</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=e254-258&author=J.+R.+Diamondauthor=R.+Salgiaauthor=M.+Varella-Garciaauthor=R.+Kantetiauthor=P.+M.+LoRussoauthor=J.+W.+Clarkauthor=L.+G.+Xuauthor=K.+Wilnerauthor=S.+G.+Eckhardtauthor=K.+A.+Chingauthor=M.+E.+Liraauthor=E.+F.+Schoenmakersauthor=J.+G.+Christensenauthor=D.+R.+Camidge&title=Initial+clinical+sensitivity+and+acquired+resistance+to+MET+inhibition+in+MET-mutated+papillary+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DL.%2BG.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DChing%26aufirst%3DK.%2BA.%26aulast%3DLira%26aufirst%3DM.%2BE.%26aulast%3DSchoenmakers%26aufirst%3DE.%2BF.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DInitial%2520clinical%2520sensitivity%2520and%2520acquired%2520resistance%2520to%2520MET%2520inhibition%2520in%2520MET-mutated%2520papillary%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3De254%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaishampayan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harzstark, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottesen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubscher, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottaro, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linehan, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, R.</span><span> </span><span class="NLM_article-title">Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">â</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2012.43.3383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23213094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2gsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=181-186&author=T.+K.+Choueiriauthor=U.+Vaishampayanauthor=J.+E.+Rosenbergauthor=T.+F.+Loganauthor=A.+L.+Harzstarkauthor=R.+M.+Bukowskiauthor=B.+I.+Riniauthor=S.+Srinivasauthor=M.+N.+Steinauthor=L.+M.+Adamsauthor=L.+H.+Ottesenauthor=K.+H.+Laubscherauthor=L.+Shermanauthor=D.+F.+McDermottauthor=N.+B.+Haasauthor=K.+T.+Flahertyauthor=R.+Rossauthor=P.+Eisenbergauthor=P.+S.+Meltzerauthor=M.+J.+Merinoauthor=D.+P.+Bottaroauthor=W.+M.+Linehanauthor=R.+Srinivasan&title=Phase+II+and+biomarker+study+of+the+dual+MET%2FVEGFR2+inhibitor+foretinib+in+patients+with+papillary+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma</span></div><div class="casAuthors">Choueiri, Toni K.; Vaishampayan, Ulka; Rosenberg, Jonathan E.; Logan, Theodore F.; Harzstark, Andrea L.; Bukowski, Ronald M.; Rini, Brian I.; Srinivas, Sandy; Stein, Mark N.; Adams, Laurel M.; Ottesen, Lone H.; Laubscher, Kevin H.; Sherman, Laurie; McDermott, David F.; Haas, Naomi B.; Flaherty, Keith T.; Ross, Robert; Eisenberg, Peter; Meltzer, Paul S.; Merino, Maria J.; Bottaro, Donald P.; Linehan, W. Marston; Srinivasan, Ramaprasad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-186</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors.  Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC).  We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC.  Patients and Methods: Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm).  Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET[7q31] amplification, or gain of chromosome 7).  The primary end point was overall response rate (ORR).  Results: Overall, 74 patients were enrolled, with 37 in each dosing cohort.  ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 mo, and median overall survival was not reached.  The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, resp.).  The most frequent adverse events of any grade assocd. with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli.  Conclusion: Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6QX38hu-PlLVg90H21EOLACvtfcHk0ljKl1htGzxg2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2gsrs%253D&md5=4933edf67e1dfc4867a9672ce526c94b</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.3383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.3383%26sid%3Dliteratum%253Aachs%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DVaishampayan%26aufirst%3DU.%26aulast%3DRosenberg%26aufirst%3DJ.%2BE.%26aulast%3DLogan%26aufirst%3DT.%2BF.%26aulast%3DHarzstark%26aufirst%3DA.%2BL.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DSrinivas%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DM.%2BN.%26aulast%3DAdams%26aufirst%3DL.%2BM.%26aulast%3DOttesen%26aufirst%3DL.%2BH.%26aulast%3DLaubscher%26aufirst%3DK.%2BH.%26aulast%3DSherman%26aufirst%3DL.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DHaas%26aufirst%3DN.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DEisenberg%26aufirst%3DP.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DMerino%26aufirst%3DM.%2BJ.%26aulast%3DBottaro%26aufirst%3DD.%2BP.%26aulast%3DLinehan%26aufirst%3DW.%2BM.%26aulast%3DSrinivasan%26aufirst%3DR.%26atitle%3DPhase%2520II%2520and%2520biomarker%2520study%2520of%2520the%2520dual%2520MET%252FVEGFR2%2520inhibitor%2520foretinib%2520in%2520patients%2520with%2520papillary%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D181%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Graziano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluccio, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canestrari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâEmidio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catalano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sisti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligorio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreoni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rulli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Oto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zingaretti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Nictolis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnani, M.</span><span> </span><span class="NLM_article-title">Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4789</span><span class="NLM_x">â</span> <span class="NLM_lpage">4795</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2011.36.7706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22042954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslygs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4789-4795&author=F.+Grazianoauthor=N.+Galluccioauthor=P.+Lorenziniauthor=A.+Ruzzoauthor=E.+Canestrariauthor=S.+D%E2%80%99Emidioauthor=V.+Catalanoauthor=V.+Sistiauthor=C.+Ligorioauthor=F.+Andreoniauthor=E.+Rulliauthor=E.+Di+Otoauthor=G.+Fiorentiniauthor=C.+Zingarettiauthor=M.+De+Nictolisauthor=F.+Cappuzzoauthor=M.+Magnani&title=Genetic+activation+of+the+MET+pathway+and+prognosis+of+patients+with+high-risk%2C+radically+resected+gastric+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer</span></div><div class="casAuthors">Graziano, Francesco; Galluccio, Nadia; Lorenzini, Paola; Ruzzo, Annamaria; Canestrari, Emanuele; D'Emidio, Silvia; Catalano, Vincenzo; Sisti, Valerio; Ligorio, Claudia; Andreoni, Francesca; Rulli, Eliana; Di Oto, Enrico; Fiorentini, Giammaria; Zingaretti, Costantino; De Nictolis, Michele; Cappuzzo, Federico; Magnani, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4789-4795</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose To investigate whether prognosis of patients with high-risk gastric cancer may depend on MET copy no. gain (CNG) or an activating truncation within a deoxyadenosine tract element (DATE) in the promoter region of the MET ligand HGF.  Patients and Methods A single-institution cohort of 230 patients with stage II/III gastric cancer was studied.  Formalin-fixed paraffin-embedded tumor specimens were used for DNA extn.  Quant. polymerase chain reaction (qPCR) for MET CNG and sequencing for HGF DATE truncation (< 25 deoxyadenosines instead of 30) were used.  Results were analyzed for assocn. with disease-free survival (DFS) and overall survival (OS).  To assess the reliability of the qPCR measurement, a random sample of cases was reanalyzed using an alternative assay (fluorescent in situ hybridization [FISH]) with calcn. of the intracorrelation coeff. (ICC).  Results In 216 assessable patients, MET CNG five or more copies and homozygous HGF-truncated DATE occurred in 21 patients (10%) and 30 patients (13%), resp.  Patients with MET CNG five or more copies (MET-pos.) showed significantly worse prognosis with multivariate hazard ratio (HR) of 3.02 (95% CI, 1.71 to 5.33; P < .001) for DFS and multivariate HR of 2.91 (95% CI, 1.65 to 5.11; P < .001) for OS.  The agreement between qPCR and FISH was high, with ICC = 0.9% (95% CI, 0.81 % to 0.95%; the closer the ICC is to 1, the greater is the agreement).  HGF-truncated DATE did not show relevant prognostic effect.  Conclusion In this study, qPCR revealed approx. 10% of white patients with gastric cancer harboring MET CNG of five or more copies.  This marker was significantly assocd. with unfavorable prognosis.  This information is relevant to the current clin. development of anti-MET compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ29BNpIYeJLVg90H21EOLACvtfcHk0lgjpbaWcdnNuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslygs74%253D&md5=cf758969ea3570bac488f9e1f723f450</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.36.7706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.36.7706%26sid%3Dliteratum%253Aachs%26aulast%3DGraziano%26aufirst%3DF.%26aulast%3DGalluccio%26aufirst%3DN.%26aulast%3DLorenzini%26aufirst%3DP.%26aulast%3DRuzzo%26aufirst%3DA.%26aulast%3DCanestrari%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Emidio%26aufirst%3DS.%26aulast%3DCatalano%26aufirst%3DV.%26aulast%3DSisti%26aufirst%3DV.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DAndreoni%26aufirst%3DF.%26aulast%3DRulli%26aufirst%3DE.%26aulast%3DDi%2BOto%26aufirst%3DE.%26aulast%3DFiorentini%26aufirst%3DG.%26aulast%3DZingaretti%26aufirst%3DC.%26aulast%3DDe%2BNictolis%26aufirst%3DM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMagnani%26aufirst%3DM.%26atitle%3DGenetic%2520activation%2520of%2520the%2520MET%2520pathway%2520and%2520prognosis%2520of%2520patients%2520with%2520high-risk%252C%2520radically%2520resected%2520gastric%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D4789%26epage%3D4795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Catenacci, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegde, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Durable complete response of metastatic gastric cancer with anti-MET therapy followed by resistance at recurrence</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">â</span> <span class="NLM_lpage">579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=573-579&author=D.+V.+Catenacciauthor=L.+Hendersonauthor=S.+Y.+Xiaoauthor=P.+Patelauthor=R.+L.+Yauchauthor=P.+Hegdeauthor=J.+Zhaauthor=A.+Panditaauthor=A.+Petersonauthor=R.+Salgia&title=Durable+complete+response+of+metastatic+gastric+cancer+with+anti-MET+therapy+followed+by+resistance+at+recurrence"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%26aulast%3DHenderson%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DS.%2BY.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DHegde%26aufirst%3DP.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DPandita%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DDurable%2520complete%2520response%2520of%2520metastatic%2520gastric%2520cancer%2520with%2520anti-MET%2520therapy%2520followed%2520by%2520resistance%2520at%2520recurrence%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D573%26epage%3D579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Lennerz, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackerman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauwers, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4803</span><span class="NLM_x">â</span> <span class="NLM_lpage">4810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2011.35.4928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=22042947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslygs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4803-4810&author=J.+K.+Lennerzauthor=E.+L.+Kwakauthor=A.+Ackermanauthor=M.+Michaelauthor=S.+B.+Foxauthor=K.+Bergethonauthor=G.+Y.+Lauwersauthor=J.+G.+Christensenauthor=K.+D.+Wilnerauthor=D.+A.+Haberauthor=R.+Salgiaauthor=Y.+J.+Bangauthor=J.+W.+Clarkauthor=B.+J.+Solomonauthor=A.+J.+Iafrate&title=MET+amplification+identifies+a+small+and+aggressive+subgroup+of+esophagogastric+adenocarcinoma+with+evidence+of+responsiveness+to+crizotinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib</span></div><div class="casAuthors">Lennerz, Jochen K.; Kwak, Eunice L.; Ackerman, Allison; Michael, Michael; Fox, Stephen B.; Bergethon, Kristin; Lauwers, Gregory Y.; Christensen, James G.; Wilner, Keith D.; Haber, Daniel A.; Salgia, Ravi; Bang, Yung-Jue; Clark, Jeffrey W.; Solomon, Benjamin J.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">4803-4810</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a mol. marker for targeted therapy.  We examd. a GEC cohort with follow-up and reported the clin. response of four addnl. patients with MET-amplified tumors to the small mol. inhibitor crizotinib as part of an expanded phase 1 cohort study.  Patients and Methods: From 2007 to 2009, patients with GEC were genetically screened as a consecutive series of 489 tumors (stages 0, I, and II, 39%; III, 25%; IV, 36%; n = 222 esophageal, including n = 21 squamous carcinomas).  MET, EGFR, and HER2 amplification status was assessed by using fluorescence in situ hybridization.  Results: Ten (2%) of 489 patients screened harbored MET amplification; 23 (4.7%) harbored EGFR amplification; 45 (8.9%) harbored HER2 amplification; and 411 (84%) were wild type for all three genes (ie, neg.).  MET-amplified tumors were typically high-grade adenocarcinomas that presented at advanced stages (5%; n = 4 of 80).  EGFR-amplified tumors showed the highest fraction of squamous cell carcinoma (17%; n = 4 of 23).  HER2, MET, and EGFR amplification were, with one exception (MET and EGFR pos.), mutually exclusive events.  Survival anal. in patients with stages III and IV disease showed substantially shorter median survival in MET/EGFR-amplified groups, with a rank order for all groups by median survival (from most to least aggressive): MET (7.1 mo; P < .001) less than EGFR (11.2 mo; P = .16) less than HER2 (16.9 mo; P = .89) when compared with the neg. group (16.2 mo).  Two of four patients with MET-amplified tumors treated with crizotinib experienced tumor shrinkage (-30% and -16%) and experienced progression after 3.7 and 3.5 mo.  Conclusion MET amplification defines a small and aggressive subset of GEC with indications of transient sensitivity to the targeted MET inhibitor crizotinib (PF-02341066).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvuLInpDQR7Vg90H21EOLACvtfcHk0lgjpbaWcdnNuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslygs7w%253D&md5=c98cb00019310228b39247e23c18d5c4</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.4928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.4928%26sid%3Dliteratum%253Aachs%26aulast%3DLennerz%26aufirst%3DJ.%2BK.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DAckerman%26aufirst%3DA.%26aulast%3DMichael%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DS.%2BB.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DLauwers%26aufirst%3DG.%2BY.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DMET%2520amplification%2520identifies%2520a%2520small%2520and%2520aggressive%2520subgroup%2520of%2520esophagogastric%2520adenocarcinoma%2520with%2520evidence%2520of%2520responsiveness%2520to%2520crizotinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D4803%26epage%3D4810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Dunn, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinne, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wykosky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quayle, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwalla, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chheda, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligon, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furnari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavenee, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depinho, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span> </span><span class="NLM_article-title">Emerging insights into the molecular and cellular basis of glioblastoma</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">â</span> <span class="NLM_lpage">784</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=756-784&author=G.+P.+Dunnauthor=M.+L.+Rinneauthor=J.+Wykoskyauthor=G.+Genoveseauthor=S.+N.+Quayleauthor=I.+F.+Dunnauthor=P.+K.+Agarwallaauthor=M.+G.+Chhedaauthor=B.+Camposauthor=A.+Wangauthor=C.+Brennanauthor=K.+L.+Ligonauthor=F.+Furnariauthor=W.+K.+Caveneeauthor=R.+A.+Depinhoauthor=L.+Chinauthor=W.+C.+Hahn&title=Emerging+insights+into+the+molecular+and+cellular+basis+of+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DG.%2BP.%26aulast%3DRinne%26aufirst%3DM.%2BL.%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DGenovese%26aufirst%3DG.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DDunn%26aufirst%3DI.%2BF.%26aulast%3DAgarwalla%26aufirst%3DP.%2BK.%26aulast%3DChheda%26aufirst%3DM.%2BG.%26aulast%3DCampos%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DLigon%26aufirst%3DK.%2BL.%26aulast%3DFurnari%26aufirst%3DF.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26aulast%3DDepinho%26aufirst%3DR.%2BA.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26atitle%3DEmerging%2520insights%2520into%2520the%2520molecular%2520and%2520cellular%2520basis%2520of%2520glioblastoma%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D756%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raizer, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laterra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reardon, D. A.</span><span> </span><span class="NLM_article-title">A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma</span> <span class="citation_source-journal">Neuro-Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">â</span> <span class="NLM_lpage">446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=437-446&author=P.+Y.+Wenauthor=D.+Schiffauthor=T.+F.+Cloughesyauthor=J.+J.+Raizerauthor=J.+Laterraauthor=M.+Smittauthor=M.+Wolfauthor=K.+S.+Olinerauthor=A.+Andersonauthor=M.+Zhuauthor=E.+Lohauthor=D.+A.+Reardon&title=A+phase+II+study+evaluating+the+efficacy+and+safety+of+AMG+102+%28rilotumumab%29+in+patients+with+recurrent+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DSchiff%26aufirst%3DD.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DRaizer%26aufirst%3DJ.%2BJ.%26aulast%3DLaterra%26aufirst%3DJ.%26aulast%3DSmitt%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DOliner%26aufirst%3DK.%2BS.%26aulast%3DAnderson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DLoh%26aufirst%3DE.%26aulast%3DReardon%26aufirst%3DD.%2BA.%26atitle%3DA%2520phase%2520II%2520study%2520evaluating%2520the%2520efficacy%2520and%2520safety%2520of%2520AMG%2520102%2520%2528rilotumumab%2529%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%26jtitle%3DNeuro-Oncology%26date%3D2011%26volume%3D13%26spage%3D437%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Chi, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batchelor, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymalâepithelial transition inhibitor</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">e30</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=e30-33&author=A.+S.+Chiauthor=T.+T.+Batchelorauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=D.+L.+Wangauthor=K.+D.+Wilnerauthor=D.+N.+Louisauthor=A.+J.+Iafrate&title=Rapid+radiographic+and+clinical+improvement+after+treatment+of+a+MET-amplified+recurrent+glioblastoma+with+a+mesenchymal%E2%80%93epithelial+transition+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DA.%2BS.%26aulast%3DBatchelor%26aufirst%3DT.%2BT.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DWang%26aufirst%3DD.%2BL.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DRapid%2520radiographic%2520and%2520clinical%2520improvement%2520after%2520treatment%2520of%2520a%2520MET-amplified%2520recurrent%2520glioblastoma%2520with%2520a%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520inhibitor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3De30%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Seiwert, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faoro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janamanchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nallasura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Dinali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanteti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingen, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3021</span><span class="NLM_x">â</span> <span class="NLM_lpage">3031</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3021-3031&author=T.+Y.+Seiwertauthor=R.+Jagadeeswaranauthor=L.+Faoroauthor=V.+Janamanchiauthor=V.+Nallasuraauthor=M.+El+Dinaliauthor=S.+Yalaauthor=R.+Kantetiauthor=E.+E.+Cohenauthor=M.+W.+Lingenauthor=L.+Martinauthor=S.+Krishnaswamyauthor=A.+Klein-Szantoauthor=J.+G.+Christensenauthor=E.+E.+Vokesauthor=R.+Salgia&title=The+MET+receptor+tyrosine+kinase+is+a+potential+novel+therapeutic+target+for+head+and+neck+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeiwert%26aufirst%3DT.%2BY.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DFaoro%26aufirst%3DL.%26aulast%3DJanamanchi%26aufirst%3DV.%26aulast%3DNallasura%26aufirst%3DV.%26aulast%3DEl%2BDinali%26aufirst%3DM.%26aulast%3DYala%26aufirst%3DS.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DLingen%26aufirst%3DM.%2BW.%26aulast%3DMartin%26aufirst%3DL.%26aulast%3DKrishnaswamy%26aufirst%3DS.%26aulast%3DKlein-Szanto%26aufirst%3DA.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DThe%2520MET%2520receptor%2520tyrosine%2520kinase%2520is%2520a%2520potential%2520novel%2520therapeutic%2520target%2520for%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D3021%26epage%3D3031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Di Renzo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggiora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortesina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1547</span><span class="NLM_x">â</span> <span class="NLM_lpage">1555</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=1547-1555&author=M.+F.+Di+Renzoauthor=M.+Oliveroauthor=T.+Martoneauthor=A.+Maffeauthor=P.+Maggioraauthor=A.+D.+Stefaniauthor=G.+Valenteauthor=S.+Giordanoauthor=G.+Cortesinaauthor=P.+M.+Comoglio&title=Somatic+mutations+of+the+MET+oncogene+are+selected+during+metastatic+spread+of+human+HNSC+carcinomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BRenzo%26aufirst%3DM.%2BF.%26aulast%3DOlivero%26aufirst%3DM.%26aulast%3DMartone%26aufirst%3DT.%26aulast%3DMaffe%26aufirst%3DA.%26aulast%3DMaggiora%26aufirst%3DP.%26aulast%3DStefani%26aufirst%3DA.%2BD.%26aulast%3DValente%26aufirst%3DG.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DCortesina%26aufirst%3DG.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DSomatic%2520mutations%2520of%2520the%2520MET%2520oncogene%2520are%2520selected%2520during%2520metastatic%2520spread%2520of%2520human%2520HNSC%2520carcinomas%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D1547%26epage%3D1555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Hansen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor targeting in head and neck cancer: Have we been just skimming the surface?</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1381</span><span class="NLM_x">â</span> <span class="NLM_lpage">1383</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1200%2FJCO.2012.47.9220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=23460713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12rtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1381-1383&author=A.+R.+Hansenauthor=L.+L.+Siu&title=Epidermal+growth+factor+receptor+targeting+in+head+and+neck+cancer%3A+Have+we+been+just+skimming+the+surface%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface?</span></div><div class="casAuthors">Hansen, Aaron R.; Siu, Lillian L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1381-1383</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The research of Martins et al. (2013) entitled, 'Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial' and Argiris et al. (2013) entitled, 'Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern Cooperative Oncol. Group trial' is reviewed with commentary and refs.  Martins et al. assessed the effect of the addn. of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib to std. cisplatin-based chemoradiotherapy on complete response rate (CRR) and progression-free survival (PFS).  They noted the lack of benefit of combining anti-EGFR therapy with concurrent chemoradiotherapy as a chemoadditive strategy in unselected patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).  On the other hand, Argiris et al. examd. the addn. of another EGFR TKI, gefitinib, to palliative chemotherapy in patients with recurrent or metastatic (RM) SCCHN.  Although Argiris et al.'s study was not designed to specifically address the suitability of gefitinib and docetaxel after combination cetuximab plus chemotherapy treatment, the history of prior chemotherapy did not impact outcome on the basis of subgroup evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFNSVOfuZa77Vg90H21EOLACvtfcHk0lgrbgjd_NRtEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12rtbg%253D&md5=125e30e5c441f7a39737b341048375fc</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.47.9220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.47.9220%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DA.%2BR.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520targeting%2520in%2520head%2520and%2520neck%2520cancer%253A%2520Have%2520we%2520been%2520just%2520skimming%2520the%2520surface%253F%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1381%26epage%3D1383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stabile, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gubish, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gooding, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandis, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegfried, J. M.</span><span> </span><span class="NLM_article-title">Dual blockade of EGFR and MET abrogates redundant signaling and proliferation in head and neck carcinoma cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4425</span><span class="NLM_x">â</span> <span class="NLM_lpage">4438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm401427c&amp;key=10.1158%2F1078-0432.CCR-10-3339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Fjm401427c&amp;key=21622718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm401427c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1SmtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4425-4438&author=H.+Xuauthor=L.+P.+Stabileauthor=C.+T.+Gubishauthor=W.+E.+Goodingauthor=J.+R.+Grandisauthor=J.+M.+Siegfried&title=Dual+blockade+of+EGFR+and+MET+abrogates+redundant+signaling+and+proliferation+in+head+and+neck+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells</span></div><div class="casAuthors">Xu, Hai; Stabile, Laura P.; Gubish, Christopher T.; Gooding, William E.; Grandis, Jennifer R.; Siegfried, Jill M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4425-4438</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Head and neck squamous cell carcinoma (HNSCC) is usually fatal, and innovative approaches targeting growth pathways are necessary to effectively treat this disease.  Both the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor (HGF)/c-Met pathways are overexpressed in HNSCC and initiate similar downstream signaling pathways.  C-Met may act in consort with EGFR and/or be activated as a compensatory pathway in the presence of EGFR blockade.  Expression levels of EGFR and c-Met were detd. by Western anal. in HNSCC cell lines and correlated with antitumor responses to inhibitors of these pathways.  Combining the c-Met inhibitor PF2341066 with the EGFR inhibitor gefitinib abrogated HNSCC cell proliferation, invasion, and wound healing significantly more than inhibition of each pathway alone in HNSCC cell lines.  When both HGF and the EGFR ligand, TGF-Î±, were present in vitro, P-AKT and P-MAPK expression were maximally inhibited by targeting both EGFR and c-Met pathways, suggesting that c-Met or EGFR can compensate when phosphorylation of the other receptor is inhibited.  We also showed that TGF-Î± can induce phosphorylation of c-Met over sixfold by 8 h in the absence of HGF, supporting a ligand-independent mechanism.  Combined targeting of c-Met and EGFR resulted in an enhanced inhibition of tumor vols. accompanied by a decreased no. of proliferating cells and increased apoptosis compared with single agent treatment in vivo.  Together, these results suggest that dual blockade of c-Met and EGFR may be a promising clin. therapeutic strategy for treating HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooC0GvK87aX7Vg90H21EOLACvtfcHk0lgrbgjd_NRtEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1SmtL0%253D&md5=d3a3a65e764c90f92214b4666e52228f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3339%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DStabile%26aufirst%3DL.%2BP.%26aulast%3DGubish%26aufirst%3DC.%2BT.%26aulast%3DGooding%26aufirst%3DW.%2BE.%26aulast%3DGrandis%26aufirst%3DJ.%2BR.%26aulast%3DSiegfried%26aufirst%3DJ.%2BM.%26atitle%3DDual%2520blockade%2520of%2520EGFR%2520and%2520MET%2520abrogates%2520redundant%2520signaling%2520and%2520proliferation%2520in%2520head%2520and%2520neck%2520carcinoma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4425%26epage%3D4438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarantopoulos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallender, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keer, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G.,  Jr.</span><span> </span><span class="NLM_article-title">Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">â</span> <span class="NLM_lpage">424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=417-424&author=T.+Seiwertauthor=J.+Sarantopoulosauthor=H.+Kallenderauthor=S.+McCallumauthor=H.+N.+Keerauthor=G.+Blumenschein&title=Phase+II+trial+of+single-agent+foretinib+%28GSK1363089%29+in+patients+with+recurrent+or+metastatic+squamous+cell+carcinoma+of+the+head+and+neck"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26aulast%3DKallender%26aufirst%3DH.%26aulast%3DMcCallum%26aufirst%3DS.%26aulast%3DKeer%26aufirst%3DH.%2BN.%26aulast%3DBlumenschein%26aufirst%3DG.%26atitle%3DPhase%2520II%2520trial%2520of%2520single-agent%2520foretinib%2520%2528GSK1363089%2529%2520in%2520patients%2520with%2520recurrent%2520or%2520metastatic%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D417%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R1W','PDB','1R1W'); return false;">PDB: 1R1W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G15" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G15','PDB','2G15'); return false;">PDB: 2G15</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WKM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WKM','PDB','2WKM'); return false;">PDB: 2WKM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WGJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WGJ','PDB','2WGJ'); return false;">PDB: 2WGJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KNB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KNB','PDB','4KNB'); return false;">PDB: 4KNB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZZE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZZE','PDB','3ZZE'); return false;">PDB: 3ZZE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZXZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZXZ','PDB','3ZXZ'); return false;">PDB: 3ZXZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DKF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DKF','PDB','3DKF'); return false;">PDB: 3DKF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QTI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QTI','PDB','3QTI'); return false;">PDB: 3QTI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8','PDB','3LQ8'); return false;">PDB: 3LQ8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3U6I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3U6I','PDB','3U6I'); return false;">PDB: 3U6I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3R7O','PDB','3R7O'); return false;">PDB: 3R7O</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401427c&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm401427c%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-11" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401427c" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67990b9e0a36d1ef","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
